[
  {
    "doc_id": "PMID_41654809",
    "source": "pubmed",
    "sentences": [
      "Diabetic retinopathy (DR) is one of the most important microvascular complications of diabetes mellitus and remains a major cause of preventable blindness worldwide.",
      "Insulin resistance plays a pivotal role in the development of diabetes and its associated complications.",
      "The triglyceride-glucose (TyG) index, a surrogate marker of insulin resistance derived from fasting plasma glucose and triglyceride levels, has gained attention as a simple and practical metabolic marker.",
      "However, data linking the TyG index with diabetic retinopathy, particularly in South Asian populations, are still limited.",
      "A hospital-based cross-sectional study was conducted at Bir Hospital, Kathmandu, Nepal, between April 2023 and October 2024.",
      "Adult patients with diabetes mellitus, excluding those with gestational diabetes, acute illness, non-diabetic causes of hypertriglyceridaemia, conditions affecting lipid or glucose metabolism, prior retinal interventions, or non-diabetic retinal diseases, underwent comprehensive clinical, biochemical, and ophthalmic evaluations.",
      "The triglyceride-glucose (TyG) index was calculated as ln [fasting triglycerides (mg/dL) × fasting plasma glucose (mg/dL) / 2], and participants were categorized into quartiles.",
      "Diabetic retinopathy was graded using internationally accepted clinical severity scales.",
      "Associations were assessed using univariate and multivariate logistic regression, and ROC curve analysis evaluated the discriminatory performance of the TyG index.",
      "Among 83 patients with diabetes mellitus (median age 56 years [IQR 48.5-64], 50.6% male, median diabetes duration 6 years",
      "[IQR 3-12]), the median triglyceride-glucose (TyG) index was 9.98 (IQR 9.485-10.445).",
      "Diabetic retinopathy (DR) prevalence was 48.2%, increasing across TyG quartiles from 9.5% in Q1 to 85.7% in Q4 (p < 0.001), with a significant trend in DR severity (p < 0.001).",
      "TyG correlated moderately with HbA1c (Spearman r = 0.54, p < 0.001).",
      "In multivariable logistic regression adjusted for age, total cholesterol, and HDL, the odds ratio for DR per standard deviation increase in TyG was 4.00 (95% CI 1.75-9.16, p = 0.001); for Q4 vs. Q1, 24.15 (95% CI 3.15-185, p = 0.002).",
      "Findings were robust in sensitivity analyses excluding insulin users (OR 4.35, 95% CI 1.40-13.5, p = 0.011) and outliers (OR 3.80, 95% CI 1.60-9.00, p = 0.002), and stratified by diabetes duration (≥ 5 years:",
      "OR 5.20, 95% CI 1.80-15.0, p = 0.002) and sex (males: OR 3.80, 95% CI 1.20-12.0, p = 0.023; females: OR 4.50, 95% CI 1.30-15.5, p = 0.017).",
      "TyG predicted DR with an area under the ROC curve of 0.83 (95% CI 0.75-0.91), comparable to HbA1c (0.77, DeLong p = 0.29); optimal cutoff 9.78 (sensitivity 88%, specificity 67%).",
      "A higher triglyceride-glucose index was strongly associated with both the presence and severity of diabetic retinopathy.",
      "Given its simplicity and reliance on routinely available laboratory parameters, the TyG index may be a useful marker for identifying diabetic patients at increased risk of retinopathy, particularly in resource-limited settings.",
      "Not applicable.",
      "This was a cross-sectional observational study and did not involve a clinical trial requiring registration."
    ],
    "summary_sentences": [
      "Diabetic retinopathy (DR) is one of the most important microvascular complications of diabetes mellitus and remains a major cause of preventable blindness worldwide.",
      "Insulin resistance plays a pivotal role in the development of diabetes and its associated complications.",
      "The triglyceride-glucose (TyG) index, a surrogate marker of insulin resistance derived from fasting plasma glucose and triglyceride levels, has gained attention as a simple and practical metabolic marker.",
      "However, data linking the TyG index with diabetic retinopathy, particularly in South Asian populations, are still limited.",
      "A hospital-based cross-sectional study was conducted at Bir Hospital, Kathmandu, Nepal, between April 2023 and October 2024.",
      "Adult patients with diabetes mellitus, excluding those with gestational diabetes, acute illness, non-diabetic causes of hypertriglyceridaemia, conditions affecting lipid or glucose metabolism, prior retinal interventions, or non-diabetic retinal diseases, underwent comprehensive clinical, biochemical, and ophthalmic evaluations.",
      "The triglyceride-glucose (TyG) index was calculated as ln [fasting triglycerides (mg/dL) × fasting plasma glucose (mg/dL) / 2], and participants were categorized into quartiles.",
      "Diabetic retinopathy was graded using internationally accepted clinical severity scales.",
      "Associations were assessed using univariate and multivariate logistic regression, and ROC curve analysis evaluated the discriminatory performance of the TyG index.",
      "Among 83 patients with diabetes mellitus (median age 56 years [IQR 48.5-64], 50.6% male, median diabetes duration 6 years",
      "[IQR 3-12]), the median triglyceride-glucose (TyG) index was 9.98 (IQR 9.485-10.445).",
      "Diabetic retinopathy (DR) prevalence was 48.2%, increasing across TyG quartiles from 9.5% in Q1 to 85.7% in Q4 (p < 0.001), with a significant trend in DR severity (p < 0.001).",
      "TyG correlated moderately with HbA1c (Spearman r = 0.54, p < 0.001).",
      "In multivariable logistic regression adjusted for age, total cholesterol, and HDL, the odds ratio for DR per standard deviation increase in TyG was 4.00 (95% CI 1.75-9.16, p = 0.001); for Q4 vs. Q1, 24.15 (95% CI 3.15-185, p = 0.002).",
      "Findings were robust in sensitivity analyses excluding insulin users (OR 4.35, 95% CI 1.40-13.5, p = 0.011) and outliers (OR 3.80, 95% CI 1.60-9.00, p = 0.002), and stratified by diabetes duration (≥ 5 years:",
      "OR 5.20, 95% CI 1.80-15.0, p = 0.002) and sex (males: OR 3.80, 95% CI 1.20-12.0, p = 0.023; females: OR 4.50, 95% CI 1.30-15.5, p = 0.017).",
      "TyG predicted DR with an area under the ROC curve of 0.83 (95% CI 0.75-0.91), comparable to HbA1c (0.77, DeLong p = 0.29); optimal cutoff 9.78 (sensitivity 88%, specificity 67%).",
      "A higher triglyceride-glucose index was strongly associated with both the presence and severity of diabetic retinopathy.",
      "Given its simplicity and reliance on routinely available laboratory parameters, the TyG index may be a useful marker for identifying diabetic patients at increased risk of retinopathy, particularly in resource-limited settings.",
      "Not applicable.",
      "This was a cross-sectional observational study and did not involve a clinical trial requiring registration."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41654775",
    "source": "pubmed",
    "sentences": [
      "This study aimed to evaluate the risk of doxorubicin-induced cardiotoxicity in newly diagnosed breast cancer patients with type 2 diabetes receiving dapagliflozin in addition to metformin, using echocardiographic methods, and to investigate the potential cardioprotective effects of dapagliflozin.",
      "In this prospective observational study, a total of 60 newly diagnosed breast cancer patients with type 2 diabetes were enrolled.",
      "Thirty patients who had been treated with metformin and subsequently received dapagliflozin in addition to metformin during doxorubicin therapy constituted the dapagliflozin group.",
      "The non-dapagliflozin group consisted of 30 patients who, while continuing metformin, were initiated on another oral antidiabetic agent (excluding dapagliflozin) alongside doxorubicin therapy.",
      "N-terminal pro-B type natriuretic peptide (NT-proBNP), left ventricular ejection fraction (LVEF), and left ventricular global longitudinal strain (LVGLS) were measured at baseline and at the 3rd month of treatment.",
      "Between-group baseline characteristics were compared using the independent samples t-test for continuous variables.",
      "Within-group changes from baseline to 3 months were analyzed with paired t-tests.",
      "Between-group comparisons of 3-month outcomes and changes (ΔLVEF, ΔLVGLS, ΔNT-proBNP) were also conducted using independent samples t-tests.",
      "To evaluate the independent effect of dapagliflozin on LVGLS, multivariable linear regression analysis was performed.",
      "Model fit was reported with adjusted R², F-statistics and 95% confidence intervals.",
      "In the non-dapagliflozin group, LVEF and NT-proBNP levels showed no significant differences between baseline and post-treatment; however, LVGLS values significantly deteriorated.",
      "In contrast, the dapagliflozin group demonstrated a significant increase in LVEF (- 2.000 [95% CI - 2.392, - 1.608]) and LVGLS (+ 1.367",
      "[95% CI + 1.159, + 1.574]), as well as a marked reduction in NT-proBNP levels (+ 64.933 [95% CI + 57.902, + 71.964]) after 3 months of treatment (p < 0.001).",
      "At the third month, the dapagliflozin group exhibited significantly better LVGLS (+ 2.133",
      "[95% CI + 1.346, + 2.921]) and lower NT-proBNP levels (+ 57.000",
      "[95% CI + 28.302, + 85.698]) compared with the non-dapagliflozin group (p < 0.001).",
      "Multivariable linear regression analysis confirmed that dapagliflozin use was independently associated with significant improvement in LVGLS at 3 months.",
      "In conclusion, dapagliflozin was associated with more favorable short-term surrogate changes in LVGLS and NT-proBNP during doxorubicin therapy.",
      "The favorable changes observed in LVEF, LVGLS, and NT-proBNP parameters suggest that dapagliflozin may be considered a potential cardioprotective agent and incorporated into preventive strategies against chemotherapy-related cardiotoxicity in diabetic patients.",
      "These hypothesis-generating findings require confirmation in larger randomized trials powered for clinical endpoints with longer follow-up.",
      "Not applicable."
    ],
    "summary_sentences": [
      "This study aimed to evaluate the risk of doxorubicin-induced cardiotoxicity in newly diagnosed breast cancer patients with type 2 diabetes receiving dapagliflozin in addition to metformin, using echocardiographic methods, and to investigate the potential cardioprotective effects of dapagliflozin.",
      "In this prospective observational study, a total of 60 newly diagnosed breast cancer patients with type 2 diabetes were enrolled.",
      "Thirty patients who had been treated with metformin and subsequently received dapagliflozin in addition to metformin during doxorubicin therapy constituted the dapagliflozin group.",
      "The non-dapagliflozin group consisted of 30 patients who, while continuing metformin, were initiated on another oral antidiabetic agent (excluding dapagliflozin) alongside doxorubicin therapy.",
      "N-terminal pro-B type natriuretic peptide (NT-proBNP), left ventricular ejection fraction (LVEF), and left ventricular global longitudinal strain (LVGLS) were measured at baseline and at the 3rd month of treatment.",
      "Between-group baseline characteristics were compared using the independent samples t-test for continuous variables.",
      "Within-group changes from baseline to 3 months were analyzed with paired t-tests.",
      "Between-group comparisons of 3-month outcomes and changes (ΔLVEF, ΔLVGLS, ΔNT-proBNP) were also conducted using independent samples t-tests.",
      "To evaluate the independent effect of dapagliflozin on LVGLS, multivariable linear regression analysis was performed.",
      "Model fit was reported with adjusted R², F-statistics and 95% confidence intervals.",
      "In the non-dapagliflozin group, LVEF and NT-proBNP levels showed no significant differences between baseline and post-treatment; however, LVGLS values significantly deteriorated.",
      "In contrast, the dapagliflozin group demonstrated a significant increase in LVEF (- 2.000 [95% CI - 2.392, - 1.608]) and LVGLS (+ 1.367",
      "[95% CI + 1.159, + 1.574]), as well as a marked reduction in NT-proBNP levels (+ 64.933 [95% CI + 57.902, + 71.964]) after 3 months of treatment (p < 0.001).",
      "At the third month, the dapagliflozin group exhibited significantly better LVGLS (+ 2.133",
      "[95% CI + 1.346, + 2.921]) and lower NT-proBNP levels (+ 57.000",
      "[95% CI + 28.302, + 85.698]) compared with the non-dapagliflozin group (p < 0.001).",
      "Multivariable linear regression analysis confirmed that dapagliflozin use was independently associated with significant improvement in LVGLS at 3 months.",
      "In conclusion, dapagliflozin was associated with more favorable short-term surrogate changes in LVGLS and NT-proBNP during doxorubicin therapy.",
      "The favorable changes observed in LVEF, LVGLS, and NT-proBNP parameters suggest that dapagliflozin may be considered a potential cardioprotective agent and incorporated into preventive strategies against chemotherapy-related cardiotoxicity in diabetic patients.",
      "These hypothesis-generating findings require confirmation in larger randomized trials powered for clinical endpoints with longer follow-up.",
      "Not applicable."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41653429",
    "source": "pubmed",
    "sentences": [
      "Despite the benefits of physical activity and exercise, including high-intensity interval training (HIIT), few cancer survivors meet the exercise oncology guidelines.",
      "Emerging evidence suggests peer support (i.e., assistance from individuals with lived experiences trained in behavior change techniques) may improve exercise adherence, yet its long-term safety and feasibility remain unclear.",
      "This study evaluates the safety and feasibility of 12 months of HIIT, with and without peer support, in cancer survivors.",
      "Breast, prostate, and colorectal cancer survivors completed 4 weeks (12 sessions) of supervised HIIT before being randomized to receive weekly peer support from people with lived experience of a cancer diagnosis (HIIT+PS) or no peer support (HIIT-Only) for 12 months.",
      "Both groups were provided 12 months of free access to local gymnasiums.",
      "Safety (adverse and severe adverse events) and feasibility (recruitment, attrition, attendance, adherence to intensity, duration, mode, peer supporter contact) were compared to a priori criteria.",
      "The a priori criterion was met for recruitment rate (38%) of study participants (n = 137).",
      "Peer supporters (n = 32) contacted participants 0.8 ± 0.5 times/week (n = 40 contacts/participant), preferring text messaging (50%) or face-to-face (41%) contacts, meeting the a priori criterion (0.77 contacts/week).",
      "Both groups met the a priori criteria for safety (n = 0 severe and n = 7 (0.5%)",
      "Grade 1/2 adverse events), duration, and mode, but not attendance or intensity across the full 12 months.",
      "A priori criterion for study attrition was met in the intervention group (23.7%) but not the HIIT-Only group (30.8%).",
      "Twelve months of HIIT with and without peer support was safe with participants meeting the prescribed duration, and mode, but not attendance or intensity.",
      "Peer support provided weekly for four of every 5 weeks appears insufficient to improve HIIT feasibility.",
      "Peer supporters preferred to provide contact via text messaging or face-to-face interactions.",
      "Future studies should explore strategies to improve long-term HIIT frequency and intensity adherence.",
      "Trial Registration:",
      "Australian New Zealand Clinical Trial Registry 12 618 001 855 213.",
      "Registered 14 November 2018.",
      "Trial registration includes all components of the WHO Trial Registration Data Set, as recommended by the ICMJE."
    ],
    "summary_sentences": [
      "Despite the benefits of physical activity and exercise, including high-intensity interval training (HIIT), few cancer survivors meet the exercise oncology guidelines.",
      "Emerging evidence suggests peer support (i.e., assistance from individuals with lived experiences trained in behavior change techniques) may improve exercise adherence, yet its long-term safety and feasibility remain unclear.",
      "This study evaluates the safety and feasibility of 12 months of HIIT, with and without peer support, in cancer survivors.",
      "Breast, prostate, and colorectal cancer survivors completed 4 weeks (12 sessions) of supervised HIIT before being randomized to receive weekly peer support from people with lived experience of a cancer diagnosis (HIIT+PS) or no peer support (HIIT-Only) for 12 months.",
      "Both groups were provided 12 months of free access to local gymnasiums.",
      "Safety (adverse and severe adverse events) and feasibility (recruitment, attrition, attendance, adherence to intensity, duration, mode, peer supporter contact) were compared to a priori criteria.",
      "The a priori criterion was met for recruitment rate (38%) of study participants (n = 137).",
      "Peer supporters (n = 32) contacted participants 0.8 ± 0.5 times/week (n = 40 contacts/participant), preferring text messaging (50%) or face-to-face (41%) contacts, meeting the a priori criterion (0.77 contacts/week).",
      "Both groups met the a priori criteria for safety (n = 0 severe and n = 7 (0.5%)",
      "Grade 1/2 adverse events), duration, and mode, but not attendance or intensity across the full 12 months.",
      "A priori criterion for study attrition was met in the intervention group (23.7%) but not the HIIT-Only group (30.8%).",
      "Twelve months of HIIT with and without peer support was safe with participants meeting the prescribed duration, and mode, but not attendance or intensity.",
      "Peer support provided weekly for four of every 5 weeks appears insufficient to improve HIIT feasibility.",
      "Peer supporters preferred to provide contact via text messaging or face-to-face interactions.",
      "Future studies should explore strategies to improve long-term HIIT frequency and intensity adherence.",
      "Trial Registration:",
      "Australian New Zealand Clinical Trial Registry 12 618 001 855 213.",
      "Registered 14 November 2018.",
      "Trial registration includes all components of the WHO Trial Registration Data Set, as recommended by the ICMJE."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41652651",
    "source": "pubmed",
    "sentences": [
      "Despite overwhelming evidence of clinical benefit for patients with heart failure (HF), the uptake of guideline-directed medical therapies (GDMT) has been slow.",
      "Collaborative approaches are critically needed to improve alignment between evidence and clinical practice.",
      "Many strategies proposed to improve GDMT implementation have been either ineffective or too resource-intensive to implement at scale across different practice contexts.",
      "Furthermore, most existing approaches focus primarily on patients with HF and reduced EF, despite growing evidence for effective pharmacologic therapy in those with HF and mildly reduced or preserved ejection fraction (HFpEF).",
      "Based on this experience, we designed the Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure (COPILOT-HF) study (NCT05734690).",
      "This is a pragmatic, randomized, open-label intervention trial to compare a comprehensive, remote, navigator-led, algorithm-driven strategy for optimization of GDMT prescribing in patients with HF across the full spectrum of ejection fraction with a control intervention focused on patient and provider education regarding the importance of GDMT optimization.",
      "The primary efficacy endpoint of the study is the proportion of patients receiving optimal HF treatment at 3 months.",
      "Additional outcomes of interest include the proportion of patients with optimal HF therapy at 6 months and 12 months as well as health resource utilization, including hospitalizations and deaths.",
      "COPILOT-HF will evaluate the effectiveness of an early implementation of a remote pharmacist-led medication titration strategy across the HF spectrum."
    ],
    "summary_sentences": [
      "Despite overwhelming evidence of clinical benefit for patients with heart failure (HF), the uptake of guideline-directed medical therapies (GDMT) has been slow.",
      "Collaborative approaches are critically needed to improve alignment between evidence and clinical practice.",
      "Many strategies proposed to improve GDMT implementation have been either ineffective or too resource-intensive to implement at scale across different practice contexts.",
      "Furthermore, most existing approaches focus primarily on patients with HF and reduced EF, despite growing evidence for effective pharmacologic therapy in those with HF and mildly reduced or preserved ejection fraction (HFpEF).",
      "Based on this experience, we designed the Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure (COPILOT-HF) study (NCT05734690).",
      "This is a pragmatic, randomized, open-label intervention trial to compare a comprehensive, remote, navigator-led, algorithm-driven strategy for optimization of GDMT prescribing in patients with HF across the full spectrum of ejection fraction with a control intervention focused on patient and provider education regarding the importance of GDMT optimization.",
      "The primary efficacy endpoint of the study is the proportion of patients receiving optimal HF treatment at 3 months.",
      "Additional outcomes of interest include the proportion of patients with optimal HF therapy at 6 months and 12 months as well as health resource utilization, including hospitalizations and deaths.",
      "COPILOT-HF will evaluate the effectiveness of an early implementation of a remote pharmacist-led medication titration strategy across the HF spectrum."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41652390",
    "source": "pubmed",
    "sentences": [
      "Diabetic macular edema (DME) is a leading cause of vision loss in patients with diabetes.",
      "In developed countries, intravitreal (IVT) anti-vascular endothelial growth factor (VEGF) injections are the standard-of-care first-line treatment for DME.",
      "However, despite the efficacy of anti-VEGF and associated improvements in prognosis, some patients show only a partial response and continue to require monthly injections.",
      "The aim of this study was to investigate the effect of switching from aflibercept 2.0 mg to faricimab (which targets both angiopoietin-2",
      "[Ang-2] and VEGF-A) on visual function, retinal anatomy and intraretinal fluid (IRF) dynamics in patients with refractory DME.",
      "A single-center, observational study of patients with aflibercept-resistant DME who switched to IVT faricimab treatment, comprising a 3-month loading phase, during which faricimab was administered monthly (total of four injections), followed by a treat-and-extend regimen.",
      "Visual acuity, anatomical parameters, and fluid dynamics were assessed from baseline to Month 6 in an interim analysis.",
      "Fourteen eyes from 10 patients were included.",
      "At Month 6, mean best-corrected visual acuity improved by + 2.7 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (not statistically significant).",
      "Mean changes in central macular thickness and outer nuclear layer (ONL) thickness at Month 6 were not significant.",
      "However, ONL thickness was significantly reduced in multiples ETDRS macular grid subfields at Month 4.",
      "Subretinal fluid volume was negligible through Month 6, with most fluid located in the intraretinal layers (97.8-100%).",
      "Total IRF decreased by 22% at Month 4, reaching a nadir of - 37% at Month 2.",
      "There was no significant change in mean vascular density from Month 0 to Month 4.",
      "Faricimab treatment led to modest early improvements in visual acuity and retinal anatomy overall in patients with refractory DME.",
      "The reduction in total IRF at Month 4 may be attributable to Ang-2 inhibition in these patients, who had previously not responded to anti-VEGF treatment alone.",
      "Longer-term studies are needed to evaluate the durability and long-term efficacy of faricimab for the treatment of refractory DME."
    ],
    "summary_sentences": [
      "Diabetic macular edema (DME) is a leading cause of vision loss in patients with diabetes.",
      "In developed countries, intravitreal (IVT) anti-vascular endothelial growth factor (VEGF) injections are the standard-of-care first-line treatment for DME.",
      "However, despite the efficacy of anti-VEGF and associated improvements in prognosis, some patients show only a partial response and continue to require monthly injections.",
      "The aim of this study was to investigate the effect of switching from aflibercept 2.0 mg to faricimab (which targets both angiopoietin-2",
      "[Ang-2] and VEGF-A) on visual function, retinal anatomy and intraretinal fluid (IRF) dynamics in patients with refractory DME.",
      "A single-center, observational study of patients with aflibercept-resistant DME who switched to IVT faricimab treatment, comprising a 3-month loading phase, during which faricimab was administered monthly (total of four injections), followed by a treat-and-extend regimen.",
      "Visual acuity, anatomical parameters, and fluid dynamics were assessed from baseline to Month 6 in an interim analysis.",
      "Fourteen eyes from 10 patients were included.",
      "At Month 6, mean best-corrected visual acuity improved by + 2.7 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (not statistically significant).",
      "Mean changes in central macular thickness and outer nuclear layer (ONL) thickness at Month 6 were not significant.",
      "However, ONL thickness was significantly reduced in multiples ETDRS macular grid subfields at Month 4.",
      "Subretinal fluid volume was negligible through Month 6, with most fluid located in the intraretinal layers (97.8-100%).",
      "Total IRF decreased by 22% at Month 4, reaching a nadir of - 37% at Month 2.",
      "There was no significant change in mean vascular density from Month 0 to Month 4.",
      "Faricimab treatment led to modest early improvements in visual acuity and retinal anatomy overall in patients with refractory DME.",
      "The reduction in total IRF at Month 4 may be attributable to Ang-2 inhibition in these patients, who had previously not responded to anti-VEGF treatment alone.",
      "Longer-term studies are needed to evaluate the durability and long-term efficacy of faricimab for the treatment of refractory DME."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41652105",
    "source": "pubmed",
    "sentences": [
      "Paclitaxel being an effective treatment for ovarian cancer, presents one of the most critical toxicities; peripheral neuropathy (PN), a debilitating side effect that might limit continuation of chemotherapy.",
      "Vitamin B was found to significantly improve PN and Gabapentin is debatably used in chemotherapy induced peripheral neuropathy (CIPN).",
      "The aim of this study was to assess the efficacy of vitamin B prophylaxis in reducing the severity of CIPN, particularly in diabetic patients with the need for Gabapentin as additional therapy and the potential impact on disease response.",
      "A clinical trial of 146 adult ovarian cancer patients received Paclitaxel for 18 weeks; randomly allocated into two arms: One arm received vitamin B prophylaxis before starting Paclitaxel and other received upon CIPN.",
      "Gabapentin was given upon aggravation of CIPN.",
      "This study showed a significant reduction in CIPN grade over time, with fewer patients progressed to higher grades in prophylactic versus non-prophylactic group, extended to significant improvement in CIPN in prophylactic versus non-prophylactic diabetic patients.",
      "Gabapentin was more significantly required in non-prophylactic versus prophylactic group.",
      "A significant correlation was found between dose modification due to CIPN and CA125 status.",
      "Finally, a significant difference in PFS between prophylactic and non-prophylactic group was found at the end of the study.",
      "These results reinforce the potential role of vitamin B prophylaxis in improving patient outcomes through significantly reducing CIPN severity and minimizing the risk of dose reductions, thereby contributing to better disease response.",
      "Trial registration number: NCT07191587, date of registration: 09/24/2025, retrospectively registered."
    ],
    "summary_sentences": [
      "Paclitaxel being an effective treatment for ovarian cancer, presents one of the most critical toxicities; peripheral neuropathy (PN), a debilitating side effect that might limit continuation of chemotherapy.",
      "Vitamin B was found to significantly improve PN and Gabapentin is debatably used in chemotherapy induced peripheral neuropathy (CIPN).",
      "The aim of this study was to assess the efficacy of vitamin B prophylaxis in reducing the severity of CIPN, particularly in diabetic patients with the need for Gabapentin as additional therapy and the potential impact on disease response.",
      "A clinical trial of 146 adult ovarian cancer patients received Paclitaxel for 18 weeks; randomly allocated into two arms: One arm received vitamin B prophylaxis before starting Paclitaxel and other received upon CIPN.",
      "Gabapentin was given upon aggravation of CIPN.",
      "This study showed a significant reduction in CIPN grade over time, with fewer patients progressed to higher grades in prophylactic versus non-prophylactic group, extended to significant improvement in CIPN in prophylactic versus non-prophylactic diabetic patients.",
      "Gabapentin was more significantly required in non-prophylactic versus prophylactic group.",
      "A significant correlation was found between dose modification due to CIPN and CA125 status.",
      "Finally, a significant difference in PFS between prophylactic and non-prophylactic group was found at the end of the study.",
      "These results reinforce the potential role of vitamin B prophylaxis in improving patient outcomes through significantly reducing CIPN severity and minimizing the risk of dose reductions, thereby contributing to better disease response.",
      "Trial registration number: NCT07191587, date of registration: 09/24/2025, retrospectively registered."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41649918",
    "source": "pubmed",
    "sentences": [
      "The execution of clinical trials in wound care significantly differs from, and is frequently more challenging than, those involving pharmaceutical agents.",
      "Populations presenting with wounds (such as trauma and ulcers) are typically heterogeneous, and often exhibit a range of comorbidities and secondary factors that influence both the nature of the lesion itself and the trajectory of wound healing.",
      "Typical comorbidities in patients with ulcers include diabetes and chronic obstructive pulmonary disease, and polypharmacy is common.",
      "Trauma-related complications, such as haemodynamic or septic shock, are frequently observed in extensive burns and other major trauma.",
      "Such complexity presents substantial obstacles to generating statistically robust and reliable outcomes, either because a consistent patient cohort is difficult to find, or extensive stratification may be necessary when different cohorts of patients with different types of lesions are put together into a single trial population.",
      "This article highlights several of the methodological and operational challenges that can arise when conducting a wound care study and tries to create some upfront awareness of the pitfalls for such studies.",
      "The author has been a chief medical officer and independent consultant to the wound care industry for >35 years, and some statements in this article are based on his personal experience and observations."
    ],
    "summary_sentences": [
      "The execution of clinical trials in wound care significantly differs from, and is frequently more challenging than, those involving pharmaceutical agents.",
      "Populations presenting with wounds (such as trauma and ulcers) are typically heterogeneous, and often exhibit a range of comorbidities and secondary factors that influence both the nature of the lesion itself and the trajectory of wound healing.",
      "Typical comorbidities in patients with ulcers include diabetes and chronic obstructive pulmonary disease, and polypharmacy is common.",
      "Trauma-related complications, such as haemodynamic or septic shock, are frequently observed in extensive burns and other major trauma.",
      "Such complexity presents substantial obstacles to generating statistically robust and reliable outcomes, either because a consistent patient cohort is difficult to find, or extensive stratification may be necessary when different cohorts of patients with different types of lesions are put together into a single trial population.",
      "This article highlights several of the methodological and operational challenges that can arise when conducting a wound care study and tries to create some upfront awareness of the pitfalls for such studies.",
      "The author has been a chief medical officer and independent consultant to the wound care industry for >35 years, and some statements in this article are based on his personal experience and observations."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41649911",
    "source": "pubmed",
    "sentences": [
      "Debridement is the removal of nonviable, contaminated, or foreign material from within or near a wound until healthy adjacent tissue is exposed.",
      "In sharp debridement, patients are expected to experience greater levels of pain because of cell damage.",
      "This study evaluated the effect of applying cold 0.9% sodium chloride (NaCl) during sharp debridement on pain in patients with diabetic foot.",
      "A randomised, controlled, single-blind trial was performed with inpatients randomised to two equally sized groups: an experimental group and a control group.",
      "During sharp debridement, cold (4-8°C) 0.9% NaCl was applied to the wounds in the experimental group while room temperature (18-26°C) 0.9% NaCl was used in the control group.",
      "Data were collected using a questionnaire form, a visual analogue scale (VAS) and a wound area form.",
      "The VAS was applied in both groups before and during the procedure.",
      "Descriptive statistics and Chi-squared, Mann-Whitney U, Student's t and Wilcoxon signed-rank tests were used to analyse the data.",
      "A total of 64 patients were included in the trial (32 in each group).",
      "Most of the participants in the experimental and control groups were male (84.4% and 65.6%, respectively) and the mean age was 61.8 years and 60.6 years, respectively.",
      "The participants were homogeneously distributed in terms of sociodemographic, clinical, laboratory and wound characteristics, with no statistically significant differences between the groups (p>0.05).",
      "Compared to pre-procedure values, VAS score decreased significantly during the procedure in the experimental group (p<0.001) but increased significantly in the control group (p<0.001).",
      "VAS scores in the experimental group were significantly higher before (p=0.003) and lower during (p<0.001) the procedure compared with the control group.",
      "In this trial, applying cold 0.9% NaCl during sharp debridement reduced pain in patients with diabetic foot."
    ],
    "summary_sentences": [
      "Debridement is the removal of nonviable, contaminated, or foreign material from within or near a wound until healthy adjacent tissue is exposed.",
      "In sharp debridement, patients are expected to experience greater levels of pain because of cell damage.",
      "This study evaluated the effect of applying cold 0.9% sodium chloride (NaCl) during sharp debridement on pain in patients with diabetic foot.",
      "A randomised, controlled, single-blind trial was performed with inpatients randomised to two equally sized groups: an experimental group and a control group.",
      "During sharp debridement, cold (4-8°C) 0.9% NaCl was applied to the wounds in the experimental group while room temperature (18-26°C) 0.9% NaCl was used in the control group.",
      "Data were collected using a questionnaire form, a visual analogue scale (VAS) and a wound area form.",
      "The VAS was applied in both groups before and during the procedure.",
      "Descriptive statistics and Chi-squared, Mann-Whitney U, Student's t and Wilcoxon signed-rank tests were used to analyse the data.",
      "A total of 64 patients were included in the trial (32 in each group).",
      "Most of the participants in the experimental and control groups were male (84.4% and 65.6%, respectively) and the mean age was 61.8 years and 60.6 years, respectively.",
      "The participants were homogeneously distributed in terms of sociodemographic, clinical, laboratory and wound characteristics, with no statistically significant differences between the groups (p>0.05).",
      "Compared to pre-procedure values, VAS score decreased significantly during the procedure in the experimental group (p<0.001) but increased significantly in the control group (p<0.001).",
      "VAS scores in the experimental group were significantly higher before (p=0.003) and lower during (p<0.001) the procedure compared with the control group.",
      "In this trial, applying cold 0.9% NaCl during sharp debridement reduced pain in patients with diabetic foot."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41649457",
    "source": "pubmed",
    "sentences": [
      "To evaluate the safety and efficacy of a novel endocapsular device used during cataract surgery at the 12-month follow-up.",
      "A cohort study was conducted in a university-affiliated private practice.",
      "Adults with age-related cataracts, intraocular lens power between 14 and 26 diopters, and no other ocular pathology were included prospectively.",
      "Exclusion criteria included diabetes, previous ocular surgery, cardiac conditions, and autoimmune diseases.",
      "One eye per patient was randomly assigned to receive the device before intraocular lens implantation.",
      "Follow-ups were conducted preoperatively and at 1 day, 1 week, and 1, 3, 6, and 12 months postoperatively.",
      "The primary safety endpoint was the incidence of adverse events; the primary efficacy endpoint was the incidence of posterior capsule opacification (PCO) postoperatively at 12 months.",
      "A control group was formed retrospectively for comparison of PCO at 12 months.",
      "Spherical equivalent, corrected distance visual acuity, and intraocular pressure were also measured.",
      "A total of 121 patients were enrolled.",
      "Sixteen adverse events occurred in 12 patients; all resolved and were deemed unrelated to the device.",
      "PCO incidence at 12 months was 0.83% in the experimental group vs. 13.0% in the control group.",
      "The spherical equivalent stabilized by 3 months.",
      "At 12 months, the mean corrected distance visual acuity and intraocular pressure were 0.03 ± 0.07 logarithm of the minimum angle of resolution and 11.23 ± 2.03 mm",
      "Hg, respectively.",
      "The new device seems to be safe and have a beneficial impact on PCO up to at least 12 months postoperatively.",
      "We report our experience with a novel, safe, endocapsular open capsule device that shows promise in preventing posterior capsule opacification in real-world clinical settings."
    ],
    "summary_sentences": [
      "To evaluate the safety and efficacy of a novel endocapsular device used during cataract surgery at the 12-month follow-up.",
      "A cohort study was conducted in a university-affiliated private practice.",
      "Adults with age-related cataracts, intraocular lens power between 14 and 26 diopters, and no other ocular pathology were included prospectively.",
      "Exclusion criteria included diabetes, previous ocular surgery, cardiac conditions, and autoimmune diseases.",
      "One eye per patient was randomly assigned to receive the device before intraocular lens implantation.",
      "Follow-ups were conducted preoperatively and at 1 day, 1 week, and 1, 3, 6, and 12 months postoperatively.",
      "The primary safety endpoint was the incidence of adverse events; the primary efficacy endpoint was the incidence of posterior capsule opacification (PCO) postoperatively at 12 months.",
      "A control group was formed retrospectively for comparison of PCO at 12 months.",
      "Spherical equivalent, corrected distance visual acuity, and intraocular pressure were also measured.",
      "A total of 121 patients were enrolled.",
      "Sixteen adverse events occurred in 12 patients; all resolved and were deemed unrelated to the device.",
      "PCO incidence at 12 months was 0.83% in the experimental group vs. 13.0% in the control group.",
      "The spherical equivalent stabilized by 3 months.",
      "At 12 months, the mean corrected distance visual acuity and intraocular pressure were 0.03 ± 0.07 logarithm of the minimum angle of resolution and 11.23 ± 2.03 mm",
      "Hg, respectively.",
      "The new device seems to be safe and have a beneficial impact on PCO up to at least 12 months postoperatively.",
      "We report our experience with a novel, safe, endocapsular open capsule device that shows promise in preventing posterior capsule opacification in real-world clinical settings."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41648727",
    "source": "pubmed",
    "sentences": [
      "Type 2 diabetes mellitus (T2DM) induces integrated cardiovascular and metabolic impairments.",
      "The comprehensive effect of aerobic exercise on these systemic alterations remains unclear.",
      "Therefore, we designed a randomized controlled trial to investigate its impact on integrated cardiovascular health - specifically assessed by nitroglycerin-mediated dilation (NMD) and myocardial global work efficiency (GWE) - and systemic energy metabolism in patients with T2DM.",
      "This study is a randomized, single-assessor-blind, parallel-group, two-arm controlled trial that will enroll 74 patients with T2DM.",
      "Participants will be randomly assigned in a 1:1 ratio to either a 12-week supervised aerobic exercise group (55-75% of HR This study provides an integrated physiological perspective on how 12-week moderate-intensity aerobic exercise influences cardiovascular function and systemic metabolism in patients with T2DM.",
      "We hypothesize that 12 weeks of aerobic exercise will significantly improve NMD and GWE, concurrent with enhanced metabolic flexibility and reduced fatigue compared to the non-exercise control group."
    ],
    "summary_sentences": [
      "Type 2 diabetes mellitus (T2DM) induces integrated cardiovascular and metabolic impairments.",
      "The comprehensive effect of aerobic exercise on these systemic alterations remains unclear.",
      "Therefore, we designed a randomized controlled trial to investigate its impact on integrated cardiovascular health - specifically assessed by nitroglycerin-mediated dilation (NMD) and myocardial global work efficiency (GWE) - and systemic energy metabolism in patients with T2DM.",
      "This study is a randomized, single-assessor-blind, parallel-group, two-arm controlled trial that will enroll 74 patients with T2DM.",
      "Participants will be randomly assigned in a 1:1 ratio to either a 12-week supervised aerobic exercise group (55-75% of HR This study provides an integrated physiological perspective on how 12-week moderate-intensity aerobic exercise influences cardiovascular function and systemic metabolism in patients with T2DM.",
      "We hypothesize that 12 weeks of aerobic exercise will significantly improve NMD and GWE, concurrent with enhanced metabolic flexibility and reduced fatigue compared to the non-exercise control group."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41647109",
    "source": "pubmed",
    "sentences": [
      "Patients with concurrent obesity, type 2 diabetes, and depression experience high disease severity and prevalence.",
      "This triad of conditions compromises quality of life and treatment adherence, further exacerbating disease progression.",
      "Therapeutic strategies for such patients must address both glycemic control and psychological well-being.",
      "Liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), offers benefits beyond glucose-lowering and weight reduction, with emerging evidence suggesting it may also alleviate depressive symptoms.",
      "Therefore, liraglutide represents a promising intervention for managing depression in patients with obesity and diabetes.",
      "This study aims to assess the therapeutic efficacy of liraglutide in overweight or obese patients with type 2 diabetes and comorbid depression, with a specific focus on its antidepressant effects.",
      "This is a randomized, double-blind, placebo-controlled pilot trial.",
      "Sixty eligible participants will be randomly assigned (1:1) to receive either liraglutide (initiated at 0.6 mg/day, titrated weekly to a maximum of 1.8 mg/day) or a matched placebo, as an adjunct to standard care for 12 weeks.",
      "The primary endpoints include blood glucose levels, glycated hemoglobin, body mass index, Hamilton Depression Rating Scale score, and metrics derived from resting-state functional magnetic resonance imaging (resting-state fMRI).",
      "Secondary endpoints will assess changes in inflammatory biomarkers (tumor necrosis factor-α, interleukin-6), oxidative stress indicators (superoxide dismutase, malondialdehyde), homeostasis model assessment of insulin resistance, insulin sensitivity index, and homeostasis model assessment of β-cell function.",
      "This trial will provide preliminary data on the effects of liraglutide on depressive symptoms in overweight/obese patients with type 2 diabetes.",
      "The findings are expected to provide a basis and reference for subsequent large-scale clinical research."
    ],
    "summary_sentences": [
      "Patients with concurrent obesity, type 2 diabetes, and depression experience high disease severity and prevalence.",
      "This triad of conditions compromises quality of life and treatment adherence, further exacerbating disease progression.",
      "Therapeutic strategies for such patients must address both glycemic control and psychological well-being.",
      "Liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), offers benefits beyond glucose-lowering and weight reduction, with emerging evidence suggesting it may also alleviate depressive symptoms.",
      "Therefore, liraglutide represents a promising intervention for managing depression in patients with obesity and diabetes.",
      "This study aims to assess the therapeutic efficacy of liraglutide in overweight or obese patients with type 2 diabetes and comorbid depression, with a specific focus on its antidepressant effects.",
      "This is a randomized, double-blind, placebo-controlled pilot trial.",
      "Sixty eligible participants will be randomly assigned (1:1) to receive either liraglutide (initiated at 0.6 mg/day, titrated weekly to a maximum of 1.8 mg/day) or a matched placebo, as an adjunct to standard care for 12 weeks.",
      "The primary endpoints include blood glucose levels, glycated hemoglobin, body mass index, Hamilton Depression Rating Scale score, and metrics derived from resting-state functional magnetic resonance imaging (resting-state fMRI).",
      "Secondary endpoints will assess changes in inflammatory biomarkers (tumor necrosis factor-α, interleukin-6), oxidative stress indicators (superoxide dismutase, malondialdehyde), homeostasis model assessment of insulin resistance, insulin sensitivity index, and homeostasis model assessment of β-cell function.",
      "This trial will provide preliminary data on the effects of liraglutide on depressive symptoms in overweight/obese patients with type 2 diabetes.",
      "The findings are expected to provide a basis and reference for subsequent large-scale clinical research."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41646468",
    "source": "pubmed",
    "sentences": [
      "Duodenal mucosal ablation (DMA) is an emerging endoscopic treatment modality for type 2 diabetes (T2D).",
      "The radiofrequency vapor ablation (RFVA) system (Aqua Medical Inc, Pleasanton, Calif, USA) is a single-use, through-the-scope, circumferential ablation catheter under investigation for DMA.",
      "In this pilot study, we assessed the safety, tolerability, procedural feasibility, and initial efficacy of RFVA.",
      "We conducted a first-in-human, prospective, single-center trial enrolling 27 patients with poorly controlled T2D (glycated hemoglobin [HbA1c], 7.5%-10%) despite ≥1 oral antidiabetic drug.",
      "DMA was performed with the patient under anesthesia in several dose titrations as follows: safety cohort (180 J once, n = 2), first treatment cohort (180 J twice, n = 11), and second treatment cohort (200 J twice; n = 14).",
      "Primary outcomes were safety (number of serious adverse events [SAEs]), tolerability (based on a visual analog scale [VAS] pain score), feasibility (procedure time), and initial efficacy (change in HbA1c at 4, 12, and 24 weeks).",
      "Twenty-seven patients with a mean T2D duration of 6 years (standard deviation [SD], 2.6) underwent DMA with 100% technical success.",
      "Mean patient age was 54 years (SD, 6.6), 48% were men, and baseline HbA1c was 8.6% (SD, 0.6).",
      "Mean procedure time was 49.7 minutes (SD, 14.3) and catheter time 34.5 minutes (SD, 10.9).",
      "There were no SAEs, and the maximum mean VAS pain score was 1.4 (SD, 2.1) on day 2.",
      "We observed a change in HbA1c at 4 weeks (-0.9%), 12 weeks (-1.2%), and 24 weeks (-0.8%) after the procedure.",
      "DMA using the RFVA system is a simple through-the-scope procedure that appears safe, well tolerated, and feasible for the treatment of T2D. (Clinical trial registration number: NCT05887635.)."
    ],
    "summary_sentences": [
      "Duodenal mucosal ablation (DMA) is an emerging endoscopic treatment modality for type 2 diabetes (T2D).",
      "The radiofrequency vapor ablation (RFVA) system (Aqua Medical Inc, Pleasanton, Calif, USA) is a single-use, through-the-scope, circumferential ablation catheter under investigation for DMA.",
      "In this pilot study, we assessed the safety, tolerability, procedural feasibility, and initial efficacy of RFVA.",
      "We conducted a first-in-human, prospective, single-center trial enrolling 27 patients with poorly controlled T2D (glycated hemoglobin [HbA1c], 7.5%-10%) despite ≥1 oral antidiabetic drug.",
      "DMA was performed with the patient under anesthesia in several dose titrations as follows: safety cohort (180 J once, n = 2), first treatment cohort (180 J twice, n = 11), and second treatment cohort (200 J twice; n = 14).",
      "Primary outcomes were safety (number of serious adverse events [SAEs]), tolerability (based on a visual analog scale [VAS] pain score), feasibility (procedure time), and initial efficacy (change in HbA1c at 4, 12, and 24 weeks).",
      "Twenty-seven patients with a mean T2D duration of 6 years (standard deviation [SD], 2.6) underwent DMA with 100% technical success.",
      "Mean patient age was 54 years (SD, 6.6), 48% were men, and baseline HbA1c was 8.6% (SD, 0.6).",
      "Mean procedure time was 49.7 minutes (SD, 14.3) and catheter time 34.5 minutes (SD, 10.9).",
      "There were no SAEs, and the maximum mean VAS pain score was 1.4 (SD, 2.1) on day 2.",
      "We observed a change in HbA1c at 4 weeks (-0.9%), 12 weeks (-1.2%), and 24 weeks (-0.8%) after the procedure.",
      "DMA using the RFVA system is a simple through-the-scope procedure that appears safe, well tolerated, and feasible for the treatment of T2D. (Clinical trial registration number: NCT05887635.)."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41645112",
    "source": "pubmed",
    "sentences": [
      "Obesity is a well-established risk factor for impaired glycaemic regulation; however, a substantial proportion of individuals with type 2 diabetes mellitus develop dysglycaemia despite not being obese by body mass index (BMI).",
      "Central adiposity may better reflect metabolic risk in such patients.",
      "This study aimed to examine the associations between anthropometric measures (BMI and waist circumference) and glycaemic parameters among newly diagnosed, untreated patients with type 2 diabetes mellitus in Uzbekistan.",
      "A cross-sectional study was conducted among 104 untreated, newly diagnosed T2DM patients at a tertiary endocrinology centre in Samarkand, Uzbekistan.",
      "BMI, waist circumference (WC), fasting plasma glucose (FPG), oral glucose tolerance test (OGTT), and glycated haemoglobin (HbA1c) were assessed.",
      "Patients were classified as obese (BMI ≥ 30 kg/m²) or non-obese (BMI < 30 kg/m²).",
      "Group comparisons were performed using Student's t-test or Mann-Whitney U test, as appropriate.",
      "Multivariable linear regression analyses were performed to examine independent associations between anthropometric measures (WC and BMI) and glycaemic parameters, adjusting for age, sex, and smoking status.",
      "The study included 104 newly diagnosed T2DM patients (mean age 52.1 ± 11.7 years; 61.5% men), with a median BMI of 28.4 [26.53-30.28] kg/m² and a mean WC of 99.5 ± 6.65 cm.",
      "Obese patients (BMI ≥ 30.0 kg/m²; n = 30) were significantly younger than non-obese patients (n = 74; 47.7 ± 9.32 vs. 53.85 ± 12.05 years; p = 0.014) and had higher FPG levels (13.4 ± 2.97 vs. 11.89 ± 2.94 mmol/L; p = 0.02).",
      "In fully adjusted models including both BMI and WC, WC and smoking status were independently associated with FPG and OGTT values, whereas BMI was not.",
      "No significant associations were observed between anthropometric measures and HbA1c.",
      "Waist circumference was independently associated with fasting plasma glucose and oral glucose tolerance test values in newly diagnosed T2DM patients, providing information complementary to BMI.",
      "These findings highlight the potential value of assessing central adiposity at the time of diabetes diagnosis.",
      "Causal relationships cannot be inferred due to the cross-sectional design.",
      "Not applicable."
    ],
    "summary_sentences": [
      "Obesity is a well-established risk factor for impaired glycaemic regulation; however, a substantial proportion of individuals with type 2 diabetes mellitus develop dysglycaemia despite not being obese by body mass index (BMI).",
      "Central adiposity may better reflect metabolic risk in such patients.",
      "This study aimed to examine the associations between anthropometric measures (BMI and waist circumference) and glycaemic parameters among newly diagnosed, untreated patients with type 2 diabetes mellitus in Uzbekistan.",
      "A cross-sectional study was conducted among 104 untreated, newly diagnosed T2DM patients at a tertiary endocrinology centre in Samarkand, Uzbekistan.",
      "BMI, waist circumference (WC), fasting plasma glucose (FPG), oral glucose tolerance test (OGTT), and glycated haemoglobin (HbA1c) were assessed.",
      "Patients were classified as obese (BMI ≥ 30 kg/m²) or non-obese (BMI < 30 kg/m²).",
      "Group comparisons were performed using Student's t-test or Mann-Whitney U test, as appropriate.",
      "Multivariable linear regression analyses were performed to examine independent associations between anthropometric measures (WC and BMI) and glycaemic parameters, adjusting for age, sex, and smoking status.",
      "The study included 104 newly diagnosed T2DM patients (mean age 52.1 ± 11.7 years; 61.5% men), with a median BMI of 28.4 [26.53-30.28] kg/m² and a mean WC of 99.5 ± 6.65 cm.",
      "Obese patients (BMI ≥ 30.0 kg/m²; n = 30) were significantly younger than non-obese patients (n = 74; 47.7 ± 9.32 vs. 53.85 ± 12.05 years; p = 0.014) and had higher FPG levels (13.4 ± 2.97 vs. 11.89 ± 2.94 mmol/L; p = 0.02).",
      "In fully adjusted models including both BMI and WC, WC and smoking status were independently associated with FPG and OGTT values, whereas BMI was not.",
      "No significant associations were observed between anthropometric measures and HbA1c.",
      "Waist circumference was independently associated with fasting plasma glucose and oral glucose tolerance test values in newly diagnosed T2DM patients, providing information complementary to BMI.",
      "These findings highlight the potential value of assessing central adiposity at the time of diabetes diagnosis.",
      "Causal relationships cannot be inferred due to the cross-sectional design.",
      "Not applicable."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41644794",
    "source": "pubmed",
    "sentences": [
      "The Physiology Of the WEight Reduced State (POWERS) study is a multi-center clinical trial designed to understand the physiological basis for observed variability in weight regain following intentional weight loss among US adults.",
      "The primary dependent variable is weight regain over one year following a 7% or greater supervised weight loss.",
      "The overarching design and study organization, along with rationale and history of the POWERS study and outcomes measures are described in accompanying papers.",
      "This paper provides the rationale for and description of biospecimens samples that will ultimately inform on the molecular and cellular basis of the physiological variability that contributes to the regulation of energy balance in the weight reduced state.",
      "Participants will be 205 healthy adults (n = 205), aged 25-59 years, with body mass index (BMI)",
      "30- ≤ 40 kg/m"
    ],
    "summary_sentences": [
      "The Physiology Of the WEight Reduced State (POWERS) study is a multi-center clinical trial designed to understand the physiological basis for observed variability in weight regain following intentional weight loss among US adults.",
      "The primary dependent variable is weight regain over one year following a 7% or greater supervised weight loss.",
      "The overarching design and study organization, along with rationale and history of the POWERS study and outcomes measures are described in accompanying papers.",
      "This paper provides the rationale for and description of biospecimens samples that will ultimately inform on the molecular and cellular basis of the physiological variability that contributes to the regulation of energy balance in the weight reduced state.",
      "Participants will be 205 healthy adults (n = 205), aged 25-59 years, with body mass index (BMI)",
      "30- ≤ 40 kg/m"
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41644499",
    "source": "pubmed",
    "sentences": [
      "Ketosis may represent a therapeutic target for age-related impairments in skeletal muscle function.",
      "This study investigated acute effects of ketosis on metabolic economy, mitochondrial function, and contractile parameters in skeletal muscle of young and older adults.",
      "Twelve young (20-25 years) and twelve older (65-85 years) healthy men, matched by age-adjusted V̇O Ketosis had no effect on metabolic economy in either young or older participants.",
      "The older group showed lower metabolic economy compared to the young group.",
      "In older participants, ketones increased ATP production and time-torque derived work capacity.",
      "Oxidative capacity was similar between groups and remained unaffected by ketones.",
      "In the older group, ketones improved peak power and increased both muscle relative decline in peak power and contraction-induced pH decline.",
      "Complex I + II respiration was lower in older compared to young participants, with no effect of ketones.",
      "Ketosis enhanced skeletal muscle work capacity and ATP production in older but not young adults, suggesting an age-specific effect of ketone bodies on muscle function that operates independently of changes in metabolic economy and mitochondrial function.",
      "These findings support ketosis as a promising ergogenic therapy for older adults.",
      "The study was pre-registered at clinicaltrials.gov (NCT05732909)."
    ],
    "summary_sentences": [
      "Ketosis may represent a therapeutic target for age-related impairments in skeletal muscle function.",
      "This study investigated acute effects of ketosis on metabolic economy, mitochondrial function, and contractile parameters in skeletal muscle of young and older adults.",
      "Twelve young (20-25 years) and twelve older (65-85 years) healthy men, matched by age-adjusted V̇O Ketosis had no effect on metabolic economy in either young or older participants.",
      "The older group showed lower metabolic economy compared to the young group.",
      "In older participants, ketones increased ATP production and time-torque derived work capacity.",
      "Oxidative capacity was similar between groups and remained unaffected by ketones.",
      "In the older group, ketones improved peak power and increased both muscle relative decline in peak power and contraction-induced pH decline.",
      "Complex I + II respiration was lower in older compared to young participants, with no effect of ketones.",
      "Ketosis enhanced skeletal muscle work capacity and ATP production in older but not young adults, suggesting an age-specific effect of ketone bodies on muscle function that operates independently of changes in metabolic economy and mitochondrial function.",
      "These findings support ketosis as a promising ergogenic therapy for older adults.",
      "The study was pre-registered at clinicaltrials.gov (NCT05732909)."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41644273",
    "source": "pubmed",
    "sentences": [
      "Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used in patients with chronic kidney disease (CKD), but existing evidence regarding their efficacy and safety remains inconsistent.",
      "To evaluate the cardiorenal outcomes and adverse effects of GLP-1 RAs in this population, we conducted a systematic review and meta-analysis of randomized controlled trials from PubMed, Embase, Cochrane Central Register of Controlled Trials, and Web of Science up to December 2024.",
      "Nine trials involving 21,717 patients, the vast majority of whom had T2DM, were included.",
      "GLP-1RAs treatment for CKD was associated with decreasing the incidence of major adverse kidney events (MAKE; RR, 0.84; 95% CI, 0.76-0.94) and major adverse cardiac and cerebrovascular events (MACE; RR, 0.84; 95% CI, 0.72-0.97), reducing all-cause mortality (RR, 0.83; 95% CI, 0.76-0.90) and albuminuria level (SMD, -1.22; 95% CI, -1.53 - 0.90).",
      "Gastrointestinal events associated with GLP-1 RA treatments including nausea (RR, 4.14; 95% CI, 2.70-6.33), vomiting (RR, 3.05; 95% CI, 1.88-4.97), diarrhea (RR, 2.65; 95% CI, 1.76-3.98), and dyspepsia (RR, 3.79; 95% CI, 1.02-14.12) have garnered significant attention.",
      "In conclusion, administration of GLP-1RAs treatment demonstrates excellent cardiorenal protective effects in CKD, primarily in patients with co-existing T2DM, though with notable gastrointestinal concerns."
    ],
    "summary_sentences": [
      "Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used in patients with chronic kidney disease (CKD), but existing evidence regarding their efficacy and safety remains inconsistent.",
      "To evaluate the cardiorenal outcomes and adverse effects of GLP-1 RAs in this population, we conducted a systematic review and meta-analysis of randomized controlled trials from PubMed, Embase, Cochrane Central Register of Controlled Trials, and Web of Science up to December 2024.",
      "Nine trials involving 21,717 patients, the vast majority of whom had T2DM, were included.",
      "GLP-1RAs treatment for CKD was associated with decreasing the incidence of major adverse kidney events (MAKE; RR, 0.84; 95% CI, 0.76-0.94) and major adverse cardiac and cerebrovascular events (MACE; RR, 0.84; 95% CI, 0.72-0.97), reducing all-cause mortality (RR, 0.83; 95% CI, 0.76-0.90) and albuminuria level (SMD, -1.22; 95% CI, -1.53 - 0.90).",
      "Gastrointestinal events associated with GLP-1 RA treatments including nausea (RR, 4.14; 95% CI, 2.70-6.33), vomiting (RR, 3.05; 95% CI, 1.88-4.97), diarrhea (RR, 2.65; 95% CI, 1.76-3.98), and dyspepsia (RR, 3.79; 95% CI, 1.02-14.12) have garnered significant attention.",
      "In conclusion, administration of GLP-1RAs treatment demonstrates excellent cardiorenal protective effects in CKD, primarily in patients with co-existing T2DM, though with notable gastrointestinal concerns."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41644158",
    "source": "pubmed",
    "sentences": [
      "Increasing evidence suggests that dolutegravir (DTG), endorsed by the WHO since 2018 for first-line antiretroviral therapy (ART), is associated with significant weight gain and potentially also with cardiometabolic disorders.",
      "In an effort to expand therapeutic options for people living with HIV (PLHIV), the EvaLuating the non-inferiority of DORAvirine vs DOlutegravir trial aims to compare the virologic efficacy of doravirine (DOR) and DTG-based regimens and to assess their safety, including a focus on cardiometabolic effects.",
      "This is an international, phase III, multicentre, open-label, non-inferiority, randomised trial that will enrol 610 ART-naïve PLHIV (HIV RNA≥1000 copies/mL at screening) across six countries (Brazil, Cameroon, France, Côte d'Ivoire, Mozambique and Thailand) spanning four continents.",
      "Key inclusion criteria include age ≥18 years, confirmed HIV-1 infection with plasma RNA levels ≥1000 copies/mL, indication for ART initiation and no prior ART exposure.",
      "Participants will be randomised in a 1:1 ratio to receive either DOR 100 mg once daily in combination with tenofovir disoproxil fumarate (TDF)",
      "(300 mg daily) plus lamivudine (3TC) (300 mg daily) or DTG (50 mg daily) in combination with TDF (300 mg once daily) plus either emtricitabine (FTC) (200 mg daily) or 3TC (300 mg daily).",
      "Randomisation will be stratified by screening HIV-1 RNA load (≤100 000 or >100 000 copies/mL) and by country.",
      "The primary outcome is virological efficacy, defined as the proportion of participants achieving HIV-1 RNA <50 copies/mL at week 48 on the assigned treatment (FDA Snapshot algorithm).",
      "Secondary outcomes include cardiometabolic safety endpoints (ie, weight gain, insulin resistance, hypertension, diabetes, waist and hip circumferences, waist-to-hip ratio, fasting glycaemia, insulin and fasting serum lipids), along with mental health, quality of life, virological and immunological parameters.",
      "Final data collection is expected by July 2028.",
      "Primary outcome results (week 48) are expected in early 2028.",
      "The project was submitted to and approved by national ethics committees and pharmaceutical regulatory authorities in all participating countries: Brazil (CEP INI FIOCRUZ (21.040-900)/CEP HGNI (26.030-380)); Cameroon (CNERSH (2024/09/1717/CE/CNERSH/SP)/Ministry of Public Health (D30-1464/AAR/MINSANTE/SG/DROS/CRC); Côte d'Ivoire: (CNESVS (0018224/MSHPCMU/CNESVS-km)/AIRP (1329/AIRP/DISMP/Om/kbaag); France (CTIS CPP/ANSM (2023-508626-10-00)); Mozambique (CNBS (20/CNBS/25)/ANARME (4635/380/ANARME)); Thailand: (IHRP (08/1944)/Thai FDA: ongoing on 19 January 2026).",
      "The trial received authorisation from the French National Commission for Data Protection and Liberties (CNIL) under approval number 924 302.",
      "Written informed consent is obtained from all participants prior to any study-specific procedures and trial enrolment, in accordance with the Declaration of Helsinki and applicable national regulations.",
      "Study findings will be disseminated through publication in peer-reviewed journals and presentations at national and international scientific conferences.",
      "Results will also be communicated to policymakers, healthcare professionals, community stakeholders and study participants through appropriate dissemination activities, including policy briefs, stakeholder meetings and lay summaries on dedicated and easily accessible platforms.",
      "NCT06203132; EU-CT, 2023-508626-10-00."
    ],
    "summary_sentences": [
      "Increasing evidence suggests that dolutegravir (DTG), endorsed by the WHO since 2018 for first-line antiretroviral therapy (ART), is associated with significant weight gain and potentially also with cardiometabolic disorders.",
      "In an effort to expand therapeutic options for people living with HIV (PLHIV), the EvaLuating the non-inferiority of DORAvirine vs DOlutegravir trial aims to compare the virologic efficacy of doravirine (DOR) and DTG-based regimens and to assess their safety, including a focus on cardiometabolic effects.",
      "This is an international, phase III, multicentre, open-label, non-inferiority, randomised trial that will enrol 610 ART-naïve PLHIV (HIV RNA≥1000 copies/mL at screening) across six countries (Brazil, Cameroon, France, Côte d'Ivoire, Mozambique and Thailand) spanning four continents.",
      "Key inclusion criteria include age ≥18 years, confirmed HIV-1 infection with plasma RNA levels ≥1000 copies/mL, indication for ART initiation and no prior ART exposure.",
      "Participants will be randomised in a 1:1 ratio to receive either DOR 100 mg once daily in combination with tenofovir disoproxil fumarate (TDF)",
      "(300 mg daily) plus lamivudine (3TC) (300 mg daily) or DTG (50 mg daily) in combination with TDF (300 mg once daily) plus either emtricitabine (FTC) (200 mg daily) or 3TC (300 mg daily).",
      "Randomisation will be stratified by screening HIV-1 RNA load (≤100 000 or >100 000 copies/mL) and by country.",
      "The primary outcome is virological efficacy, defined as the proportion of participants achieving HIV-1 RNA <50 copies/mL at week 48 on the assigned treatment (FDA Snapshot algorithm).",
      "Secondary outcomes include cardiometabolic safety endpoints (ie, weight gain, insulin resistance, hypertension, diabetes, waist and hip circumferences, waist-to-hip ratio, fasting glycaemia, insulin and fasting serum lipids), along with mental health, quality of life, virological and immunological parameters.",
      "Final data collection is expected by July 2028.",
      "Primary outcome results (week 48) are expected in early 2028.",
      "The project was submitted to and approved by national ethics committees and pharmaceutical regulatory authorities in all participating countries: Brazil (CEP INI FIOCRUZ (21.040-900)/CEP HGNI (26.030-380)); Cameroon (CNERSH (2024/09/1717/CE/CNERSH/SP)/Ministry of Public Health (D30-1464/AAR/MINSANTE/SG/DROS/CRC); Côte d'Ivoire: (CNESVS (0018224/MSHPCMU/CNESVS-km)/AIRP (1329/AIRP/DISMP/Om/kbaag); France (CTIS CPP/ANSM (2023-508626-10-00)); Mozambique (CNBS (20/CNBS/25)/ANARME (4635/380/ANARME)); Thailand: (IHRP (08/1944)/Thai FDA: ongoing on 19 January 2026).",
      "The trial received authorisation from the French National Commission for Data Protection and Liberties (CNIL) under approval number 924 302.",
      "Written informed consent is obtained from all participants prior to any study-specific procedures and trial enrolment, in accordance with the Declaration of Helsinki and applicable national regulations.",
      "Study findings will be disseminated through publication in peer-reviewed journals and presentations at national and international scientific conferences.",
      "Results will also be communicated to policymakers, healthcare professionals, community stakeholders and study participants through appropriate dissemination activities, including policy briefs, stakeholder meetings and lay summaries on dedicated and easily accessible platforms.",
      "NCT06203132; EU-CT, 2023-508626-10-00."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41644156",
    "source": "pubmed",
    "sentences": [
      "Inadequate production of the essential stress hormone, cortisol, results in adrenal insufficiency (AI), which is associated with significant morbidity and mortality.",
      "The current standard diagnostic test for AI is the Short Synacthen Test (SST), but this is both invasive and resource-intensive, involving cannulation and blood sampling.",
      "A novel formulation, Nasacthin, has been developed in which the same Active Pharmaceutical Ingredient can be delivered intranasally, with the resultant glucocorticoid levels either measured in serum, or in saliva samples to render the test non-invasive, thus creating a potentially more cost-effective test.",
      "The Salivary Test of Adrenal Response to Liquid Intranasal Tetracosactide (STARLIT-3) study aims to determine the diagnostic utility of the test in patients with AI.",
      "STARLIT-3 is a randomised 2-way crossover trial which aims to collect data from 32 AI patients allocated to receive both Synacthen and Nasacthin in a random order across two study visits.",
      "Paired blood and saliva samples will be collected from participants at baseline, and then at 30 and 60 min after drug administration.",
      "Glucocorticoid levels in study samples will be quantified with the aim to determine whether the Nasacthin test is able to correctly diagnose patients with AI by estimating the positive percent agreement with the standard SST using serum cortisol at 30 and 60 min. Data on any reported harms and on the acceptability, usability and tolerability of the Nasacthin test will also be collected.",
      "The study and subsequent amendments have been reviewed and approved by South Central-Hampshire A Research Ethics Committee.",
      "Results will be published in peer-reviewed journals and presented at national and international conferences.",
      "Plans for dissemination of results to trial participants will be developed in collaboration with patient and public involvement and engagement groups.",
      "ISRCTN26461337."
    ],
    "summary_sentences": [
      "Inadequate production of the essential stress hormone, cortisol, results in adrenal insufficiency (AI), which is associated with significant morbidity and mortality.",
      "The current standard diagnostic test for AI is the Short Synacthen Test (SST), but this is both invasive and resource-intensive, involving cannulation and blood sampling.",
      "A novel formulation, Nasacthin, has been developed in which the same Active Pharmaceutical Ingredient can be delivered intranasally, with the resultant glucocorticoid levels either measured in serum, or in saliva samples to render the test non-invasive, thus creating a potentially more cost-effective test.",
      "The Salivary Test of Adrenal Response to Liquid Intranasal Tetracosactide (STARLIT-3) study aims to determine the diagnostic utility of the test in patients with AI.",
      "STARLIT-3 is a randomised 2-way crossover trial which aims to collect data from 32 AI patients allocated to receive both Synacthen and Nasacthin in a random order across two study visits.",
      "Paired blood and saliva samples will be collected from participants at baseline, and then at 30 and 60 min after drug administration.",
      "Glucocorticoid levels in study samples will be quantified with the aim to determine whether the Nasacthin test is able to correctly diagnose patients with AI by estimating the positive percent agreement with the standard SST using serum cortisol at 30 and 60 min. Data on any reported harms and on the acceptability, usability and tolerability of the Nasacthin test will also be collected.",
      "The study and subsequent amendments have been reviewed and approved by South Central-Hampshire A Research Ethics Committee.",
      "Results will be published in peer-reviewed journals and presented at national and international conferences.",
      "Plans for dissemination of results to trial participants will be developed in collaboration with patient and public involvement and engagement groups.",
      "ISRCTN26461337."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41643935",
    "source": "pubmed",
    "sentences": [
      "Approaches to randomized clinical trial (RCT) implementation changed during the COVID-19 pandemic as clinical trials transitioned to largely virtual implementation which may continue in the future.",
      "Without careful consideration, virtual RCTs may exacerbate the historical under-representation of women, the elderly, and racial and ethnic minorities that has occurred in the past.",
      "The following study presents an approach to virtualizing an RCT for an mHealth intervention.",
      "Study participants were recruited from Federally Qualified Health Centers in medically underserved areas of the New York City metropolitan area.",
      "Recruitment began in January 2020 but was paused in March 2020 due to the COVID-19 pandemic's onset.",
      "The research team developed a virtual protocol for recruitment, onboarding, and study implementation.",
      "Study participants were predominantly from immigrant, low-income, and racial and ethnic minority groups.",
      "Our virtualization approach included an easier-to-understand consent form, expanded virtual training materials, and greater one-on-one attention during training.",
      "Despite the transition to virtual protocols, we did not detect statistically significant differences in key demographic characteristics, clinical factors, or mobile device proficiency between recruitment modalities, though the small in-person sample size (n = 21) limits definitive conclusions about selection bias.",
      "Our study represents an early investigation into how the change from in-person clinical trial recruitment and study implementation to virtual during the COVID-19 pandemic may impact recruitment of participants from medically underserved communities into RCTs.",
      "This approach may be used in future trials testing mHealth and other technological interventions without exacerbating the under-representation of medically underserved populations."
    ],
    "summary_sentences": [
      "Approaches to randomized clinical trial (RCT) implementation changed during the COVID-19 pandemic as clinical trials transitioned to largely virtual implementation which may continue in the future.",
      "Without careful consideration, virtual RCTs may exacerbate the historical under-representation of women, the elderly, and racial and ethnic minorities that has occurred in the past.",
      "The following study presents an approach to virtualizing an RCT for an mHealth intervention.",
      "Study participants were recruited from Federally Qualified Health Centers in medically underserved areas of the New York City metropolitan area.",
      "Recruitment began in January 2020 but was paused in March 2020 due to the COVID-19 pandemic's onset.",
      "The research team developed a virtual protocol for recruitment, onboarding, and study implementation.",
      "Study participants were predominantly from immigrant, low-income, and racial and ethnic minority groups.",
      "Our virtualization approach included an easier-to-understand consent form, expanded virtual training materials, and greater one-on-one attention during training.",
      "Despite the transition to virtual protocols, we did not detect statistically significant differences in key demographic characteristics, clinical factors, or mobile device proficiency between recruitment modalities, though the small in-person sample size (n = 21) limits definitive conclusions about selection bias.",
      "Our study represents an early investigation into how the change from in-person clinical trial recruitment and study implementation to virtual during the COVID-19 pandemic may impact recruitment of participants from medically underserved communities into RCTs.",
      "This approach may be used in future trials testing mHealth and other technological interventions without exacerbating the under-representation of medically underserved populations."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41643256",
    "source": "pubmed",
    "sentences": [
      "Bariatric surgery is the most effective treatment modality for individuals with morbid obesity, providing significant and durable weight loss and comorbidity resolution.",
      "Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide receptor agonists have shown promise as weight loss drugs, in addition to their use in the treatment of metabolic disorders.",
      "While multimodal weight management is the standard of care for individuals with morbid obesity, the benefit of antecedent GLP-1 therapy prior to bariatric surgery has not been well-studied.",
      "The objective of this study is to conduct a clinical trial testing the hypothesis that preoperative treatment with a dual GLP-1/glucose-dependent insulinotropic polypeptide receptor agonist enhances preoperative weight loss and decreases tissue inflammation, resulting in improved postoperative outcomes.",
      "We designed a randomized controlled trial (RCT) comparing preoperative treatment with tirzepatide versus standard medical care prior to minimally invasive bariatric surgery with a target enrollment of 50 patients randomized 1:1.",
      "For 3 mo preoperatively, the control arm will receive standard care in the form of dietary and lifestyle modification recommendations, whereas the treatment arm will receive weekly tirzepatide, in addition to standard care.",
      "Blood will be collected at enrollment through 12-mo postoperatively and analyzed for inflammatory and metabolic markers.",
      "Tissues (adipose, stomach, and liver) will be collected intraoperatively for transcriptome profiling and histological assessment.",
      "This is an ongoing trial with no reportable results.",
      "Completion of this pilot RCT will provide data to support initiation of a multicenter RCT to determine therapeutic efficacy, and mechanisms of action, by which patients could benefit from preoperative treatment with tirzepatide."
    ],
    "summary_sentences": [
      "Bariatric surgery is the most effective treatment modality for individuals with morbid obesity, providing significant and durable weight loss and comorbidity resolution.",
      "Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide receptor agonists have shown promise as weight loss drugs, in addition to their use in the treatment of metabolic disorders.",
      "While multimodal weight management is the standard of care for individuals with morbid obesity, the benefit of antecedent GLP-1 therapy prior to bariatric surgery has not been well-studied.",
      "The objective of this study is to conduct a clinical trial testing the hypothesis that preoperative treatment with a dual GLP-1/glucose-dependent insulinotropic polypeptide receptor agonist enhances preoperative weight loss and decreases tissue inflammation, resulting in improved postoperative outcomes.",
      "We designed a randomized controlled trial (RCT) comparing preoperative treatment with tirzepatide versus standard medical care prior to minimally invasive bariatric surgery with a target enrollment of 50 patients randomized 1:1.",
      "For 3 mo preoperatively, the control arm will receive standard care in the form of dietary and lifestyle modification recommendations, whereas the treatment arm will receive weekly tirzepatide, in addition to standard care.",
      "Blood will be collected at enrollment through 12-mo postoperatively and analyzed for inflammatory and metabolic markers.",
      "Tissues (adipose, stomach, and liver) will be collected intraoperatively for transcriptome profiling and histological assessment.",
      "This is an ongoing trial with no reportable results.",
      "Completion of this pilot RCT will provide data to support initiation of a multicenter RCT to determine therapeutic efficacy, and mechanisms of action, by which patients could benefit from preoperative treatment with tirzepatide."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41642563",
    "source": "pubmed",
    "sentences": [
      "Mirogabalin besylate is a selective α2δ-1 ligand approved for diabetic peripheral neuropathic pain.",
      "This study evaluated the pharmacokinetic (PK) bioequivalence and safety of generic 5 mg and 10 mg mirogabalin formulations compared with the reference product (Tarlige This pooled analysis comprised two independent, randomized, open-label, two-period crossover trials: one evaluating the 5 mg formulation (24 participants/group) and another evaluating the 10 mg formulation (36 participants/group).",
      "Liquid chromatography-tandem mass spectrometry (LC-MS/MS) assays have been validated over ranges of 1.00-200 ng/mL (5-mg study) and 0.50-500 ng/mL (10-mg study) for plasma mirogabalin quantification.",
      "Primary endpoints were peak plasma concentration (C For the 5 mg formulation, the fasting study demonstrated bioequivalence with a C",
      "Both generic formulations met bioequivalence criteria to Tarlige ( http://www.chinadrugtrials.org.cn ): 5 mg: CTR20232783; 10 mg: CTR20242717."
    ],
    "summary_sentences": [
      "Mirogabalin besylate is a selective α2δ-1 ligand approved for diabetic peripheral neuropathic pain.",
      "This study evaluated the pharmacokinetic (PK) bioequivalence and safety of generic 5 mg and 10 mg mirogabalin formulations compared with the reference product (Tarlige This pooled analysis comprised two independent, randomized, open-label, two-period crossover trials: one evaluating the 5 mg formulation (24 participants/group) and another evaluating the 10 mg formulation (36 participants/group).",
      "Liquid chromatography-tandem mass spectrometry (LC-MS/MS) assays have been validated over ranges of 1.00-200 ng/mL (5-mg study) and 0.50-500 ng/mL (10-mg study) for plasma mirogabalin quantification.",
      "Primary endpoints were peak plasma concentration (C For the 5 mg formulation, the fasting study demonstrated bioequivalence with a C",
      "Both generic formulations met bioequivalence criteria to Tarlige ( http://www.chinadrugtrials.org.cn ): 5 mg: CTR20232783; 10 mg: CTR20242717."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41641314",
    "source": "pubmed",
    "sentences": [
      "Amino acid metabolism is closely linked with kidney physiology and pathology.",
      "In acute kidney injury, chronic kidney disease, diabetic kidney disease, and autosomal dominant polycystic kidney disease, disturbances in the branched-chain amino acids, tryptophan, glutamine, taurine, and sulfur amino acids pathways are consistently observed.",
      "Specific metabolites such as D-serine, kynurenine intermediates, and branched-chain keto acids are associated with disease progression.",
      "Taurine and indoxyl sulfate have also been proposed as therapeutic targets.",
      "At the nephron level, transporters and enzymes controlling amino acid flux influence nitrogen balance, oxidative stress, fibrosis, inflammation, and tubular injury.",
      "In chronic kidney disease, impaired amino acid handling contributes to protein-energy wasting, altered muscle metabolism, and systemic complications.",
      "In autosomal dominant polycystic kidney disease, cyst fluid metabolomics has revealed alterations in tryptophan and polyamine metabolism.",
      "The use of nutritional interventions, microbiome modulation, and selective supplementation as therapeutic strategies is being explored, although clinical trial evidence remains limited.",
      "Several key issues remain unresolved, including the need for isotope tracer studies to define renal amino acid kinetics in humans, the rigorous validation of metabolite biomarkers across diverse populations, the integration of diet and microbiome-derived metabolites into mechanistic frameworks, and the systematic evaluation of sex-specific differences.",
      "Longitudinal studies are scarce, thus restricting predictive power and therapeutic translation.",
      "Further mechanistic clarification may support the development of biomarkers and targeted therapies."
    ],
    "summary_sentences": [
      "Amino acid metabolism is closely linked with kidney physiology and pathology.",
      "In acute kidney injury, chronic kidney disease, diabetic kidney disease, and autosomal dominant polycystic kidney disease, disturbances in the branched-chain amino acids, tryptophan, glutamine, taurine, and sulfur amino acids pathways are consistently observed.",
      "Specific metabolites such as D-serine, kynurenine intermediates, and branched-chain keto acids are associated with disease progression.",
      "Taurine and indoxyl sulfate have also been proposed as therapeutic targets.",
      "At the nephron level, transporters and enzymes controlling amino acid flux influence nitrogen balance, oxidative stress, fibrosis, inflammation, and tubular injury.",
      "In chronic kidney disease, impaired amino acid handling contributes to protein-energy wasting, altered muscle metabolism, and systemic complications.",
      "In autosomal dominant polycystic kidney disease, cyst fluid metabolomics has revealed alterations in tryptophan and polyamine metabolism.",
      "The use of nutritional interventions, microbiome modulation, and selective supplementation as therapeutic strategies is being explored, although clinical trial evidence remains limited.",
      "Several key issues remain unresolved, including the need for isotope tracer studies to define renal amino acid kinetics in humans, the rigorous validation of metabolite biomarkers across diverse populations, the integration of diet and microbiome-derived metabolites into mechanistic frameworks, and the systematic evaluation of sex-specific differences.",
      "Longitudinal studies are scarce, thus restricting predictive power and therapeutic translation.",
      "Further mechanistic clarification may support the development of biomarkers and targeted therapies."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41640096",
    "source": "pubmed",
    "sentences": [
      "The Prevention of Lower Urinary Tract Symptoms (PLUS) Research Consortium, supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), has had a successful and productive ten years, accomplishing several major achievements, including over 65 peer-reviewed publications.",
      "This multicenter, transdisciplinary Consortium developed the concept of bladder health and studied it systematically in RISE FOR HEALTH (RISE).",
      "The resources developed and the data generated will be made available for use through the NIDDK repository, providing the content for many more accomplishments in the field of bladder health.",
      "Clinical Trial Registration: NCT05365971."
    ],
    "summary_sentences": [
      "The Prevention of Lower Urinary Tract Symptoms (PLUS) Research Consortium, supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), has had a successful and productive ten years, accomplishing several major achievements, including over 65 peer-reviewed publications.",
      "This multicenter, transdisciplinary Consortium developed the concept of bladder health and studied it systematically in RISE FOR HEALTH (RISE).",
      "The resources developed and the data generated will be made available for use through the NIDDK repository, providing the content for many more accomplishments in the field of bladder health.",
      "Clinical Trial Registration: NCT05365971."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41639820",
    "source": "pubmed",
    "sentences": [
      "This study assessed serum Adiponectin (APN) and Soluble Intercellular Adhesion Molecule-1 (sICAM-1) levels in diabetic foot ulcer (DFU) patients for evaluating disease severity and prognosis.",
      "In this retrospective cohort study, 92 DFU patients were assessed during a 6-month outcome evaluation period and categorized by ulcer healing into good prognosis (healed, n = 50) or poor prognosis (unhealed, n = 42).",
      "Serum APN and sICAM-1 levels were measured by Enzyme-Linked Immunosorbent Assay (ELISA) and and analyzed for correlations with disease severity and infection grades.",
      "Receiver Operating Characteristic (ROC) curves evaluated their predictive value for poor prognosis.",
      "Serum APN was negatively correlated with infection and disease severity, whereas sICAM-1 exhibited a positive correlation.",
      "The good prognosis group had significantly higher APN and lower sICAM-1 levels compared to the poor prognosis group.",
      "Both biomarkers predicted poor prognosis: APN (Area Under the Curve (AUC) = 0.765), sICAM-1 (AUC = 0.841).",
      "Combining both markers yielded an AUC of 0.853.",
      "Serum APN and sICAM-1 levels are associated with DFU severity and prognosis, supporting their potential as predictive biomarkers in clinical practice.",
      "Not applicable."
    ],
    "summary_sentences": [
      "This study assessed serum Adiponectin (APN) and Soluble Intercellular Adhesion Molecule-1 (sICAM-1) levels in diabetic foot ulcer (DFU) patients for evaluating disease severity and prognosis.",
      "In this retrospective cohort study, 92 DFU patients were assessed during a 6-month outcome evaluation period and categorized by ulcer healing into good prognosis (healed, n = 50) or poor prognosis (unhealed, n = 42).",
      "Serum APN and sICAM-1 levels were measured by Enzyme-Linked Immunosorbent Assay (ELISA) and and analyzed for correlations with disease severity and infection grades.",
      "Receiver Operating Characteristic (ROC) curves evaluated their predictive value for poor prognosis.",
      "Serum APN was negatively correlated with infection and disease severity, whereas sICAM-1 exhibited a positive correlation.",
      "The good prognosis group had significantly higher APN and lower sICAM-1 levels compared to the poor prognosis group.",
      "Both biomarkers predicted poor prognosis: APN (Area Under the Curve (AUC) = 0.765), sICAM-1 (AUC = 0.841).",
      "Combining both markers yielded an AUC of 0.853.",
      "Serum APN and sICAM-1 levels are associated with DFU severity and prognosis, supporting their potential as predictive biomarkers in clinical practice.",
      "Not applicable."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41639504",
    "source": "pubmed",
    "sentences": [
      "In their recent study, Zhang et al. (Aging Clin Exp Res, 2025) report an association between a composite unhealthy lifestyle score and the risk of comorbid type 2 diabetes mellitus (T2DM) and arthritis in the CHARLS cohort.",
      "While the topic is of significant public health relevance, we have identified several substantive methodological and interpretative limitations that temper the conclusions.",
      "Chief among these are the oversimplified and unvalidated definition of lifestyle exposures, particularly \"unhealthy diet,\" and the equal weighting of disparate risk factors without biological justification.",
      "Crucially, the analysis fails to adequately control for body mass index, a potent confounder and likely mediator in the T2DM-arthritis pathway.",
      "Furthermore, the aggregation of all arthritis subtypes obscures potentially distinct etiologies, and the assertion of \"synergy\" lacks formal statistical interaction testing.",
      "Finally, the study remains purely associational, omitting mechanistic investigation into proposed pathways like inflammation.",
      "Future research must address these limitations through precise exposure measurement, rigorous confounding control, disease subtyping, and formal mediation analyses to translate this epidemiological observation into causal insight and actionable prevention strategies."
    ],
    "summary_sentences": [
      "In their recent study, Zhang et al. (Aging Clin Exp Res, 2025) report an association between a composite unhealthy lifestyle score and the risk of comorbid type 2 diabetes mellitus (T2DM) and arthritis in the CHARLS cohort.",
      "While the topic is of significant public health relevance, we have identified several substantive methodological and interpretative limitations that temper the conclusions.",
      "Chief among these are the oversimplified and unvalidated definition of lifestyle exposures, particularly \"unhealthy diet,\" and the equal weighting of disparate risk factors without biological justification.",
      "Crucially, the analysis fails to adequately control for body mass index, a potent confounder and likely mediator in the T2DM-arthritis pathway.",
      "Furthermore, the aggregation of all arthritis subtypes obscures potentially distinct etiologies, and the assertion of \"synergy\" lacks formal statistical interaction testing.",
      "Finally, the study remains purely associational, omitting mechanistic investigation into proposed pathways like inflammation.",
      "Future research must address these limitations through precise exposure measurement, rigorous confounding control, disease subtyping, and formal mediation analyses to translate this epidemiological observation into causal insight and actionable prevention strategies."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41637422",
    "source": "pubmed",
    "sentences": [
      "Benign cystic thyroid nodules are commonly encountered in clinical practice and often require intervention due to compressive symptoms or cosmetic concerns.",
      "While ethanol ablation (EA) has been widely used, radiofrequency ablation (RFA) has emerged as a promising alternative, particularly for nodules with a significant solid component.",
      "This study aimed to evaluate the short-term efficacy and safety of single-session RFA in treating purely cystic and predominantly cystic thyroid nodules (PCTNs).",
      "This prospective study included 38 patients with benign cystic thyroid nodules (10 purely cystic and 28 PCTNs) treated with single-session RFA.",
      "Pre- and post-treatment evaluations were performed using ultrasound imaging and thyroid function tests at 1, 6, and 12 months.",
      "The primary endpoint was volume reduction rate (VRR), and therapeutic success was defined as VRR > 50%.",
      "Complications were assessed according to international image-guided tumor ablation criteria.",
      "This study was registered at ClinicalTrials.gov (identifier: NCT07115576).",
      "RFA resulted in significant volume reduction, with VRR improving from 65.97 ± 22.19% at 1 month to 83.29 ± 17.33% at 6 months and 82.49 ± 23.18% at 12 months (p = 0.004).",
      "Purely cystic nodules demonstrated higher VRR than PCTNs at all follow-up points (p < 0.05).",
      "Thyroid function remained stable post-procedure.",
      "The therapeutic success rate was 83.3% at 1 month and 86.7% at 12 months, with no major complications reported.",
      "Purely cystic nodules showed a consistently higher and more durable response than PCTNs.",
      "Single-session RFA appears to be a safe and effective minimally invasive treatment option for large benign thyroid nodules, although confirmation in comparative studies is needed.",
      "The technique is particularly advantageous for purely cystic nodules and offers a minimally invasive alternative to surgery or multiple EA sessions.",
      "ClinicalTrials.gov",
      "NCT07115576."
    ],
    "summary_sentences": [
      "Benign cystic thyroid nodules are commonly encountered in clinical practice and often require intervention due to compressive symptoms or cosmetic concerns.",
      "While ethanol ablation (EA) has been widely used, radiofrequency ablation (RFA) has emerged as a promising alternative, particularly for nodules with a significant solid component.",
      "This study aimed to evaluate the short-term efficacy and safety of single-session RFA in treating purely cystic and predominantly cystic thyroid nodules (PCTNs).",
      "This prospective study included 38 patients with benign cystic thyroid nodules (10 purely cystic and 28 PCTNs) treated with single-session RFA.",
      "Pre- and post-treatment evaluations were performed using ultrasound imaging and thyroid function tests at 1, 6, and 12 months.",
      "The primary endpoint was volume reduction rate (VRR), and therapeutic success was defined as VRR > 50%.",
      "Complications were assessed according to international image-guided tumor ablation criteria.",
      "This study was registered at ClinicalTrials.gov (identifier: NCT07115576).",
      "RFA resulted in significant volume reduction, with VRR improving from 65.97 ± 22.19% at 1 month to 83.29 ± 17.33% at 6 months and 82.49 ± 23.18% at 12 months (p = 0.004).",
      "Purely cystic nodules demonstrated higher VRR than PCTNs at all follow-up points (p < 0.05).",
      "Thyroid function remained stable post-procedure.",
      "The therapeutic success rate was 83.3% at 1 month and 86.7% at 12 months, with no major complications reported.",
      "Purely cystic nodules showed a consistently higher and more durable response than PCTNs.",
      "Single-session RFA appears to be a safe and effective minimally invasive treatment option for large benign thyroid nodules, although confirmation in comparative studies is needed.",
      "The technique is particularly advantageous for purely cystic nodules and offers a minimally invasive alternative to surgery or multiple EA sessions.",
      "ClinicalTrials.gov",
      "NCT07115576."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41636548",
    "source": "pubmed",
    "sentences": [
      "Glucagon-like peptide-1 receptor agonists and glucose-dependent insulinotropic polypeptide coagonists have revolutionized the treatment of type 2 diabetes and obesity.",
      "They demonstrate significant cardiovascular benefits, including a reduction in major adverse cardiovascular events and heart failure hospitalizations.",
      "However, these medications are associated with substantial lean body mass loss, comprising 15-45% of total weight reduction.",
      "This review examines the pathophysiological mechanisms underlying muscle loss with incretin-based therapies, analyzes clinical trial data on body composition changes, explores the bidirectional relationship between sarcopenia and cardiovascular disease, and evaluates emerging pharmacological and lifestyle interventions to preserve muscle mass.",
      "Understanding and mitigating muscle loss is critical for optimizing cardiovascular outcomes, particularly in older adults and those with established heart disease, where sarcopenia is associated with increased mortality and functional decline."
    ],
    "summary_sentences": [
      "Glucagon-like peptide-1 receptor agonists and glucose-dependent insulinotropic polypeptide coagonists have revolutionized the treatment of type 2 diabetes and obesity.",
      "They demonstrate significant cardiovascular benefits, including a reduction in major adverse cardiovascular events and heart failure hospitalizations.",
      "However, these medications are associated with substantial lean body mass loss, comprising 15-45% of total weight reduction.",
      "This review examines the pathophysiological mechanisms underlying muscle loss with incretin-based therapies, analyzes clinical trial data on body composition changes, explores the bidirectional relationship between sarcopenia and cardiovascular disease, and evaluates emerging pharmacological and lifestyle interventions to preserve muscle mass.",
      "Understanding and mitigating muscle loss is critical for optimizing cardiovascular outcomes, particularly in older adults and those with established heart disease, where sarcopenia is associated with increased mortality and functional decline."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41636295",
    "source": "pubmed",
    "sentences": [
      "Several factors, as genetics, diet, and gut microbiota, are associated with the development of type 1 diabetes (T1D).",
      "Akkermansia muciniphila, an abundant bacterium in human microbiota, has anti-inflammatory properties and can correct metabolic disorders.",
      "The effects of the administration of inulin, a prebiotic which increases Akkermansia muciniphila gut levels, are unknown in subjects with T1D. 49 subjects with T1D, age 46",
      "[37-53] years, 30 females (61%), duration of disease 20",
      "[11-27] years, HbA1c 64",
      "[59-72] mmol/mol, were randomized in group A (inulin 3 g twice daily for 3 months + insulin, n=24) and in group B (insulin alone, n=25).",
      "Body weight, glycated hemoglobin (HbA1c), daily insulin units, continuous glucose monitoring (CGM) metrics, and Bristol stool scale (BSS) score were collected at enrollment and after 3 months.",
      "After 3 months, subjects in group A showed a significant decrease in body weight [group A -2",
      "(-3; 0) kg and group B 0",
      "(-1; 1) kg, p=0.03] and daily insulin units",
      "[group A -1.5 UI (-3.1; 0) vs. group B 0.6 (0; 1.7), p=0.01].",
      "After 3 months, changes in HbA1c and CGM were similar between groups.",
      "In both groups, there was no change in BSS score (p=0.39) nor in Akkermansia muciniphila gut levels.",
      "Inulin was associated with a slight body weight decrease and insulin need reduction, but not with an increase in Akkermansia muciniphila levels.",
      "More studies are required to explore this issue."
    ],
    "summary_sentences": [
      "Several factors, as genetics, diet, and gut microbiota, are associated with the development of type 1 diabetes (T1D).",
      "Akkermansia muciniphila, an abundant bacterium in human microbiota, has anti-inflammatory properties and can correct metabolic disorders.",
      "The effects of the administration of inulin, a prebiotic which increases Akkermansia muciniphila gut levels, are unknown in subjects with T1D. 49 subjects with T1D, age 46",
      "[37-53] years, 30 females (61%), duration of disease 20",
      "[11-27] years, HbA1c 64",
      "[59-72] mmol/mol, were randomized in group A (inulin 3 g twice daily for 3 months + insulin, n=24) and in group B (insulin alone, n=25).",
      "Body weight, glycated hemoglobin (HbA1c), daily insulin units, continuous glucose monitoring (CGM) metrics, and Bristol stool scale (BSS) score were collected at enrollment and after 3 months.",
      "After 3 months, subjects in group A showed a significant decrease in body weight [group A -2",
      "(-3; 0) kg and group B 0",
      "(-1; 1) kg, p=0.03] and daily insulin units",
      "[group A -1.5 UI (-3.1; 0) vs. group B 0.6 (0; 1.7), p=0.01].",
      "After 3 months, changes in HbA1c and CGM were similar between groups.",
      "In both groups, there was no change in BSS score (p=0.39) nor in Akkermansia muciniphila gut levels.",
      "Inulin was associated with a slight body weight decrease and insulin need reduction, but not with an increase in Akkermansia muciniphila levels.",
      "More studies are required to explore this issue."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41635446",
    "source": "pubmed",
    "sentences": [
      "Severe hypoglycemia (SH) in adults with type 1 diabetes mellitus (T1DM) is associated with significant morbidity and mortality; however, its underlying causes are often complex and multifactorial.",
      "Improved tools to identify individuals at a high risk of SH are critically needed.",
      "In this study, machine learning techniques were applied to continuous glucose monitoring (CGM) data to identify distinguishing features between individuals with and without SH episodes.",
      "We analyzed data from the real-world study of adults with T1DM enrolled in the FGM-Japan study.",
      "Eleven machine learning algorithms using continuous glucose monitoring (CGM) metrics were applied to identify SH and assess the relative importance of the contributing features.",
      "The CGM metrics included mean glucose/GMI, time above range (TAR > 250 and > 180 mg/dL), time in range (TIR 70-180 mg/dL), time below range (TBR < 70 and < 54 mg/dL), coefficient of variation (%CV), and glycemic risk index (GRI).",
      "The model performance was evaluated using the area under the receiver operating characteristic curve (AUC), accuracy, precision, recall, and F1 score.",
      "Data from 264 adults with T1DM were analyzed.",
      "Across the models, XGBoost showed the highest AUC, significantly outperforming logistic regression, k-NN, and SVM but performed marginally below Naive Bayes.",
      "The F1-score analysis showed that logistic regression and neural networks provided a better balance between precision and recall.",
      "The model using four CGM variables (TBR < 70, %CV, GMI, and GRI) achieved the highest AUC of 0.794.",
      "XGBoost offers strong overall discrimination; however, simpler models exhibit better F1 performance.",
      "Features like 'TBR', '%CV', 'GMI,' and 'GRI' were key features, suggesting their usefulness in identifying individuals at risk for adverse glycemic events.",
      "Clinical Trial Registry No. UMIN000039376.",
      "The online version contains supplementary material available at 10.1007/s13340-025-00872-4."
    ],
    "summary_sentences": [
      "Severe hypoglycemia (SH) in adults with type 1 diabetes mellitus (T1DM) is associated with significant morbidity and mortality; however, its underlying causes are often complex and multifactorial.",
      "Improved tools to identify individuals at a high risk of SH are critically needed.",
      "In this study, machine learning techniques were applied to continuous glucose monitoring (CGM) data to identify distinguishing features between individuals with and without SH episodes.",
      "We analyzed data from the real-world study of adults with T1DM enrolled in the FGM-Japan study.",
      "Eleven machine learning algorithms using continuous glucose monitoring (CGM) metrics were applied to identify SH and assess the relative importance of the contributing features.",
      "The CGM metrics included mean glucose/GMI, time above range (TAR > 250 and > 180 mg/dL), time in range (TIR 70-180 mg/dL), time below range (TBR < 70 and < 54 mg/dL), coefficient of variation (%CV), and glycemic risk index (GRI).",
      "The model performance was evaluated using the area under the receiver operating characteristic curve (AUC), accuracy, precision, recall, and F1 score.",
      "Data from 264 adults with T1DM were analyzed.",
      "Across the models, XGBoost showed the highest AUC, significantly outperforming logistic regression, k-NN, and SVM but performed marginally below Naive Bayes.",
      "The F1-score analysis showed that logistic regression and neural networks provided a better balance between precision and recall.",
      "The model using four CGM variables (TBR < 70, %CV, GMI, and GRI) achieved the highest AUC of 0.794.",
      "XGBoost offers strong overall discrimination; however, simpler models exhibit better F1 performance.",
      "Features like 'TBR', '%CV', 'GMI,' and 'GRI' were key features, suggesting their usefulness in identifying individuals at risk for adverse glycemic events.",
      "Clinical Trial Registry No. UMIN000039376.",
      "The online version contains supplementary material available at 10.1007/s13340-025-00872-4."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41634765",
    "source": "pubmed",
    "sentences": [
      "The Daqing Diabetes Prevention Study II (Daqing DPS-II) builds on the landmark study Daqing Diabetes Prevention Study to develop real-world implementation strategies for preventing type 2 diabetes (T2DM).",
      "This study aims to evaluate the effectiveness of digital and complex lifestyle intervention in reducing the incidence of T2DM among adults with increased risk of T2DM, compared to usual care over a 36-month period.",
      "A three-arm, stratified, cluster-randomized controlled trial will be conducted in eight factories in Daqing, with clusters as the unit of randomization and individual participants as the unit of analysis.",
      "Fifty-seven clusters will be randomly allocated (1:1:1) to one of three groups: (1) Digital-based lifestyle intervention, (2) complex lifestyle intervention, or (3) usual care.",
      "Eligible participants will be adults aged 25-55 with increased risk of T2DM, defined by IFG, IGT, HbA1c 5.7-6.4%, and/or 1-h PG above 8.6 mmol/L, while not meeting the criteria for diabetes.",
      "Exclusion criteria include significant cardiovascular disease (CVD) within 6 months, impaired liver function, renal dysfunction, other significant medical or psychological conditions, or participation in similar studies.",
      "The interventions will run for 3 years.",
      "The primary outcomes are the 3-year cumulative incidence of T2DM.",
      "The study will utilize the RE-AIM framework and Implementation Outcome Framework (IOF) to assess Reach, Adoption, Implementation, Maintenance, Feasibility, Acceptability, and Appropriateness through process measures.",
      "Data collection will include plasma glucose (0, 1, and 2 h) and insulin levels (0, 1, and 2 h) based on the oral glucose tolerance test, laboratory tests, blood pressure, body mass index, waist circumference, and dietary and physical activity behaviors, diabetes knowledge, and quality of life.",
      "These measures will be assessed by trained doctors or nurses at baseline and at 6-,12-, 24-, and 36-month follow-ups.",
      "The study will provide evidence on how population-level strategies of digital and complex lifestyle intervention can be implemented in real-world settings to prevent diabetes.",
      "If proven effective, these strategies could be integrated into Workplace Wellness Program in China and other countries to prevent diabetes and other noncommunicable diseases.",
      "Chinese Clinical Trial Registry ChiCTR2400080790.",
      "Registered on 7th February 2024 TRIAL ACRONYM:",
      "Daqing DPS-II: Daqing Diabetes Prevention Study II."
    ],
    "summary_sentences": [
      "The Daqing Diabetes Prevention Study II (Daqing DPS-II) builds on the landmark study Daqing Diabetes Prevention Study to develop real-world implementation strategies for preventing type 2 diabetes (T2DM).",
      "This study aims to evaluate the effectiveness of digital and complex lifestyle intervention in reducing the incidence of T2DM among adults with increased risk of T2DM, compared to usual care over a 36-month period.",
      "A three-arm, stratified, cluster-randomized controlled trial will be conducted in eight factories in Daqing, with clusters as the unit of randomization and individual participants as the unit of analysis.",
      "Fifty-seven clusters will be randomly allocated (1:1:1) to one of three groups: (1) Digital-based lifestyle intervention, (2) complex lifestyle intervention, or (3) usual care.",
      "Eligible participants will be adults aged 25-55 with increased risk of T2DM, defined by IFG, IGT, HbA1c 5.7-6.4%, and/or 1-h PG above 8.6 mmol/L, while not meeting the criteria for diabetes.",
      "Exclusion criteria include significant cardiovascular disease (CVD) within 6 months, impaired liver function, renal dysfunction, other significant medical or psychological conditions, or participation in similar studies.",
      "The interventions will run for 3 years.",
      "The primary outcomes are the 3-year cumulative incidence of T2DM.",
      "The study will utilize the RE-AIM framework and Implementation Outcome Framework (IOF) to assess Reach, Adoption, Implementation, Maintenance, Feasibility, Acceptability, and Appropriateness through process measures.",
      "Data collection will include plasma glucose (0, 1, and 2 h) and insulin levels (0, 1, and 2 h) based on the oral glucose tolerance test, laboratory tests, blood pressure, body mass index, waist circumference, and dietary and physical activity behaviors, diabetes knowledge, and quality of life.",
      "These measures will be assessed by trained doctors or nurses at baseline and at 6-,12-, 24-, and 36-month follow-ups.",
      "The study will provide evidence on how population-level strategies of digital and complex lifestyle intervention can be implemented in real-world settings to prevent diabetes.",
      "If proven effective, these strategies could be integrated into Workplace Wellness Program in China and other countries to prevent diabetes and other noncommunicable diseases.",
      "Chinese Clinical Trial Registry ChiCTR2400080790.",
      "Registered on 7th February 2024 TRIAL ACRONYM:",
      "Daqing DPS-II: Daqing Diabetes Prevention Study II."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41634174",
    "source": "pubmed",
    "sentences": [
      "Connected insulin pens and smart caps automatically capture dosing data and can prompt patients about missed prandial boluses, but independent randomised evidence in type 1 diabetes is scarce.",
      "We aimed to assess whether a connected insulin pen cap improves glycaemic management and treatment satisfaction compared with an otherwise identical non-connected cap.",
      "We conducted an investigator-initiated, randomised, open-label, parallel-group trial in a European public hospital over 8 weeks.",
      "Adults with type 1 diabetes treated with multiple daily injections and who had suboptimal glycaemic management (baseline time above range [>10.0 mmol/l, >180 mg/dl] >25%) were randomly assigned (1:1) to a connected pen cap (Insulclock 2.0; Insulcloud, Madrid, Spain) or an identical cap for which the Bluetooth connectivity had been disabled (disconnected).",
      "Allocation was performed using opaque sealed envelopes, and no masking was applied.",
      "The primary outcome was time above range, with two thresholds (>10.0 mmol/l, >180 mg/dl and >13.9 mmol/l, >250 mg/dl) based on intermittently scanned CGM downloads.",
      "Analyses followed the intention-to-treat principle, using longitudinal mixed models and multiple imputation.",
      "Secondary outcomes included time in range, glycaemic variability (standard deviation and coefficient of variation), HbA Forty-two participants were randomised for inclusion in the study (21 per group: 25 women, 17 men).",
      "One withdrew before baseline, leaving 41 in the intention-to-treat analysis.",
      "Compared with the control group, the connected-cap group had lower time above range >13.9 mmol/l (mean difference -4.8 percentage points; 95% CI -9.5, -0.1; p=0.045) and reduced glucose standard deviation (-0.35 mmol/l; 95% CI -0.64, -0.06; p=0.018).",
      "HbA",
      "In routine clinical care, use of a connected pen cap reduced severe hyperglycaemia, glycaemic variability and hypoglycaemia avoidance behaviours in adults with type 1 diabetes and suboptimal glycaemic management, without affecting treatment satisfaction.",
      "These findings support the integration of low-burden, data-driven tools into public diabetes care.",
      "Larger and longer trials should evaluate the durability and cost-effectiveness of these interventions.",
      "ClinicalTrials.gov",
      "NCT06845891 FUNDING: Investigator-initiated study without industry funding; devices were procured by the hospital.",
      "Funders had no role in study design, conduct, analysis or reporting."
    ],
    "summary_sentences": [
      "Connected insulin pens and smart caps automatically capture dosing data and can prompt patients about missed prandial boluses, but independent randomised evidence in type 1 diabetes is scarce.",
      "We aimed to assess whether a connected insulin pen cap improves glycaemic management and treatment satisfaction compared with an otherwise identical non-connected cap.",
      "We conducted an investigator-initiated, randomised, open-label, parallel-group trial in a European public hospital over 8 weeks.",
      "Adults with type 1 diabetes treated with multiple daily injections and who had suboptimal glycaemic management (baseline time above range [>10.0 mmol/l, >180 mg/dl] >25%) were randomly assigned (1:1) to a connected pen cap (Insulclock 2.0; Insulcloud, Madrid, Spain) or an identical cap for which the Bluetooth connectivity had been disabled (disconnected).",
      "Allocation was performed using opaque sealed envelopes, and no masking was applied.",
      "The primary outcome was time above range, with two thresholds (>10.0 mmol/l, >180 mg/dl and >13.9 mmol/l, >250 mg/dl) based on intermittently scanned CGM downloads.",
      "Analyses followed the intention-to-treat principle, using longitudinal mixed models and multiple imputation.",
      "Secondary outcomes included time in range, glycaemic variability (standard deviation and coefficient of variation), HbA Forty-two participants were randomised for inclusion in the study (21 per group: 25 women, 17 men).",
      "One withdrew before baseline, leaving 41 in the intention-to-treat analysis.",
      "Compared with the control group, the connected-cap group had lower time above range >13.9 mmol/l (mean difference -4.8 percentage points; 95% CI -9.5, -0.1; p=0.045) and reduced glucose standard deviation (-0.35 mmol/l; 95% CI -0.64, -0.06; p=0.018).",
      "HbA",
      "In routine clinical care, use of a connected pen cap reduced severe hyperglycaemia, glycaemic variability and hypoglycaemia avoidance behaviours in adults with type 1 diabetes and suboptimal glycaemic management, without affecting treatment satisfaction.",
      "These findings support the integration of low-burden, data-driven tools into public diabetes care.",
      "Larger and longer trials should evaluate the durability and cost-effectiveness of these interventions.",
      "ClinicalTrials.gov",
      "NCT06845891 FUNDING: Investigator-initiated study without industry funding; devices were procured by the hospital.",
      "Funders had no role in study design, conduct, analysis or reporting."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41632754",
    "source": "pubmed",
    "sentences": [
      "Optimal glycaemic targets for women with gestational diabetes mellitus (GDM) are unclear.",
      "The aim of this study was to compare maternal and child health 4.5 years after women with GDM had been randomised to use tight or less tight targets for glycaemic control during their pregnancy.",
      "The TARGET trial was a stepped-wedge, cluster-randomised trial conducted between May 29, 2015 and November 7, 2017 at 10 hospitals in New Zealand.",
      "All hospitals were initially allocated to use less tight glycaemic treatment targets (fasting plasma glucose (FPG) <5.5 mmol/L (<99 mg/dL), 1-hour <8.0 mmol/L (<144 mg/dL), 2 hour postprandial <7.0 mmol/L (<126 mg/dL)) for women with GDM and every 4 months two hospitals were randomised to use tighter targets (FPG ≤ 5.0 mmol/L (≤90 mg/dL), 1-hour ≤7.4",
      "mmol/L (≤133 mg/dL), 2 hour postprandial ≤6.7 mmol/L) (≤121 mg/dL).",
      "Women with GDM, blinded to the targets in use, were eligible.",
      "The primary outcome was large for gestational age.",
      "This is a post-hoc follow-up study of the TARGET randomised trial, conducted from October 2020 to June 2022.",
      "We assessed 315/427 (74%) eligible mothers and 313/427 (73%) of their children.",
      "Primary outcomes were maternal glycated haemoglobin (HbA1c) and child body mass index (BMI) z-score.",
      "Secondary outcomes included maternal cardiometabolic risk, body size, and healthcare utilisation, and for the child, body size, vision, hearing, motor function, and behavioural outcomes.",
      "Data were collected from maternal and child health questionnaires, and their health records.",
      "Maternal HbA1c results were similar between tight and less tight glycaemic groups (40 mmol/mol standard deviation (SD) 12.6 versus 38 mmol/mol SD 8.8; adjusted mean difference (adjMD) 2.17",
      "(95% confidence interval (CI)",
      "[-0.26, 4.60]; P = 0.080)).",
      "Child BMI z-scores were similar between groups (mean z-score 0.83 SD 1.72 versus 0.75 SD 1.48; adjMD 0.12 (95% CI",
      "[-0.24, 0.48]; P = 0.498)), although children in the tight glycaemic group were taller (107.8 cm SD 5.5 versus 106.0 cm SD 5.5; adjMD 1.83 (95% CI",
      "[0.58, 3.08];",
      "P = 0.004)).",
      "Worse child outcomes were seen in the tight glycaemic group for coordination difficulties (31/109, 28.4% versus 21/118, 17.8%; adjusted relative risk (adjRR) 1.66 (95% CI",
      "[1.01, 2.73];",
      "P = 0.044)), behaviour (likely on the autism spectrum 10/108, 9.3% versus 3/117, 2.6%;",
      "adjRR 3.67 (95% CI",
      "[1.02, 13.23];",
      "P = 0.047)) and total difficulties scores from the strengths and difficulties questionnaire (mean score 8.4 SD 5.1 versus 6.8 SD 4.5; adjMD 1.75 (95% CI",
      "[0.51, 3.00]; P = 0.006)).",
      "The main limitation was the use of questionnaires rather than health professional assessments for some of the outcomes.",
      "Tight compared to less tight glycaemic targets in women with GDM during pregnancy did not result in lower maternal HbA1c or lower child BMI z-scores 4.5 years later, and may be associated with adverse child motor and behavioural outcomes."
    ],
    "summary_sentences": [
      "Optimal glycaemic targets for women with gestational diabetes mellitus (GDM) are unclear.",
      "The aim of this study was to compare maternal and child health 4.5 years after women with GDM had been randomised to use tight or less tight targets for glycaemic control during their pregnancy.",
      "The TARGET trial was a stepped-wedge, cluster-randomised trial conducted between May 29, 2015 and November 7, 2017 at 10 hospitals in New Zealand.",
      "All hospitals were initially allocated to use less tight glycaemic treatment targets (fasting plasma glucose (FPG) <5.5 mmol/L (<99 mg/dL), 1-hour <8.0 mmol/L (<144 mg/dL), 2 hour postprandial <7.0 mmol/L (<126 mg/dL)) for women with GDM and every 4 months two hospitals were randomised to use tighter targets (FPG ≤ 5.0 mmol/L (≤90 mg/dL), 1-hour ≤7.4",
      "mmol/L (≤133 mg/dL), 2 hour postprandial ≤6.7 mmol/L) (≤121 mg/dL).",
      "Women with GDM, blinded to the targets in use, were eligible.",
      "The primary outcome was large for gestational age.",
      "This is a post-hoc follow-up study of the TARGET randomised trial, conducted from October 2020 to June 2022.",
      "We assessed 315/427 (74%) eligible mothers and 313/427 (73%) of their children.",
      "Primary outcomes were maternal glycated haemoglobin (HbA1c) and child body mass index (BMI) z-score.",
      "Secondary outcomes included maternal cardiometabolic risk, body size, and healthcare utilisation, and for the child, body size, vision, hearing, motor function, and behavioural outcomes.",
      "Data were collected from maternal and child health questionnaires, and their health records.",
      "Maternal HbA1c results were similar between tight and less tight glycaemic groups (40 mmol/mol standard deviation (SD) 12.6 versus 38 mmol/mol SD 8.8; adjusted mean difference (adjMD) 2.17",
      "(95% confidence interval (CI)",
      "[-0.26, 4.60]; P = 0.080)).",
      "Child BMI z-scores were similar between groups (mean z-score 0.83 SD 1.72 versus 0.75 SD 1.48; adjMD 0.12 (95% CI",
      "[-0.24, 0.48]; P = 0.498)), although children in the tight glycaemic group were taller (107.8 cm SD 5.5 versus 106.0 cm SD 5.5; adjMD 1.83 (95% CI",
      "[0.58, 3.08];",
      "P = 0.004)).",
      "Worse child outcomes were seen in the tight glycaemic group for coordination difficulties (31/109, 28.4% versus 21/118, 17.8%; adjusted relative risk (adjRR) 1.66 (95% CI",
      "[1.01, 2.73];",
      "P = 0.044)), behaviour (likely on the autism spectrum 10/108, 9.3% versus 3/117, 2.6%;",
      "adjRR 3.67 (95% CI",
      "[1.02, 13.23];",
      "P = 0.047)) and total difficulties scores from the strengths and difficulties questionnaire (mean score 8.4 SD 5.1 versus 6.8 SD 4.5; adjMD 1.75 (95% CI",
      "[0.51, 3.00]; P = 0.006)).",
      "The main limitation was the use of questionnaires rather than health professional assessments for some of the outcomes.",
      "Tight compared to less tight glycaemic targets in women with GDM during pregnancy did not result in lower maternal HbA1c or lower child BMI z-scores 4.5 years later, and may be associated with adverse child motor and behavioural outcomes."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41632249",
    "source": "pubmed",
    "sentences": [
      "Complex systemic immune dysregulation and chronic inflammation in rheumatological diseases lead to long-term inflammation and morbidity, which are primarily controlled by systemic immunosuppressant agents with diverse effects, underscoring the need for more precise and innovative treatments.",
      "The unmatched specificity in targeting disease-driving genes and pathways makes small interfering RNA (siRNA) a transformative treatment approach.",
      "This review examines how siRNA can precisely transform the therapy of rheumatological diseases by targeting critical molecular pathways associated with inflammation, immunological dysregulation, and tissue damage.",
      "While this study elucidates siRNA therapies targeting inflammatory pathways to treat rheumatological diseases, it moves beyond the conventional therapeutic application of siRNAs targeting pro-inflammatory cytokines; it explicitly focuses on upstream signaling hubs within synovial fibroblasts, T cells, and plasma cells, as well as on non-inflammatory mechanisms that lead to bone damage.",
      "The review also integrates in vitro and in vivo, as well as preclinical siRNA studies, to identify the most promising targets and determine whether these siRNA modifications, combined with delivery systems, achieve body-wide and joint-specific immune-stromal network reprogramming through targeted delivery without causing total immune system breakdown."
    ],
    "summary_sentences": [
      "Complex systemic immune dysregulation and chronic inflammation in rheumatological diseases lead to long-term inflammation and morbidity, which are primarily controlled by systemic immunosuppressant agents with diverse effects, underscoring the need for more precise and innovative treatments.",
      "The unmatched specificity in targeting disease-driving genes and pathways makes small interfering RNA (siRNA) a transformative treatment approach.",
      "This review examines how siRNA can precisely transform the therapy of rheumatological diseases by targeting critical molecular pathways associated with inflammation, immunological dysregulation, and tissue damage.",
      "While this study elucidates siRNA therapies targeting inflammatory pathways to treat rheumatological diseases, it moves beyond the conventional therapeutic application of siRNAs targeting pro-inflammatory cytokines; it explicitly focuses on upstream signaling hubs within synovial fibroblasts, T cells, and plasma cells, as well as on non-inflammatory mechanisms that lead to bone damage.",
      "The review also integrates in vitro and in vivo, as well as preclinical siRNA studies, to identify the most promising targets and determine whether these siRNA modifications, combined with delivery systems, achieve body-wide and joint-specific immune-stromal network reprogramming through targeted delivery without causing total immune system breakdown."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41632246",
    "source": "pubmed",
    "sentences": [
      "Gestational diabetes mellitus (GDM) is a prevalent metabolic disorder during pregnancy associated with adverse maternal and fetal outcomes, highlighting the urgent need for novel, genetically supported drug targets due to suboptimal glycemic control and safety concerns with existing therapies.",
      "This study integrated cis-expression quantitative trait loci (cis-eQTL) of druggable genes with genome-wide association data to identify putative causal genes for GDM through two-sample Mendelian randomization (MR), with significant associations further validated using multi-tissue summary data-based Mendelian randomization (SMR), colocalization analysis, cis-protein quantitative trait loci (cis-pQTL) MR, and single-cell RNA sequencing (scRNA-seq) to confirm tissue-",
      "and cell type specific expression.",
      "MR analysis identified 15 genes significantly associated with GDM risk after Bonferroni correction, with SMR and colocalization analyses confirming robust associations for five key genes: higher expression of NRBP1, LPL, and BTN3A2 was causally linked to reduced GDM risk, while elevated GSTM1 and GRINA levels were associated with increased risk.",
      "ScRNA-seq revealed distinct expression patterns in placental cell types, with NRBP1 and GRINA highly expressed in trophoblasts and certain immune cell populations.",
      "Phenome-wide association studies revealed no significant pleiotropic effects, and pharmacological drug-target databases identified several compounds with potential regulatory interactions.",
      "This multi-omics study successfully identifies several genetically supported, druggable targets for GDM, providing a robust foundation for developing mechanism-based therapeutics and precision prevention strategies in pregnancy metabolism."
    ],
    "summary_sentences": [
      "Gestational diabetes mellitus (GDM) is a prevalent metabolic disorder during pregnancy associated with adverse maternal and fetal outcomes, highlighting the urgent need for novel, genetically supported drug targets due to suboptimal glycemic control and safety concerns with existing therapies.",
      "This study integrated cis-expression quantitative trait loci (cis-eQTL) of druggable genes with genome-wide association data to identify putative causal genes for GDM through two-sample Mendelian randomization (MR), with significant associations further validated using multi-tissue summary data-based Mendelian randomization (SMR), colocalization analysis, cis-protein quantitative trait loci (cis-pQTL) MR, and single-cell RNA sequencing (scRNA-seq) to confirm tissue-",
      "and cell type specific expression.",
      "MR analysis identified 15 genes significantly associated with GDM risk after Bonferroni correction, with SMR and colocalization analyses confirming robust associations for five key genes: higher expression of NRBP1, LPL, and BTN3A2 was causally linked to reduced GDM risk, while elevated GSTM1 and GRINA levels were associated with increased risk.",
      "ScRNA-seq revealed distinct expression patterns in placental cell types, with NRBP1 and GRINA highly expressed in trophoblasts and certain immune cell populations.",
      "Phenome-wide association studies revealed no significant pleiotropic effects, and pharmacological drug-target databases identified several compounds with potential regulatory interactions.",
      "This multi-omics study successfully identifies several genetically supported, druggable targets for GDM, providing a robust foundation for developing mechanism-based therapeutics and precision prevention strategies in pregnancy metabolism."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41631732",
    "source": "pubmed",
    "sentences": [
      "Bariatric surgery can improve health outcomes but high-quality comparative evidence about different procedures is limited.",
      "To compare the effectiveness and cost-effectiveness of Roux-en-Y gastric bypass (Bypass), adjustable gastric banding (Band) and sleeve gastrectomy (Sleeve) for people living with severe obesity.",
      "Multicentre, parallel-group, randomised controlled trial conducted in 12 National Health Service hospitals.",
      "Adults with a body mass index ≥ 35 kg/m Bypass, Band and Sleeve surgery.",
      "Primary outcomes were self-reported quality of life (EQ-5D-5L utility score) and weight (at least 50% excess weight lost) at 3 years.",
      "Sleeve and Bypass were each considered superior to Band if there was non-inferior excess weight loss (< 12% difference between groups) and superior quality of life.",
      "Sleeve was considered superior to Bypass by the same criteria.",
      "Secondary outcomes included comorbidities, adverse health events, generic and disease-specific quality of life at 6, 12, 24 and 36 months post randomisation, dietary intake, binge eating behaviour and cost-effectiveness.",
      "One thousand three hundred and fifty-one participants were randomised between December 2012 and September 2019.",
      "Five participants withdrew consent to use their data, leaving 1346 (462 Bypass, 464 Band, 420 Sleeve).",
      "The mean age was 47.3 years, 1020 (75.9%) were women and the mean weight and body mass index was 129.7 kg and 46.4 kg/m",
      "The study was impacted by the COVID-19 pandemic which prevented some participants having surgery and/or attending hospital for study follow-up appointments, which impacted on the completeness of data for these visits.",
      "Bypass and Sleeve are more effective than Band.",
      "Sleeve has inferior excess weight loss and lower mean quality-of-life score than Bypass.",
      "Longer-term follow-up is needed to determine the sustainability of observed effects and to examine adverse events.",
      "A comparison of optimal gastric bypass and optimal medical therapy for severe obesity is now needed to inform decision-making and health policy.",
      "This trial is registered as ClinicalTrials.gov: NCT02841527, ISRCTN00786323.",
      "This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 09/127/53) and is published in full in People who are overweight or obese may benefit from surgery to lose weight (bariatric surgery), improve quality of life and health.",
      "While several operations are available, it is uncertain which procedure leads to the best results for patients and the National Health Service.",
      "One thousand three hundred and forty-six adults with severe obesity referred for bariatric surgery from 12 hospitals in the United Kingdom.",
      "The people who took part were allocated by chance to one of three surgical procedures aimed at achieving weight loss: gastric bypass, gastric band or sleeve gastrectomy.",
      "Participants were followed up for 3 years.",
      "We collected information on weight loss, blood markers, diet, hospital visits and safety information (e.g. side effects) over this period.",
      "Participants were also asked to complete questionnaires about their health-related quality of life and income.",
      "The people having bypass surgery and sleeve surgery had greater weight loss and better quality of life at 3 years compared to those people having band surgery.",
      "Bypass surgery led to greater weight loss compared to sleeve surgery.",
      "There were fewer side effects after sleeve surgery compared to bypass and band surgery.",
      "Bypass surgery was found to provide the best value for money for the National Health Service."
    ],
    "summary_sentences": [
      "Bariatric surgery can improve health outcomes but high-quality comparative evidence about different procedures is limited.",
      "To compare the effectiveness and cost-effectiveness of Roux-en-Y gastric bypass (Bypass), adjustable gastric banding (Band) and sleeve gastrectomy (Sleeve) for people living with severe obesity.",
      "Multicentre, parallel-group, randomised controlled trial conducted in 12 National Health Service hospitals.",
      "Adults with a body mass index ≥ 35 kg/m Bypass, Band and Sleeve surgery.",
      "Primary outcomes were self-reported quality of life (EQ-5D-5L utility score) and weight (at least 50% excess weight lost) at 3 years.",
      "Sleeve and Bypass were each considered superior to Band if there was non-inferior excess weight loss (< 12% difference between groups) and superior quality of life.",
      "Sleeve was considered superior to Bypass by the same criteria.",
      "Secondary outcomes included comorbidities, adverse health events, generic and disease-specific quality of life at 6, 12, 24 and 36 months post randomisation, dietary intake, binge eating behaviour and cost-effectiveness.",
      "One thousand three hundred and fifty-one participants were randomised between December 2012 and September 2019.",
      "Five participants withdrew consent to use their data, leaving 1346 (462 Bypass, 464 Band, 420 Sleeve).",
      "The mean age was 47.3 years, 1020 (75.9%) were women and the mean weight and body mass index was 129.7 kg and 46.4 kg/m",
      "The study was impacted by the COVID-19 pandemic which prevented some participants having surgery and/or attending hospital for study follow-up appointments, which impacted on the completeness of data for these visits.",
      "Bypass and Sleeve are more effective than Band.",
      "Sleeve has inferior excess weight loss and lower mean quality-of-life score than Bypass.",
      "Longer-term follow-up is needed to determine the sustainability of observed effects and to examine adverse events.",
      "A comparison of optimal gastric bypass and optimal medical therapy for severe obesity is now needed to inform decision-making and health policy.",
      "This trial is registered as ClinicalTrials.gov: NCT02841527, ISRCTN00786323.",
      "This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 09/127/53) and is published in full in People who are overweight or obese may benefit from surgery to lose weight (bariatric surgery), improve quality of life and health.",
      "While several operations are available, it is uncertain which procedure leads to the best results for patients and the National Health Service.",
      "One thousand three hundred and forty-six adults with severe obesity referred for bariatric surgery from 12 hospitals in the United Kingdom.",
      "The people who took part were allocated by chance to one of three surgical procedures aimed at achieving weight loss: gastric bypass, gastric band or sleeve gastrectomy.",
      "Participants were followed up for 3 years.",
      "We collected information on weight loss, blood markers, diet, hospital visits and safety information (e.g. side effects) over this period.",
      "Participants were also asked to complete questionnaires about their health-related quality of life and income.",
      "The people having bypass surgery and sleeve surgery had greater weight loss and better quality of life at 3 years compared to those people having band surgery.",
      "Bypass surgery led to greater weight loss compared to sleeve surgery.",
      "There were fewer side effects after sleeve surgery compared to bypass and band surgery.",
      "Bypass surgery was found to provide the best value for money for the National Health Service."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41631344",
    "source": "pubmed",
    "sentences": [
      "Delayed gastric emptying is a known effect of glucagon-like peptide-1 receptor agonists, such as semaglutide.",
      "While tachyphylaxis has been reported, recent clinical data indicate an increased risk of residual gastric content on pre-operative gastric ultrasound in patients who are fasted.",
      "However, the limited available data do not control for several important potential confounders.",
      "We conducted a prospective, multicentre, matched case-control study, enrolling patients receiving semaglutide treatment for diabetes mellitus or weight loss and having elective surgery.",
      "For each patient receiving semaglutide treatment, we included a matched control based on age, BMI and diabetes mellitus status in a 1:1 ratio.",
      "In both cohorts, gastric ultrasound was performed in the supine position, followed by the right lateral decubitus position.",
      "A patient was considered to have a 'full stomach' if solid gastric content was visible in any position or if the calculated gastric volume in the right lateral decubitus position exceeded 1.5 ml.kg We enrolled 44 patients receiving semaglutide treatment and 44 matched controls.",
      "A full stomach was observed in 21/43 (49%) of patients receiving semaglutide treatment compared with 8/44 (18%) of controls (odds ratio 4.29, 95%CI 1.63-11.29, p = 0.003).",
      "Solid gastric contents were significantly more frequent in patients receiving semaglutide treatment (18/43 (42%)) compared with controls (3/44 (7%), odds ratio 9.85, 95%CI 2.57-37.76, p < 0.001).",
      "Calculated gastric volume did not differ significantly.",
      "This study compared gastric ultrasound findings in patients receiving semaglutide treatment with matched controls, thereby accounting directly for baseline delayed gastric emptying.",
      "Our findings highlight a persistently elevated pulmonary aspiration risk, even after withholding one administration of semaglutide and accounting for age, diabetes mellitus status and obesity.",
      "Where available, gastric ultrasound should be used to guide individualised anaesthetic management and optimise peri-operative safety.",
      "We studied people who were having planned surgery.",
      "Half of them were taking semaglutide (a medicine used for diabetes or weight loss), and the other half were similar people who were not taking it.",
      "Before surgery, doctors did an ultrasound scan of the stomach to see if there was food left inside.",
      "Semaglutide can slow how fast food leaves the stomach.",
      "This can be dangerous during surgery because food in the stomach can go into the lungs while a person is asleep.",
      "We wanted to check if people taking semaglutide still had food in their stomachs, even after fasting, and compare them fairly with similar people not taking the medicine.",
      "Nearly half of the people taking semaglutide still had food in their stomach before surgery.",
      "Only about 1 in 5 people not taking semaglutide had food in their stomach.",
      "Solid food was much more common in the stomachs of people taking semaglutide.",
      "The total amount of stomach contents was similar between groups, but the type of content mattered.",
      "These results show that people taking semaglutide may have a higher risk during surgery.",
      "Using stomach ultrasound can help doctors plan safer anaesthesia for each patient."
    ],
    "summary_sentences": [
      "Delayed gastric emptying is a known effect of glucagon-like peptide-1 receptor agonists, such as semaglutide.",
      "While tachyphylaxis has been reported, recent clinical data indicate an increased risk of residual gastric content on pre-operative gastric ultrasound in patients who are fasted.",
      "However, the limited available data do not control for several important potential confounders.",
      "We conducted a prospective, multicentre, matched case-control study, enrolling patients receiving semaglutide treatment for diabetes mellitus or weight loss and having elective surgery.",
      "For each patient receiving semaglutide treatment, we included a matched control based on age, BMI and diabetes mellitus status in a 1:1 ratio.",
      "In both cohorts, gastric ultrasound was performed in the supine position, followed by the right lateral decubitus position.",
      "A patient was considered to have a 'full stomach' if solid gastric content was visible in any position or if the calculated gastric volume in the right lateral decubitus position exceeded 1.5 ml.kg We enrolled 44 patients receiving semaglutide treatment and 44 matched controls.",
      "A full stomach was observed in 21/43 (49%) of patients receiving semaglutide treatment compared with 8/44 (18%) of controls (odds ratio 4.29, 95%CI 1.63-11.29, p = 0.003).",
      "Solid gastric contents were significantly more frequent in patients receiving semaglutide treatment (18/43 (42%)) compared with controls (3/44 (7%), odds ratio 9.85, 95%CI 2.57-37.76, p < 0.001).",
      "Calculated gastric volume did not differ significantly.",
      "This study compared gastric ultrasound findings in patients receiving semaglutide treatment with matched controls, thereby accounting directly for baseline delayed gastric emptying.",
      "Our findings highlight a persistently elevated pulmonary aspiration risk, even after withholding one administration of semaglutide and accounting for age, diabetes mellitus status and obesity.",
      "Where available, gastric ultrasound should be used to guide individualised anaesthetic management and optimise peri-operative safety.",
      "We studied people who were having planned surgery.",
      "Half of them were taking semaglutide (a medicine used for diabetes or weight loss), and the other half were similar people who were not taking it.",
      "Before surgery, doctors did an ultrasound scan of the stomach to see if there was food left inside.",
      "Semaglutide can slow how fast food leaves the stomach.",
      "This can be dangerous during surgery because food in the stomach can go into the lungs while a person is asleep.",
      "We wanted to check if people taking semaglutide still had food in their stomachs, even after fasting, and compare them fairly with similar people not taking the medicine.",
      "Nearly half of the people taking semaglutide still had food in their stomach before surgery.",
      "Only about 1 in 5 people not taking semaglutide had food in their stomach.",
      "Solid food was much more common in the stomachs of people taking semaglutide.",
      "The total amount of stomach contents was similar between groups, but the type of content mattered.",
      "These results show that people taking semaglutide may have a higher risk during surgery.",
      "Using stomach ultrasound can help doctors plan safer anaesthesia for each patient."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41631108",
    "source": "pubmed",
    "sentences": [
      "Converging lines of preclinical evidence support the neuroprotective properties of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Parkinson's disease (PD).",
      "Nevertheless, results from randomized-controlled clinical trials (RCTs) remain conflicting.",
      "To assess the safety and efficacy of GLP-1 RAs in PD.",
      "Systematic review and meta-analysis of randomized placebo-controlled clinical trials.",
      "A systematic search of MEDLINE and Scopus databases was conducted on October 7, 2025, for randomized placebo-controlled clinical trials investigating GLP-1 RAs in adults with PD.",
      "Risk of bias was evaluated using the Cochrane Collaboration risk-of-bias (RoB2) tool.",
      "Four RCTs comprising 667 PD patients (377 receiving GLP-1 RAs) were included.",
      "Between baseline and end-of-treatment, no differences were observed in the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III score change between GLP-1 RA- and placebo-treated patients in either off-medication (standardized mean difference (SMD): -0.16; 95% CI: -0.64 to 0.32; GLP-1 RAs were not associated with improvements in motor or non-motor domains of PD.",
      "However, robust preclinical evidence and promising findings in select subpopulations warrant further RCTs to evaluate their neuroprotective potential, prioritizing long-acting and brain-penetrant agents that effectively engage central GLP-1 circuits for PD treatment.",
      "The pre-specified protocol of the present systematic review and meta-analysis has been registered in the International Prospective Register of Ongoing Systematic Reviews PROSPERO (registration ID: CRD420251008703).",
      "Efficacy and safety of glucagon-like peptide-1 receptor agonists in Parkinson’s disease: a systematic review and meta-analysis Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are medications approved for type 2 diabetes and obesity that have shown neuroprotective effects in preclinical models of Parkinson’s disease (PD).",
      "However, clinical trial results have been inconsistent.",
      "In this systematic review and meta-analysis, we evaluated the overall safety and effectiveness of GLP-1 RAs in people with PD by analyzing data from all available randomized placebo-controlled clinical trials.",
      "Our findings indicate that GLP-1 RAs do not lead to measurable improvements in motor symptoms, cognitive performance, or quality of life when compared to placebo.",
      "Although the risk of serious adverse events was similar between treatment and placebo groups, GLP-1 RAs were associated with an increased risk of weight loss and gastrointestinal adverse events.",
      "Despite the lack of demonstrated clinical benefit, strong preclinical evidence and exploratory signals in specific patient subgroups support the need for further high-quality trials, particularly with long-acting and brain-penetrant GLP-1 RAs in early-stage PD populations."
    ],
    "summary_sentences": [
      "Converging lines of preclinical evidence support the neuroprotective properties of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Parkinson's disease (PD).",
      "Nevertheless, results from randomized-controlled clinical trials (RCTs) remain conflicting.",
      "To assess the safety and efficacy of GLP-1 RAs in PD.",
      "Systematic review and meta-analysis of randomized placebo-controlled clinical trials.",
      "A systematic search of MEDLINE and Scopus databases was conducted on October 7, 2025, for randomized placebo-controlled clinical trials investigating GLP-1 RAs in adults with PD.",
      "Risk of bias was evaluated using the Cochrane Collaboration risk-of-bias (RoB2) tool.",
      "Four RCTs comprising 667 PD patients (377 receiving GLP-1 RAs) were included.",
      "Between baseline and end-of-treatment, no differences were observed in the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III score change between GLP-1 RA- and placebo-treated patients in either off-medication (standardized mean difference (SMD): -0.16; 95% CI: -0.64 to 0.32; GLP-1 RAs were not associated with improvements in motor or non-motor domains of PD.",
      "However, robust preclinical evidence and promising findings in select subpopulations warrant further RCTs to evaluate their neuroprotective potential, prioritizing long-acting and brain-penetrant agents that effectively engage central GLP-1 circuits for PD treatment.",
      "The pre-specified protocol of the present systematic review and meta-analysis has been registered in the International Prospective Register of Ongoing Systematic Reviews PROSPERO (registration ID: CRD420251008703).",
      "Efficacy and safety of glucagon-like peptide-1 receptor agonists in Parkinson’s disease: a systematic review and meta-analysis Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are medications approved for type 2 diabetes and obesity that have shown neuroprotective effects in preclinical models of Parkinson’s disease (PD).",
      "However, clinical trial results have been inconsistent.",
      "In this systematic review and meta-analysis, we evaluated the overall safety and effectiveness of GLP-1 RAs in people with PD by analyzing data from all available randomized placebo-controlled clinical trials.",
      "Our findings indicate that GLP-1 RAs do not lead to measurable improvements in motor symptoms, cognitive performance, or quality of life when compared to placebo.",
      "Although the risk of serious adverse events was similar between treatment and placebo groups, GLP-1 RAs were associated with an increased risk of weight loss and gastrointestinal adverse events.",
      "Despite the lack of demonstrated clinical benefit, strong preclinical evidence and exploratory signals in specific patient subgroups support the need for further high-quality trials, particularly with long-acting and brain-penetrant GLP-1 RAs in early-stage PD populations."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41630857",
    "source": "pubmed",
    "sentences": [
      "There is a paucity of studies investigating the National Institutes of Health (NIH) funding priorities for back pain research.",
      "This study analyzed the portfolio of NIH research grants awarded for back pain in the United States.",
      "NIH grant data were collected from the NIH RePORTER database (2016-2023).",
      "Principal investigator (PI) characteristics were collected from academic websites including sex, graduate degree, and academic rank.",
      "NIH funding was analyzed for twenty clinical areas and compound annual growth rates (CAGRs) were calculated over the study period.",
      "Nonparametric tests were used to compare NIH funding totals by PI characteristics.",
      "From 2016 to 2023, the NIH research budget increased from $31.5 to $45.0 billion (CAGR 5.2%).",
      "Annual NIH funding for back pain research increased from $23.3 to $69.0 million (CAGR 17.0%) and totaled $523 million over the study period.",
      "Dementia ($19.7 billion, CAGR 19.2%) and diabetes ($8.9 billion, CAGR 1.3%) had the most NIH funding.",
      "The National Institute of Neurological Disorders and Stroke (45.0%) was the top funding institute and the R01 was the top funded grant mechanism (32.8%).",
      "The clinical areas receiving the most NIH funding for back pain research were pathophysiology (20.2%), social determinants (19.6%), and clinical trial networks (16.3%).",
      "Several PI characteristics were associated with higher NIH funding totals for back pain research including PhD degree and full professor rank (p<.001).",
      "Annual NIH funding for back pain research increased over the study period yet remains superseded by other clinical areas.",
      "Future coordinated efforts may be needed to stimulate NIH grant funding for back pain research."
    ],
    "summary_sentences": [
      "There is a paucity of studies investigating the National Institutes of Health (NIH) funding priorities for back pain research.",
      "This study analyzed the portfolio of NIH research grants awarded for back pain in the United States.",
      "NIH grant data were collected from the NIH RePORTER database (2016-2023).",
      "Principal investigator (PI) characteristics were collected from academic websites including sex, graduate degree, and academic rank.",
      "NIH funding was analyzed for twenty clinical areas and compound annual growth rates (CAGRs) were calculated over the study period.",
      "Nonparametric tests were used to compare NIH funding totals by PI characteristics.",
      "From 2016 to 2023, the NIH research budget increased from $31.5 to $45.0 billion (CAGR 5.2%).",
      "Annual NIH funding for back pain research increased from $23.3 to $69.0 million (CAGR 17.0%) and totaled $523 million over the study period.",
      "Dementia ($19.7 billion, CAGR 19.2%) and diabetes ($8.9 billion, CAGR 1.3%) had the most NIH funding.",
      "The National Institute of Neurological Disorders and Stroke (45.0%) was the top funding institute and the R01 was the top funded grant mechanism (32.8%).",
      "The clinical areas receiving the most NIH funding for back pain research were pathophysiology (20.2%), social determinants (19.6%), and clinical trial networks (16.3%).",
      "Several PI characteristics were associated with higher NIH funding totals for back pain research including PhD degree and full professor rank (p<.001).",
      "Annual NIH funding for back pain research increased over the study period yet remains superseded by other clinical areas.",
      "Future coordinated efforts may be needed to stimulate NIH grant funding for back pain research."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41629834",
    "source": "pubmed",
    "sentences": [
      "Lifestyle interventions are critical for optimizing maternal and child health outcomes during pregnancy.",
      "As a mind-body exercise rooted in the principles of traditional Chinese Medicine (TCM), qigong shows promise as adaptable prenatal interventions, but the evidence is limited.",
      "This multicenter randomized controlled trial (RCT) protocol aims to evaluate the additive effect of a qigong intervention program, compared to routine lifestyle intervention alone, on reducing the rate of caesarean section (primary outcome) and improving a range of secondary maternal and child health outcomes.",
      "This multicenter RCT will be conducted across 11 institutions in China.",
      "A total of 1062 participants aged 18-45 years, with singleton pregnancies at 11-13 This rigorously designed multicenter RCT protocol addresses a significant gap by investigating whether integrating the traditional mind-body practice of qigong into standard prenatal lifestyle education confers additional benefits for reducing cesarean sections and enhancing broader maternal-child health metrics.",
      "The findings will provide robust evidence on the clinical value of this TCM intervention in integrative prenatal care to improve pregnancy outcomes and maternal and child well-being.",
      "This trial was registered at International Traditional Medicine Clinical Trial Registry, ITMCTR2025002612."
    ],
    "summary_sentences": [
      "Lifestyle interventions are critical for optimizing maternal and child health outcomes during pregnancy.",
      "As a mind-body exercise rooted in the principles of traditional Chinese Medicine (TCM), qigong shows promise as adaptable prenatal interventions, but the evidence is limited.",
      "This multicenter randomized controlled trial (RCT) protocol aims to evaluate the additive effect of a qigong intervention program, compared to routine lifestyle intervention alone, on reducing the rate of caesarean section (primary outcome) and improving a range of secondary maternal and child health outcomes.",
      "This multicenter RCT will be conducted across 11 institutions in China.",
      "A total of 1062 participants aged 18-45 years, with singleton pregnancies at 11-13 This rigorously designed multicenter RCT protocol addresses a significant gap by investigating whether integrating the traditional mind-body practice of qigong into standard prenatal lifestyle education confers additional benefits for reducing cesarean sections and enhancing broader maternal-child health metrics.",
      "The findings will provide robust evidence on the clinical value of this TCM intervention in integrative prenatal care to improve pregnancy outcomes and maternal and child well-being.",
      "This trial was registered at International Traditional Medicine Clinical Trial Registry, ITMCTR2025002612."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41629827",
    "source": "pubmed",
    "sentences": [
      "The global burden of chronic kidney disease (CKD) is increasing, driven largely by risk factors such as hypertension and diabetes.",
      "Modifiable lifestyle factors, particularly diet, may play a key role in renal health.",
      "This study aimed to investigate the association between diet quality, assessed by the Healthy Eating Index-2015 (HEI-2015), and kidney function in a large sample of Iranian adults from the general population.",
      "This cross-sectional analysis used baseline data from the Ravansar Non-Communicable Diseases (RaNCD) cohort study, involving 8,787 adults aged 35-65 years.",
      "Dietary intake was assessed using a validated Food Frequency Questionnaire (FFQ), and diet quality was calculated using the HEI-2015.",
      "Kidney function was determined by estimating the glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) study equation.",
      "The association between HEI-2015 quartiles and the odds of reduced eGFR (defined as < 60 mL/min/1.73 m²) was examined using logistic regression.",
      "Among the participants, 46.97% were men.",
      "A significant, inverse, dose-response association was observed between HEI-2015 scores and the odds of reduced eGFR.",
      "In the fully adjusted model, participants in the highest HEI quartile had 55% lower odds of reduced eGFR compared to those in the lowest quartile (OR: 0.45; 95% CI: 0.36, 0.58).",
      "Dietary analysis showed that individuals with preserved kidney function consumed significantly more fruits, vegetables, and seafood, but less sodium and added sugars (P < 0.05).",
      "Higher diet quality, as measured by the HEI-2015, is significantly associated with better kidney function and lower odds of reduced eGFR.",
      "These findings highlight the potential for dietary interventions that promote overall healthy eating patterns to contribute to the primary prevention of CKD.",
      "Not applicable."
    ],
    "summary_sentences": [
      "The global burden of chronic kidney disease (CKD) is increasing, driven largely by risk factors such as hypertension and diabetes.",
      "Modifiable lifestyle factors, particularly diet, may play a key role in renal health.",
      "This study aimed to investigate the association between diet quality, assessed by the Healthy Eating Index-2015 (HEI-2015), and kidney function in a large sample of Iranian adults from the general population.",
      "This cross-sectional analysis used baseline data from the Ravansar Non-Communicable Diseases (RaNCD) cohort study, involving 8,787 adults aged 35-65 years.",
      "Dietary intake was assessed using a validated Food Frequency Questionnaire (FFQ), and diet quality was calculated using the HEI-2015.",
      "Kidney function was determined by estimating the glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) study equation.",
      "The association between HEI-2015 quartiles and the odds of reduced eGFR (defined as < 60 mL/min/1.73 m²) was examined using logistic regression.",
      "Among the participants, 46.97% were men.",
      "A significant, inverse, dose-response association was observed between HEI-2015 scores and the odds of reduced eGFR.",
      "In the fully adjusted model, participants in the highest HEI quartile had 55% lower odds of reduced eGFR compared to those in the lowest quartile (OR: 0.45; 95% CI: 0.36, 0.58).",
      "Dietary analysis showed that individuals with preserved kidney function consumed significantly more fruits, vegetables, and seafood, but less sodium and added sugars (P < 0.05).",
      "Higher diet quality, as measured by the HEI-2015, is significantly associated with better kidney function and lower odds of reduced eGFR.",
      "These findings highlight the potential for dietary interventions that promote overall healthy eating patterns to contribute to the primary prevention of CKD.",
      "Not applicable."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41629143",
    "source": "pubmed",
    "sentences": [
      "Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have redefined the therapeutic landscape of heart failure (HF), both with reduced (HFrEF) and preserved (HFpEF) ejection fraction.",
      "Historically, treatment has relied on diuretics to relieve congestion, with limited prognostic impact and dose-related adverse effects.",
      "SGLT2i, originally developed for type 2 diabetes mellitus, have demonstrated in randomized trials a significant reduction in hospitalizations and cardiovascular mortality, with benefits extending to non-diabetic patients.",
      "SGLT2 inhibitorsTheir",
      "mechanism combines moderate osmotic natriuresis, selective reduction of extracellular volume, renal protection, and minimal neurohormonal activation.",
      "In contrast to loop diuretics, which induce rapid volume depletion and RAAS activation, SGLT2i stabilize sodium-water balance without significant hemodynamic compromise.",
      "In clinical practice, their combination with diuretics requires careful titration to prevent hypovolemia, hypotension, and renal dysfunction, especially in frail elderly patients.",
      "Evidence suggests that SGLT2i may reduce chronic diuretic requirements, improve renal function, and provide additional cardiovascular protection.",
      "These findings support their early and integrated use, positioning SGLT2i as a cornerstone in the contemporary management of heart failure."
    ],
    "summary_sentences": [
      "Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have redefined the therapeutic landscape of heart failure (HF), both with reduced (HFrEF) and preserved (HFpEF) ejection fraction.",
      "Historically, treatment has relied on diuretics to relieve congestion, with limited prognostic impact and dose-related adverse effects.",
      "SGLT2i, originally developed for type 2 diabetes mellitus, have demonstrated in randomized trials a significant reduction in hospitalizations and cardiovascular mortality, with benefits extending to non-diabetic patients.",
      "SGLT2 inhibitorsTheir",
      "mechanism combines moderate osmotic natriuresis, selective reduction of extracellular volume, renal protection, and minimal neurohormonal activation.",
      "In contrast to loop diuretics, which induce rapid volume depletion and RAAS activation, SGLT2i stabilize sodium-water balance without significant hemodynamic compromise.",
      "In clinical practice, their combination with diuretics requires careful titration to prevent hypovolemia, hypotension, and renal dysfunction, especially in frail elderly patients.",
      "Evidence suggests that SGLT2i may reduce chronic diuretic requirements, improve renal function, and provide additional cardiovascular protection.",
      "These findings support their early and integrated use, positioning SGLT2i as a cornerstone in the contemporary management of heart failure."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41628860",
    "source": "pubmed",
    "sentences": [
      "Medical nutritional therapy, an evidence-based application of the nutrition care process guided by a registered dietitian nutritionist, is an integral part of diabetes management, with emerging evidence suggesting distinct nutritional requirements in this population.",
      "A thorough review of the existing literature reveals an imperative to address the specific requirements for vitamins and minerals in this population.",
      "Current guidelines have given limited attention to micronutrients, despite the higher prevalence of deficiencies and the altered patterns of association between serum micronutrient levels and multiple health outcomes among individuals with type 2 diabetes (T2D).",
      "To enhance diabetes management, an international multidisciplinary panel of 20 experts from 12 countries participated in a modified Delphi process, which was informed by a narrative review conducted by the research team, to reach consensus on 18 statements, encompassing 11 nutrient-specific recommendations and 7 statements outlining future directions in diabetes nutrition therapy research.",
      "The plan for this consensus has been registered on the Practice Guideline Registration for Transparency (PREPARE) (Registration Number: PREPARE-2025CN1178).",
      "The expert panel proposed potential target serum levels, screening strategies, and micronutrient supplementation for people with T2D and that personalized nutritional strategies integrating individual characteristics, genetic information, and gut microbiota represent key areas for future research."
    ],
    "summary_sentences": [
      "Medical nutritional therapy, an evidence-based application of the nutrition care process guided by a registered dietitian nutritionist, is an integral part of diabetes management, with emerging evidence suggesting distinct nutritional requirements in this population.",
      "A thorough review of the existing literature reveals an imperative to address the specific requirements for vitamins and minerals in this population.",
      "Current guidelines have given limited attention to micronutrients, despite the higher prevalence of deficiencies and the altered patterns of association between serum micronutrient levels and multiple health outcomes among individuals with type 2 diabetes (T2D).",
      "To enhance diabetes management, an international multidisciplinary panel of 20 experts from 12 countries participated in a modified Delphi process, which was informed by a narrative review conducted by the research team, to reach consensus on 18 statements, encompassing 11 nutrient-specific recommendations and 7 statements outlining future directions in diabetes nutrition therapy research.",
      "The plan for this consensus has been registered on the Practice Guideline Registration for Transparency (PREPARE) (Registration Number: PREPARE-2025CN1178).",
      "The expert panel proposed potential target serum levels, screening strategies, and micronutrient supplementation for people with T2D and that personalized nutritional strategies integrating individual characteristics, genetic information, and gut microbiota represent key areas for future research."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41628730",
    "source": "pubmed",
    "sentences": [
      "Previous evidence on the associations of dairy intake with risk of cardiometabolic diseases has been inconsistent with studies showing either inverse, null or positive associations.",
      "We aimed to assess these associations in China, where dairy consumption level is low and cardiometabolic disease patterns differ from those in the West.",
      "The China Kadoorie Biobank is a prospective cohort study with ∼512,000 adult participants recruited from ten diverse localities in China during 2004-08.",
      "At baseline and periodic resurveys, information on the consumption frequency of major food groups was collected using a validated interviewer-administered laptop-based questionnaire.",
      "During approximately 5.4 million person-years of follow-up, 18,306 diabetes, 33,946 ischemic heart diseases (IHD, including 3888 acute myocardial infarction [MI]), 33,670 ischemic stroke (IS), 7191 intracerebral haemorrhage (ICH) cases, and 13,241 cardiovascular deaths were recorded.",
      "Cox regression was used to calculate adjusted hazard ratios (HRs) relating dairy intake to cardiometabolic diseases risk.",
      "At baseline, 10.7% of participants regularly consumed (i.e. ≥4 days/week) dairy products, while 70.0% reported never or rare consumption.",
      "After adjusting for potential confounders including BMI, dairy consumption was significantly and positively associated with IHD but inversely associated with risks of acute MI, ICH and cardiovascular death, with HRs for regular consumers vs non-consumers being 1.09 (95% CI: 1.06-1.12), 0.88 (0.80-0.98), 0.69 (0.62-0.76) and 0.82 (0.77-0.87), respectively, but not with diabetes and IS.",
      "These associations were largely independent of systolic blood pressure.",
      "In Chinese adults, higher dairy consumption was associated with lower risks of acute MI, ICH and cardiovascular death.",
      "Future studies are warranted to further elucidate these relationships and their causality."
    ],
    "summary_sentences": [
      "Previous evidence on the associations of dairy intake with risk of cardiometabolic diseases has been inconsistent with studies showing either inverse, null or positive associations.",
      "We aimed to assess these associations in China, where dairy consumption level is low and cardiometabolic disease patterns differ from those in the West.",
      "The China Kadoorie Biobank is a prospective cohort study with ∼512,000 adult participants recruited from ten diverse localities in China during 2004-08.",
      "At baseline and periodic resurveys, information on the consumption frequency of major food groups was collected using a validated interviewer-administered laptop-based questionnaire.",
      "During approximately 5.4 million person-years of follow-up, 18,306 diabetes, 33,946 ischemic heart diseases (IHD, including 3888 acute myocardial infarction [MI]), 33,670 ischemic stroke (IS), 7191 intracerebral haemorrhage (ICH) cases, and 13,241 cardiovascular deaths were recorded.",
      "Cox regression was used to calculate adjusted hazard ratios (HRs) relating dairy intake to cardiometabolic diseases risk.",
      "At baseline, 10.7% of participants regularly consumed (i.e. ≥4 days/week) dairy products, while 70.0% reported never or rare consumption.",
      "After adjusting for potential confounders including BMI, dairy consumption was significantly and positively associated with IHD but inversely associated with risks of acute MI, ICH and cardiovascular death, with HRs for regular consumers vs non-consumers being 1.09 (95% CI: 1.06-1.12), 0.88 (0.80-0.98), 0.69 (0.62-0.76) and 0.82 (0.77-0.87), respectively, but not with diabetes and IS.",
      "These associations were largely independent of systolic blood pressure.",
      "In Chinese adults, higher dairy consumption was associated with lower risks of acute MI, ICH and cardiovascular death.",
      "Future studies are warranted to further elucidate these relationships and their causality."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41628529",
    "source": "pubmed",
    "sentences": [
      "Latent autoimmune diabetes in adults (LADA) exhibits clinical features overlapping type 1 and type 2 diabetes.",
      "However, the burden and longitudinal progression of subclinical atherosclerosis (AS) in LADA, particularly under different treatments, remain insufficiently defined.",
      "This retrospective secondary analysis used data from a previously conducted clinical trial evaluating β-cell-preserving therapies in LADA.",
      "A total of 103 adults with diabetes were included (64 LADA, 39 T2DM).",
      "Carotid and femoral intima-media thickness (IMT) were assessed using high-resolution B-mode ultrasound at baseline, and 48 LADA patients underwent repeat assessment after two years.",
      "Participants received either insulin-based therapy or oral antidiabetic drugs (OADs), including sulfonylureas (SUs) and non-SU agents.",
      "Multivariable regression and mixed-effects models were used to compare baseline IMT and evaluate longitudinal IMT change.",
      "Compared with T2DM, LADA participants were younger (p = 0.002) and had higher HbA1c (p = 0.001), with similar lipid profiles.",
      "Baseline carotid IMT was lower in LADA in unadjusted analyses but was comparable after multivariable adjustment (p = 0.579).",
      "Over two years, insulin-treated LADA participants showed no significant progression of carotid or femoral IMT.",
      "In contrast, SU exposure was associated with significant carotid IMT progression (p = 0.048) and a trend toward increased femoral IMT.",
      "After adjustment for confounders, subclinical atherosclerosis in LADA was comparable to that in T2DM.",
      "In longitudinal analyses within LADA, insulin-based therapy was associated with stable IMT, whereas SU exposure was associated with greater IMT progression.",
      "These findings support further prospective studies to clarify treatment-related vascular effects in LADA and to inform cardiovascular risk-focused management."
    ],
    "summary_sentences": [
      "Latent autoimmune diabetes in adults (LADA) exhibits clinical features overlapping type 1 and type 2 diabetes.",
      "However, the burden and longitudinal progression of subclinical atherosclerosis (AS) in LADA, particularly under different treatments, remain insufficiently defined.",
      "This retrospective secondary analysis used data from a previously conducted clinical trial evaluating β-cell-preserving therapies in LADA.",
      "A total of 103 adults with diabetes were included (64 LADA, 39 T2DM).",
      "Carotid and femoral intima-media thickness (IMT) were assessed using high-resolution B-mode ultrasound at baseline, and 48 LADA patients underwent repeat assessment after two years.",
      "Participants received either insulin-based therapy or oral antidiabetic drugs (OADs), including sulfonylureas (SUs) and non-SU agents.",
      "Multivariable regression and mixed-effects models were used to compare baseline IMT and evaluate longitudinal IMT change.",
      "Compared with T2DM, LADA participants were younger (p = 0.002) and had higher HbA1c (p = 0.001), with similar lipid profiles.",
      "Baseline carotid IMT was lower in LADA in unadjusted analyses but was comparable after multivariable adjustment (p = 0.579).",
      "Over two years, insulin-treated LADA participants showed no significant progression of carotid or femoral IMT.",
      "In contrast, SU exposure was associated with significant carotid IMT progression (p = 0.048) and a trend toward increased femoral IMT.",
      "After adjustment for confounders, subclinical atherosclerosis in LADA was comparable to that in T2DM.",
      "In longitudinal analyses within LADA, insulin-based therapy was associated with stable IMT, whereas SU exposure was associated with greater IMT progression.",
      "These findings support further prospective studies to clarify treatment-related vascular effects in LADA and to inform cardiovascular risk-focused management."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41627802",
    "source": "pubmed",
    "sentences": [
      "Heart failure (HF) is a common complication of type 2 diabetes (T2D).",
      "Oral semaglutide reduced the risk of major adverse cardiovascular (CV) events (MACE; comprising CV death, nonfatal myocardial infarction, or nonfatal stroke) in people with T2D in the SOUL trial, but the impact on HF outcomes in these participants is unknown.",
      "To evaluate the effect of oral semaglutide on HF events, MACE, and safety among participants with or without HF at baseline.",
      "This is a secondary analysis of the double-blind, placebo-controlled, event-driven, phase 3b SOUL randomized clinical trial, which was conducted at 444 centers in 33 countries.",
      "Participants were enrolled from June 17, 2019, to March 24, 2021, and had T2D and atherosclerotic CV disease and/or chronic kidney disease, stratified according to the presence or absence of HF history at baseline.",
      "Data were analyzed from December 2024 to August 2025.",
      "Once-daily oral semaglutide or placebo in addition to standard of care.",
      "Prespecified composite HF outcome (time to first occurrence of HF hospitalization, urgent HF visit, or CV death).",
      "Overall, 9650 participants (median [IQR] age, 66.0",
      "[61.0-72.0] years; 2790",
      "[28.9%] female) were randomized, with a mean (SD) follow-up of 47.5 (10.9) months.",
      "Of these participants, 2229 (23.1%) had HF history (991 [10.3%] with preserved ejection fraction, 592",
      "[6.1%] with reduced ejection fraction, and 646 [6.7%] with unknown subtype).",
      "For participants with HF at baseline, the hazard ratio (HR) for risk of the composite HF outcome with oral semaglutide vs placebo was 0.78 (95% CI, 0.63-0.96) and was 1.01 (95% CI, 0.84-1.20) in those without HF at baseline (P for interaction = .06).",
      "Among participants with HF, the HR was 0.59 (95% CI, 0.39-0.86) in those with preserved ejection fraction and 0.98 (95% CI, 0.70-1.38) in those with reduced ejection fraction.",
      "There was no heterogeneity in the risk reduction of MACE with oral semaglutide in participants with HF history (HR, 0.83; 95% CI, 0.68-1.01) or without HF history (HR, 0.86; 95% CI, 0.75-0.98) (P for interaction = .77).",
      "Serious adverse event occurrence among participants with HF was similar with oral semaglutide (594 [53.8%]) and placebo (642 [57.1%]).",
      "In this secondary analysis of the SOUL randomized clinical trial, among individuals with T2D, atherosclerotic CV disease, and/or chronic kidney disease, a reduction of HF events was observed with use of oral semaglutide compared with placebo in those with a history of HF, without increasing the risk of serious adverse events.",
      "These data support the potential benefit of oral semaglutide in reducing HF events in people with T2D and HF. ClinicalTrials.gov",
      "Identifier: NCT03914326."
    ],
    "summary_sentences": [
      "Heart failure (HF) is a common complication of type 2 diabetes (T2D).",
      "Oral semaglutide reduced the risk of major adverse cardiovascular (CV) events (MACE; comprising CV death, nonfatal myocardial infarction, or nonfatal stroke) in people with T2D in the SOUL trial, but the impact on HF outcomes in these participants is unknown.",
      "To evaluate the effect of oral semaglutide on HF events, MACE, and safety among participants with or without HF at baseline.",
      "This is a secondary analysis of the double-blind, placebo-controlled, event-driven, phase 3b SOUL randomized clinical trial, which was conducted at 444 centers in 33 countries.",
      "Participants were enrolled from June 17, 2019, to March 24, 2021, and had T2D and atherosclerotic CV disease and/or chronic kidney disease, stratified according to the presence or absence of HF history at baseline.",
      "Data were analyzed from December 2024 to August 2025.",
      "Once-daily oral semaglutide or placebo in addition to standard of care.",
      "Prespecified composite HF outcome (time to first occurrence of HF hospitalization, urgent HF visit, or CV death).",
      "Overall, 9650 participants (median [IQR] age, 66.0",
      "[61.0-72.0] years; 2790",
      "[28.9%] female) were randomized, with a mean (SD) follow-up of 47.5 (10.9) months.",
      "Of these participants, 2229 (23.1%) had HF history (991 [10.3%] with preserved ejection fraction, 592",
      "[6.1%] with reduced ejection fraction, and 646 [6.7%] with unknown subtype).",
      "For participants with HF at baseline, the hazard ratio (HR) for risk of the composite HF outcome with oral semaglutide vs placebo was 0.78 (95% CI, 0.63-0.96) and was 1.01 (95% CI, 0.84-1.20) in those without HF at baseline (P for interaction = .06).",
      "Among participants with HF, the HR was 0.59 (95% CI, 0.39-0.86) in those with preserved ejection fraction and 0.98 (95% CI, 0.70-1.38) in those with reduced ejection fraction.",
      "There was no heterogeneity in the risk reduction of MACE with oral semaglutide in participants with HF history (HR, 0.83; 95% CI, 0.68-1.01) or without HF history (HR, 0.86; 95% CI, 0.75-0.98) (P for interaction = .77).",
      "Serious adverse event occurrence among participants with HF was similar with oral semaglutide (594 [53.8%]) and placebo (642 [57.1%]).",
      "In this secondary analysis of the SOUL randomized clinical trial, among individuals with T2D, atherosclerotic CV disease, and/or chronic kidney disease, a reduction of HF events was observed with use of oral semaglutide compared with placebo in those with a history of HF, without increasing the risk of serious adverse events.",
      "These data support the potential benefit of oral semaglutide in reducing HF events in people with T2D and HF. ClinicalTrials.gov",
      "Identifier: NCT03914326."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41627541",
    "source": "pubmed",
    "sentences": [
      "To evaluate the efficacy of α-amylase enzyme prepared from fermented deglycyrrhizinated licorice root extract (FDGL) in treating early-stage diabetic polyneuropathy (DPN).",
      "A double-blind, placebo-controlled randomized trial involving 83 type 1 and II diabetic patients aged 15–65 years with diabetes duration ≤ 5 years, serum amylase < 45 IU/L. Patients were not complaining of clinical diabetic polyneuropathy (DPN), yet they showed demonstrable electrophysiological changes (vibration perception threshold",
      "[VPT] > 15 V), low nerve conduction velocity (NCV), and low serum amylase levels.",
      "Patients were randomized to receive either FDGL capsules (gp A; 0.5 gm twice daily containing 1250 IU of α-amylase) or a matched placebo (gp B) for 6 months.",
      "For comparison, 20 healthy volunteers matched for age, sex, and body constitution were recruited (control gp).",
      "Primary outcomes were the changes in motor nerve conduction velocity (MCV) and vibration perception threshold (VPT) from baseline.",
      "Secondary outcomes included changes in sensory nerve conduction velocity (SCV), serum amylase levels, and HbA1C. Outcomes were assessed at baseline, after 3, and 6 months.",
      "The study was registered on ClinicalTrials.gov (NCT07148804).",
      "A total of 83 diabetic patients were analyzed.",
      "Compared to placebo, patients who received FDGL (GpA) demonstrated a significant increase in MCV, SCV, and serum amylase with a reduction in VPT at 3 and 6-month follow-up ( Oral administration of α-amylase enzyme in FDGL significantly improved nerve conduction and restored serum amylase levels in both type I and II diabetic patients.",
      "Further studies are needed to verify its effect on other complications.",
      "This study was registered at ClinicalTrials.gov (NCT07148804).",
      "The online version contains supplementary material available at 10.1007/s12020-025-04476-5."
    ],
    "summary_sentences": [
      "To evaluate the efficacy of α-amylase enzyme prepared from fermented deglycyrrhizinated licorice root extract (FDGL) in treating early-stage diabetic polyneuropathy (DPN).",
      "A double-blind, placebo-controlled randomized trial involving 83 type 1 and II diabetic patients aged 15–65 years with diabetes duration ≤ 5 years, serum amylase < 45 IU/L. Patients were not complaining of clinical diabetic polyneuropathy (DPN), yet they showed demonstrable electrophysiological changes (vibration perception threshold",
      "[VPT] > 15 V), low nerve conduction velocity (NCV), and low serum amylase levels.",
      "Patients were randomized to receive either FDGL capsules (gp A; 0.5 gm twice daily containing 1250 IU of α-amylase) or a matched placebo (gp B) for 6 months.",
      "For comparison, 20 healthy volunteers matched for age, sex, and body constitution were recruited (control gp).",
      "Primary outcomes were the changes in motor nerve conduction velocity (MCV) and vibration perception threshold (VPT) from baseline.",
      "Secondary outcomes included changes in sensory nerve conduction velocity (SCV), serum amylase levels, and HbA1C. Outcomes were assessed at baseline, after 3, and 6 months.",
      "The study was registered on ClinicalTrials.gov (NCT07148804).",
      "A total of 83 diabetic patients were analyzed.",
      "Compared to placebo, patients who received FDGL (GpA) demonstrated a significant increase in MCV, SCV, and serum amylase with a reduction in VPT at 3 and 6-month follow-up ( Oral administration of α-amylase enzyme in FDGL significantly improved nerve conduction and restored serum amylase levels in both type I and II diabetic patients.",
      "Further studies are needed to verify its effect on other complications.",
      "This study was registered at ClinicalTrials.gov (NCT07148804).",
      "The online version contains supplementary material available at 10.1007/s12020-025-04476-5."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41627441",
    "source": "pubmed",
    "sentences": [
      "Heart failure (HF), including heart failure with reduced ejection fraction (HFrEF), remains a major public health issue with increasing disease burden.",
      "Recent advances, particularly data on sodium-glucose cotransporter-2 inhibitors (SGLT2i), have shifted HFrEF treatment paradigms based on strong evidence from randomised-controlled trials (RCTs).",
      "There is a lack of data reflecting HFrEF patient outcomes in relation to SGLT2i treatment in a real-world environment.",
      "The ongoing H Of 810 HFrEF patients (513 SGLT2i, 297 no-SGLT2i), the median age was 70 years, and 23% were female.",
      "Baseline characteristics were comparable between groups.",
      "Median LVEF was 30%, and 39% had type 2 diabetes.",
      "Use of renin-angiotensin-aldosterone system inhibitors, beta-blockers, and mineralocorticoid receptor antagonists (MRA) was more common in the SGLT2i group.",
      "Patients treated with SGLT2i at baseline had significantly lower all-cause mortality during FU in unadjusted time-to-event analyses (HR [95% CI] 0.53",
      "[0.33-0.88]; p = 0.012).",
      "However, in multivariate analyses, only MRA treatment was independently associated with reduced mortality risk during FU (HR [95% CI] 0.41",
      "[0.23-0.74]; p = 0.003).",
      "In a sub-cohort of patients being continuously treated with an SGLT2i during FU, the observed effect of SGLT2i was more pronounced (unadjusted HR",
      "[95% CI] 0.46",
      "[0.28-0.77], p = 0.0023), and continuous SGLT2i treatment was significantly associated with lower all-cause mortality in multivariate analyses (adjusted HR [95% CI] 0.54",
      "[0.30-0.99], p = 0.046).",
      "In this prospective German HF registry, SGLT2i treatment was significantly associated with reduced all-cause mortality in HFrEF patients only with continuous use during FU.",
      "Treatment with MRA was independently associated with lower all-cause mortality in all performed analyses.",
      "These findings add to the available body of evidence regarding the real-world effectiveness of SGLT2i in HFrEF.",
      "NCT04844944."
    ],
    "summary_sentences": [
      "Heart failure (HF), including heart failure with reduced ejection fraction (HFrEF), remains a major public health issue with increasing disease burden.",
      "Recent advances, particularly data on sodium-glucose cotransporter-2 inhibitors (SGLT2i), have shifted HFrEF treatment paradigms based on strong evidence from randomised-controlled trials (RCTs).",
      "There is a lack of data reflecting HFrEF patient outcomes in relation to SGLT2i treatment in a real-world environment.",
      "The ongoing H Of 810 HFrEF patients (513 SGLT2i, 297 no-SGLT2i), the median age was 70 years, and 23% were female.",
      "Baseline characteristics were comparable between groups.",
      "Median LVEF was 30%, and 39% had type 2 diabetes.",
      "Use of renin-angiotensin-aldosterone system inhibitors, beta-blockers, and mineralocorticoid receptor antagonists (MRA) was more common in the SGLT2i group.",
      "Patients treated with SGLT2i at baseline had significantly lower all-cause mortality during FU in unadjusted time-to-event analyses (HR [95% CI] 0.53",
      "[0.33-0.88]; p = 0.012).",
      "However, in multivariate analyses, only MRA treatment was independently associated with reduced mortality risk during FU (HR [95% CI] 0.41",
      "[0.23-0.74]; p = 0.003).",
      "In a sub-cohort of patients being continuously treated with an SGLT2i during FU, the observed effect of SGLT2i was more pronounced (unadjusted HR",
      "[95% CI] 0.46",
      "[0.28-0.77], p = 0.0023), and continuous SGLT2i treatment was significantly associated with lower all-cause mortality in multivariate analyses (adjusted HR [95% CI] 0.54",
      "[0.30-0.99], p = 0.046).",
      "In this prospective German HF registry, SGLT2i treatment was significantly associated with reduced all-cause mortality in HFrEF patients only with continuous use during FU.",
      "Treatment with MRA was independently associated with lower all-cause mortality in all performed analyses.",
      "These findings add to the available body of evidence regarding the real-world effectiveness of SGLT2i in HFrEF.",
      "NCT04844944."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41628090",
    "source": "pubmed",
    "sentences": [
      "Chinese immigrants face numerous social determinants of health (SDOH) challenges that limit access to evidence-based diabetes self-management education and support programs (DSMES).",
      "To address these challenges, our team developed the LINK-IT intervention.",
      "This manuscript presents the study protocol for the LINK-IT trial.",
      "The LINK-IT trial is a 12-month, 3-arm randomized controlled trial aiming to enroll 405 Chinese immigrants with T2D (HbA1c≥7%) from multiple community and clinical settings in New York City.",
      "A total of 405 participants will be randomly allocated to one of three groups (n = 135 per group): (1) video-based DSMES plus community health worker (CHW) support (VIDEO+CHW), (2) video-based DSMES only (VIDEO), or (3) wait-list control (CONTROL).",
      "The VIDEO+CHW group will receive 24 culturally and linguistically tailored DSMES videos (one per week for 24 weeks) delivered via text message links, along with biweekly (every other week) phone calls from trained CHWs to review video content, support goal setting, and address SDOH barriers.",
      "The VIDEO group will receive the same video intervention without CHW support.",
      "The CONTROL group will receive usual care and will be offered access to the videos upon study completion.",
      "The primary outcome is the change in HbA1c at 6 months.",
      "Secondary outcomes include changes in HbA1c at 12 months, self-efficacy for diabetes, dietary intake, physical activity, medication adherence and emotional support at 6 and 12 months.",
      "Data will be analyzed using an intention-to-treat approach with linear mixed-effects models.",
      "This study protocol has been approved by the Institutional Review Board of the NYU Grossman School of Medicine (S23-01274).",
      "All study procedures will adhere to the ethical principles outlined in the Declaration of Helsinki.",
      "Written or verbal informed consent will be obtained from all participants.",
      "Study results will be disseminated through peer-reviewed publications, presentations at scientific conferences, and community events.",
      "The LINK-IT trial was registered on March 20, 2024, on ClinicalTrials.gov under the identifier NCT06319716; https://clinicaltrials.gov/study/NCT06319716."
    ],
    "summary_sentences": [
      "Chinese immigrants face numerous social determinants of health (SDOH) challenges that limit access to evidence-based diabetes self-management education and support programs (DSMES).",
      "To address these challenges, our team developed the LINK-IT intervention.",
      "This manuscript presents the study protocol for the LINK-IT trial.",
      "The LINK-IT trial is a 12-month, 3-arm randomized controlled trial aiming to enroll 405 Chinese immigrants with T2D (HbA1c≥7%) from multiple community and clinical settings in New York City.",
      "A total of 405 participants will be randomly allocated to one of three groups (n = 135 per group): (1) video-based DSMES plus community health worker (CHW) support (VIDEO+CHW), (2) video-based DSMES only (VIDEO), or (3) wait-list control (CONTROL).",
      "The VIDEO+CHW group will receive 24 culturally and linguistically tailored DSMES videos (one per week for 24 weeks) delivered via text message links, along with biweekly (every other week) phone calls from trained CHWs to review video content, support goal setting, and address SDOH barriers.",
      "The VIDEO group will receive the same video intervention without CHW support.",
      "The CONTROL group will receive usual care and will be offered access to the videos upon study completion.",
      "The primary outcome is the change in HbA1c at 6 months.",
      "Secondary outcomes include changes in HbA1c at 12 months, self-efficacy for diabetes, dietary intake, physical activity, medication adherence and emotional support at 6 and 12 months.",
      "Data will be analyzed using an intention-to-treat approach with linear mixed-effects models.",
      "This study protocol has been approved by the Institutional Review Board of the NYU Grossman School of Medicine (S23-01274).",
      "All study procedures will adhere to the ethical principles outlined in the Declaration of Helsinki.",
      "Written or verbal informed consent will be obtained from all participants.",
      "Study results will be disseminated through peer-reviewed publications, presentations at scientific conferences, and community events.",
      "The LINK-IT trial was registered on March 20, 2024, on ClinicalTrials.gov under the identifier NCT06319716; https://clinicaltrials.gov/study/NCT06319716."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41627616",
    "source": "pubmed",
    "sentences": [
      "Thyroid hormones are mainly concerning with regulation of organs metabolism.",
      "Hypothyroidism is a pathological condition characterized by decrease of T3 and T4 level that negatively impact various organs especially liver and lung.",
      "Dapagliflozin (DAPA) is an anti diabetic drug posses antioxidant and anti apoptotic properties AIM OF THE STUDY:",
      "The aim of this work is to identify the effect of DAPA on disturbance of liver and lung functions result from hypothyroidism MATERIALS AND METHODS: Twenty four rats (6 rats/group) were divided into four groups: control group, DAPA group that received DAPA (1 mg/kg/day for five weeks), PTU group that received propylthiouracil (15 mg/kg/day for five weeks), PTU+ DAPA group that received PTU and DAPA as described in the other groups RESULTS:",
      "Hypothyroidism induced oxidative stress associated mitophagy disturbance in both lung and liver with development of apoptosis in liver.",
      "DAPA avoided this effect CONCLUSION:",
      "DAPA protects against liver and lung injury result from hypothyroidism."
    ],
    "summary_sentences": [
      "Thyroid hormones are mainly concerning with regulation of organs metabolism.",
      "Hypothyroidism is a pathological condition characterized by decrease of T3 and T4 level that negatively impact various organs especially liver and lung.",
      "Dapagliflozin (DAPA) is an anti diabetic drug posses antioxidant and anti apoptotic properties AIM OF THE STUDY:",
      "The aim of this work is to identify the effect of DAPA on disturbance of liver and lung functions result from hypothyroidism MATERIALS AND METHODS: Twenty four rats (6 rats/group) were divided into four groups: control group, DAPA group that received DAPA (1 mg/kg/day for five weeks), PTU group that received propylthiouracil (15 mg/kg/day for five weeks), PTU+ DAPA group that received PTU and DAPA as described in the other groups RESULTS:",
      "Hypothyroidism induced oxidative stress associated mitophagy disturbance in both lung and liver with development of apoptosis in liver.",
      "DAPA avoided this effect CONCLUSION:",
      "DAPA protects against liver and lung injury result from hypothyroidism."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41626986",
    "source": "pubmed",
    "sentences": [
      "A critical step in systematic reviews involves the definition of a search strategy, with keywords and Boolean logic, to filter electronic databases.",
      "We hypothesize that it is possible to screen articles in electronic databases using large language models (LLMs) as an alternative to search equations.",
      "To investigate this matter, we compared two methods to identify randomized controlled trials (RCTs) in electronic databases: filtering databases using the Cochrane highly sensitive search and an assessment by an LLM.We retrieved studies indexed in PubMed with a publication date between September 1 and September 30, 2024 using the sole keyword \"diabetes.\"",
      "We compared the performance of the Cochrane highly sensitive search and the assessment of all titles and abstracts extracted directly from the database by GPT-4o-mini to identify RCTs.",
      "Reference standard was the manual screening of retrieved articles by two independent reviewers.",
      "The search retrieved 6377 records, of which 210 (3.5%) were primary reports of RCTs.",
      "The Cochrane highly sensitive search filtered 2197 records and missed one RCT (sensitivity 99.5%, 95% CI 97.4% to100%; specificity 67.8%, 95% CI 66.6% to 68.9%).",
      "Assessment of all titles and abstracts from the electronic database by GPT filtered 1080 records and included all 210 primary reports of RCTs (sensitivity 100%, 95% CI 98.3% to100%; specificity 85.9%, 95% CI 85.0% to 86.8%).LLMs can screen all articles in electronic databases to identify RCTs as an alternative to the Cochrane highly sensitive search.",
      "This calls for the evaluation of LLMs as an alternative to rigid search strategies."
    ],
    "summary_sentences": [
      "A critical step in systematic reviews involves the definition of a search strategy, with keywords and Boolean logic, to filter electronic databases.",
      "We hypothesize that it is possible to screen articles in electronic databases using large language models (LLMs) as an alternative to search equations.",
      "To investigate this matter, we compared two methods to identify randomized controlled trials (RCTs) in electronic databases: filtering databases using the Cochrane highly sensitive search and an assessment by an LLM.We retrieved studies indexed in PubMed with a publication date between September 1 and September 30, 2024 using the sole keyword \"diabetes.\"",
      "We compared the performance of the Cochrane highly sensitive search and the assessment of all titles and abstracts extracted directly from the database by GPT-4o-mini to identify RCTs.",
      "Reference standard was the manual screening of retrieved articles by two independent reviewers.",
      "The search retrieved 6377 records, of which 210 (3.5%) were primary reports of RCTs.",
      "The Cochrane highly sensitive search filtered 2197 records and missed one RCT (sensitivity 99.5%, 95% CI 97.4% to100%; specificity 67.8%, 95% CI 66.6% to 68.9%).",
      "Assessment of all titles and abstracts from the electronic database by GPT filtered 1080 records and included all 210 primary reports of RCTs (sensitivity 100%, 95% CI 98.3% to100%; specificity 85.9%, 95% CI 85.0% to 86.8%).LLMs can screen all articles in electronic databases to identify RCTs as an alternative to the Cochrane highly sensitive search.",
      "This calls for the evaluation of LLMs as an alternative to rigid search strategies."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41625815",
    "source": "pubmed",
    "sentences": [
      "Diabetes mellitus is a leading cause of global mortality with significant health complications.",
      "Yoga and naturopathy have demonstrated beneficial effects on blood glucose control and psychological well-being.",
      "A four-arm randomized study was conducted with 120 type 2 diabetic patients aged 40-60 years.",
      "Participants were randomly assigned to YG (yoga, 60 minutes), GH (gastro-hepatic pack, 20 minutes), CYG (combined yoga and gastro-hepatic pack, 80 minutes), or the control group.",
      "HbA1c, fasting and postprandial blood sugar, Perceived Stress Scale, and Diabetes Distress Scale were measured before and after intervention.",
      "A significant reduction in glycemic parameters was observed in all groups post-intervention, with HbA1c decreasing from 8.17 ± 1.11 to 6.95 ± 0.85 in YG, 8.04 ± 0.98 to 6.93 ± 0.67 in GH, and 8.23 ± 1.23 to 6.29 ± 0.59 in CYG (p < 0.001).",
      "Fasting blood sugar (FBS) and post-prandial blood sugar (PPBS) also significantly declined (p < 0.001).",
      "Psychological measures improved, with PSS scores dropping from 17.7 ± 3.2 to 9.80 ± 1.67 in YG and 16.0 ± 2.3 to 9.53 ± 1.48 in CYG; smaller reductions occurred in GH and Control.",
      "DDS scores significantly decreased (p < 0.001).",
      "CYG showed the greatest overall improvement.",
      "No adverse events were reported.",
      "The combined yoga and gastro‑hepatic pack (CYG) intervention outperformed either alone in reducing stress and improving glycemic control in type 2 diabetes.",
      "This safe, holistic approach enhances overall quality of life, though long-term studies are needed to confirm the sustainability of these benefits and their impact on diabetes-related complications."
    ],
    "summary_sentences": [
      "Diabetes mellitus is a leading cause of global mortality with significant health complications.",
      "Yoga and naturopathy have demonstrated beneficial effects on blood glucose control and psychological well-being.",
      "A four-arm randomized study was conducted with 120 type 2 diabetic patients aged 40-60 years.",
      "Participants were randomly assigned to YG (yoga, 60 minutes), GH (gastro-hepatic pack, 20 minutes), CYG (combined yoga and gastro-hepatic pack, 80 minutes), or the control group.",
      "HbA1c, fasting and postprandial blood sugar, Perceived Stress Scale, and Diabetes Distress Scale were measured before and after intervention.",
      "A significant reduction in glycemic parameters was observed in all groups post-intervention, with HbA1c decreasing from 8.17 ± 1.11 to 6.95 ± 0.85 in YG, 8.04 ± 0.98 to 6.93 ± 0.67 in GH, and 8.23 ± 1.23 to 6.29 ± 0.59 in CYG (p < 0.001).",
      "Fasting blood sugar (FBS) and post-prandial blood sugar (PPBS) also significantly declined (p < 0.001).",
      "Psychological measures improved, with PSS scores dropping from 17.7 ± 3.2 to 9.80 ± 1.67 in YG and 16.0 ± 2.3 to 9.53 ± 1.48 in CYG; smaller reductions occurred in GH and Control.",
      "DDS scores significantly decreased (p < 0.001).",
      "CYG showed the greatest overall improvement.",
      "No adverse events were reported.",
      "The combined yoga and gastro‑hepatic pack (CYG) intervention outperformed either alone in reducing stress and improving glycemic control in type 2 diabetes.",
      "This safe, holistic approach enhances overall quality of life, though long-term studies are needed to confirm the sustainability of these benefits and their impact on diabetes-related complications."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41625439",
    "source": "pubmed",
    "sentences": [
      "Hand conditions in diabetes, namely, limited joint mobility (LJM), flexor tenosynovitis (FT), carpal tunnel syndrome (CTS), and Dupuytren disease (DD), share a common pathophysiological process involving pro-fibrotic inflammation in flexor structures.",
      "A unified, quantitative measure of disease severity across these conditions is lacking, limiting correlational research.",
      "We evaluated mean metacarpophalangeal (MCP) joint extension as a potential measure of severity.",
      "We assessed 2,405 adults, including individuals with type 1 diabetes (n=291), type 2 diabetes (n=877), prediabetes (n=326), and non-diabetic controls (n=911).",
      "MCP extension was calculated as the average maximum passive extension of the second to fifth fingers, measured with a protractor.",
      "Validity was determined by correlating MCP extension with physician-rated severity (convergent) and hand grip strength and the Duruöz Hand Index (DHI, both divergent).",
      "Inter-rater reliability was tested in 128 individuals, and sensitivity to change was evaluated in 143 participants assessed at two time points.",
      "Mean MCP extension was significantly lower in individuals with all hand conditions (42.4° LJM, 42.8°FT, 39.9° DD, 51.7 °CTS) than in those without (58.6°, all p<0.05).",
      "MCP extension correlated with physician-rated severity (-0.5, p<0.01) and weakly with DHI (R Mean MCP extension is a valid, reliable, and responsive measure for assessing fibro-inflammatory hand conditions in diabetes.",
      "https://ctri.nic.in/Clinicaltrials/login.php, identifier CTRI/2020/12/030057."
    ],
    "summary_sentences": [
      "Hand conditions in diabetes, namely, limited joint mobility (LJM), flexor tenosynovitis (FT), carpal tunnel syndrome (CTS), and Dupuytren disease (DD), share a common pathophysiological process involving pro-fibrotic inflammation in flexor structures.",
      "A unified, quantitative measure of disease severity across these conditions is lacking, limiting correlational research.",
      "We evaluated mean metacarpophalangeal (MCP) joint extension as a potential measure of severity.",
      "We assessed 2,405 adults, including individuals with type 1 diabetes (n=291), type 2 diabetes (n=877), prediabetes (n=326), and non-diabetic controls (n=911).",
      "MCP extension was calculated as the average maximum passive extension of the second to fifth fingers, measured with a protractor.",
      "Validity was determined by correlating MCP extension with physician-rated severity (convergent) and hand grip strength and the Duruöz Hand Index (DHI, both divergent).",
      "Inter-rater reliability was tested in 128 individuals, and sensitivity to change was evaluated in 143 participants assessed at two time points.",
      "Mean MCP extension was significantly lower in individuals with all hand conditions (42.4° LJM, 42.8°FT, 39.9° DD, 51.7 °CTS) than in those without (58.6°, all p<0.05).",
      "MCP extension correlated with physician-rated severity (-0.5, p<0.01) and weakly with DHI (R Mean MCP extension is a valid, reliable, and responsive measure for assessing fibro-inflammatory hand conditions in diabetes.",
      "https://ctri.nic.in/Clinicaltrials/login.php, identifier CTRI/2020/12/030057."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41625336",
    "source": "pubmed",
    "sentences": [
      "Metabolic dysfunction-associated steatotic liver disease (MASLD) is both common and, in some cases, a progressive condition.",
      "Emerging pharmacological options have shown promise in select patient sub-groups (e.g., resmetirom for MASH with fibrosis; GLP-1 receptor agonists for obesity/diabetes with metabolic benefits), but structured lifestyle programs remain foundational in routine care.",
      "This study evaluates the cost-utility analysis of a multidisciplinary, kinesiology-supervised lifestyle-improving program for patients with MASLD, supported by clinical evidence.",
      "We analyzed 27 adults with MASLD, a cohort established from an initial group of 43 subjects, who participated in a structured program of supervised exercise and dietary counseling.",
      "Health-related quality of life (SF-36 mapped to EQ-5D) and associated clinical markers, including hepatic steatosis (ultrasound), blood pressure, and serum aminotransferases, were evaluated at baseline and after the program.",
      "A cost-utility analysis was conducted from the healthcare system's perspective, estimating the incremental cost-effectiveness ratios (ICERs and €/QALY) with deterministic and probabilistic sensitivity analyses.",
      "Pharmaceutical expenditures and projected disease progression costs were also explored using administrative data and literature-based models.",
      "Health-related quality of life improved after the program, with a quality-adjusted life year (QALY) gain of 0.081 (95% CI: 0.001-0.161).",
      "The base-case ICER was €17,778/QALY.",
      "The probability of cost-effectiveness was 71% at €25,000/QALY, 84% at €30,000/QALY, and 95% at €40,000/QALY.",
      "Ultrasound steatosis showed a distributional shift toward lower grades with an unchanged median (Wilcoxon p = 0.007).",
      "Systolic/diastolic blood pressure decreased by -5.6/-3.7 mmHg (p = 0.05 and p = 0.03), and AST/ALT declined (both p < 0.01).",
      "At the 2-year follow-up, 55.6% of patients reported maintaining regular physical activity.",
      "Outpatient pharmaceutical expenditures showed a decline from €74 to €50 per patient/year between 2018 and 2021, with reduced variability across patients.",
      "However, this trend did not reach statistical significance in mixed-effects analyses (p = 0.06).",
      "In this pre-post observational study, the supervised program was associated with favorable cost-utility outcomes and distributional improvements in selected clinical markers.",
      "These findings support the program's potential value in routine care and warrant confirmation in controlled studies.",
      "https://clinicaltrials.gov/expert-search?term, identifier NCT06026293."
    ],
    "summary_sentences": [
      "Metabolic dysfunction-associated steatotic liver disease (MASLD) is both common and, in some cases, a progressive condition.",
      "Emerging pharmacological options have shown promise in select patient sub-groups (e.g., resmetirom for MASH with fibrosis; GLP-1 receptor agonists for obesity/diabetes with metabolic benefits), but structured lifestyle programs remain foundational in routine care.",
      "This study evaluates the cost-utility analysis of a multidisciplinary, kinesiology-supervised lifestyle-improving program for patients with MASLD, supported by clinical evidence.",
      "We analyzed 27 adults with MASLD, a cohort established from an initial group of 43 subjects, who participated in a structured program of supervised exercise and dietary counseling.",
      "Health-related quality of life (SF-36 mapped to EQ-5D) and associated clinical markers, including hepatic steatosis (ultrasound), blood pressure, and serum aminotransferases, were evaluated at baseline and after the program.",
      "A cost-utility analysis was conducted from the healthcare system's perspective, estimating the incremental cost-effectiveness ratios (ICERs and €/QALY) with deterministic and probabilistic sensitivity analyses.",
      "Pharmaceutical expenditures and projected disease progression costs were also explored using administrative data and literature-based models.",
      "Health-related quality of life improved after the program, with a quality-adjusted life year (QALY) gain of 0.081 (95% CI: 0.001-0.161).",
      "The base-case ICER was €17,778/QALY.",
      "The probability of cost-effectiveness was 71% at €25,000/QALY, 84% at €30,000/QALY, and 95% at €40,000/QALY.",
      "Ultrasound steatosis showed a distributional shift toward lower grades with an unchanged median (Wilcoxon p = 0.007).",
      "Systolic/diastolic blood pressure decreased by -5.6/-3.7 mmHg (p = 0.05 and p = 0.03), and AST/ALT declined (both p < 0.01).",
      "At the 2-year follow-up, 55.6% of patients reported maintaining regular physical activity.",
      "Outpatient pharmaceutical expenditures showed a decline from €74 to €50 per patient/year between 2018 and 2021, with reduced variability across patients.",
      "However, this trend did not reach statistical significance in mixed-effects analyses (p = 0.06).",
      "In this pre-post observational study, the supervised program was associated with favorable cost-utility outcomes and distributional improvements in selected clinical markers.",
      "These findings support the program's potential value in routine care and warrant confirmation in controlled studies.",
      "https://clinicaltrials.gov/expert-search?term, identifier NCT06026293."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41625236",
    "source": "pubmed",
    "sentences": [
      "Type 2 diabetes (T2D) is strongly linked to chronic inflammation and oxidative stress, which drive cardiovascular complications.",
      "Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) demonstrate cardioprotective benefits that may extend beyond glycemic control, but their effects on key inflammatory and oxidative stress biomarkers compared to other glucose-lowering medications remain inconsistently reported across individual studies.",
      "A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted.",
      "Databases were searched for RCTs comparing GLP-1 RAs against other antidiabetic drugs or placebo in adults with T2D, reporting changes in inflammatory biomarkers (C-reactive protein [CRP], interleukin-6",
      "[IL-6], tumor necrosis factor-alpha [TNF-α]) or the oxidative stress marker malondialdehyde (MDA).",
      "Data were pooled using a random-effects model, and outcomes were stratified by comparator type (placebo, insulin, other oral antidiabetic drugs [OADs]).",
      "Forty RCTs (n=6029 participants) were included.",
      "GLP-1 RA therapy significantly reduced CRP levels compared to placebo (SMD = -0.59; 95% CI: -0.84 to -0.34) and other OADs (SMD = -1.06; 95% CI: -1.64 to -0.47).",
      "A significant reduction in TNF-α was observed versus placebo (SMD = -0.61; 95% CI: -0.89 to -0.32) and oral antidiabetic drugs add on (SMD = -1.62; 95% CI: -2.86 to -0.38).",
      "Data for MDA were limited and showed a non-significant trend toward reduction.",
      "GLP-1 RAs also significantly reduced IL-6 versus insulin (SMD = -0.24; 95% CI: -0.46 to -0.02).",
      "While significant heterogeneity was noted across the analyses, sensitivity analyses confirmed a consistent direction of effect, reinforcing the class-wide anti-inflammatory properties of GLP-1 RAs.",
      "GLP-1 RAs significantly improve key biomarkers of systemic inflammation (CRP, TNF-α) in patients with T2D compared to various active comparators and placebo.",
      "These pleiotropic effects provide a mechanistic rationale for their cardiovascular benefits and support their use as a multifaceted therapeutic strategy in T2D management.",
      "https://www.crd.york.ac.uk/PROSPERO/view/CRD420251157476, identifier CRD420251157476."
    ],
    "summary_sentences": [
      "Type 2 diabetes (T2D) is strongly linked to chronic inflammation and oxidative stress, which drive cardiovascular complications.",
      "Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) demonstrate cardioprotective benefits that may extend beyond glycemic control, but their effects on key inflammatory and oxidative stress biomarkers compared to other glucose-lowering medications remain inconsistently reported across individual studies.",
      "A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted.",
      "Databases were searched for RCTs comparing GLP-1 RAs against other antidiabetic drugs or placebo in adults with T2D, reporting changes in inflammatory biomarkers (C-reactive protein [CRP], interleukin-6",
      "[IL-6], tumor necrosis factor-alpha [TNF-α]) or the oxidative stress marker malondialdehyde (MDA).",
      "Data were pooled using a random-effects model, and outcomes were stratified by comparator type (placebo, insulin, other oral antidiabetic drugs [OADs]).",
      "Forty RCTs (n=6029 participants) were included.",
      "GLP-1 RA therapy significantly reduced CRP levels compared to placebo (SMD = -0.59; 95% CI: -0.84 to -0.34) and other OADs (SMD = -1.06; 95% CI: -1.64 to -0.47).",
      "A significant reduction in TNF-α was observed versus placebo (SMD = -0.61; 95% CI: -0.89 to -0.32) and oral antidiabetic drugs add on (SMD = -1.62; 95% CI: -2.86 to -0.38).",
      "Data for MDA were limited and showed a non-significant trend toward reduction.",
      "GLP-1 RAs also significantly reduced IL-6 versus insulin (SMD = -0.24; 95% CI: -0.46 to -0.02).",
      "While significant heterogeneity was noted across the analyses, sensitivity analyses confirmed a consistent direction of effect, reinforcing the class-wide anti-inflammatory properties of GLP-1 RAs.",
      "GLP-1 RAs significantly improve key biomarkers of systemic inflammation (CRP, TNF-α) in patients with T2D compared to various active comparators and placebo.",
      "These pleiotropic effects provide a mechanistic rationale for their cardiovascular benefits and support their use as a multifaceted therapeutic strategy in T2D management.",
      "https://www.crd.york.ac.uk/PROSPERO/view/CRD420251157476, identifier CRD420251157476."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41624204",
    "source": "pubmed",
    "sentences": [
      "In cohort studies, intake of insoluble cereal fiber is associated with multiple health benefits, including preserved cognitive functions.",
      "However, evidence from intervention studies is sparse.",
      "In the Optimal Fiber Trial (OptiFiT), lifestyle changes and supplementation with oat fiber in prediabetes patients improved glycemic metabolism and body composition, which could be linked to cognitive changes.",
      "In OptiFiT, 180 patients with impaired glucose tolerance received either an insoluble fiber supplement or a placebo for 2 years in a double-blind, randomized approach, and underwent a parallel 1-year complex lifestyle intervention program.",
      "Annual visits included metabolic, anthropometric, and cognitive assessments: Mini-Mental State Examination (MMSE), Verbal Learning Memory Test (VLMT), Regensburg Word Fluency Test (RWFT), Number Connection Test (NCT), Number Recall Test (NRT), and Rey-Osterrieth Complex Figure Test (RCFT).",
      "Group-wise comparisons were conducted both globally as well as stratified by age.",
      "Cognitive functions only slightly improved-particularly in VLMT and RWFT-without major differences by group or age.",
      "At baseline, cognitive function measured by RCFT recall, VLMT, RWFT, and backwards NRT was inversely correlated with age, but not with HbA1c, fasting, or postprandial glucose levels.",
      "Beneficial effects of insoluble fiber and lifestyle intervention on glycemia might not translate into preserved cognitive capabilities in middle-to-higher aged patients with prediabetes in a 2-year intervention period.",
      "Long-term intervention studies in patients with both cognitive vulnerability and metabolic susceptibility are warranted.",
      "Such large RCTs should also corroborate putatively involved mechanisms in the epidemiologically assumed protection from cognitive decline.",
      "Clinicaltrials.gov, identifier NCT01681173."
    ],
    "summary_sentences": [
      "In cohort studies, intake of insoluble cereal fiber is associated with multiple health benefits, including preserved cognitive functions.",
      "However, evidence from intervention studies is sparse.",
      "In the Optimal Fiber Trial (OptiFiT), lifestyle changes and supplementation with oat fiber in prediabetes patients improved glycemic metabolism and body composition, which could be linked to cognitive changes.",
      "In OptiFiT, 180 patients with impaired glucose tolerance received either an insoluble fiber supplement or a placebo for 2 years in a double-blind, randomized approach, and underwent a parallel 1-year complex lifestyle intervention program.",
      "Annual visits included metabolic, anthropometric, and cognitive assessments: Mini-Mental State Examination (MMSE), Verbal Learning Memory Test (VLMT), Regensburg Word Fluency Test (RWFT), Number Connection Test (NCT), Number Recall Test (NRT), and Rey-Osterrieth Complex Figure Test (RCFT).",
      "Group-wise comparisons were conducted both globally as well as stratified by age.",
      "Cognitive functions only slightly improved-particularly in VLMT and RWFT-without major differences by group or age.",
      "At baseline, cognitive function measured by RCFT recall, VLMT, RWFT, and backwards NRT was inversely correlated with age, but not with HbA1c, fasting, or postprandial glucose levels.",
      "Beneficial effects of insoluble fiber and lifestyle intervention on glycemia might not translate into preserved cognitive capabilities in middle-to-higher aged patients with prediabetes in a 2-year intervention period.",
      "Long-term intervention studies in patients with both cognitive vulnerability and metabolic susceptibility are warranted.",
      "Such large RCTs should also corroborate putatively involved mechanisms in the epidemiologically assumed protection from cognitive decline.",
      "Clinicaltrials.gov, identifier NCT01681173."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41623136",
    "source": "pubmed",
    "sentences": [
      "As type 2 diabetes (T2D) continues to rise globally and remains a major driver of cardiovascular disease, its remission has emerged as a therapeutic target.",
      "Current evidence supports bariatric surgery and low-calorie diets with meal replacements.",
      "No clinical trial to date has evaluated plant-based dietary alternatives as an intensive lifestyle intervention (ILI) strategy, despite the emphasis on plant-based diets in current clinical practice guidelines for diabetes and cardiovascular disease.",
      "The REmission of diabetes using a PlAnt-based weight loss InteRvention (REPAIR) trial will assess whether a 52-week plant-based ILI targeting ≥15% weight loss is effective for diabetes remission in a multi-ethnic Canadian population.",
      "The REPAIR trial is a prospective, randomised, 2-arm, open-label, blinded-endpoint efficacy trial.",
      "Participants will include 160 adults with early T2D (<6 years) and living with obesity.",
      "They will be randomised to standard of care or a 2-phase ILI targeting ≥15% weight loss consisting of a 12-week weight loss phase on a plant-based total diet meal replacement, followed by a 40-week weight loss maintenance phase on a plant-based dietary pattern combined with a 16-week structured exercise program, and a 52-week (19-session) sustainable behaviour change curriculum.",
      "The primary outcome is diabetes remission (HbA1c <6.5% without glucose-lowering medication for ≥3 months) and the key secondary outcome is the proportion achieving ≥15% weight loss at 52 weeks.",
      "This trial will provide high-quality clinical evidence on the use of plant-based ILIs to address the epidemics of obesity and diabetes to inform public health policies and programs in Canada and beyond."
    ],
    "summary_sentences": [
      "As type 2 diabetes (T2D) continues to rise globally and remains a major driver of cardiovascular disease, its remission has emerged as a therapeutic target.",
      "Current evidence supports bariatric surgery and low-calorie diets with meal replacements.",
      "No clinical trial to date has evaluated plant-based dietary alternatives as an intensive lifestyle intervention (ILI) strategy, despite the emphasis on plant-based diets in current clinical practice guidelines for diabetes and cardiovascular disease.",
      "The REmission of diabetes using a PlAnt-based weight loss InteRvention (REPAIR) trial will assess whether a 52-week plant-based ILI targeting ≥15% weight loss is effective for diabetes remission in a multi-ethnic Canadian population.",
      "The REPAIR trial is a prospective, randomised, 2-arm, open-label, blinded-endpoint efficacy trial.",
      "Participants will include 160 adults with early T2D (<6 years) and living with obesity.",
      "They will be randomised to standard of care or a 2-phase ILI targeting ≥15% weight loss consisting of a 12-week weight loss phase on a plant-based total diet meal replacement, followed by a 40-week weight loss maintenance phase on a plant-based dietary pattern combined with a 16-week structured exercise program, and a 52-week (19-session) sustainable behaviour change curriculum.",
      "The primary outcome is diabetes remission (HbA1c <6.5% without glucose-lowering medication for ≥3 months) and the key secondary outcome is the proportion achieving ≥15% weight loss at 52 weeks.",
      "This trial will provide high-quality clinical evidence on the use of plant-based ILIs to address the epidemics of obesity and diabetes to inform public health policies and programs in Canada and beyond."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41623057",
    "source": "pubmed",
    "sentences": [
      "The pullback pressure gradient (PPG) is a novel physiological metric that quantifies coronary artery disease patterns as focal or diffuse on a scale from 0 to 1.",
      "This study assessed the relationship between PPG and residual angina at 1 year.",
      "PPG Global is a prospective, investigator-initiated, single-arm, multicenter study that enrolled patients with at least 1 lesion with a fractional flow reserve ≤0.80 intended to be treated with PCI.",
      "After the PPG calculation, physicians could revise treatment assignment to medical therapy or coronary artery bypass graft surgery instead of PCI.",
      "Focal and diffuse disease were defined based on the median PPG value of 0.62.",
      "Patient-reported outcomes were assessed using the Seattle Angina Questionnaire at baseline and 1-year follow-up.",
      "The study included 947 patients with PPG and the Seattle Angina Questionnaire at 1 year.",
      "The mean age was 67.6±10.2 years, 24% were female, and 29% had diabetes.",
      "At 1 year, patients with focal coronary artery disease reported less angina than those with diffuse coronary artery disease (Seattle Angina Questionnaire angina frequency score, 95.3±9.9 versus 92.5±15.0; In patients with flow-limiting coronary artery disease, the presence of focal disease defined by high PPG was associated with greater symptomatic relief at 1 year compared with diffuse disease (low PPG).",
      "By reflecting the physiological pattern of disease and its relation to symptom relief after treatment, PPG may help inform revascularization strategies."
    ],
    "summary_sentences": [
      "The pullback pressure gradient (PPG) is a novel physiological metric that quantifies coronary artery disease patterns as focal or diffuse on a scale from 0 to 1.",
      "This study assessed the relationship between PPG and residual angina at 1 year.",
      "PPG Global is a prospective, investigator-initiated, single-arm, multicenter study that enrolled patients with at least 1 lesion with a fractional flow reserve ≤0.80 intended to be treated with PCI.",
      "After the PPG calculation, physicians could revise treatment assignment to medical therapy or coronary artery bypass graft surgery instead of PCI.",
      "Focal and diffuse disease were defined based on the median PPG value of 0.62.",
      "Patient-reported outcomes were assessed using the Seattle Angina Questionnaire at baseline and 1-year follow-up.",
      "The study included 947 patients with PPG and the Seattle Angina Questionnaire at 1 year.",
      "The mean age was 67.6±10.2 years, 24% were female, and 29% had diabetes.",
      "At 1 year, patients with focal coronary artery disease reported less angina than those with diffuse coronary artery disease (Seattle Angina Questionnaire angina frequency score, 95.3±9.9 versus 92.5±15.0; In patients with flow-limiting coronary artery disease, the presence of focal disease defined by high PPG was associated with greater symptomatic relief at 1 year compared with diffuse disease (low PPG).",
      "By reflecting the physiological pattern of disease and its relation to symptom relief after treatment, PPG may help inform revascularization strategies."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41622389",
    "source": "pubmed",
    "sentences": [
      "Calsequestrin 2 (CASQ2) has emerged as a central sensor and modulator of calcium (Ca"
    ],
    "summary_sentences": [
      "Calsequestrin 2 (CASQ2) has emerged as a central sensor and modulator of calcium (Ca"
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41619944",
    "source": "pubmed",
    "sentences": [
      "Early identification of individuals at risk for type 2 diabetes (T2D) is essential for prevention.",
      "We evaluated a novel model-derived disposition index without insulin (mDI-woI), which requires only glucose values from a three time-point oral glucose tolerance test (OGTT: 0, 60, 120 min).",
      "Among 5,742 healthy Koreans (age 51.2 ± 8.6 years, BMI 24.5 ± 3.1 kg/m mDI-woI and mean OGTT glucose (mean G) showed the strongest prediction for incident T2D (AUC = 0.79 each), outperforming fasting plasma glucose (0.67), 1 h-PG (0.77), 2 h-PG (0.72), HbA1c (0.71), and oDI (0.68; all P < 0.001).",
      "In individuals who progressed to T2D, baseline mDI-woI, mean G, and 1-PG exceeded their thresholds while fasting and 2 h glucose were still below prediabetes cutoffs, indicating earlier risk detection.",
      "Moreover, the novel marker mDI-woI is the earliest one, 4 years earlier than mean G and 4.5 years earlier than 1 h-PG, the next two earliest.",
      "Using only three glucose measurements without measuring insulin, mDI-woI provides a simple, sensitive, and clinically practical early marker that outperforms current diabetes criteria for predicting T2D progression, with strong potential for large-scale studies."
    ],
    "summary_sentences": [
      "Early identification of individuals at risk for type 2 diabetes (T2D) is essential for prevention.",
      "We evaluated a novel model-derived disposition index without insulin (mDI-woI), which requires only glucose values from a three time-point oral glucose tolerance test (OGTT: 0, 60, 120 min).",
      "Among 5,742 healthy Koreans (age 51.2 ± 8.6 years, BMI 24.5 ± 3.1 kg/m mDI-woI and mean OGTT glucose (mean G) showed the strongest prediction for incident T2D (AUC = 0.79 each), outperforming fasting plasma glucose (0.67), 1 h-PG (0.77), 2 h-PG (0.72), HbA1c (0.71), and oDI (0.68; all P < 0.001).",
      "In individuals who progressed to T2D, baseline mDI-woI, mean G, and 1-PG exceeded their thresholds while fasting and 2 h glucose were still below prediabetes cutoffs, indicating earlier risk detection.",
      "Moreover, the novel marker mDI-woI is the earliest one, 4 years earlier than mean G and 4.5 years earlier than 1 h-PG, the next two earliest.",
      "Using only three glucose measurements without measuring insulin, mDI-woI provides a simple, sensitive, and clinically practical early marker that outperforms current diabetes criteria for predicting T2D progression, with strong potential for large-scale studies."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41617091",
    "source": "pubmed",
    "sentences": [
      "There have been multiple attempts to identify biological factors that predict long-term weight change.",
      "Previous investigators have theorized that variations in how humans metabolize dietary macronutrients (storage as opposed to oxidation) might be one of these characteristics, but to date there has been no effort to address this hypothesis.",
      "We used a retrospective cohort study design to test the hypothesis that greater meal fat storage in subcutaneous adipose tissue would be associated with greater future weight gain.",
      "Body composition, demographic, and meal fatty acid metabolism data was collated from 154 non-obese research volunteers who participated in studies conducted at Mayo Clinic between 1997 and 2012 that used either The long-term (19 ± 7) years weight change for females was correlated with meal fat storage (P = 0.003, r=0.38) and meal fat oxidation measured using The finding that weight change is correlated with dietary fatty acid metabolism for adult, non-obese females suggests that inter-individual variations in how women process dietary fat can influence long-term energy balance.",
      "NCT00254371; the other protocols were not considered clinical trials at the time they were conducted.",
      "https://clinicaltrials.gov/study/NCT00254371?term=testosterone&cond=%22Sarcopenia%22&viewType=Table&rank=9."
    ],
    "summary_sentences": [
      "There have been multiple attempts to identify biological factors that predict long-term weight change.",
      "Previous investigators have theorized that variations in how humans metabolize dietary macronutrients (storage as opposed to oxidation) might be one of these characteristics, but to date there has been no effort to address this hypothesis.",
      "We used a retrospective cohort study design to test the hypothesis that greater meal fat storage in subcutaneous adipose tissue would be associated with greater future weight gain.",
      "Body composition, demographic, and meal fatty acid metabolism data was collated from 154 non-obese research volunteers who participated in studies conducted at Mayo Clinic between 1997 and 2012 that used either The long-term (19 ± 7) years weight change for females was correlated with meal fat storage (P = 0.003, r=0.38) and meal fat oxidation measured using The finding that weight change is correlated with dietary fatty acid metabolism for adult, non-obese females suggests that inter-individual variations in how women process dietary fat can influence long-term energy balance.",
      "NCT00254371; the other protocols were not considered clinical trials at the time they were conducted.",
      "https://clinicaltrials.gov/study/NCT00254371?term=testosterone&cond=%22Sarcopenia%22&viewType=Table&rank=9."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41616812",
    "source": "pubmed",
    "sentences": [
      "AMPLIPHY is the first Phase 3 study comparing sepiapterin versus sapropterin in children and adults with phenylketonuria (PKU).",
      "AMPLIPHY was an international, Phase 3, two-part, open-label study in participants with PKU aged ≥2 years.",
      "Participants responsive to sepiapterin (60 mg/kg/day) in Part 1 (≥20% reduction in blood phenylalanine [Phe]) entered Part 2, a crossover treatment period, and were randomized 1:1 to alternative treatment sequences of sepiapterin (60 mg/kg/day, licensed dosage) and sapropterin (20 mg/kg/day, maximum licensed dosage) for 4 weeks each, with a 14-day washout between treatments.",
      "The primary endpoint was mean change in blood Phe from baseline to Weeks 3-4 of each treatment period (Part 2).",
      "Of 82 participants enrolled, 67 (81.7%) and 62 (75.6%) had reductions in blood Phe ≥20% and ≥ 30%, respectively, in Part 1.",
      "Sixty-two participants were randomized in Part 2 (mean [SD] age, 15.8 [10.8] years).",
      "In the primary analysis set (≥30% reduction in blood Phe in Part 1, n = 58), mean (SD) baseline blood Phe before sepiapterin and sapropterin treatment was 725.8 (302.1) and 790.4 (370.0) μmol/L, respectively.",
      "Least-squares mean (SE) reduction in blood Phe from baseline was -437.0 (28.0) and - 256.6 (28.2) μmol/L, respectively, representing a least-squares mean difference of -180.4 μmol/L (95% CI:",
      "-229.5, -131.4; p < 0.0001) and a relative 70% greater reduction with sepiapterin versus sapropterin.",
      "Both treatments were well tolerated, with safety profiles consistent with previous reports.",
      "Sepiapterin was superior to the highest approved dose of sapropterin in lowering blood Phe.",
      "No new safety signals were observed.",
      "The trial was registered in the UK Clinical Study Registry, ISRCTN, on January 29, 2024 (ID number, ISRCTN79102999; https://www.isrctn.com/ISRCTN79102999)."
    ],
    "summary_sentences": [
      "AMPLIPHY is the first Phase 3 study comparing sepiapterin versus sapropterin in children and adults with phenylketonuria (PKU).",
      "AMPLIPHY was an international, Phase 3, two-part, open-label study in participants with PKU aged ≥2 years.",
      "Participants responsive to sepiapterin (60 mg/kg/day) in Part 1 (≥20% reduction in blood phenylalanine [Phe]) entered Part 2, a crossover treatment period, and were randomized 1:1 to alternative treatment sequences of sepiapterin (60 mg/kg/day, licensed dosage) and sapropterin (20 mg/kg/day, maximum licensed dosage) for 4 weeks each, with a 14-day washout between treatments.",
      "The primary endpoint was mean change in blood Phe from baseline to Weeks 3-4 of each treatment period (Part 2).",
      "Of 82 participants enrolled, 67 (81.7%) and 62 (75.6%) had reductions in blood Phe ≥20% and ≥ 30%, respectively, in Part 1.",
      "Sixty-two participants were randomized in Part 2 (mean [SD] age, 15.8 [10.8] years).",
      "In the primary analysis set (≥30% reduction in blood Phe in Part 1, n = 58), mean (SD) baseline blood Phe before sepiapterin and sapropterin treatment was 725.8 (302.1) and 790.4 (370.0) μmol/L, respectively.",
      "Least-squares mean (SE) reduction in blood Phe from baseline was -437.0 (28.0) and - 256.6 (28.2) μmol/L, respectively, representing a least-squares mean difference of -180.4 μmol/L (95% CI:",
      "-229.5, -131.4; p < 0.0001) and a relative 70% greater reduction with sepiapterin versus sapropterin.",
      "Both treatments were well tolerated, with safety profiles consistent with previous reports.",
      "Sepiapterin was superior to the highest approved dose of sapropterin in lowering blood Phe.",
      "No new safety signals were observed.",
      "The trial was registered in the UK Clinical Study Registry, ISRCTN, on January 29, 2024 (ID number, ISRCTN79102999; https://www.isrctn.com/ISRCTN79102999)."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41616799",
    "source": "pubmed",
    "sentences": [
      "Inclisiran, a small interfering RNA targeting hepatic PCSK9, was previously studied in various adult patient populations, but it has not yet been assessed in paediatric patients with heterozygous familial hypercholesterolaemia (HeFH), a genetic disorder characterised by elevated LDL cholesterol.",
      "The ORION-16 study aimed to evaluate the efficacy and safety of inclisiran treatment in adolescents with HeFH.",
      "ORION-16 was a two-part (1-year double-blind, 1-year open-label), randomised, phase 3 trial at 51 sites across 26 countries.",
      "In Part 1, adolescents (aged 12 to <18 years) with HeFH and elevated LDL cholesterol on maximally tolerated statin treatment with or without other lipid-lowering therapy were randomly assigned 2:1 (via interactive response technology) to either inclisiran sodium 300 mg subcutaneously or placebo (administered on days 1, 90, and 270); in Part 2, all patients received inclisiran (days 360",
      "[only patients previously assigned to receive placebo], 450, and 630).",
      "The primary endpoint was the percentage change in LDL cholesterol from baseline to day 330, assessed in all randomly assigned patients.",
      "Safety was assessed in all patients who received at least one dose of study drug.",
      "Endpoints in Part 2 were analysed in all patients who entered and received at least one dose of study drug in Part 2.",
      "ORION-16 is registered at ClinicalTrials.gov (NCT04652726) and is completed.",
      "Between Feb 17, 2021, and Dec 14, 2022, 141 patients were randomly assigned (93 to inclisiran, 48 to placebo; median age 15·1 years",
      "[IQR 13·4-16·8]; 75 [53%] female; 128 [91%] White).",
      "In Part 1, the least squares mean percentage change in LDL cholesterol from baseline to day 330 was -27·1% in the inclisiran group and 1·4% in the placebo group, with a between-group difference of -28·5% (95% CI -35·8 to -21·3; p<0·0001).",
      "In Part 2, at day 720, a mean percentage change in LDL cholesterol from baseline of -33·7% (SD 24·0) was observed.",
      "Inclisiran was well tolerated, with a safety profile comparable to studies in adults.",
      "Injection site reactions were more frequent with inclisiran (15 [16%] of 93 patients) than with placebo (three [6%] of 48) in Part 1 (13 [9%] of 139 in Part 2); all were mild and did not lead to study drug discontinuation.",
      "There were no treatment-related serious adverse events, and no deaths during the study.",
      "In adolescents with HeFH, inclisiran was effective in lowering LDL cholesterol, with sustained efficacy over 2 years, and was well tolerated.",
      "These results support inclisiran as a potentially useful addition for the treatment of adolescents with HeFH, providing an infrequent dosing regimen.",
      "Novartis Pharma."
    ],
    "summary_sentences": [
      "Inclisiran, a small interfering RNA targeting hepatic PCSK9, was previously studied in various adult patient populations, but it has not yet been assessed in paediatric patients with heterozygous familial hypercholesterolaemia (HeFH), a genetic disorder characterised by elevated LDL cholesterol.",
      "The ORION-16 study aimed to evaluate the efficacy and safety of inclisiran treatment in adolescents with HeFH.",
      "ORION-16 was a two-part (1-year double-blind, 1-year open-label), randomised, phase 3 trial at 51 sites across 26 countries.",
      "In Part 1, adolescents (aged 12 to <18 years) with HeFH and elevated LDL cholesterol on maximally tolerated statin treatment with or without other lipid-lowering therapy were randomly assigned 2:1 (via interactive response technology) to either inclisiran sodium 300 mg subcutaneously or placebo (administered on days 1, 90, and 270); in Part 2, all patients received inclisiran (days 360",
      "[only patients previously assigned to receive placebo], 450, and 630).",
      "The primary endpoint was the percentage change in LDL cholesterol from baseline to day 330, assessed in all randomly assigned patients.",
      "Safety was assessed in all patients who received at least one dose of study drug.",
      "Endpoints in Part 2 were analysed in all patients who entered and received at least one dose of study drug in Part 2.",
      "ORION-16 is registered at ClinicalTrials.gov (NCT04652726) and is completed.",
      "Between Feb 17, 2021, and Dec 14, 2022, 141 patients were randomly assigned (93 to inclisiran, 48 to placebo; median age 15·1 years",
      "[IQR 13·4-16·8]; 75 [53%] female; 128 [91%] White).",
      "In Part 1, the least squares mean percentage change in LDL cholesterol from baseline to day 330 was -27·1% in the inclisiran group and 1·4% in the placebo group, with a between-group difference of -28·5% (95% CI -35·8 to -21·3; p<0·0001).",
      "In Part 2, at day 720, a mean percentage change in LDL cholesterol from baseline of -33·7% (SD 24·0) was observed.",
      "Inclisiran was well tolerated, with a safety profile comparable to studies in adults.",
      "Injection site reactions were more frequent with inclisiran (15 [16%] of 93 patients) than with placebo (three [6%] of 48) in Part 1 (13 [9%] of 139 in Part 2); all were mild and did not lead to study drug discontinuation.",
      "There were no treatment-related serious adverse events, and no deaths during the study.",
      "In adolescents with HeFH, inclisiran was effective in lowering LDL cholesterol, with sustained efficacy over 2 years, and was well tolerated.",
      "These results support inclisiran as a potentially useful addition for the treatment of adolescents with HeFH, providing an infrequent dosing regimen.",
      "Novartis Pharma."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41615170",
    "source": "pubmed",
    "sentences": [
      "Contrast-induced nephropathy (CIN) is a common complication following angiographic procedures, potentially related to the volume of contrast agent administered.",
      "However, it is unclear whether the type of contrast also influences its occurrence.",
      "To evaluate the interaction between contrast volume and contrast type (iso-osmolar vs low-osmolar) in the development of CIN.",
      "A post hoc subanalysis was performed on patients undergoing diagnostic or therapeutic coronary procedures who were randomized 1:1 to receive low-osmolar or iso-osmolar contrast media.",
      "The overall sample (n = 2,268) was stratified by contrast volume:",
      "Group I (< 150 mL; n = 1,985) and Group II (≥ 150 mL; n = 283), and groups were compared by contrast type.",
      "The primary endpoint was CIN at 48- and 96-hours post-procedure.",
      "CIN was defined as a ≥ 25% or ≥ 0.5 mg/dL increase in serum creatinine from baseline at 48 hours.",
      "The effects of contrast type and volume were tested with logistic regression including an interaction term, adjusted for acute coronary syndrome, ventricular dysfunction, baseline creatinine, sex, and age (p < 0.05).",
      "We included 2,268 consecutive patients; two-thirds were male; hypertension was present in 85%, diabetes in 52%, and chronic kidney disease in 31%.",
      "Mean contrast volume was 75.3 ± 28.0 mL in Group I and 188.6 ± 46.9 mL in Group II.",
      "The incidence of CIN was higher with greater volume (14.8% vs 17.7%) but not statistically significant (adjusted odds ratio = 1.25; 95% CI = 0.89-1.73; p = 0.191).",
      "The model with the interaction term showed no evidence of an interaction between the type of contrast and volume (p > 0.999).",
      "The type of contrast was not associated with CIN, even among patients exposed to higher contrast volumes.",
      "A nefropatia induzida por contraste (NIC)",
      "é complicação frequente após procedimentos angiográficos e pode estar relacionada ao volume de contraste administrado.",
      "Permanece incerto se o tipo de contraste também influencia sua ocorrência.",
      "Avaliar a interação entre volume e tipo de contraste (iso-osmolar ou de baixa osmolaridade)",
      "no desenvolvimento de NIC.",
      "Subanálise post hoc de pacientes submetidos a procedimentos coronários diagnósticos e terapêuticos, randomizados 1:1 para contraste de baixa osmolaridade ou iso-osmolaridade.",
      "A amostra total (n = 2.268) foi estratificada por volume: Grupo I (< 150 ml; n = 1.985) e Grupo II (≥ 150 ml; n = 283), e comparada segundo o tipo de contraste.",
      "O desfecho primário foi NIC em 48 e 96 horas após o procedimento.",
      "NIC foi definida como elevação da creatinina sérica >",
      "25% ou ≥ 0,5",
      "mg/dl em relação ao nível basal após 48 horas.",
      "O efeito do tipo e do volume de contraste foi testado por regressão logística com termo de interação, ajustada para síndrome coronária aguda, disfunção ventricular, creatinina basal, sexo e idade (valor p < 0,05).",
      "Foram incluídos 2.268 pacientes consecutivos; dois terços do sexo masculino; hipertensão arterial sistêmica em 85%, diabetes melito em 52% e doença renal crônica em 31%.",
      "No Grupo I, o volume médio de contraste foi 75,3 ±",
      "28,0",
      "ml; no Grupo II, 188,6 ±",
      "46,9",
      "ml.",
      "A incidência de NIC foi maior",
      "no grupo com maior volume (14,8% vs. 17,7%), sem significância estatística (odds ratio ajustado = 1,25; intervalo de confiança de 95% 0,89-1,73; p = 0,191).",
      "O modelo com termo de interação não evidenciou correlação entre tipo de contraste e volume (p > 0,999).",
      "Não houve associação entre o tipo de contraste e a ocorrência de NIC, mesmo entre pacientes expostos a maiores volumes de contraste."
    ],
    "summary_sentences": [
      "Contrast-induced nephropathy (CIN) is a common complication following angiographic procedures, potentially related to the volume of contrast agent administered.",
      "However, it is unclear whether the type of contrast also influences its occurrence.",
      "To evaluate the interaction between contrast volume and contrast type (iso-osmolar vs low-osmolar) in the development of CIN.",
      "A post hoc subanalysis was performed on patients undergoing diagnostic or therapeutic coronary procedures who were randomized 1:1 to receive low-osmolar or iso-osmolar contrast media.",
      "The overall sample (n = 2,268) was stratified by contrast volume:",
      "Group I (< 150 mL; n = 1,985) and Group II (≥ 150 mL; n = 283), and groups were compared by contrast type.",
      "The primary endpoint was CIN at 48- and 96-hours post-procedure.",
      "CIN was defined as a ≥ 25% or ≥ 0.5 mg/dL increase in serum creatinine from baseline at 48 hours.",
      "The effects of contrast type and volume were tested with logistic regression including an interaction term, adjusted for acute coronary syndrome, ventricular dysfunction, baseline creatinine, sex, and age (p < 0.05).",
      "We included 2,268 consecutive patients; two-thirds were male; hypertension was present in 85%, diabetes in 52%, and chronic kidney disease in 31%.",
      "Mean contrast volume was 75.3 ± 28.0 mL in Group I and 188.6 ± 46.9 mL in Group II.",
      "The incidence of CIN was higher with greater volume (14.8% vs 17.7%) but not statistically significant (adjusted odds ratio = 1.25; 95% CI = 0.89-1.73; p = 0.191).",
      "The model with the interaction term showed no evidence of an interaction between the type of contrast and volume (p > 0.999).",
      "The type of contrast was not associated with CIN, even among patients exposed to higher contrast volumes.",
      "A nefropatia induzida por contraste (NIC)",
      "é complicação frequente após procedimentos angiográficos e pode estar relacionada ao volume de contraste administrado.",
      "Permanece incerto se o tipo de contraste também influencia sua ocorrência.",
      "Avaliar a interação entre volume e tipo de contraste (iso-osmolar ou de baixa osmolaridade)",
      "no desenvolvimento de NIC.",
      "Subanálise post hoc de pacientes submetidos a procedimentos coronários diagnósticos e terapêuticos, randomizados 1:1 para contraste de baixa osmolaridade ou iso-osmolaridade.",
      "A amostra total (n = 2.268) foi estratificada por volume: Grupo I (< 150 ml; n = 1.985) e Grupo II (≥ 150 ml; n = 283), e comparada segundo o tipo de contraste.",
      "O desfecho primário foi NIC em 48 e 96 horas após o procedimento.",
      "NIC foi definida como elevação da creatinina sérica >",
      "25% ou ≥ 0,5",
      "mg/dl em relação ao nível basal após 48 horas.",
      "O efeito do tipo e do volume de contraste foi testado por regressão logística com termo de interação, ajustada para síndrome coronária aguda, disfunção ventricular, creatinina basal, sexo e idade (valor p < 0,05).",
      "Foram incluídos 2.268 pacientes consecutivos; dois terços do sexo masculino; hipertensão arterial sistêmica em 85%, diabetes melito em 52% e doença renal crônica em 31%.",
      "No Grupo I, o volume médio de contraste foi 75,3 ±",
      "28,0",
      "ml; no Grupo II, 188,6 ±",
      "46,9",
      "ml.",
      "A incidência de NIC foi maior",
      "no grupo com maior volume (14,8% vs. 17,7%), sem significância estatística (odds ratio ajustado = 1,25; intervalo de confiança de 95% 0,89-1,73; p = 0,191).",
      "O modelo com termo de interação não evidenciou correlação entre tipo de contraste e volume (p > 0,999).",
      "Não houve associação entre o tipo de contraste e a ocorrência de NIC, mesmo entre pacientes expostos a maiores volumes de contraste."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41612982",
    "source": "pubmed",
    "sentences": [
      "Despite its increasing prevalence, effective treatment options for metabolic dysfunction-associated steatotic liver disease (MASLD) are limited.",
      "We assessed the efficacy of a dietary supplement containing dihydromyricetin (DHM) in MASLD.",
      "Adult MASLD patients were randomized to receive a dietary supplement containing DHM (300 mg/day), vitamins C/E and choline (group A), or identical placebo (group B) for 12 months.",
      "Patients were assessed every ≤6 months for clinical and laboratory parameters and liver stiffness measurements (LSM).",
      "Fifty-five patients were randomized to group A (n=28) or B (n=27), but 9 patients (group A/B=2/7) were withdrawn early for personal reasons.",
      "Median liver enzymes decreased at 6 or 12 months only in group A. Group A compared to B patients achieved higher 12-month rates of combined alanine aminotransferase (ALT)/γ-glutamyl transpeptidase (GGT) normalization (35% vs. 5%, P=0.028).",
      "Only in group A, glucose, glycated hemoglobin and total/low density lipoprotein mean levels had declined significantly at 6 and/or 12 months, whereas median liver stiffness measurements (LSM) were lower than baseline at both 6 and 12 months.",
      "In multivariate analysis, group A was the only factor associated with ALT/GGT normalization (P=0.038).",
      "Generalized estimating equation analysis revealed a significant treatment by time interaction for 12-month combined ALT/GGT normalization only in group A (P=0.021).",
      "The 6/12-month use of DHM supplement seems to result in improvements in liver enzymes and LSM, as well as in diabetes and lipid parameters in MASLD patients.",
      "Therefore, the use of such a supplement in MASLD needs further evaluation."
    ],
    "summary_sentences": [
      "Despite its increasing prevalence, effective treatment options for metabolic dysfunction-associated steatotic liver disease (MASLD) are limited.",
      "We assessed the efficacy of a dietary supplement containing dihydromyricetin (DHM) in MASLD.",
      "Adult MASLD patients were randomized to receive a dietary supplement containing DHM (300 mg/day), vitamins C/E and choline (group A), or identical placebo (group B) for 12 months.",
      "Patients were assessed every ≤6 months for clinical and laboratory parameters and liver stiffness measurements (LSM).",
      "Fifty-five patients were randomized to group A (n=28) or B (n=27), but 9 patients (group A/B=2/7) were withdrawn early for personal reasons.",
      "Median liver enzymes decreased at 6 or 12 months only in group A. Group A compared to B patients achieved higher 12-month rates of combined alanine aminotransferase (ALT)/γ-glutamyl transpeptidase (GGT) normalization (35% vs. 5%, P=0.028).",
      "Only in group A, glucose, glycated hemoglobin and total/low density lipoprotein mean levels had declined significantly at 6 and/or 12 months, whereas median liver stiffness measurements (LSM) were lower than baseline at both 6 and 12 months.",
      "In multivariate analysis, group A was the only factor associated with ALT/GGT normalization (P=0.038).",
      "Generalized estimating equation analysis revealed a significant treatment by time interaction for 12-month combined ALT/GGT normalization only in group A (P=0.021).",
      "The 6/12-month use of DHM supplement seems to result in improvements in liver enzymes and LSM, as well as in diabetes and lipid parameters in MASLD patients.",
      "Therefore, the use of such a supplement in MASLD needs further evaluation."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41612233",
    "source": "pubmed",
    "sentences": [
      "Drug resistant tuberculosis (DR-TB) poses a massive threat to public health, and monoresistance to isoniazid (Hr-TB) is not often diagnosed.",
      "This study aims to determine rates of Hr-TB and multidrug resistance (MDR-TB) among TB isolates and assess risk factors for TB diagnosis and drug resistance in Almaty, Kazakhstan to inform public health policy.",
      "From December 2021 to July 2022, sputum samples were collected from 1214 unique patients over age 18 with presumptive TB who were not currently on TB treatment.",
      "All samples were tested with both Mycobacterial Growth Indicator Tube (MGIT) liquid culture and the Becton-Dickinson real-time PCR (BD MAX™ MDR-TB) for detection of M. tuberculosis and drug resistance to isoniazid (INH), rifampicin (RIF), ethambutol (EMB), and pyrazinamide (PZA).",
      "Rates of monoresistance and MDR-TB were calculated, and univariate and multivariable logistic regression models were run to determine odds ratios for potential risk factors for TB, Hr-TB, and MDR-TB diagnosis using MGIT results.",
      "Any resistance to INH was found in 115 (43.7% [95% CI: 37.9-49.8%]) of 263 TB isolates diagnosed by MGIT, and Hr-TB was diagnosed in 34 MGIT TB isolates (12.9% [95% CI: 9.4-17.5%]).",
      "Among 359 BD MAX TB isolates, 51 (14.2% [95% CI: 11.0-18.2%]) were Hr-TB.",
      "MDR-TB was diagnosed in 70 MGIT TB isolates (26.6% [95% CI: 21.6-32.3%]) and 65 BD MAX TB isolates (24.7% [95% CI: 14.5-22.4%]).",
      "Male patients, those aged 35-44 and 45-54, and patients with self-reported diabetes mellitus had higher odds of TB diagnosis compared to female patients, those aged 65+, and those with no self-reported comorbid conditions, but no significant associations were found between patient characteristics and odds of Hr-TB or MDR-TB diagnosis.",
      "Rapid and accurate diagnosis of INH monoresistance is critical to understand national burdens of Hr-TB, improve treatment regimens, and prevent increases in MDR-TB in Kazakhstan.",
      "Current TB diagnostics that do not detect resistance to INH are inadequate to characterize Hr-TB.",
      "Therefore, high-burden MDR-TB countries should consider using diagnostics that detect resistance to both INH and RIF in national TB prevalence and drug resistance surveys.",
      "Not applicable."
    ],
    "summary_sentences": [
      "Drug resistant tuberculosis (DR-TB) poses a massive threat to public health, and monoresistance to isoniazid (Hr-TB) is not often diagnosed.",
      "This study aims to determine rates of Hr-TB and multidrug resistance (MDR-TB) among TB isolates and assess risk factors for TB diagnosis and drug resistance in Almaty, Kazakhstan to inform public health policy.",
      "From December 2021 to July 2022, sputum samples were collected from 1214 unique patients over age 18 with presumptive TB who were not currently on TB treatment.",
      "All samples were tested with both Mycobacterial Growth Indicator Tube (MGIT) liquid culture and the Becton-Dickinson real-time PCR (BD MAX™ MDR-TB) for detection of M. tuberculosis and drug resistance to isoniazid (INH), rifampicin (RIF), ethambutol (EMB), and pyrazinamide (PZA).",
      "Rates of monoresistance and MDR-TB were calculated, and univariate and multivariable logistic regression models were run to determine odds ratios for potential risk factors for TB, Hr-TB, and MDR-TB diagnosis using MGIT results.",
      "Any resistance to INH was found in 115 (43.7% [95% CI: 37.9-49.8%]) of 263 TB isolates diagnosed by MGIT, and Hr-TB was diagnosed in 34 MGIT TB isolates (12.9% [95% CI: 9.4-17.5%]).",
      "Among 359 BD MAX TB isolates, 51 (14.2% [95% CI: 11.0-18.2%]) were Hr-TB.",
      "MDR-TB was diagnosed in 70 MGIT TB isolates (26.6% [95% CI: 21.6-32.3%]) and 65 BD MAX TB isolates (24.7% [95% CI: 14.5-22.4%]).",
      "Male patients, those aged 35-44 and 45-54, and patients with self-reported diabetes mellitus had higher odds of TB diagnosis compared to female patients, those aged 65+, and those with no self-reported comorbid conditions, but no significant associations were found between patient characteristics and odds of Hr-TB or MDR-TB diagnosis.",
      "Rapid and accurate diagnosis of INH monoresistance is critical to understand national burdens of Hr-TB, improve treatment regimens, and prevent increases in MDR-TB in Kazakhstan.",
      "Current TB diagnostics that do not detect resistance to INH are inadequate to characterize Hr-TB.",
      "Therefore, high-burden MDR-TB countries should consider using diagnostics that detect resistance to both INH and RIF in national TB prevalence and drug resistance surveys.",
      "Not applicable."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41612188",
    "source": "pubmed",
    "sentences": [
      "The aim of this study was to confirm the association of systemic immune-inflammation index (SII) with relapse and metastasis of cervical squamous cell carcinoma (CSCC) in patients over 50 years and older.",
      "This retrospective study included 470 patients aged 50 years and older with CSCC who were treated at the Second Affiliated Hospital of Dalian Medical University between January 2020 and January 2023.",
      "The patients were divided into two groups according to median SII: high SII (n = 235) and low SII (n = 235).",
      "Univariate and multivariate logistic regression analysis, subgroup analysis, and receiver operating characteristic curve (ROC) analysis were used to explore the association of SII with relapse and metastasis.",
      "The total population was 470, of which 161 (34%) relapsed and 133 metastasized (28.3%).",
      "Compared with low SII, high SII group had higher probability of relapse and metastasis (P < 0.05).",
      "Multivariate logistic regression analysis showed that, after adjusting for all confounding factors, each additional standard deviation in SII increased the risk of relapse by 28.5%, and the risk of relapse was 1.568 times higher for high SII than for low SII (P < 0.05).",
      "In addition, each additional unit in log Higher levels of SII are significantly associated with a higher risk of relapse and metastasis, indicating that SII may have important clinical value in the prognosis assessment of CSCC."
    ],
    "summary_sentences": [
      "The aim of this study was to confirm the association of systemic immune-inflammation index (SII) with relapse and metastasis of cervical squamous cell carcinoma (CSCC) in patients over 50 years and older.",
      "This retrospective study included 470 patients aged 50 years and older with CSCC who were treated at the Second Affiliated Hospital of Dalian Medical University between January 2020 and January 2023.",
      "The patients were divided into two groups according to median SII: high SII (n = 235) and low SII (n = 235).",
      "Univariate and multivariate logistic regression analysis, subgroup analysis, and receiver operating characteristic curve (ROC) analysis were used to explore the association of SII with relapse and metastasis.",
      "The total population was 470, of which 161 (34%) relapsed and 133 metastasized (28.3%).",
      "Compared with low SII, high SII group had higher probability of relapse and metastasis (P < 0.05).",
      "Multivariate logistic regression analysis showed that, after adjusting for all confounding factors, each additional standard deviation in SII increased the risk of relapse by 28.5%, and the risk of relapse was 1.568 times higher for high SII than for low SII (P < 0.05).",
      "In addition, each additional unit in log Higher levels of SII are significantly associated with a higher risk of relapse and metastasis, indicating that SII may have important clinical value in the prognosis assessment of CSCC."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41611361",
    "source": "pubmed",
    "sentences": [
      "The prevalence of type 2 diabetes in Mexico is among the highest in the world and a major public health problem.",
      "The aim of this study was to examine the association between the percentage of Indigenous American genomic ancestry (AMR) and the prevalence of both prediabetes and type 2 diabetes in a large study of Mexican adults.",
      "In this cross-sectional study, we analysed data from 134 548 individuals from the Mexico City Prospective Study (MCPS), including sociodemographic, clinical, and genetic data.",
      "Type 2 diabetes was defined as a self-reported previous diagnosis, glucose-lowering medication, or glycated hemoglobin (HbA Between April 14, 1998, and Sept 28, 2004, 159 755 participants were recruited into MCPS.",
      "Among these, 134 548 participants were selected for subsequent analyses (mean age 52 years",
      "[SD 12·6]; 90 688 [67·4%] women and 43 860",
      "[32·6%] men); mean AMR ancestry percentage was 66·2% (SD 17·9).",
      "Across AMR tenths (mean AMR ranging from 34·8% [SD 7·9] to 94·7% [SD 2·7]), the prevalence of prediabetes increased from 19·2% (2573 of 13 376) to 26·3% (3529 of 13 421) and of type 2 diabetes from 13·5% (1805 of 13 376) to 23·4% (3142 of 13 421).",
      "After adjustment for age and sex, each 20% absolute increase in AMR was associated with substantially increased odds of type 2 diabetes (odds ratio [OR] 1·45",
      "[95% CI 1·43-1·48]) and of prediabetes (OR 1·28",
      "[1·26-1·30]).",
      "Further adjustment for socioeconomic status, lifestyle factors, and adiposity reduced these ORs to 1·33 (1·31-1·36) for type 2 diabetes and 1·18 (1·16-1·20) for prediabetes.",
      "Consequently, at the population mean AMR ancestry percentage, these fully adjusted ORs were 2·59 (2·44-2·75) for type 2 diabetes and 1·75 (1·65-1·85) for prediabetes, whereas among Indigenous populations with 100% AMR ancestry, ORs were 4·23 (3·85-4·64) for type 2 diabetes and 2·33 (2·14-2·54) for prediabetes.",
      "ORs for type 2 diabetes and prediabetes associated with higher AMR were higher for women than for men, for younger than for older participants, and were further reduced in magnitude following additional adjustment for a type 2 diabetes polygenic risk score.",
      "The percentage of inherited AMR ancestry is strongly associated with prediabetes and type 2 diabetes in this admixed Mexican population.",
      "These findings suggest that most of the Mexican population has a higher genetic susceptibility to type 2 diabetes than European-ancestry populations, underscoring the need for health systems to implement earlier, more intensive, and population-targeted preventive strategies.",
      "Mexican Health Ministry, National Council of Science and Technology for Mexico, Wellcome Trust, Cancer Research UK, British Heart Foundation, Kidney Research UK, and UK Medical Research Council."
    ],
    "summary_sentences": [
      "The prevalence of type 2 diabetes in Mexico is among the highest in the world and a major public health problem.",
      "The aim of this study was to examine the association between the percentage of Indigenous American genomic ancestry (AMR) and the prevalence of both prediabetes and type 2 diabetes in a large study of Mexican adults.",
      "In this cross-sectional study, we analysed data from 134 548 individuals from the Mexico City Prospective Study (MCPS), including sociodemographic, clinical, and genetic data.",
      "Type 2 diabetes was defined as a self-reported previous diagnosis, glucose-lowering medication, or glycated hemoglobin (HbA Between April 14, 1998, and Sept 28, 2004, 159 755 participants were recruited into MCPS.",
      "Among these, 134 548 participants were selected for subsequent analyses (mean age 52 years",
      "[SD 12·6]; 90 688 [67·4%] women and 43 860",
      "[32·6%] men); mean AMR ancestry percentage was 66·2% (SD 17·9).",
      "Across AMR tenths (mean AMR ranging from 34·8% [SD 7·9] to 94·7% [SD 2·7]), the prevalence of prediabetes increased from 19·2% (2573 of 13 376) to 26·3% (3529 of 13 421) and of type 2 diabetes from 13·5% (1805 of 13 376) to 23·4% (3142 of 13 421).",
      "After adjustment for age and sex, each 20% absolute increase in AMR was associated with substantially increased odds of type 2 diabetes (odds ratio [OR] 1·45",
      "[95% CI 1·43-1·48]) and of prediabetes (OR 1·28",
      "[1·26-1·30]).",
      "Further adjustment for socioeconomic status, lifestyle factors, and adiposity reduced these ORs to 1·33 (1·31-1·36) for type 2 diabetes and 1·18 (1·16-1·20) for prediabetes.",
      "Consequently, at the population mean AMR ancestry percentage, these fully adjusted ORs were 2·59 (2·44-2·75) for type 2 diabetes and 1·75 (1·65-1·85) for prediabetes, whereas among Indigenous populations with 100% AMR ancestry, ORs were 4·23 (3·85-4·64) for type 2 diabetes and 2·33 (2·14-2·54) for prediabetes.",
      "ORs for type 2 diabetes and prediabetes associated with higher AMR were higher for women than for men, for younger than for older participants, and were further reduced in magnitude following additional adjustment for a type 2 diabetes polygenic risk score.",
      "The percentage of inherited AMR ancestry is strongly associated with prediabetes and type 2 diabetes in this admixed Mexican population.",
      "These findings suggest that most of the Mexican population has a higher genetic susceptibility to type 2 diabetes than European-ancestry populations, underscoring the need for health systems to implement earlier, more intensive, and population-targeted preventive strategies.",
      "Mexican Health Ministry, National Council of Science and Technology for Mexico, Wellcome Trust, Cancer Research UK, British Heart Foundation, Kidney Research UK, and UK Medical Research Council."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41611090",
    "source": "pubmed",
    "sentences": [
      "Health-related quality of life (HRQoL) is a central aspect of overall health and a crucial factor in dietary interventions, as it may determine both dietary compliance and sustained adherence.",
      "We assessed the effect on HRQoL between: 1) the Low-Carbohydrate High-Fat (LCHF) diet and 2) the High-Carbohydrate Low-Fat (HCLF) diet and evaluated the impact on dietary compliance and sustained adherence.",
      "This is a prespecified secondary analysis from a randomized controlled trial in people with type 2 diabetes.",
      "Participants were randomized 2:1 to follow either LCHF or HCLF for six months with a post-intervention visit nine months after inclusion.",
      "Liver biopsies were performed at baseline and after six months, the Diabetes-39 HRQoL questionnaire, standard clinical and compliance assessments were conducted at baseline, three months, six months and nine months (post-intervention), sustained adherence was assessed at the post-intervention visit.",
      "We randomized 165 participants, 96 (58%) were female.",
      "At baseline, the median age was 56 (IQR, 50-63) years, mean BMI was 33+7 kg/m HRQoL improved in both dietary intervention groups with no difference between groups.",
      "Dietary compliance was associated with improved HRQoL and may play a role in sustained adherence to the LCHF diet.",
      "ClinicalTrials.gov (NCT03068078), https://clinicaltrials.gov/study/NCT03068078."
    ],
    "summary_sentences": [
      "Health-related quality of life (HRQoL) is a central aspect of overall health and a crucial factor in dietary interventions, as it may determine both dietary compliance and sustained adherence.",
      "We assessed the effect on HRQoL between: 1) the Low-Carbohydrate High-Fat (LCHF) diet and 2) the High-Carbohydrate Low-Fat (HCLF) diet and evaluated the impact on dietary compliance and sustained adherence.",
      "This is a prespecified secondary analysis from a randomized controlled trial in people with type 2 diabetes.",
      "Participants were randomized 2:1 to follow either LCHF or HCLF for six months with a post-intervention visit nine months after inclusion.",
      "Liver biopsies were performed at baseline and after six months, the Diabetes-39 HRQoL questionnaire, standard clinical and compliance assessments were conducted at baseline, three months, six months and nine months (post-intervention), sustained adherence was assessed at the post-intervention visit.",
      "We randomized 165 participants, 96 (58%) were female.",
      "At baseline, the median age was 56 (IQR, 50-63) years, mean BMI was 33+7 kg/m HRQoL improved in both dietary intervention groups with no difference between groups.",
      "Dietary compliance was associated with improved HRQoL and may play a role in sustained adherence to the LCHF diet.",
      "ClinicalTrials.gov (NCT03068078), https://clinicaltrials.gov/study/NCT03068078."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41610902",
    "source": "pubmed",
    "sentences": [
      "Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1 RA) reduce cardiovascular and kidney risk in patients with type 2 diabetes (T2D), yet real-world use remains suboptimal.",
      "Remote care models offer a promising approach to improve access; there is limited data on the safety of and adverse events (AEs) associated with prescribing and titrating these therapies through a protocol-driven remote management program.",
      "The DRIVE trial was a pragmatic, randomized clinical trial evaluating the safety of a remote disease management program that initiated SGLT2i and/or GLP1 RA in patients with T2D and elevated cardiovascular or kidney risk.",
      "Participants were enrolled at a large integrated health care system in Massachusetts between March 2021 and December 2022.",
      "Participants were randomized to one of two implementation strategies: a sequential approach (two months of education first followed by medication initiation) or a bundled approach (simultaneous education and medication initiation).",
      "Non-clinical navigators and clinical pharmacists, supervised by physicians, oversaw medication initiation and monitoring under a collaborative drug therapy management agreement and protocol that included algorithms for initiation and titration of SGLT2i and GLP1 RA, as well as adjustment of concurrent glucose-lowering medications to reduce the risk of hypoglycemia Safety outcomes were collected through chart review and patient report, including targeted AEs, hospitalizations, emergency department visits, and urgent care visits.",
      "Targeted AEs were prospectively collected over the first six months after enrollment: for SGLT2i initiators, symptoms of genital mycotic infection, urinary tract infection, or volume depletion; for GLP 1 RA initiators, nausea, vomiting, diarrhea, and abdominal pain.",
      "Hospitalizations, emergency department visits, and urgent care visits over the first six months after enrollment were retrospectively collected through electronic health record review.",
      "Of 200 participants enrolled, 106 (53%) initiated SGLT2i (n=68) or GLP1 RA (n=40).",
      "Among SGLT2i users, 29.4% reported an AE, most commonly genital mycotic infections (10.3%) and symptoms of volume depletion (11.8%); 10.3% discontinued due to AEs.",
      "Among GLP1 RA users, 55.0% experienced AEs, predominantly gastrointestinal; 10.0% discontinued due to AEs.",
      "No severe hypoglycemia, emergency department visits, or hospitalizations occurred.",
      "A remote, pharmacist- and navigator-led program safely initiated SGLT2i and GLP1 RA in a high-risk T2D population, with AE rates comparable to clinical trials and high persistence.",
      "These findings support the feasibility of remote prescribing with appropriate clinical oversight and structured AE management.",
      "Registry: ClinicalTrials.gov; URL: https://clinicaltrials.gov/study/NCT06046560; unique identifier: NCT06046560."
    ],
    "summary_sentences": [
      "Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1 RA) reduce cardiovascular and kidney risk in patients with type 2 diabetes (T2D), yet real-world use remains suboptimal.",
      "Remote care models offer a promising approach to improve access; there is limited data on the safety of and adverse events (AEs) associated with prescribing and titrating these therapies through a protocol-driven remote management program.",
      "The DRIVE trial was a pragmatic, randomized clinical trial evaluating the safety of a remote disease management program that initiated SGLT2i and/or GLP1 RA in patients with T2D and elevated cardiovascular or kidney risk.",
      "Participants were enrolled at a large integrated health care system in Massachusetts between March 2021 and December 2022.",
      "Participants were randomized to one of two implementation strategies: a sequential approach (two months of education first followed by medication initiation) or a bundled approach (simultaneous education and medication initiation).",
      "Non-clinical navigators and clinical pharmacists, supervised by physicians, oversaw medication initiation and monitoring under a collaborative drug therapy management agreement and protocol that included algorithms for initiation and titration of SGLT2i and GLP1 RA, as well as adjustment of concurrent glucose-lowering medications to reduce the risk of hypoglycemia Safety outcomes were collected through chart review and patient report, including targeted AEs, hospitalizations, emergency department visits, and urgent care visits.",
      "Targeted AEs were prospectively collected over the first six months after enrollment: for SGLT2i initiators, symptoms of genital mycotic infection, urinary tract infection, or volume depletion; for GLP 1 RA initiators, nausea, vomiting, diarrhea, and abdominal pain.",
      "Hospitalizations, emergency department visits, and urgent care visits over the first six months after enrollment were retrospectively collected through electronic health record review.",
      "Of 200 participants enrolled, 106 (53%) initiated SGLT2i (n=68) or GLP1 RA (n=40).",
      "Among SGLT2i users, 29.4% reported an AE, most commonly genital mycotic infections (10.3%) and symptoms of volume depletion (11.8%); 10.3% discontinued due to AEs.",
      "Among GLP1 RA users, 55.0% experienced AEs, predominantly gastrointestinal; 10.0% discontinued due to AEs.",
      "No severe hypoglycemia, emergency department visits, or hospitalizations occurred.",
      "A remote, pharmacist- and navigator-led program safely initiated SGLT2i and GLP1 RA in a high-risk T2D population, with AE rates comparable to clinical trials and high persistence.",
      "These findings support the feasibility of remote prescribing with appropriate clinical oversight and structured AE management.",
      "Registry: ClinicalTrials.gov; URL: https://clinicaltrials.gov/study/NCT06046560; unique identifier: NCT06046560."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41610839",
    "source": "pubmed",
    "sentences": [
      "Semaglutide has become an alternative to resmetirom for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH).",
      "However, the effect of type 2 diabetes mellitus (T2DM) on fibrosis response to these drugs is unknown.",
      "Our primary research question asked whether semaglutide or resmetirom treatment leads to fibrosis improvement in diabetic and nondiabetic noncirrhotic MASH.",
      "Data sources included MEDLINE, Cochrane Library, EMBASE, meeting abstracts, clinical trial registries, and regulatory authorities' websites through October 10, 2025, coveringrandomized controlled trials (RCTs) evaluating the effect of semaglutide and/or resmetirom on liver histology in noncirrhotic MASH patients.",
      "Three reviewers extracted data for study characteristics, outcomes of interest, and risk of bias and summarized the strength of evidence using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach.",
      "Main outcome (a ≥1 stage histological fibrosis improvement) was pooled using a risk ratio (RR) and random-effects model.",
      "Eight out of 3,751 identified records, describing three placebo-controlled RCTs with histological endpoints (2,086 noncirrhotic MASH patients, 62% with T2DM, trial duration range 52-72 weeks) were included.",
      "In MASH patients with T2DM, semaglutide did not improve fibrosis stage (RR = 1.21, 95% CI 0.94-1.56, p = 0.13; I T2DM modifies fibrosis response to semaglutide and resmetirom in noncirrhotic MASH.",
      "This study received no funding."
    ],
    "summary_sentences": [
      "Semaglutide has become an alternative to resmetirom for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH).",
      "However, the effect of type 2 diabetes mellitus (T2DM) on fibrosis response to these drugs is unknown.",
      "Our primary research question asked whether semaglutide or resmetirom treatment leads to fibrosis improvement in diabetic and nondiabetic noncirrhotic MASH.",
      "Data sources included MEDLINE, Cochrane Library, EMBASE, meeting abstracts, clinical trial registries, and regulatory authorities' websites through October 10, 2025, coveringrandomized controlled trials (RCTs) evaluating the effect of semaglutide and/or resmetirom on liver histology in noncirrhotic MASH patients.",
      "Three reviewers extracted data for study characteristics, outcomes of interest, and risk of bias and summarized the strength of evidence using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach.",
      "Main outcome (a ≥1 stage histological fibrosis improvement) was pooled using a risk ratio (RR) and random-effects model.",
      "Eight out of 3,751 identified records, describing three placebo-controlled RCTs with histological endpoints (2,086 noncirrhotic MASH patients, 62% with T2DM, trial duration range 52-72 weeks) were included.",
      "In MASH patients with T2DM, semaglutide did not improve fibrosis stage (RR = 1.21, 95% CI 0.94-1.56, p = 0.13; I T2DM modifies fibrosis response to semaglutide and resmetirom in noncirrhotic MASH.",
      "This study received no funding."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41609947",
    "source": "pubmed",
    "sentences": [
      "The DANFLU-1 trial suggested lower incidence of hospitalizations for pneumonia and influenza, respiratory disease and all-cause mortality among older adults receiving high-dose (HD-IV) versus standard-dose (SD-IV) influenza vaccine.",
      "This study assessed the relative effectiveness of HD-IV versus SD-IV according to comorbidity in elderly individuals.",
      "This was a post-hoc analysis of the DANFLU-1 randomized controlled feasibility trial of HD-IV versus SD-IV conducted during the 2021-2022 influenza season in adults aged 65-79 years.",
      "Outcomes assessed included influenza-related, respiratory, and cardiovascular hospitalizations, and mortality.",
      "We tested for effect modification by level of the Charlson Comorbidity Index (CCI) using ICD-10 codes up to 10 years prior to randomization.",
      "Of the 12,477 randomly assigned participants (mean age 71.7 ± 3.9 years, 47.1% female), 8,020 (64.3%) had CCI = 0, 3,560 (28.5%) had CCI = 1-2 and 893 (7.2%) had CCI ≥ 3.",
      "When comparing HD-IV with SD-IV, hazard ratios of hospitalizations for pneumonia and influenza were similar across CCI groups (HR [95%CI]: 0.15",
      "[0.03-0.68] for CCI = 0, 0.36",
      "[0.11-1.15] for CCI = 1-2, 1.00 [0.25-4.00] for CCI ≥ 3).",
      "Comparable patterns were found for hospitalizations for respiratory disease (0.46",
      "[0.17-1.20] for CCI = 0, 0.67",
      "[0.32-1.39] for CCI = 1-2, 0.66",
      "[0.24-1.87] for CCI ≥ 3) and all-cause mortality (0.28",
      "[0.09-0.86] for CCI = 0, 0.70",
      "[0.30-1.63] for CCI = 1-2, 0.57",
      "[0.24-1.36] for CCI ≥ 3).",
      "There was no statistical evidence of effect modification by CCI for any outcome.",
      "The lower incidences of clinical outcomes for HD-IV compared to SD-IV were not significantly modified by CCI.",
      "The potential benefit of HD-IV versus SD-IV may therefore be applicable regardless of comorbidity burden.",
      "Further research is required to confirm these findings."
    ],
    "summary_sentences": [
      "The DANFLU-1 trial suggested lower incidence of hospitalizations for pneumonia and influenza, respiratory disease and all-cause mortality among older adults receiving high-dose (HD-IV) versus standard-dose (SD-IV) influenza vaccine.",
      "This study assessed the relative effectiveness of HD-IV versus SD-IV according to comorbidity in elderly individuals.",
      "This was a post-hoc analysis of the DANFLU-1 randomized controlled feasibility trial of HD-IV versus SD-IV conducted during the 2021-2022 influenza season in adults aged 65-79 years.",
      "Outcomes assessed included influenza-related, respiratory, and cardiovascular hospitalizations, and mortality.",
      "We tested for effect modification by level of the Charlson Comorbidity Index (CCI) using ICD-10 codes up to 10 years prior to randomization.",
      "Of the 12,477 randomly assigned participants (mean age 71.7 ± 3.9 years, 47.1% female), 8,020 (64.3%) had CCI = 0, 3,560 (28.5%) had CCI = 1-2 and 893 (7.2%) had CCI ≥ 3.",
      "When comparing HD-IV with SD-IV, hazard ratios of hospitalizations for pneumonia and influenza were similar across CCI groups (HR [95%CI]: 0.15",
      "[0.03-0.68] for CCI = 0, 0.36",
      "[0.11-1.15] for CCI = 1-2, 1.00 [0.25-4.00] for CCI ≥ 3).",
      "Comparable patterns were found for hospitalizations for respiratory disease (0.46",
      "[0.17-1.20] for CCI = 0, 0.67",
      "[0.32-1.39] for CCI = 1-2, 0.66",
      "[0.24-1.87] for CCI ≥ 3) and all-cause mortality (0.28",
      "[0.09-0.86] for CCI = 0, 0.70",
      "[0.30-1.63] for CCI = 1-2, 0.57",
      "[0.24-1.36] for CCI ≥ 3).",
      "There was no statistical evidence of effect modification by CCI for any outcome.",
      "The lower incidences of clinical outcomes for HD-IV compared to SD-IV were not significantly modified by CCI.",
      "The potential benefit of HD-IV versus SD-IV may therefore be applicable regardless of comorbidity burden.",
      "Further research is required to confirm these findings."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41609932",
    "source": "pubmed",
    "sentences": [
      "Antidepressant augmentation with bupropion was recently demonstrated to increase fall risk in older adults, though specific subpopulations that may have increased risk have not yet been identified.",
      "To determine risk factors for falls in older adults with Major Depressive Disorder (MDD) receiving bupropion augmentation.",
      "Older adults with major depression were followed for approximately ten weeks during a randomized controlled trial (RCT) with three treatment arms, including bupropion augmentation.",
      "Data from the bupropion augmentation arm, which had higher fall rates, were analyzed.",
      "194 older adults with MDD randomized to bupropion augmentation.",
      "Participants' report of falls during biweekly study visits.",
      "The following baseline characteristics were significantly correlated (p < 0.05) with total number of falls: number of falls during the previous 6 months (r = 0.42), burden of physical illness measured with the Cumulative Illness Rating Scale-Geriatric (r = 0.26), physical function score on the Patient-Reported Outcomes Measurement Information System (r = -0.23), and baseline Patient Health Questionnaire-9 Score (r = 0.16).",
      "There were significant main effects of bupropion dosage level (low, medium, or high) (p = 0.04) and number of falls during the six months prior to study entry (p < 0.001).",
      "Study fall rates extrapolated out to the number of falls per year of treatment for subgroups distinguished by dosage level and prior falls ranged from 1.39 falls/year (no history of falls, low dosage bupropion) to 12.32 falls/year (3 + falls during the 6 months prior to study entry, high dosage bupropion).",
      "The risk of falls during bupropion augmentation is a function of the patient's personal history of falls and the dosage of bupropion.",
      "Careful patient selection and personalization of dosing strategy might reduce the risk of falls in older depressed patients treated with bupropion."
    ],
    "summary_sentences": [
      "Antidepressant augmentation with bupropion was recently demonstrated to increase fall risk in older adults, though specific subpopulations that may have increased risk have not yet been identified.",
      "To determine risk factors for falls in older adults with Major Depressive Disorder (MDD) receiving bupropion augmentation.",
      "Older adults with major depression were followed for approximately ten weeks during a randomized controlled trial (RCT) with three treatment arms, including bupropion augmentation.",
      "Data from the bupropion augmentation arm, which had higher fall rates, were analyzed.",
      "194 older adults with MDD randomized to bupropion augmentation.",
      "Participants' report of falls during biweekly study visits.",
      "The following baseline characteristics were significantly correlated (p < 0.05) with total number of falls: number of falls during the previous 6 months (r = 0.42), burden of physical illness measured with the Cumulative Illness Rating Scale-Geriatric (r = 0.26), physical function score on the Patient-Reported Outcomes Measurement Information System (r = -0.23), and baseline Patient Health Questionnaire-9 Score (r = 0.16).",
      "There were significant main effects of bupropion dosage level (low, medium, or high) (p = 0.04) and number of falls during the six months prior to study entry (p < 0.001).",
      "Study fall rates extrapolated out to the number of falls per year of treatment for subgroups distinguished by dosage level and prior falls ranged from 1.39 falls/year (no history of falls, low dosage bupropion) to 12.32 falls/year (3 + falls during the 6 months prior to study entry, high dosage bupropion).",
      "The risk of falls during bupropion augmentation is a function of the patient's personal history of falls and the dosage of bupropion.",
      "Careful patient selection and personalization of dosing strategy might reduce the risk of falls in older depressed patients treated with bupropion."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41609778",
    "source": "pubmed",
    "sentences": [
      "This study could facilitate the generation of automated quantitative assessments, providing clinicians and clinical trials with a continuous severity scale of retinal leakage to improve the prediction of future diabetic retinopathy (DR) worsening.",
      "To examine ultra-widefield fluorescein angiography (UWF-FA) retinal leakage associated with DR progression and complications.",
      "This cohort study was a post hoc analysis of the DRCR Retina Network Protocol AA clinical trial.",
      "Participants were adults with nonproliferative diabetic retinopathy (NPDR).",
      "Data was collected from February 2015 to March 2020.",
      "Analysis was performed June 2023 to April 2024.",
      "Treatment of DR or diabetic macular edema was at the investigator's discretion.",
      "Time to Diabetic Retinopathy Severity Scale (DRSS) worsening of 2 or more steps, vitreous hemorrhage (VH), and proliferative diabetic retinopathy (PDR) over 4 years.",
      "Baseline and 1-year leakage index, calculated as the area with leakage divided by the total area in the analyzable retina on UWF-FA, were evaluated as risk factors.",
      "Among 537 eyes (363 participants; mean [SD] age, 61  years; 183 [50%] male, 180 [50%] female), the baseline leakage index (mean [SD], 3.5%",
      "[3.9%]) was associated with DRSS worsening over 4 years (hazard ratio [HR] for 1% increase, 1.09; 95% CI, 1.05-1.13; P < .001).",
      "At 1 year, 114 of 453 eyes (25%) had an absolute leakage increase 1% or greater from baseline, which was associated with a higher risk of DRSS worsening over 4 years (61% vs 33%; HR, 2.63; 95% CI, 1.90-3.64; P < .001).",
      "Baseline leakage and a 1% or greater increase at 1 year were also associated with development of VH and PDR.",
      "In eyes with NPDR, higher leakage at baseline and an increase from baseline to 1 year were associated with greater risk of DRSS worsening and vision-threatening complications, including VH and PDR.",
      "These findings support quantitative leakage assessment at baseline and over time as a promising biomarker for predicting the severity and progression of diabetic retinopathy."
    ],
    "summary_sentences": [
      "This study could facilitate the generation of automated quantitative assessments, providing clinicians and clinical trials with a continuous severity scale of retinal leakage to improve the prediction of future diabetic retinopathy (DR) worsening.",
      "To examine ultra-widefield fluorescein angiography (UWF-FA) retinal leakage associated with DR progression and complications.",
      "This cohort study was a post hoc analysis of the DRCR Retina Network Protocol AA clinical trial.",
      "Participants were adults with nonproliferative diabetic retinopathy (NPDR).",
      "Data was collected from February 2015 to March 2020.",
      "Analysis was performed June 2023 to April 2024.",
      "Treatment of DR or diabetic macular edema was at the investigator's discretion.",
      "Time to Diabetic Retinopathy Severity Scale (DRSS) worsening of 2 or more steps, vitreous hemorrhage (VH), and proliferative diabetic retinopathy (PDR) over 4 years.",
      "Baseline and 1-year leakage index, calculated as the area with leakage divided by the total area in the analyzable retina on UWF-FA, were evaluated as risk factors.",
      "Among 537 eyes (363 participants; mean [SD] age, 61  years; 183 [50%] male, 180 [50%] female), the baseline leakage index (mean [SD], 3.5%",
      "[3.9%]) was associated with DRSS worsening over 4 years (hazard ratio [HR] for 1% increase, 1.09; 95% CI, 1.05-1.13; P < .001).",
      "At 1 year, 114 of 453 eyes (25%) had an absolute leakage increase 1% or greater from baseline, which was associated with a higher risk of DRSS worsening over 4 years (61% vs 33%; HR, 2.63; 95% CI, 1.90-3.64; P < .001).",
      "Baseline leakage and a 1% or greater increase at 1 year were also associated with development of VH and PDR.",
      "In eyes with NPDR, higher leakage at baseline and an increase from baseline to 1 year were associated with greater risk of DRSS worsening and vision-threatening complications, including VH and PDR.",
      "These findings support quantitative leakage assessment at baseline and over time as a promising biomarker for predicting the severity and progression of diabetic retinopathy."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41608717",
    "source": "pubmed",
    "sentences": [
      "Approximately 20% of ischemic strokes in the United States result from carotid artery stenosis.",
      "Carotid artery stenting (CAS) can reduce stroke risk, but variability in poststenting health outcomes and their predictors is poorly understood.",
      "We examined the 30-day post-CAS health status and derived its most important predictors.",
      "The Stenting and Angioplasty with Protection of Patients with High Risk for Endarterectomy (SAPPHIRE) Worldwide Registry measured preprocedural and 30-day health status for patients undergoing transfemoral CAS using the 36-item Short Form Survey Mental Component Summary and Physical Component Summary, EuroQoL 5-Dimension Index Value, and Visual Analogue Scale.",
      "Random Forest models ranked 66 preprocedural candidate variables by relative importance (RI) in predicting 30-day post-CAS health status, stratified by patient symptomatic status.",
      "Variables with the highest relative importance were identified and used to develop predictive multivariable linear regression models, which were evaluated using R-square (coefficient of determination) and root mean square error.",
      "Health status was assessed using the 36-item Short Form Survey in 3017 patients and EuroQoL 5-Dimension in 3930 patients.",
      "Random forest models identified 9 key predictors of post-CAS health status: preprocedural health status (RI 100%), Modified Rankin Scale score (RI 26.2%-76.5%), National Institutes of Health Stroke Scale score (RI 12.1%-28.0%), history of stroke (RI 9.2%-19.8%), congestive heart failure (RI 12.3%-19.7%), spinal immobility (RI 6.7%-31.0%), diabetes mellitus (RI 8.1%-32.9%), severe pulmonary disease/chronic obstructive pulmonary disease (RI 13.8%-45.6%), and non-Hispanic/Latino ethnicity (RI 8.4%-32.4%).",
      "Multivariable linear regression models explained ∼36%-61% of the health status variance, with 36-item Short Form Survey models (R-square = 36%-61%) outperforming EuroQoL 5-Dimension models (R-square 37%-44%) with regard to R-square and visual fit of observed versus predicted values.",
      "We derived multivariable linear regression-based prediction models that partially explained 30-day post-CAS health status outcomes.",
      "Preprocedural health status scores, stroke scale scores, and medical comorbidities may have utility in appropriately risk-stratifying patients under consideration for CAS and should be considered when discussing health status benefits in pre-CAS treatment shared decision-making discussions.",
      "This study analyzed data from the SAPPHIRE Worldwide:",
      "Stenting and Angioplasty with Protection of Patients with High Risk for Endarterectomy trial.",
      "NCT00403078.URL: https://clinicaltrials.gov/study/NCT00403078."
    ],
    "summary_sentences": [
      "Approximately 20% of ischemic strokes in the United States result from carotid artery stenosis.",
      "Carotid artery stenting (CAS) can reduce stroke risk, but variability in poststenting health outcomes and their predictors is poorly understood.",
      "We examined the 30-day post-CAS health status and derived its most important predictors.",
      "The Stenting and Angioplasty with Protection of Patients with High Risk for Endarterectomy (SAPPHIRE) Worldwide Registry measured preprocedural and 30-day health status for patients undergoing transfemoral CAS using the 36-item Short Form Survey Mental Component Summary and Physical Component Summary, EuroQoL 5-Dimension Index Value, and Visual Analogue Scale.",
      "Random Forest models ranked 66 preprocedural candidate variables by relative importance (RI) in predicting 30-day post-CAS health status, stratified by patient symptomatic status.",
      "Variables with the highest relative importance were identified and used to develop predictive multivariable linear regression models, which were evaluated using R-square (coefficient of determination) and root mean square error.",
      "Health status was assessed using the 36-item Short Form Survey in 3017 patients and EuroQoL 5-Dimension in 3930 patients.",
      "Random forest models identified 9 key predictors of post-CAS health status: preprocedural health status (RI 100%), Modified Rankin Scale score (RI 26.2%-76.5%), National Institutes of Health Stroke Scale score (RI 12.1%-28.0%), history of stroke (RI 9.2%-19.8%), congestive heart failure (RI 12.3%-19.7%), spinal immobility (RI 6.7%-31.0%), diabetes mellitus (RI 8.1%-32.9%), severe pulmonary disease/chronic obstructive pulmonary disease (RI 13.8%-45.6%), and non-Hispanic/Latino ethnicity (RI 8.4%-32.4%).",
      "Multivariable linear regression models explained ∼36%-61% of the health status variance, with 36-item Short Form Survey models (R-square = 36%-61%) outperforming EuroQoL 5-Dimension models (R-square 37%-44%) with regard to R-square and visual fit of observed versus predicted values.",
      "We derived multivariable linear regression-based prediction models that partially explained 30-day post-CAS health status outcomes.",
      "Preprocedural health status scores, stroke scale scores, and medical comorbidities may have utility in appropriately risk-stratifying patients under consideration for CAS and should be considered when discussing health status benefits in pre-CAS treatment shared decision-making discussions.",
      "This study analyzed data from the SAPPHIRE Worldwide:",
      "Stenting and Angioplasty with Protection of Patients with High Risk for Endarterectomy trial.",
      "NCT00403078.URL: https://clinicaltrials.gov/study/NCT00403078."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41607684",
    "source": "pubmed",
    "sentences": [
      "For most patients with pregnancy hyperglycemia, treatment includes lifestyle behavioral counseling for a healthy diet and physical activity (PA).",
      "Outside of pregnancy, emerging evidence suggests that the To describe the rationale and protocol of the Time to Move Randomized Crossover Trial, which evaluates the effects of morning vs. evening PA on glucose levels across the 24-hour cycle.",
      "The eligibility criteria include singleton pregnancies in patients aged 18-40 years, identified as having gestational glucose intolerance [(GGI), a non-fasted, 50-g glucose challenge test, 1-hour value ≥130 mg/dl] or gestational diabetes mellitus [(GDM), by the one- or two-step procedure, at ≥24 weeks].",
      "Participants who provide consent are randomized to first perform either morning PA (between 5 a.m. and 9 a.m., within 30 min-40 min of starting breakfast) or evening PA (between 4 p.m. and 8 p.m., within 30 min-40 min of starting dinner).",
      "All PA episodes consist of 30 min of moderate-intensity walking or stepping.",
      "Participants ultimately contribute 2 days in each of the three treatment conditions: morning PA, evening PA, and no PA, with one washout day between treatment conditions.",
      "Timestamped glucose measurements are obtained using Dexcom G6 or G7 continuous glucose monitors (CGM).",
      "The primary analysis will be intention-to-treat; per-protocol associations will also be explored.",
      "PA adherence is assessed using ActiGraph PA monitoring devices (i.e., the CentrePoint Insight Watch, worn on the non-dominant wrist), which provide continuous timestamped estimates of movement.",
      "Participants upload photos (i.e., in real time) of all foods and beverages consumed throughout the study period, and the timestamps of these photos are used to identify postprandial periods.",
      "One 24-hour dietary recall, aided by photo uploads, is also completed for each treatment condition.",
      "The Time to Move Randomized Crossover Trial addresses the gap in scientific knowledge regarding whether the ClinicalTrials.gov, identifier NCT06125704."
    ],
    "summary_sentences": [
      "For most patients with pregnancy hyperglycemia, treatment includes lifestyle behavioral counseling for a healthy diet and physical activity (PA).",
      "Outside of pregnancy, emerging evidence suggests that the To describe the rationale and protocol of the Time to Move Randomized Crossover Trial, which evaluates the effects of morning vs. evening PA on glucose levels across the 24-hour cycle.",
      "The eligibility criteria include singleton pregnancies in patients aged 18-40 years, identified as having gestational glucose intolerance [(GGI), a non-fasted, 50-g glucose challenge test, 1-hour value ≥130 mg/dl] or gestational diabetes mellitus [(GDM), by the one- or two-step procedure, at ≥24 weeks].",
      "Participants who provide consent are randomized to first perform either morning PA (between 5 a.m. and 9 a.m., within 30 min-40 min of starting breakfast) or evening PA (between 4 p.m. and 8 p.m., within 30 min-40 min of starting dinner).",
      "All PA episodes consist of 30 min of moderate-intensity walking or stepping.",
      "Participants ultimately contribute 2 days in each of the three treatment conditions: morning PA, evening PA, and no PA, with one washout day between treatment conditions.",
      "Timestamped glucose measurements are obtained using Dexcom G6 or G7 continuous glucose monitors (CGM).",
      "The primary analysis will be intention-to-treat; per-protocol associations will also be explored.",
      "PA adherence is assessed using ActiGraph PA monitoring devices (i.e., the CentrePoint Insight Watch, worn on the non-dominant wrist), which provide continuous timestamped estimates of movement.",
      "Participants upload photos (i.e., in real time) of all foods and beverages consumed throughout the study period, and the timestamps of these photos are used to identify postprandial periods.",
      "One 24-hour dietary recall, aided by photo uploads, is also completed for each treatment condition.",
      "The Time to Move Randomized Crossover Trial addresses the gap in scientific knowledge regarding whether the ClinicalTrials.gov, identifier NCT06125704."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41606898",
    "source": "pubmed",
    "sentences": [
      "Understanding how inflammatory dietary potential modulates the gut microbiota diversity, composition, and function remains a topic of ongoing debate.",
      "The present study aims to assess the longitudinal relationship between inflammatory dietary potential and gut microbiota characteristics in older adults with overweight/obesity and metabolic syndrome.",
      "This longitudinal sub-study and secondary analyses nested under the context of the PREvención con Dieta Mediterránea-Plus (PREDIMED-Plus) randomized clinical trial included 648 participants (mean age 65 ± 5 years, 47 % women).",
      "Inflammatory dietary potential was based on energy-adjusted dietary inflammatory index (E-DII) score, assessed using a validated 143-item food frequency questionnaire.",
      "Gut microbiota was characterized using 16S rRNA sequencing and 518 identified faecal metabolites were analysed through liquid chromatography-tandem mass spectrometry.",
      "The relationship between E-DII score (exposure) and gut microbiota alpha and beta diversity and composition, in terms of microbial genera, and faecal metabolites (outcome) with available data at two timepoints (baseline and 1-year thereafter), and longitudinally, was subsequently analysed.",
      "Anti-inflammatory dietary potential as measured by lower E-DII score, either as continuous or categorical, demonstrated significant associations with increased alpha diversity indices (i.e., Chao1, Inverse Simpson and Shannon; all P < 0.05), and distinct beta diversity profiles at baseline (R Anti-inflammatory dietary potential of diet may enhance gut microbiota diversity and potentially modulate its composition in older adults with metabolic syndrome."
    ],
    "summary_sentences": [
      "Understanding how inflammatory dietary potential modulates the gut microbiota diversity, composition, and function remains a topic of ongoing debate.",
      "The present study aims to assess the longitudinal relationship between inflammatory dietary potential and gut microbiota characteristics in older adults with overweight/obesity and metabolic syndrome.",
      "This longitudinal sub-study and secondary analyses nested under the context of the PREvención con Dieta Mediterránea-Plus (PREDIMED-Plus) randomized clinical trial included 648 participants (mean age 65 ± 5 years, 47 % women).",
      "Inflammatory dietary potential was based on energy-adjusted dietary inflammatory index (E-DII) score, assessed using a validated 143-item food frequency questionnaire.",
      "Gut microbiota was characterized using 16S rRNA sequencing and 518 identified faecal metabolites were analysed through liquid chromatography-tandem mass spectrometry.",
      "The relationship between E-DII score (exposure) and gut microbiota alpha and beta diversity and composition, in terms of microbial genera, and faecal metabolites (outcome) with available data at two timepoints (baseline and 1-year thereafter), and longitudinally, was subsequently analysed.",
      "Anti-inflammatory dietary potential as measured by lower E-DII score, either as continuous or categorical, demonstrated significant associations with increased alpha diversity indices (i.e., Chao1, Inverse Simpson and Shannon; all P < 0.05), and distinct beta diversity profiles at baseline (R Anti-inflammatory dietary potential of diet may enhance gut microbiota diversity and potentially modulate its composition in older adults with metabolic syndrome."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41606717",
    "source": "pubmed",
    "sentences": [
      "Resveratrol (RSV) has been extensively investigated for its antioxidant and anti-inflammatory properties across various disease settings; however, its upstream mechanisms in diabetic retinopathy (DR) remain insufficiently characterized.",
      "Given that early DR involves oxidative stress, mitochondrial disruption, and microglia-associated inflammatory amplification, this systematic review aims to synthesize preclinical evidence on how RSV influences these early molecular and cellular events in diabetic retinal models.",
      "A systematic search of PubMed, EBSCO, and ProQuest identified in vitro and in vivo studies examining RSV in diabetes-induced retinal disease.",
      "Eligible studies evaluated mechanistic outcomes related to oxidative stress, inflammation, mitochondrial function, or neurovascular integrity.",
      "Risk of bias was assessed using SYRCLE’s tool for in vivo studies and QUIN-based criteria for in vitro studies.",
      "Twenty studies met inclusion criteria.",
      "RSV consistently activated SIRT1 and improved mitophagy and mitochondrial dynamics, leading to reduced ROS-mediated inflammatory activation.",
      "RSV also modulated apoptotic pathways by suppressing caspase activity and enhancing SIRT1/PGC-1α–associated survival signalling.",
      "Antioxidant defences were strengthened through Nrf2/HO-1 activation, increasing endogenous antioxidant capacity and lowering oxidative injury markers.",
      "The most prominent and consistent finding was RSV’s strong anti-inflammatory effect, characterized by reduced TNF-α, IL-6, and IL-1β, inhibition of NF-κB and HMGB1 signaling, and attenuation of microglia-driven inflammatory amplification, supporting a shift toward an anti-inflammatory signaling profile.",
      "In vivo studies generally used daily doses ≥ 10 mg/kg, with longer durations producing more consistent neuroinflammatory improvement.",
      "RSV exerts broad protective actions in DR by modulating mitochondrial function, inflammation, oxidative stress, and angiogenic signaling.",
      "With its upstream, multitarget profile, RSV represents a promising adjunctive or early-stage therapeutic candidate.",
      "Clinical studies are needed to establish optimal dosing, delivery methods, and translational efficacy in human DR.",
      "Not applicable.",
      "The online version contains supplementary material available at 10.1186/s12886-026-04623-0."
    ],
    "summary_sentences": [
      "Resveratrol (RSV) has been extensively investigated for its antioxidant and anti-inflammatory properties across various disease settings; however, its upstream mechanisms in diabetic retinopathy (DR) remain insufficiently characterized.",
      "Given that early DR involves oxidative stress, mitochondrial disruption, and microglia-associated inflammatory amplification, this systematic review aims to synthesize preclinical evidence on how RSV influences these early molecular and cellular events in diabetic retinal models.",
      "A systematic search of PubMed, EBSCO, and ProQuest identified in vitro and in vivo studies examining RSV in diabetes-induced retinal disease.",
      "Eligible studies evaluated mechanistic outcomes related to oxidative stress, inflammation, mitochondrial function, or neurovascular integrity.",
      "Risk of bias was assessed using SYRCLE’s tool for in vivo studies and QUIN-based criteria for in vitro studies.",
      "Twenty studies met inclusion criteria.",
      "RSV consistently activated SIRT1 and improved mitophagy and mitochondrial dynamics, leading to reduced ROS-mediated inflammatory activation.",
      "RSV also modulated apoptotic pathways by suppressing caspase activity and enhancing SIRT1/PGC-1α–associated survival signalling.",
      "Antioxidant defences were strengthened through Nrf2/HO-1 activation, increasing endogenous antioxidant capacity and lowering oxidative injury markers.",
      "The most prominent and consistent finding was RSV’s strong anti-inflammatory effect, characterized by reduced TNF-α, IL-6, and IL-1β, inhibition of NF-κB and HMGB1 signaling, and attenuation of microglia-driven inflammatory amplification, supporting a shift toward an anti-inflammatory signaling profile.",
      "In vivo studies generally used daily doses ≥ 10 mg/kg, with longer durations producing more consistent neuroinflammatory improvement.",
      "RSV exerts broad protective actions in DR by modulating mitochondrial function, inflammation, oxidative stress, and angiogenic signaling.",
      "With its upstream, multitarget profile, RSV represents a promising adjunctive or early-stage therapeutic candidate.",
      "Clinical studies are needed to establish optimal dosing, delivery methods, and translational efficacy in human DR.",
      "Not applicable.",
      "The online version contains supplementary material available at 10.1186/s12886-026-04623-0."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41606584",
    "source": "pubmed",
    "sentences": [
      "High blood pressure(BP) is a modifiable risk factor for premature mortality, adverse cardiovascular outcomes and kidney diseases in individuals with type 2 diabetes(T2D).",
      "We studied the age-specific associations between BP and incident cardiovascular disease(CVD), chronic kidney disease(CKD), kidney failure, and all-cause death among individuals with T2D. We included individuals with T2D who underwent structured diabetes assessment between 2000 and 2022 in Hong Kong Special Administrative Region, People's Republic of China.",
      "Participants were stratified by baseline age(18-44 years, 45-59 years, 60-74 years, and 75 years or older).",
      "Cox proportional hazard model was used to estimate hazard ratios for the risk of incident CVD, CKD, kidney failure and all-cause death associated with systolic blood pressure(SBP) and",
      "diastolic blood pressure(DBP) categories, referenced to SBP 120-129 mmHg and DBP 70-79 mmHg within each age stratum.",
      "Non-linear association between SBP/ DBP and clinical outcomes was modelled using restricted cubic splines(RCS).",
      "We included 429,740 individuals with T2D (mean age 61.9 years, 52.7% men, 75.3% pre-existing hypertension).",
      "SBP above 120-129 mmHg and DBP above 70-79 mmHg were associated with a proportional increase in risks for CVD, CKD, kidney failure and death across ages adjusted for demographics, diabetes duration, BMI, smoking status, HbA1c, lipids, albuminuria, history of CVD, CKD and use of BP-lowering medications.",
      "The strength of the risk associations was greatest in youngest age group and declined with increasing age.",
      "Among individual components of CVD, risks conferred by an incremental increase in SBP or DBP were high for hemorrhagic stroke.",
      "A 10 mmHg or 1-SD increase in SBP / DBP conferred a 1.2 to 1.5-fold increase in hazards for hemorrhagic stroke among individuals aged 18-44 years (p-interaction < 0.001).",
      "RCS indicated variable linear and nonlinear associations between SBP/DBP and CVD, kidney disease, or death across age categories.",
      "We observed heterogeneity in the relationship between BP and various clinical outcomes across ages in a diabetes population.",
      "Risk associations were strongest among young individuals, emphasising the importance of BP management in this population."
    ],
    "summary_sentences": [
      "High blood pressure(BP) is a modifiable risk factor for premature mortality, adverse cardiovascular outcomes and kidney diseases in individuals with type 2 diabetes(T2D).",
      "We studied the age-specific associations between BP and incident cardiovascular disease(CVD), chronic kidney disease(CKD), kidney failure, and all-cause death among individuals with T2D. We included individuals with T2D who underwent structured diabetes assessment between 2000 and 2022 in Hong Kong Special Administrative Region, People's Republic of China.",
      "Participants were stratified by baseline age(18-44 years, 45-59 years, 60-74 years, and 75 years or older).",
      "Cox proportional hazard model was used to estimate hazard ratios for the risk of incident CVD, CKD, kidney failure and all-cause death associated with systolic blood pressure(SBP) and",
      "diastolic blood pressure(DBP) categories, referenced to SBP 120-129 mmHg and DBP 70-79 mmHg within each age stratum.",
      "Non-linear association between SBP/ DBP and clinical outcomes was modelled using restricted cubic splines(RCS).",
      "We included 429,740 individuals with T2D (mean age 61.9 years, 52.7% men, 75.3% pre-existing hypertension).",
      "SBP above 120-129 mmHg and DBP above 70-79 mmHg were associated with a proportional increase in risks for CVD, CKD, kidney failure and death across ages adjusted for demographics, diabetes duration, BMI, smoking status, HbA1c, lipids, albuminuria, history of CVD, CKD and use of BP-lowering medications.",
      "The strength of the risk associations was greatest in youngest age group and declined with increasing age.",
      "Among individual components of CVD, risks conferred by an incremental increase in SBP or DBP were high for hemorrhagic stroke.",
      "A 10 mmHg or 1-SD increase in SBP / DBP conferred a 1.2 to 1.5-fold increase in hazards for hemorrhagic stroke among individuals aged 18-44 years (p-interaction < 0.001).",
      "RCS indicated variable linear and nonlinear associations between SBP/DBP and CVD, kidney disease, or death across age categories.",
      "We observed heterogeneity in the relationship between BP and various clinical outcomes across ages in a diabetes population.",
      "Risk associations were strongest among young individuals, emphasising the importance of BP management in this population."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41606578",
    "source": "pubmed",
    "sentences": [
      "To comparatively evaluate the effects of mineral trioxide aggregate (MTA) mixed with distilled water (DW), phosphate-buffered saline (PBS), and disodium hydrogen phosphate (DSHP) on the root dentine of teeth affected by diabetes mellitus (DM).",
      "Five samples of MTA were mixed with either distilled water (DW), phosphate-buffered saline (PBS), or disodium hydrogen phosphate (DSHP).",
      "Then, they were assessed for surface characteristics using high-resolution scanning electron microscopy-energy-dispersive X-ray spectroscopy (HRSEM-EDX), surface microhardness via Vickers indentation, and in vitro bioactivity after 21 days of immersion in simulated body fluid.",
      "For the other in vitro tests, 82 single-root human permanent premolars (nondiabetic = 41; diabetic = 41) were decoronated to a standardized length of 12 ± 1 mm.",
      "Following tubular density evaluation (n = 5) using HRSEM, push-out bond strength (n = 18) and fracture resistance (n = 9) were assessed using a universal testing machine, whereas the cement-dentine interface (n = 9) was analyzed using HRSEM-EDX.",
      "The root specimens were then randomly subdivided into subgroups based on the different ionic MTA formulations as follows: subgroup",
      "I: MTA + DW, subgroup II: MTA + PBS, and subgroup III: MTA + DSHP.",
      "Statistical analysis was conducted using GraphPad Prism 10.4.1, using independent t-tests and two-way analysis of variance with Bonferroni correction for comparisons (P < 0.05).",
      "MTA + PBS exhibited a uniform matrix with distinct crystalline structures and the highest microhardness (69.2 ± 3.97 VHN), followed by MTA + DSHP and MTA + DW test materials.",
      "All formulations promoted apatite formation, with MTA + PBS showing dense, homogenous platelet-like crystals.",
      "Tubular density was reported to be higher in diabetic dentine (P < 0.05).",
      "MTA + PBS demonstrated superior cement-dentine interface, push-out bond strength, and fracture resistance, followed by MTA + DSHP and MTA + DW in both DM and non-DM root dentine specimens (P < 0.05).",
      "DM significantly affects the physicochemical and biological properties of root dentine.",
      "Among the various test ionic formulations, MTA + PBS exhibited superior surface characteristics, physicochemical, and biological characteristics compared to MTA + DSHP and MTA + DW.",
      "Hence, MTA mixed with phosphate ionic vehicles, is clinically recommended for effective endodontic management of diabetic dentine.",
      "Not applicable."
    ],
    "summary_sentences": [
      "To comparatively evaluate the effects of mineral trioxide aggregate (MTA) mixed with distilled water (DW), phosphate-buffered saline (PBS), and disodium hydrogen phosphate (DSHP) on the root dentine of teeth affected by diabetes mellitus (DM).",
      "Five samples of MTA were mixed with either distilled water (DW), phosphate-buffered saline (PBS), or disodium hydrogen phosphate (DSHP).",
      "Then, they were assessed for surface characteristics using high-resolution scanning electron microscopy-energy-dispersive X-ray spectroscopy (HRSEM-EDX), surface microhardness via Vickers indentation, and in vitro bioactivity after 21 days of immersion in simulated body fluid.",
      "For the other in vitro tests, 82 single-root human permanent premolars (nondiabetic = 41; diabetic = 41) were decoronated to a standardized length of 12 ± 1 mm.",
      "Following tubular density evaluation (n = 5) using HRSEM, push-out bond strength (n = 18) and fracture resistance (n = 9) were assessed using a universal testing machine, whereas the cement-dentine interface (n = 9) was analyzed using HRSEM-EDX.",
      "The root specimens were then randomly subdivided into subgroups based on the different ionic MTA formulations as follows: subgroup",
      "I: MTA + DW, subgroup II: MTA + PBS, and subgroup III: MTA + DSHP.",
      "Statistical analysis was conducted using GraphPad Prism 10.4.1, using independent t-tests and two-way analysis of variance with Bonferroni correction for comparisons (P < 0.05).",
      "MTA + PBS exhibited a uniform matrix with distinct crystalline structures and the highest microhardness (69.2 ± 3.97 VHN), followed by MTA + DSHP and MTA + DW test materials.",
      "All formulations promoted apatite formation, with MTA + PBS showing dense, homogenous platelet-like crystals.",
      "Tubular density was reported to be higher in diabetic dentine (P < 0.05).",
      "MTA + PBS demonstrated superior cement-dentine interface, push-out bond strength, and fracture resistance, followed by MTA + DSHP and MTA + DW in both DM and non-DM root dentine specimens (P < 0.05).",
      "DM significantly affects the physicochemical and biological properties of root dentine.",
      "Among the various test ionic formulations, MTA + PBS exhibited superior surface characteristics, physicochemical, and biological characteristics compared to MTA + DSHP and MTA + DW.",
      "Hence, MTA mixed with phosphate ionic vehicles, is clinically recommended for effective endodontic management of diabetic dentine.",
      "Not applicable."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41606330",
    "source": "pubmed",
    "sentences": [
      "Environmental differences in genetic effect sizes, namely, gene-environment interactions, may uncover the genetic encoding of phenotypic plasticity"
    ],
    "summary_sentences": [
      "Environmental differences in genetic effect sizes, namely, gene-environment interactions, may uncover the genetic encoding of phenotypic plasticity"
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41605502",
    "source": "pubmed",
    "sentences": [
      "More than 15% of US adults with type 2 diabetes have persistent hyperglycemia.",
      "Adults with persistent hyperglycemia and type 2 diabetes have an elevated health risk of a variety of outcomes, including amputation and mortality from cardiovascular disease and from all causes.",
      "Nutrition-focused interventions can be effective for improving glycemic control, reducing antihyperglycemic medications, and reducing body weight, all of which are critical outcomes for adults with type 2 diabetes.",
      "Carbohydrate intake impacts postprandial glycemia more than any other dietary factor.",
      "The American Diabetes Association now recommends a very low-carbohydrate diet, because of its ability to improve glycemic control, for the treatment of type 2 diabetes.",
      "However, typical nutrition-focused interventions can be burdensome, as the interventions often have complex instructions and require changing one's diet completely.",
      "Additionally, adults with type 2 diabetes and persistent hyperglycemia may be more likely to have low health literacy levels, which can be a barrier to adherence to complex interventions.",
      "This study aimed to evaluate the effectiveness of a digital, small-steps intervention that focuses on implementing a very low-carbohydrate dietary pattern specifically at breakfast for adults with type 2 diabetes and persistent hyperglycemia.",
      "The goal is to determine whether this targeted dietary modification can lead to reductions in hemoglobin A The Breakfast Study will enroll adults with a hemoglobin",
      "A As of October 2025, we have enrolled 119 participants.",
      "The results will be published separately.",
      "The Breakfast Study is a nonrandomized, pre-post trial to assess the acceptability, feasibility, and preliminary effectiveness of an accessible, very low-carbohydrate breakfast for adults with type 2 diabetes and persistent hyperglycemia.",
      "This study could provide support for continued research investigating how to lower barriers to dietary interventions for type 2 diabetes.",
      "ClinicalTrials.gov",
      "NCT05986097; https://clinicaltrials.gov/study/NCT05986097. DERR1-10.2196/81041."
    ],
    "summary_sentences": [
      "More than 15% of US adults with type 2 diabetes have persistent hyperglycemia.",
      "Adults with persistent hyperglycemia and type 2 diabetes have an elevated health risk of a variety of outcomes, including amputation and mortality from cardiovascular disease and from all causes.",
      "Nutrition-focused interventions can be effective for improving glycemic control, reducing antihyperglycemic medications, and reducing body weight, all of which are critical outcomes for adults with type 2 diabetes.",
      "Carbohydrate intake impacts postprandial glycemia more than any other dietary factor.",
      "The American Diabetes Association now recommends a very low-carbohydrate diet, because of its ability to improve glycemic control, for the treatment of type 2 diabetes.",
      "However, typical nutrition-focused interventions can be burdensome, as the interventions often have complex instructions and require changing one's diet completely.",
      "Additionally, adults with type 2 diabetes and persistent hyperglycemia may be more likely to have low health literacy levels, which can be a barrier to adherence to complex interventions.",
      "This study aimed to evaluate the effectiveness of a digital, small-steps intervention that focuses on implementing a very low-carbohydrate dietary pattern specifically at breakfast for adults with type 2 diabetes and persistent hyperglycemia.",
      "The goal is to determine whether this targeted dietary modification can lead to reductions in hemoglobin A The Breakfast Study will enroll adults with a hemoglobin",
      "A As of October 2025, we have enrolled 119 participants.",
      "The results will be published separately.",
      "The Breakfast Study is a nonrandomized, pre-post trial to assess the acceptability, feasibility, and preliminary effectiveness of an accessible, very low-carbohydrate breakfast for adults with type 2 diabetes and persistent hyperglycemia.",
      "This study could provide support for continued research investigating how to lower barriers to dietary interventions for type 2 diabetes.",
      "ClinicalTrials.gov",
      "NCT05986097; https://clinicaltrials.gov/study/NCT05986097. DERR1-10.2196/81041."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41601988",
    "source": "pubmed",
    "sentences": [
      "Diabetic nephropathy (DN) is one of the common complications of diabetes, which is the leading cause of end-stage renal disease worldwide.",
      "Ginkgo biloba extract (GBE) has shown effectiveness in DN animal models and represents a promising therapeutic candidate.",
      "However, a comprehensive preclinical meta-analysis remains to be conducted, and the dose-time effect of GBE in the treatment of DN has not been evaluated.",
      "To evaluate the therapeutic effectiveness, mechanism and dose-time effect of GBE for DN by systematic review and meta-analysis.",
      "Seven databases (PubMed, Web of science, Embase, CBM, CNKI, Wanfang and VIP databases) were searched in this systematic review up to July 2025.",
      "Study quality was assessed using SYRCLE bias risk tool.",
      "STATA 14.0 software was employed to evaluate fasting blood glucose serum creatinine (SCr), blood urea nitrogen 24-h urine protein (24 h Upro), kidney index and indicators related to inflammatory response, oxidative stress, fibrosis, and glycolipid metabolism.",
      "The dose-time effect of Ginkgo biloba extract was evaluated by three-dimensional dose-time-effect analysis.",
      "30 pertinent articles were included in the meta-analysis.",
      "Comparative analysis revealed that GBE exhibited statistically significant effect in reducing FBG, SCr, BUN, 24 h Upro, and KI.",
      "Furthermore, it also improved inflammatory indicators such as interleukin 1β (IL-1β), interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α), as well as oxidative stress indicators like superoxide dismutase (SOD), malondialdehyde (MDA), antioxidation capability (AOC) and glutathione peroxidases (GSH-Px).",
      "Additionally, GBE showed positive effect in alleviating fibrosis and reducing serum total cholesterol (TC) and advanced glycation end products (AGEs).",
      "The dose-time-effect diagram showed that the rational dose of GBE for DN treatment was 36-200 mg/kg/d for 8-12 weeks.",
      "GBE may delay the progression of DN through multimodal mechanisms, including inhibition of inflammatory responses, attenuation of oxidative stress, suppression of fibrotic pathways, and modulation of glycolipid metabolism.",
      "https://www.crd.york.ac.uk/PROSPERO/view/CRD420250652386."
    ],
    "summary_sentences": [
      "Diabetic nephropathy (DN) is one of the common complications of diabetes, which is the leading cause of end-stage renal disease worldwide.",
      "Ginkgo biloba extract (GBE) has shown effectiveness in DN animal models and represents a promising therapeutic candidate.",
      "However, a comprehensive preclinical meta-analysis remains to be conducted, and the dose-time effect of GBE in the treatment of DN has not been evaluated.",
      "To evaluate the therapeutic effectiveness, mechanism and dose-time effect of GBE for DN by systematic review and meta-analysis.",
      "Seven databases (PubMed, Web of science, Embase, CBM, CNKI, Wanfang and VIP databases) were searched in this systematic review up to July 2025.",
      "Study quality was assessed using SYRCLE bias risk tool.",
      "STATA 14.0 software was employed to evaluate fasting blood glucose serum creatinine (SCr), blood urea nitrogen 24-h urine protein (24 h Upro), kidney index and indicators related to inflammatory response, oxidative stress, fibrosis, and glycolipid metabolism.",
      "The dose-time effect of Ginkgo biloba extract was evaluated by three-dimensional dose-time-effect analysis.",
      "30 pertinent articles were included in the meta-analysis.",
      "Comparative analysis revealed that GBE exhibited statistically significant effect in reducing FBG, SCr, BUN, 24 h Upro, and KI.",
      "Furthermore, it also improved inflammatory indicators such as interleukin 1β (IL-1β), interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α), as well as oxidative stress indicators like superoxide dismutase (SOD), malondialdehyde (MDA), antioxidation capability (AOC) and glutathione peroxidases (GSH-Px).",
      "Additionally, GBE showed positive effect in alleviating fibrosis and reducing serum total cholesterol (TC) and advanced glycation end products (AGEs).",
      "The dose-time-effect diagram showed that the rational dose of GBE for DN treatment was 36-200 mg/kg/d for 8-12 weeks.",
      "GBE may delay the progression of DN through multimodal mechanisms, including inhibition of inflammatory responses, attenuation of oxidative stress, suppression of fibrotic pathways, and modulation of glycolipid metabolism.",
      "https://www.crd.york.ac.uk/PROSPERO/view/CRD420250652386."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41601869",
    "source": "pubmed",
    "sentences": [
      "Individuals with obesity and type 2 diabetes (T2D) constitute a high-risk subgroup that frequently exhibits suboptimal glycemic control even under standard management strategies.",
      "This study aimed to characterize the baseline metabolic and sociodemographic profiles of participants enrolled in a randomized controlled trial evaluating the efficacy of a diabetes-specific meal replacement (DSMR), and to identify predictors of suboptimal glycemic control.",
      "A total of 156 adults with T2D and BMI ≥ 25 kg/m The cohort had a mean age of 52.2 years and mean HbA1c of 8.52%, indicating suboptimal glycemic control.",
      "While no correlation was found between BMI and HbA1c, HOMA-IR and ALT were positively associated with suboptimal glycemic status.",
      "In the final regression model, HOMA-IR (OR = 1.099, Elevated insulin resistance and liver-related markers were independent predictors of suboptimal glycemic control.",
      "The result underscores the importance of targeting metabolic dysfunction beyond weight alone in interventions for high-risk T2D populations.",
      "These findings also support the mechanistic rationale for targeted nutrition-based strategies aimed at improving insulin sensitivity and hepatic function.",
      "Moreover, they provide valuable context for interpreting participant responses within the ongoing trial.",
      "The DSMR used in this trial may offer a viable and sustainable option to improve glycemic control among high-risk individuals with T2D. https://www.thaiclinicaltrials.org/show/TCTR20210921004, TCTR20210921004."
    ],
    "summary_sentences": [
      "Individuals with obesity and type 2 diabetes (T2D) constitute a high-risk subgroup that frequently exhibits suboptimal glycemic control even under standard management strategies.",
      "This study aimed to characterize the baseline metabolic and sociodemographic profiles of participants enrolled in a randomized controlled trial evaluating the efficacy of a diabetes-specific meal replacement (DSMR), and to identify predictors of suboptimal glycemic control.",
      "A total of 156 adults with T2D and BMI ≥ 25 kg/m The cohort had a mean age of 52.2 years and mean HbA1c of 8.52%, indicating suboptimal glycemic control.",
      "While no correlation was found between BMI and HbA1c, HOMA-IR and ALT were positively associated with suboptimal glycemic status.",
      "In the final regression model, HOMA-IR (OR = 1.099, Elevated insulin resistance and liver-related markers were independent predictors of suboptimal glycemic control.",
      "The result underscores the importance of targeting metabolic dysfunction beyond weight alone in interventions for high-risk T2D populations.",
      "These findings also support the mechanistic rationale for targeted nutrition-based strategies aimed at improving insulin sensitivity and hepatic function.",
      "Moreover, they provide valuable context for interpreting participant responses within the ongoing trial.",
      "The DSMR used in this trial may offer a viable and sustainable option to improve glycemic control among high-risk individuals with T2D. https://www.thaiclinicaltrials.org/show/TCTR20210921004, TCTR20210921004."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41599916",
    "source": "pubmed",
    "sentences": [
      "Pediatric obesity is an increasingly prevalent, chronic, and multifactorial disease.",
      "Achieving successful and sustained weight reduction with current interventions remains challenging due to significant heterogeneity in treatment response.",
      "This review summarizes current evidence describing variability in outcomes across lifestyle, pharmacologic, and metabolic/bariatric surgery interventions in children and adolescents, and examines key biological, metabolic, behavioral, environmental, and psychosocial factors that influence response.",
      "In adults, recent findings on energy balance obesity phenotypes (characterized by abnormal satiation, abnormal postprandial satiety, abnormal hedonic eating, and reduced energy expenditure) have demonstrated promise in predicting weight loss outcomes and guiding tailored interventions.",
      "However, data on obesity phenotyping within children and adolescents remain limited.",
      "Addressing this gap is essential for advancing precision medicine approaches in pediatric obesity, with the potential to improve treatment selection, enhance effectiveness, and optimize long-term clinical outcomes."
    ],
    "summary_sentences": [
      "Pediatric obesity is an increasingly prevalent, chronic, and multifactorial disease.",
      "Achieving successful and sustained weight reduction with current interventions remains challenging due to significant heterogeneity in treatment response.",
      "This review summarizes current evidence describing variability in outcomes across lifestyle, pharmacologic, and metabolic/bariatric surgery interventions in children and adolescents, and examines key biological, metabolic, behavioral, environmental, and psychosocial factors that influence response.",
      "In adults, recent findings on energy balance obesity phenotypes (characterized by abnormal satiation, abnormal postprandial satiety, abnormal hedonic eating, and reduced energy expenditure) have demonstrated promise in predicting weight loss outcomes and guiding tailored interventions.",
      "However, data on obesity phenotyping within children and adolescents remain limited.",
      "Addressing this gap is essential for advancing precision medicine approaches in pediatric obesity, with the potential to improve treatment selection, enhance effectiveness, and optimize long-term clinical outcomes."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41596325",
    "source": "pubmed",
    "sentences": [
      "Heart failure with preserved ejection fraction (HFpEF) accounts for about half of heart failure cases and is linked to aging, obesity, diabetes, and multimorbidity, yet disease-modifying therapies remain limited.",
      "A major barrier is heterogeneity:",
      "HFpEF comprises overlapping inflammatory, fibrotic, cardiometabolic, and hemodynamic/vascular endophenotypes embedded within systemic cardiorenal and cardiohepatic cross-talk, which conventional metrics such as left ventricular ejection fraction (LVEF), natriuretic peptides (NPs), and standard imaging capture incompletely.",
      "In this narrative review, we synthesize clinical, mechanistic, and trial data to describe HFpEF endophenotypes and their multi-organ interactions; critically appraise why traditional diagnostic and enrollment strategies contributed to neutral outcomes in landmark trials; and survey emerging cardiovascular multi-omics studies.",
      "We then outline an integrative systems-biology framework that applies (i) within-layer analyses and cross-layer integration, (ii) network-based driver nomination and biomarker discovery, and (iii) target nomination to link molecular programs with circulating markers and candidate therapies.",
      "Finally, we discuss practical challenges in implementing multi-omics HFpEF research and highlight future directions such as artificial intelligence (AI)-enabled multi-omics integration, cross-organ profiling, and biomarker-guided, endotype-enriched platform trials.",
      "Collectively, these advances position HFpEF as a proving ground for precision cardiology, in which therapies are matched to molecularly defined disease programs rather than ejection-fraction cutoffs alone."
    ],
    "summary_sentences": [
      "Heart failure with preserved ejection fraction (HFpEF) accounts for about half of heart failure cases and is linked to aging, obesity, diabetes, and multimorbidity, yet disease-modifying therapies remain limited.",
      "A major barrier is heterogeneity:",
      "HFpEF comprises overlapping inflammatory, fibrotic, cardiometabolic, and hemodynamic/vascular endophenotypes embedded within systemic cardiorenal and cardiohepatic cross-talk, which conventional metrics such as left ventricular ejection fraction (LVEF), natriuretic peptides (NPs), and standard imaging capture incompletely.",
      "In this narrative review, we synthesize clinical, mechanistic, and trial data to describe HFpEF endophenotypes and their multi-organ interactions; critically appraise why traditional diagnostic and enrollment strategies contributed to neutral outcomes in landmark trials; and survey emerging cardiovascular multi-omics studies.",
      "We then outline an integrative systems-biology framework that applies (i) within-layer analyses and cross-layer integration, (ii) network-based driver nomination and biomarker discovery, and (iii) target nomination to link molecular programs with circulating markers and candidate therapies.",
      "Finally, we discuss practical challenges in implementing multi-omics HFpEF research and highlight future directions such as artificial intelligence (AI)-enabled multi-omics integration, cross-organ profiling, and biomarker-guided, endotype-enriched platform trials.",
      "Collectively, these advances position HFpEF as a proving ground for precision cardiology, in which therapies are matched to molecularly defined disease programs rather than ejection-fraction cutoffs alone."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41596262",
    "source": "pubmed",
    "sentences": [
      "Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT2) inhibitors have reshaped pharmacological management of type 2 diabetes, but emerging safety signals suggest a possible association with intestinal obstruction.",
      "Because many candidates for these agents already harbor risk factors for ileus and bowel obstruction, clarifying agent- and dose-specific gastrointestinal safety is clinically important.",
      "We aimed to re-evaluate the risk of intestinal obstruction across individual GLP-1 receptor agonists and SGLT2 inhibitors, with particular attention to dose stratification.",
      "We systematically searched eight databases through 21 January 2025 to identify randomized controlled trials (RCTs) comparing GLP-1 receptor agonists or SGLT2 inhibitors with placebo or active comparators in adults.",
      "The primary outcome was incident intestinal obstruction (small or large bowel).",
      "A frequentist random-effects network meta-analysis estimated odds ratios (ORs) with 95% confidence intervals (CIs) across drugs and dose tiers; Bayesian models and surface under the cumulative ranking (SUCRA) metrics were used for sensitivity analyses and treatment ranking.",
      "Risk of bias and certainty of evidence were assessed with standard Cochrane and GRADE-adapted tools.",
      "Fifty RCTs (47 publications; 192,359 participants) met inclusion criteria.",
      "Overall, canagliflozin use was associated with a higher incidence of intestinal obstruction than control therapies (OR 2.56, 95% CI 1.01-6.49), corresponding to an absolute risk difference of 0.15% and a number needed to harm of 658.",
      "High-dose canagliflozin (300 mg/day) showed the clearest signal (OR 3.42, 95% CI 1.08-10.76).",
      "In contrast, liraglutide was associated with a lower risk of intestinal obstruction (OR 0.44, 95% CI 0.24-0.81), with an absolute risk reduction of 0.34% and a number needed to treat of 295.",
      "No other GLP-1 receptor agonist or SGLT2 inhibitor demonstrated a statistically significant increase in obstruction risk.",
      "Frequentist and Bayesian analyses yielded concordant estimates and rankings.",
      "From a randomized-trial perspective, intestinal obstruction risk is not elevated for most GLP-1 receptor agonists and SGLT2 inhibitors.",
      "A dose-dependent safety signal was observed only for high-dose canagliflozin, whereas liraglutide may confer a protective effect.",
      "These findings refine gastrointestinal safety profiles for modern antidiabetic agents and may inform perioperative bowel management, drug selection, and dose optimization in patients at risk for ileus or adhesive obstruction."
    ],
    "summary_sentences": [
      "Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT2) inhibitors have reshaped pharmacological management of type 2 diabetes, but emerging safety signals suggest a possible association with intestinal obstruction.",
      "Because many candidates for these agents already harbor risk factors for ileus and bowel obstruction, clarifying agent- and dose-specific gastrointestinal safety is clinically important.",
      "We aimed to re-evaluate the risk of intestinal obstruction across individual GLP-1 receptor agonists and SGLT2 inhibitors, with particular attention to dose stratification.",
      "We systematically searched eight databases through 21 January 2025 to identify randomized controlled trials (RCTs) comparing GLP-1 receptor agonists or SGLT2 inhibitors with placebo or active comparators in adults.",
      "The primary outcome was incident intestinal obstruction (small or large bowel).",
      "A frequentist random-effects network meta-analysis estimated odds ratios (ORs) with 95% confidence intervals (CIs) across drugs and dose tiers; Bayesian models and surface under the cumulative ranking (SUCRA) metrics were used for sensitivity analyses and treatment ranking.",
      "Risk of bias and certainty of evidence were assessed with standard Cochrane and GRADE-adapted tools.",
      "Fifty RCTs (47 publications; 192,359 participants) met inclusion criteria.",
      "Overall, canagliflozin use was associated with a higher incidence of intestinal obstruction than control therapies (OR 2.56, 95% CI 1.01-6.49), corresponding to an absolute risk difference of 0.15% and a number needed to harm of 658.",
      "High-dose canagliflozin (300 mg/day) showed the clearest signal (OR 3.42, 95% CI 1.08-10.76).",
      "In contrast, liraglutide was associated with a lower risk of intestinal obstruction (OR 0.44, 95% CI 0.24-0.81), with an absolute risk reduction of 0.34% and a number needed to treat of 295.",
      "No other GLP-1 receptor agonist or SGLT2 inhibitor demonstrated a statistically significant increase in obstruction risk.",
      "Frequentist and Bayesian analyses yielded concordant estimates and rankings.",
      "From a randomized-trial perspective, intestinal obstruction risk is not elevated for most GLP-1 receptor agonists and SGLT2 inhibitors.",
      "A dose-dependent safety signal was observed only for high-dose canagliflozin, whereas liraglutide may confer a protective effect.",
      "These findings refine gastrointestinal safety profiles for modern antidiabetic agents and may inform perioperative bowel management, drug selection, and dose optimization in patients at risk for ileus or adhesive obstruction."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41593683",
    "source": "pubmed",
    "sentences": [
      "Evidence for the net benefit of aspirin for primary prevention of cardiovascular disease (CVD) is finely balanced, leading to variation in guideline recommendations internationally.",
      "External validity of randomised clinical trial (RCT) evidence may therefore be of particular importance.",
      "The aim of this study is to characterise real-world patients according to their eligibility for guideline-cited aspirin RCTs for primary CVD prevention.",
      "Eligibility criteria from 14 RCTs were applied to a linked primary care/hospital discharge dataset of people ≥ 40 years without CVD.",
      "Proportions eligible for each trial were calculated, and characteristics of eligible and ineligible patients compared for each trial, including Cox regression analysis of event rates for major adverse cardiovascular events (MACE), major bleeding events, and non-cardiovascular mortality.",
      "Of 570,211 included patients (300,500 [52.7%] women, 336,877 [59%] < 60 years), the median proportion ineligible for 14 RCTs was 90.7% (range 42.5-99.4%) and 24.0% of patients were ineligible for all RCTs.",
      "On average, trial-ineligible populations were younger (median age trial-ineligible 57.8 vs trial-eligible 62.6 years, p = 0.008) and a lower proportion had hypertension (23.9% vs 50.9%, p = 0.004), diabetes (6.4% vs 11.5%, p = 0.015), or a regular statin prescription (11.8% vs 26.7%, p = 0.001).",
      "Trial-ineligible populations had a higher hazard of MACE compared to trial-eligible in four RCTs and lower in ten (hazard ratio [HR] range across all RCTs 0.45",
      "[95%CI 0.40-0.51] to 2.78 [95%CI 2.61-2.96]).",
      "Hazards of bleeding events in the trial-ineligible were lower than the trial-eligible in eight RCTs and higher in four (HR range across all RCTs 0.63",
      "[95%CI, 0.59-0.66] to 1.69",
      "[95%CI, 1.53-1.86]), and time-varying hazards of non-CVD death were consistently lower in four RCTs and higher in five (HR range across all RCTs and time points 0.29",
      "[95%CI 0.24-0.36] to 11.42",
      "[95%CI 9.91-13.17]).",
      "Compared with trial-ineligible populations within the same age and sex strata, RCTs recruited people of varying CVD risk but often excluded people at high risk of bleeding or non-CVD death, highlighting that many trials may overestimate the net benefit of aspirin for primary prevention."
    ],
    "summary_sentences": [
      "Evidence for the net benefit of aspirin for primary prevention of cardiovascular disease (CVD) is finely balanced, leading to variation in guideline recommendations internationally.",
      "External validity of randomised clinical trial (RCT) evidence may therefore be of particular importance.",
      "The aim of this study is to characterise real-world patients according to their eligibility for guideline-cited aspirin RCTs for primary CVD prevention.",
      "Eligibility criteria from 14 RCTs were applied to a linked primary care/hospital discharge dataset of people ≥ 40 years without CVD.",
      "Proportions eligible for each trial were calculated, and characteristics of eligible and ineligible patients compared for each trial, including Cox regression analysis of event rates for major adverse cardiovascular events (MACE), major bleeding events, and non-cardiovascular mortality.",
      "Of 570,211 included patients (300,500 [52.7%] women, 336,877 [59%] < 60 years), the median proportion ineligible for 14 RCTs was 90.7% (range 42.5-99.4%) and 24.0% of patients were ineligible for all RCTs.",
      "On average, trial-ineligible populations were younger (median age trial-ineligible 57.8 vs trial-eligible 62.6 years, p = 0.008) and a lower proportion had hypertension (23.9% vs 50.9%, p = 0.004), diabetes (6.4% vs 11.5%, p = 0.015), or a regular statin prescription (11.8% vs 26.7%, p = 0.001).",
      "Trial-ineligible populations had a higher hazard of MACE compared to trial-eligible in four RCTs and lower in ten (hazard ratio [HR] range across all RCTs 0.45",
      "[95%CI 0.40-0.51] to 2.78 [95%CI 2.61-2.96]).",
      "Hazards of bleeding events in the trial-ineligible were lower than the trial-eligible in eight RCTs and higher in four (HR range across all RCTs 0.63",
      "[95%CI, 0.59-0.66] to 1.69",
      "[95%CI, 1.53-1.86]), and time-varying hazards of non-CVD death were consistently lower in four RCTs and higher in five (HR range across all RCTs and time points 0.29",
      "[95%CI 0.24-0.36] to 11.42",
      "[95%CI 9.91-13.17]).",
      "Compared with trial-ineligible populations within the same age and sex strata, RCTs recruited people of varying CVD risk but often excluded people at high risk of bleeding or non-CVD death, highlighting that many trials may overestimate the net benefit of aspirin for primary prevention."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41592063",
    "source": "pubmed",
    "sentences": [
      "This study evaluated the accuracy of phosphatidylethanol (PEth), a direct biomarker of alcohol consumption, in distinguishing individuals with and without heavy drinking days, and sought to establish an optimal cutoff using data from a recent clinical trial in alcohol use disorder (AUD).",
      "Data from a 26-week randomized, double-blind, placebo-controlled clinical trial of 127 individuals with AUD were analyzed.",
      "A total of 447 blood PEth samples were compared with self-reported heavy drinking days (≥60 grams of alcohol/day for men and ≥48 g/day for women) via Timeline Follow back method and weekly alcohol logs.",
      "Spearman correlations between PEth and self-reports were calculated for the past 7, 14, 21, and 28 days at each study visit.",
      "Periods with the strongest correlations (past 14-21 days at the Week 4 follow-up) were used for receiver operating characteristic (ROC) analyses.",
      "Among 127 participants, 63 completed the 26-week follow-up.",
      "Moderate-to-strong correlations were observed, strongest at Week 4 (Rho = 0.65, 95% CI, 0.52-0.75, P < .001).",
      "ROC analysis at Week 4 showed high discrimination between participants with ≥1 heavy drinking days versus no heavy drinking days (AUC = 0.90, 95% CI, 0.86-0.92), with a PEth cutoff of 0.145 μmol/L (101.9 ng/ml), yielding 95% sensitivity (95% CI, 86-98) and 80% specificity (95% CI, 61-92).",
      "Our findings support the use of PEth as an objective measure of heavy drinking days in a clinical setting.",
      "Further research is needed to validate these findings in larger cohorts."
    ],
    "summary_sentences": [
      "This study evaluated the accuracy of phosphatidylethanol (PEth), a direct biomarker of alcohol consumption, in distinguishing individuals with and without heavy drinking days, and sought to establish an optimal cutoff using data from a recent clinical trial in alcohol use disorder (AUD).",
      "Data from a 26-week randomized, double-blind, placebo-controlled clinical trial of 127 individuals with AUD were analyzed.",
      "A total of 447 blood PEth samples were compared with self-reported heavy drinking days (≥60 grams of alcohol/day for men and ≥48 g/day for women) via Timeline Follow back method and weekly alcohol logs.",
      "Spearman correlations between PEth and self-reports were calculated for the past 7, 14, 21, and 28 days at each study visit.",
      "Periods with the strongest correlations (past 14-21 days at the Week 4 follow-up) were used for receiver operating characteristic (ROC) analyses.",
      "Among 127 participants, 63 completed the 26-week follow-up.",
      "Moderate-to-strong correlations were observed, strongest at Week 4 (Rho = 0.65, 95% CI, 0.52-0.75, P < .001).",
      "ROC analysis at Week 4 showed high discrimination between participants with ≥1 heavy drinking days versus no heavy drinking days (AUC = 0.90, 95% CI, 0.86-0.92), with a PEth cutoff of 0.145 μmol/L (101.9 ng/ml), yielding 95% sensitivity (95% CI, 86-98) and 80% specificity (95% CI, 61-92).",
      "Our findings support the use of PEth as an objective measure of heavy drinking days in a clinical setting.",
      "Further research is needed to validate these findings in larger cohorts."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41591636",
    "source": "pubmed",
    "sentences": [
      "Once-weekly efsitora resulted in similar efficacy and safety compared with daily basal insulins glargine or degludec in the treatment of adults with type 2 diabetes in the QWINT phase 3 development program.",
      "To fully assess once-weekly insulin's potential and address common barriers associated with insulin therapy (e.g., clinical inertia, fear of injections, treatment complexity), other aspects of the participants' treatment experiences were investigated using patient-reported outcome (PRO) measurements.",
      "The results of these PROs from QWINT-1 to -4 are presented here.",
      "Six different PRO instruments were completed across the studies at primary timepoints and treatment period endpoint (QWINT-1, week 26/52; QWINT-2, week 26/52; QWINT-3, week 26/52/78; QWINT-4, week 26) by participants enrolled in the phase 3 QWINT clinical trials.",
      "The PRO instruments included Treatment Related Impact Measure-Diabetes (Trim-D) (QWINT-1, -2, and -3), Diabetes Treatment Satisfaction Questionnaire (DTSQ) (QWINT-1 and -3), Simplicity of Diabetes Treatment Questionnaire (SIM-Q) (QWINT-1, -2, and -3), Basal Insulin Experience (BIE) (all QWINTs), EQ-5D-5L (QWINT-2, -3, and -4), and Short Form-36 Health Survey Version 2(SF-36v2) (QWINT-2).",
      "Efsitora-treated participants demonstrated greater or similar improvements than comparators for most of the measured PROs at the primary timepoint in all four studies, particularly in QWINT-3 and -4 (prior insulin experience).",
      "Notably, for those treated with efsitora, there were significantly larger improvements than comparators in the PRO domains of treatment burden, daily life, diabetes management, compliance, satisfaction, and psychological health, as measured using the TRIM-D and DTSQc.",
      "Participants treated with efsitora had similar scores across both health-related quality of life measures, EQ-5D-5L and SF-36v2, at the primary endpoint when evaluated versus the comparator.",
      "Participants in the QWINT-1 to -4 studies demonstrated a strong preference for efsitora, along with improved overall functioning, well-being, and treatment burden compared to daily basal insulins.",
      "QWINT-1: NCT05662332; QWINT-2: NCT05362058; QWINT-3:",
      "NCT05275400; QWINT-4: NCT05462756.",
      "Insulin efsitora alfa (efsitora) is an innovative once-weekly basal insulin treatment evaluated in the Phase 3 QWINT clinical trials.",
      "The QWINT -1 to -4 clinical trials evaluated the efficacy and safety of efsitora, and the experience of adults with type 2 diabetes (T2D) treated with efsitora compared to daily insulin treatments.",
      "Efsitora had similar glycemic control and safety compared to daily basal insulin.",
      "Furthermore, patient-reported outcomes (PROs) showed greater improvements in treatment burden and satisfaction with efsitora, which was preferred more often compared to daily basal insulin.",
      "The PROs included six questionnaires: Treatment Related Impact Measure-Diabetes (TRIM-D) (QWINT-1, -2, and -3) measuring impact of diabetes treatment on a person’s functioning, wellbeing, and satisfaction with diabetes therapy; Diabetes Treatment Satisfaction Questionnaire (DTSQ) (QWINT-1, and -3) assessing treatment satisfaction; Simplicity of Diabetes Treatment Questionnaire (SIM-Q) (QWINT-1, -2, and -3) measuring simplicity of the treatment; Basal Insulin Experience (BIE) to evaluate participants’ preference (QWINT-3, and -4) for their insulin treatment and likelihood (all QWINTs) of incorporating into their diabetes management routine; EQ-5D-5L (QWINT-2,-3, and -4) measuring overall quality of life; and Short Form-36 Version 2 Health Survey Acute Form (SF-36v2) (QWINT-2) assessing health across eight domains.",
      "Participants reported that they would be very likely to incorporate efsitora into their diabetes management routine.",
      "With the positive results from the QWINT trials and strong PRO preferences, efsitora shows promise for treating people with T2D."
    ],
    "summary_sentences": [
      "Once-weekly efsitora resulted in similar efficacy and safety compared with daily basal insulins glargine or degludec in the treatment of adults with type 2 diabetes in the QWINT phase 3 development program.",
      "To fully assess once-weekly insulin's potential and address common barriers associated with insulin therapy (e.g., clinical inertia, fear of injections, treatment complexity), other aspects of the participants' treatment experiences were investigated using patient-reported outcome (PRO) measurements.",
      "The results of these PROs from QWINT-1 to -4 are presented here.",
      "Six different PRO instruments were completed across the studies at primary timepoints and treatment period endpoint (QWINT-1, week 26/52; QWINT-2, week 26/52; QWINT-3, week 26/52/78; QWINT-4, week 26) by participants enrolled in the phase 3 QWINT clinical trials.",
      "The PRO instruments included Treatment Related Impact Measure-Diabetes (Trim-D) (QWINT-1, -2, and -3), Diabetes Treatment Satisfaction Questionnaire (DTSQ) (QWINT-1 and -3), Simplicity of Diabetes Treatment Questionnaire (SIM-Q) (QWINT-1, -2, and -3), Basal Insulin Experience (BIE) (all QWINTs), EQ-5D-5L (QWINT-2, -3, and -4), and Short Form-36 Health Survey Version 2(SF-36v2) (QWINT-2).",
      "Efsitora-treated participants demonstrated greater or similar improvements than comparators for most of the measured PROs at the primary timepoint in all four studies, particularly in QWINT-3 and -4 (prior insulin experience).",
      "Notably, for those treated with efsitora, there were significantly larger improvements than comparators in the PRO domains of treatment burden, daily life, diabetes management, compliance, satisfaction, and psychological health, as measured using the TRIM-D and DTSQc.",
      "Participants treated with efsitora had similar scores across both health-related quality of life measures, EQ-5D-5L and SF-36v2, at the primary endpoint when evaluated versus the comparator.",
      "Participants in the QWINT-1 to -4 studies demonstrated a strong preference for efsitora, along with improved overall functioning, well-being, and treatment burden compared to daily basal insulins.",
      "QWINT-1: NCT05662332; QWINT-2: NCT05362058; QWINT-3:",
      "NCT05275400; QWINT-4: NCT05462756.",
      "Insulin efsitora alfa (efsitora) is an innovative once-weekly basal insulin treatment evaluated in the Phase 3 QWINT clinical trials.",
      "The QWINT -1 to -4 clinical trials evaluated the efficacy and safety of efsitora, and the experience of adults with type 2 diabetes (T2D) treated with efsitora compared to daily insulin treatments.",
      "Efsitora had similar glycemic control and safety compared to daily basal insulin.",
      "Furthermore, patient-reported outcomes (PROs) showed greater improvements in treatment burden and satisfaction with efsitora, which was preferred more often compared to daily basal insulin.",
      "The PROs included six questionnaires: Treatment Related Impact Measure-Diabetes (TRIM-D) (QWINT-1, -2, and -3) measuring impact of diabetes treatment on a person’s functioning, wellbeing, and satisfaction with diabetes therapy; Diabetes Treatment Satisfaction Questionnaire (DTSQ) (QWINT-1, and -3) assessing treatment satisfaction; Simplicity of Diabetes Treatment Questionnaire (SIM-Q) (QWINT-1, -2, and -3) measuring simplicity of the treatment; Basal Insulin Experience (BIE) to evaluate participants’ preference (QWINT-3, and -4) for their insulin treatment and likelihood (all QWINTs) of incorporating into their diabetes management routine; EQ-5D-5L (QWINT-2,-3, and -4) measuring overall quality of life; and Short Form-36 Version 2 Health Survey Acute Form (SF-36v2) (QWINT-2) assessing health across eight domains.",
      "Participants reported that they would be very likely to incorporate efsitora into their diabetes management routine.",
      "With the positive results from the QWINT trials and strong PRO preferences, efsitora shows promise for treating people with T2D."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41589057",
    "source": "pubmed",
    "sentences": [
      "Sotagliflozin, an inhibitor of sodium-glucose co-transporter (SGLT)-1 and 2, reduces albuminuria, slows GFR decline, and may have diuretic and osmoregulatory effects.",
      "The effect of sotagliflozin added to insulin was assessed on markers of neurohormone activation and volume homeostasis in patients with type 1 diabetes (T1D).",
      "This is a post-hoc analysis of the randomised, double-blinded, placebo-controlled inTandem3 trial, which assessed efficacy of sotagliflozin 400 mg/d versus placebo as an adjunct to insulin.",
      "The present biomarker analysis included 362 participants (26%) who had biological samples collected at baseline and week 24.",
      "Plasma renin, copeptin, serum N-terminal pro b-type natriuretic peptide (NT-proBNP), and markers of tubular injury, inflammation, haematopoiesis, and iron homeostasis were measured at baseline and following week 24 treatment; fractional excretion of lithium (FE Participants were 46 years of age (60% female) with a mean eGFR and median UACR of 88.4 mL/min/1.73 m",
      "In this T1D population, sotagliflozin increased copeptin levels, FE"
    ],
    "summary_sentences": [
      "Sotagliflozin, an inhibitor of sodium-glucose co-transporter (SGLT)-1 and 2, reduces albuminuria, slows GFR decline, and may have diuretic and osmoregulatory effects.",
      "The effect of sotagliflozin added to insulin was assessed on markers of neurohormone activation and volume homeostasis in patients with type 1 diabetes (T1D).",
      "This is a post-hoc analysis of the randomised, double-blinded, placebo-controlled inTandem3 trial, which assessed efficacy of sotagliflozin 400 mg/d versus placebo as an adjunct to insulin.",
      "The present biomarker analysis included 362 participants (26%) who had biological samples collected at baseline and week 24.",
      "Plasma renin, copeptin, serum N-terminal pro b-type natriuretic peptide (NT-proBNP), and markers of tubular injury, inflammation, haematopoiesis, and iron homeostasis were measured at baseline and following week 24 treatment; fractional excretion of lithium (FE Participants were 46 years of age (60% female) with a mean eGFR and median UACR of 88.4 mL/min/1.73 m",
      "In this T1D population, sotagliflozin increased copeptin levels, FE"
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41588568",
    "source": "pubmed",
    "sentences": [
      "This study aims to evaluate the predictive performance of clinical characteristics and beta-cell function markers for future insulin requirements in Chinese individuals with type 2 diabetes who were not insulin deficient.",
      "A prospective cohort of 2421 individuals with type 2 diabetes and fasting plasma C-peptide ≥ 0.25 nmol/L (1996-2012) was followed until 2019 for insulin requirement, defined as insulin initiation or two consecutive HbA1c ≥ 8.5% while on at least two non-insulin glucose-lowering drugs.",
      "Cox regression with stepwise selection was used to identify predictors and derive a clinical risk score.",
      "Model calibration was assessed using the Hosmer-Lemeshow test, and discrimination using the Harrell's C-index and area under the receiver operating characteristic curve (AUC) at one, five and 10 years.",
      "Over a median follow-up of 10.2 (IQR 4.0-14.1) years, 1143 individuals progressed to insulin requirements.",
      "Younger age at diabetes diagnosis, male sex, poorer glycaemic control, kidney complications and greater use of non-insulin glucose-lowering drugs were identified as independent predictors.",
      "The clinical risk score demonstrated better discrimination (C-index: 0.729, AUCs: 0.829 at 1 year, 0.792 at 5 years, 0.779 at 10 years) than fasting plasma C-peptide (C-index: 0.532, AUCs: 0.502, 0.553, 0.537), C-peptide-to-glucose ratio (C-index: 0.560, AUCs: 0.660, 0.572, 0.571) and HOMA2-%B (C-index: 0.618, AUCs: 0.734, 0.651, 0.639)",
      "(all p < 0.001).",
      "Adding fasting plasma C-peptide or HOMA2-%B to the clinical model did not significantly improve its predictive performance.",
      "Clinical characteristics outperformed fasting beta-cell function markers in predicting insulin requirements in non-insulin-deficient type 2 diabetes."
    ],
    "summary_sentences": [
      "This study aims to evaluate the predictive performance of clinical characteristics and beta-cell function markers for future insulin requirements in Chinese individuals with type 2 diabetes who were not insulin deficient.",
      "A prospective cohort of 2421 individuals with type 2 diabetes and fasting plasma C-peptide ≥ 0.25 nmol/L (1996-2012) was followed until 2019 for insulin requirement, defined as insulin initiation or two consecutive HbA1c ≥ 8.5% while on at least two non-insulin glucose-lowering drugs.",
      "Cox regression with stepwise selection was used to identify predictors and derive a clinical risk score.",
      "Model calibration was assessed using the Hosmer-Lemeshow test, and discrimination using the Harrell's C-index and area under the receiver operating characteristic curve (AUC) at one, five and 10 years.",
      "Over a median follow-up of 10.2 (IQR 4.0-14.1) years, 1143 individuals progressed to insulin requirements.",
      "Younger age at diabetes diagnosis, male sex, poorer glycaemic control, kidney complications and greater use of non-insulin glucose-lowering drugs were identified as independent predictors.",
      "The clinical risk score demonstrated better discrimination (C-index: 0.729, AUCs: 0.829 at 1 year, 0.792 at 5 years, 0.779 at 10 years) than fasting plasma C-peptide (C-index: 0.532, AUCs: 0.502, 0.553, 0.537), C-peptide-to-glucose ratio (C-index: 0.560, AUCs: 0.660, 0.572, 0.571) and HOMA2-%B (C-index: 0.618, AUCs: 0.734, 0.651, 0.639)",
      "(all p < 0.001).",
      "Adding fasting plasma C-peptide or HOMA2-%B to the clinical model did not significantly improve its predictive performance.",
      "Clinical characteristics outperformed fasting beta-cell function markers in predicting insulin requirements in non-insulin-deficient type 2 diabetes."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41587834",
    "source": "pubmed",
    "sentences": [
      "Despite availability of effective diabetes medications, 27% of Israeli patients did not reach glycemic control goals in 2019.",
      "Financial hardship markedly impacts diabetes management.",
      "The American Diabetes Association recommends financial incentive initiatives as part of quality improvement programs.",
      "We investigated the impact of a conditional reduction in medication out-of-pocket costs vs standard payment on glycemic control.",
      "A total of 186 patients with uncontrolled type 2 diabetes were recruited from neighborhoods having low socioeconomic status and randomly assigned to an intervention group or a control group.",
      "Patients in the intervention group were offered a discount on drug expenses (up to 600 new Israeli shekels or US $156, distributed through vouchers redeemable at pharmacies) that was conditional on improved glycemic control.",
      "Patients in the control group paid for their medications as usual.",
      "At baseline, study participants had a mean glycated hemoglobin (HbA Financial incentives have the potential to enhance diabetes control in populations having low socioeconomic status and could be integrated into health plans as an optional program for patients with chronic disease in disadvantaged areas."
    ],
    "summary_sentences": [
      "Despite availability of effective diabetes medications, 27% of Israeli patients did not reach glycemic control goals in 2019.",
      "Financial hardship markedly impacts diabetes management.",
      "The American Diabetes Association recommends financial incentive initiatives as part of quality improvement programs.",
      "We investigated the impact of a conditional reduction in medication out-of-pocket costs vs standard payment on glycemic control.",
      "A total of 186 patients with uncontrolled type 2 diabetes were recruited from neighborhoods having low socioeconomic status and randomly assigned to an intervention group or a control group.",
      "Patients in the intervention group were offered a discount on drug expenses (up to 600 new Israeli shekels or US $156, distributed through vouchers redeemable at pharmacies) that was conditional on improved glycemic control.",
      "Patients in the control group paid for their medications as usual.",
      "At baseline, study participants had a mean glycated hemoglobin (HbA Financial incentives have the potential to enhance diabetes control in populations having low socioeconomic status and could be integrated into health plans as an optional program for patients with chronic disease in disadvantaged areas."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41587134",
    "source": "pubmed",
    "sentences": [
      "Describe the design and rationale of the MAGIC (ClinicalTrials.gov identifier, NCT05681884) trial assessing change in retinal non-perfusion (RNP) among eyes with non-proliferative diabetic retinopathy (NPDR) in sham and treated patients.",
      "Phase 2 prospective, randomized, multicenter, open-label, clinical trial.",
      "Adults with NPDR and substantial RNP (> 5 disc areas) on ultra-widefield fluorescein angiography (UWFA) images.",
      "Patients will be randomized (1:1) into 1 of 2 arms: Group 1 receiving intravitreal faricimab 6 mg every 4 weeks (Q4W) and Group 2 being observed Q16W. At 48 weeks, Group 1 will receive faricimab Q16W and Group 2 will initiate faricimab Q4W through the final trial endpoint at year 2.",
      "The primary endpoint is change in RNP area through week 48.",
      "Secondary endpoints include change in RNP area through week 96; percentage of neovascularization, vitreous hemorrhage, DME, and/or PDR development; change in best-corrected visual acuity (BCVA); change in central subfield thickness (CST); contrast sensitivity (CS) measured using the quantitative Contrast Sensitivity Function (qCSF); detection of apoptosing retinal cells (DARC) analysis; and proportion of subjects with ≥ 2-step improvement in Diabetic Retinopathy Severity Score (DRSS).",
      "Safety outcomes include incidence and severity of adverse events.",
      "Study design rationale.",
      "Recruitment commenced in May 2023 and was completed in May 2024.",
      "Group 1 will be dosed Q4W to maximize detection of an impact on RNP progression compared to the untreated Group 2.",
      "During year 2, Group 1 will be dosed Q16W to assess for maintenance of any changes in RNP trajectory achieved during year 1.",
      "Group 2 will assess the natural history of RNP progression through year 1, then transition to maximal dosing to evaluate for a potential change in trajectory of RNP progression.",
      "Additional assessments, including CS and DARC, will address the unmet need for a better understanding of visual dysfunction among patients with NPDR and investigate the potential role of apoptosis in RNP, respectively.",
      "MAGIC is a randomized clinical trial that assesses RNP progression among eyes with NPDR, including its natural history and the impact of faricimab.",
      "Its innovative study design also explores the utility of novel assessments of retinal physiology and function."
    ],
    "summary_sentences": [
      "Describe the design and rationale of the MAGIC (ClinicalTrials.gov identifier, NCT05681884) trial assessing change in retinal non-perfusion (RNP) among eyes with non-proliferative diabetic retinopathy (NPDR) in sham and treated patients.",
      "Phase 2 prospective, randomized, multicenter, open-label, clinical trial.",
      "Adults with NPDR and substantial RNP (> 5 disc areas) on ultra-widefield fluorescein angiography (UWFA) images.",
      "Patients will be randomized (1:1) into 1 of 2 arms: Group 1 receiving intravitreal faricimab 6 mg every 4 weeks (Q4W) and Group 2 being observed Q16W. At 48 weeks, Group 1 will receive faricimab Q16W and Group 2 will initiate faricimab Q4W through the final trial endpoint at year 2.",
      "The primary endpoint is change in RNP area through week 48.",
      "Secondary endpoints include change in RNP area through week 96; percentage of neovascularization, vitreous hemorrhage, DME, and/or PDR development; change in best-corrected visual acuity (BCVA); change in central subfield thickness (CST); contrast sensitivity (CS) measured using the quantitative Contrast Sensitivity Function (qCSF); detection of apoptosing retinal cells (DARC) analysis; and proportion of subjects with ≥ 2-step improvement in Diabetic Retinopathy Severity Score (DRSS).",
      "Safety outcomes include incidence and severity of adverse events.",
      "Study design rationale.",
      "Recruitment commenced in May 2023 and was completed in May 2024.",
      "Group 1 will be dosed Q4W to maximize detection of an impact on RNP progression compared to the untreated Group 2.",
      "During year 2, Group 1 will be dosed Q16W to assess for maintenance of any changes in RNP trajectory achieved during year 1.",
      "Group 2 will assess the natural history of RNP progression through year 1, then transition to maximal dosing to evaluate for a potential change in trajectory of RNP progression.",
      "Additional assessments, including CS and DARC, will address the unmet need for a better understanding of visual dysfunction among patients with NPDR and investigate the potential role of apoptosis in RNP, respectively.",
      "MAGIC is a randomized clinical trial that assesses RNP progression among eyes with NPDR, including its natural history and the impact of faricimab.",
      "Its innovative study design also explores the utility of novel assessments of retinal physiology and function."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41587099",
    "source": "pubmed",
    "sentences": [
      "We recently developed and validated a hierarchical composite endpoint (HCE) for chronic kidney disease (CKD) progression combining time-to-event kidney outcomes with the rate of estimated glomerular filtration rate (eGFR) decline (eGFR slope).",
      "The CKD progression HCE is an informative endpoint for clinical trials in rare kidney diseases, such as focal segmental glomerulosclerosis (FSGS), where event-driven trials are often infeasible.",
      "We applied a HCE for CKD progression to the subset of patients with FSGS from the DAPA-CKD trial, a randomized double-blind, placebo-controlled clinical trial, to assess the effects of the sodium glucose co-transporter 2 inhibitor dapagliflozin on CKD progression in 4304 participants.",
      "We compared treatment effects for the primary composite endpoint (sustained 50% eGFR decline, kidney failure, or death due to kidney or cardiovascular causes), eGFR slope, and CKD progression HCE.",
      "We also compared statistical power for these outcomes using a bootstrap sampling procedure to evaluate the impact on trial efficiency.",
      "Overall, 115 participants were included (mean age, 54 years; 68% male; median urinary albumin-to-creatinine ratio, 1283 mg/g; mean eGFR, 42 mL/min/1.73m2).",
      "The effect of dapagliflozin on the primary composite endpoint (hazard ratio 0.45",
      "[95% confidence interval",
      "[CI]: 0.13, 1.49]) and total eGFR slope (0.9 mL/min/1.73m2 (95%CI: -0.6, 2.3) were consistent with the overall trial results but the 95% CI crossed unity.",
      "The win-odds for the CKD progression HCE suggested benefits for dapagliflozin and the 95%CI did not cross unity (win-odds:",
      "1.52 [95%CI: 1.01, 2.28]).",
      "Power calculations suggested that for a given sample size, statistical power was higher for the CKD progression HCE compared with the primary composite endpoint or eGFR slope.",
      "Our findings suggest that a CKD progression HCE, which integrates established CKD endpoints and eGFR slope, provides a sensitive and efficient measure to assess treatment effects in patients with FSGS.",
      "Validation of the HCE in prospective clinical trials will support its implementation."
    ],
    "summary_sentences": [
      "We recently developed and validated a hierarchical composite endpoint (HCE) for chronic kidney disease (CKD) progression combining time-to-event kidney outcomes with the rate of estimated glomerular filtration rate (eGFR) decline (eGFR slope).",
      "The CKD progression HCE is an informative endpoint for clinical trials in rare kidney diseases, such as focal segmental glomerulosclerosis (FSGS), where event-driven trials are often infeasible.",
      "We applied a HCE for CKD progression to the subset of patients with FSGS from the DAPA-CKD trial, a randomized double-blind, placebo-controlled clinical trial, to assess the effects of the sodium glucose co-transporter 2 inhibitor dapagliflozin on CKD progression in 4304 participants.",
      "We compared treatment effects for the primary composite endpoint (sustained 50% eGFR decline, kidney failure, or death due to kidney or cardiovascular causes), eGFR slope, and CKD progression HCE.",
      "We also compared statistical power for these outcomes using a bootstrap sampling procedure to evaluate the impact on trial efficiency.",
      "Overall, 115 participants were included (mean age, 54 years; 68% male; median urinary albumin-to-creatinine ratio, 1283 mg/g; mean eGFR, 42 mL/min/1.73m2).",
      "The effect of dapagliflozin on the primary composite endpoint (hazard ratio 0.45",
      "[95% confidence interval",
      "[CI]: 0.13, 1.49]) and total eGFR slope (0.9 mL/min/1.73m2 (95%CI: -0.6, 2.3) were consistent with the overall trial results but the 95% CI crossed unity.",
      "The win-odds for the CKD progression HCE suggested benefits for dapagliflozin and the 95%CI did not cross unity (win-odds:",
      "1.52 [95%CI: 1.01, 2.28]).",
      "Power calculations suggested that for a given sample size, statistical power was higher for the CKD progression HCE compared with the primary composite endpoint or eGFR slope.",
      "Our findings suggest that a CKD progression HCE, which integrates established CKD endpoints and eGFR slope, provides a sensitive and efficient measure to assess treatment effects in patients with FSGS.",
      "Validation of the HCE in prospective clinical trials will support its implementation."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41586239",
    "source": "pubmed",
    "sentences": [
      "To evaluate the short-term metabolic effects of a low-carbohydrate diet (LCD) compared with a control diet (CON) in hospitalized patients with insulin-deficient diabetes, with particular focus on glycemic variability (GV).",
      "This non-randomized clinical trial included 359 inpatients with fasting C-peptide levels ≤1.0",
      "ng/mL. Participants chose either an LCD or CON during hospitalization.",
      "GV was assessed using capillary and continuous glucose monitoring, with coefficient of variation (CV) as primary outcome.",
      "Secondary measures included other GV metrics, antidiabetic medication use, ketone levels, and adverse events.",
      "Subgroup analysis was conducted based on baseline C-peptide levels.",
      "LCD led to a greater reduction in CV (diet-by-time interaction, Short-term LCD intervention improved GV in insulin-deficient diabetes, especially in patients with more significant ChiCTR2000038006, https://www.chictr.org.cn/showproj.html?proj=60712."
    ],
    "summary_sentences": [
      "To evaluate the short-term metabolic effects of a low-carbohydrate diet (LCD) compared with a control diet (CON) in hospitalized patients with insulin-deficient diabetes, with particular focus on glycemic variability (GV).",
      "This non-randomized clinical trial included 359 inpatients with fasting C-peptide levels ≤1.0",
      "ng/mL. Participants chose either an LCD or CON during hospitalization.",
      "GV was assessed using capillary and continuous glucose monitoring, with coefficient of variation (CV) as primary outcome.",
      "Secondary measures included other GV metrics, antidiabetic medication use, ketone levels, and adverse events.",
      "Subgroup analysis was conducted based on baseline C-peptide levels.",
      "LCD led to a greater reduction in CV (diet-by-time interaction, Short-term LCD intervention improved GV in insulin-deficient diabetes, especially in patients with more significant ChiCTR2000038006, https://www.chictr.org.cn/showproj.html?proj=60712."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41585790",
    "source": "pubmed",
    "sentences": [
      "This randomized, open-label, parallel-controlled trial investigated the efficacy and safety of needle-free injection (NFI) compared to conventional insulin pen (CIP) in patients with type 2 diabetes mellitus (T2DM) undergoing intensive insulin therapy.",
      "A total of 64 hospitalized patients were randomly assigned to receive either NFI or CIP as part of a basal-bolus insulin regimen for 12 ± 2 days.",
      "Glycemic parameters were continuously monitored using a flash glucose monitoring (FGM) system.",
      "The NFI group showed significantly greater reductions in fasting plasma glucose (FPG) and 2-hour postprandial glucose (2hPPG), along with a more pronounced increase in serum 1,5-anhydroglucitol (1,5-AG) levels compared to the CIP group (all P < 0.05).",
      "Glycemic variability was also reduced in the NFI group, as indicated by higher time in range (TIR) and lower mean amplitude (MAGE) and largest amplitude (LAGE) of glycemic excursions (P < 0.05).",
      "Participants in the NFI group reached glycemic targets faster than those in the CIP group (1.88 ± 1.36 vs. 2.94 ± 1.59 days, P < 0.05), while daily insulin requirements remained comparable.",
      "Furthermore, the NFI group reported fewer injection-site adverse reactions, significantly lower pain scores, and higher treatment satisfaction (P < 0.001), with no increase in hypoglycemic events.",
      "These findings suggest that needle-free injection is a safe and effective alternative to conventional insulin delivery in hospitalized patients with T2DM, offering improved glycemic control, reduced glucose variability, and enhanced treatment experience.",
      "identifier ChiCTR1900022412."
    ],
    "summary_sentences": [
      "This randomized, open-label, parallel-controlled trial investigated the efficacy and safety of needle-free injection (NFI) compared to conventional insulin pen (CIP) in patients with type 2 diabetes mellitus (T2DM) undergoing intensive insulin therapy.",
      "A total of 64 hospitalized patients were randomly assigned to receive either NFI or CIP as part of a basal-bolus insulin regimen for 12 ± 2 days.",
      "Glycemic parameters were continuously monitored using a flash glucose monitoring (FGM) system.",
      "The NFI group showed significantly greater reductions in fasting plasma glucose (FPG) and 2-hour postprandial glucose (2hPPG), along with a more pronounced increase in serum 1,5-anhydroglucitol (1,5-AG) levels compared to the CIP group (all P < 0.05).",
      "Glycemic variability was also reduced in the NFI group, as indicated by higher time in range (TIR) and lower mean amplitude (MAGE) and largest amplitude (LAGE) of glycemic excursions (P < 0.05).",
      "Participants in the NFI group reached glycemic targets faster than those in the CIP group (1.88 ± 1.36 vs. 2.94 ± 1.59 days, P < 0.05), while daily insulin requirements remained comparable.",
      "Furthermore, the NFI group reported fewer injection-site adverse reactions, significantly lower pain scores, and higher treatment satisfaction (P < 0.001), with no increase in hypoglycemic events.",
      "These findings suggest that needle-free injection is a safe and effective alternative to conventional insulin delivery in hospitalized patients with T2DM, offering improved glycemic control, reduced glucose variability, and enhanced treatment experience.",
      "identifier ChiCTR1900022412."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41583249",
    "source": "pubmed",
    "sentences": [
      "Patients with type 2 diabetes mellitus (T2DM) have a high-risk condition of developing cardiovascular disease, and therefore, therapeutic strategies should consider cardiovascular risk reduction.",
      "Previously, we demonstrated that circulating glucagon-like peptide-1 (GLP-1) levels are significantly lower in Japanese patients with coronary artery disease (CAD) compared with non-CAD subjects.",
      "Once-weekly semaglutide, a GLP-1 receptor agonist, has demonstrated clinical cardiometabolic benefits; however, its effect on vascular endothelial function in Japanese patients with T2DM remains unclear.",
      "This retrospective observational study included patients with T2DM who were hospitalized at Jinnouchi Hospital and initiated once-weekly subcutaneous semaglutide therapy since 2021.",
      "Vascular endothelial function was assessed using reactive hyperemia peripheral arterial tonometry, expressed as the reactive hyperemia index (RHI), before and after semaglutide treatment.",
      "Clinical parameters including body weight (BW), glycated hemoglobin A1c (HbA1c), low-density lipoprotein cholesterol (LDL-cho), and high-sensitivity C-reactive protein (hsCRP) were also evaluated.",
      "A total of 24 patients (mean age: 55 years; n=20 (83.3%) male) were included.",
      "RHI significantly increased following semaglutide therapy (baseline: 1.62±0.19 versus follow-up: 2.04±0.60; p<0.01).",
      "BW, HbA1c, and LDL-cho also showed significant reductions (all p<0.01).",
      "HsCRP tended to decrease, though not significantly.",
      "None of the changes in BW, HbA1c, LDL-cho, or hsCRP correlated with the changes in RHI.",
      "Once-weekly semaglutide treatment significantly provided potential improvement in vascular endothelial function in Japanese patients with T2DM, supporting the cardiovascular protective role of semaglutide therapy in the clinical management of T2DM."
    ],
    "summary_sentences": [
      "Patients with type 2 diabetes mellitus (T2DM) have a high-risk condition of developing cardiovascular disease, and therefore, therapeutic strategies should consider cardiovascular risk reduction.",
      "Previously, we demonstrated that circulating glucagon-like peptide-1 (GLP-1) levels are significantly lower in Japanese patients with coronary artery disease (CAD) compared with non-CAD subjects.",
      "Once-weekly semaglutide, a GLP-1 receptor agonist, has demonstrated clinical cardiometabolic benefits; however, its effect on vascular endothelial function in Japanese patients with T2DM remains unclear.",
      "This retrospective observational study included patients with T2DM who were hospitalized at Jinnouchi Hospital and initiated once-weekly subcutaneous semaglutide therapy since 2021.",
      "Vascular endothelial function was assessed using reactive hyperemia peripheral arterial tonometry, expressed as the reactive hyperemia index (RHI), before and after semaglutide treatment.",
      "Clinical parameters including body weight (BW), glycated hemoglobin A1c (HbA1c), low-density lipoprotein cholesterol (LDL-cho), and high-sensitivity C-reactive protein (hsCRP) were also evaluated.",
      "A total of 24 patients (mean age: 55 years; n=20 (83.3%) male) were included.",
      "RHI significantly increased following semaglutide therapy (baseline: 1.62±0.19 versus follow-up: 2.04±0.60; p<0.01).",
      "BW, HbA1c, and LDL-cho also showed significant reductions (all p<0.01).",
      "HsCRP tended to decrease, though not significantly.",
      "None of the changes in BW, HbA1c, LDL-cho, or hsCRP correlated with the changes in RHI.",
      "Once-weekly semaglutide treatment significantly provided potential improvement in vascular endothelial function in Japanese patients with T2DM, supporting the cardiovascular protective role of semaglutide therapy in the clinical management of T2DM."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41582689",
    "source": "pubmed",
    "sentences": [
      "The precise mechanism of sodium glucose co-transporter 2 (SGLT2) inhibitor on reno-protective effect has been still unclear.",
      "In this study, we hypothesised that SGLT2 inhibitor prevents diabetic kidney disease via reduction of hypoxia-induced factors.",
      "In this multicenter, prospective, randomised, double blinded clinical trial, people with type 2 diabetes and microalbuminuria were randomised equally to empagliflozin (10 mg/day) (n = 40) and placebo (n = 39) and followed 24 weeks.",
      "The primary endpoint was change in urinary albumin creatinine ratio (ACR) and urinary liver type fatty acid binding protein (L-FABP) excretion from baseline to 24 weeks.",
      "Major secondary outcome was change in serum vascular endothelial growth factor (VEGF), angiopoietin-like proteins 2 (ANGPTL2), angiopoietin-like proteins 4 (ANGPTL4), and adrenomedullin (AM) levels.",
      "Although the reduction of ACR was significantly greater in the empagliflozin group than the placebo group at 4 and 12 weeks, the difference of change at 24 weeks between the two groups was not statistically significant (Empagliflozin group-Placebo group: -0.3643, 95% CI: -0.7571",
      "to 0.0285, p = 0.0686).",
      "There was no difference in urinary L-FABP excretion between the empagliflozin and placebo groups.",
      "Serum VEGF and ANGPTL2 decreased significantly more in the empagliflozin group, whereas there were no significant differences in AM and ANGPTL4.",
      "These results demonstrated that empagliflozin partially suppressed the hypoxia-induced angiogenic factors overproduction in addition to a declining trend in ACR in the early stage of diabetic kidney disease, which might contribute to the mechanisms of reno-protective effects of this agent (jRCTs051200147)."
    ],
    "summary_sentences": [
      "The precise mechanism of sodium glucose co-transporter 2 (SGLT2) inhibitor on reno-protective effect has been still unclear.",
      "In this study, we hypothesised that SGLT2 inhibitor prevents diabetic kidney disease via reduction of hypoxia-induced factors.",
      "In this multicenter, prospective, randomised, double blinded clinical trial, people with type 2 diabetes and microalbuminuria were randomised equally to empagliflozin (10 mg/day) (n = 40) and placebo (n = 39) and followed 24 weeks.",
      "The primary endpoint was change in urinary albumin creatinine ratio (ACR) and urinary liver type fatty acid binding protein (L-FABP) excretion from baseline to 24 weeks.",
      "Major secondary outcome was change in serum vascular endothelial growth factor (VEGF), angiopoietin-like proteins 2 (ANGPTL2), angiopoietin-like proteins 4 (ANGPTL4), and adrenomedullin (AM) levels.",
      "Although the reduction of ACR was significantly greater in the empagliflozin group than the placebo group at 4 and 12 weeks, the difference of change at 24 weeks between the two groups was not statistically significant (Empagliflozin group-Placebo group: -0.3643, 95% CI: -0.7571",
      "to 0.0285, p = 0.0686).",
      "There was no difference in urinary L-FABP excretion between the empagliflozin and placebo groups.",
      "Serum VEGF and ANGPTL2 decreased significantly more in the empagliflozin group, whereas there were no significant differences in AM and ANGPTL4.",
      "These results demonstrated that empagliflozin partially suppressed the hypoxia-induced angiogenic factors overproduction in addition to a declining trend in ACR in the early stage of diabetic kidney disease, which might contribute to the mechanisms of reno-protective effects of this agent (jRCTs051200147)."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41582387",
    "source": "pubmed",
    "sentences": [
      "Dapagliflozin, an SGLT2 inhibitor developed for Type 2 Diabetes Mellitus (T2DM), has shown multiple cardiovascular benefits.",
      "This study evaluated its effects on lipid profile and IR pattern in South Indian patients with T2DM and Heart Failure (HF).",
      "This randomized trial was conducted over 180 days in 58 patients with T2DM and HF, assigned in a 1:1 ratio to standard therapy or standard therapy plus dapagliflozin 10 mg daily.",
      "Lipid, glycemic, and IR parameters were assessed at baseline, 12 weeks, and 24 weeks.",
      "Dapagliflozin group showed marked improvements in BMI (p = 0.01), TC (p = 0.02), TG (p = 0.01), HDL (p = 0.001), LDL (p = 0.002), and VLDL (p = 0.01), FPG (p = 0.0001), PPG (p = 0.002) and HbA1c (p = 0.01), HOMA-IR (p = 0.002), HOMA2%B (p = 0.003), and decreased insulin levels (p = 0.001) by 24 weeks.",
      "In contrast, significant changes were noted only in LDL (p = 0.01), HDL (p = 0.03), and TG (p = 0.01) in the standard group.",
      "A positive correlation was observed between the mean change in TG and HOMA-IR after 24 weeks of dapagliflozin treatment.",
      "Dapagliflozin improved lipid profile and reduced IR, demonstrating benefits in T2DM and HF patients, which aligned with the findings from the larger SGLT2i trials.",
      "Study limitations included the small sample size, single-center setting, and an open-label design.",
      "Dapagliflozin improved lipid and IR, highlighting its potential as an adjunctive therapy in patients with co-morbid T2DM and HF.",
      "CTRI/2024/01/06208."
    ],
    "summary_sentences": [
      "Dapagliflozin, an SGLT2 inhibitor developed for Type 2 Diabetes Mellitus (T2DM), has shown multiple cardiovascular benefits.",
      "This study evaluated its effects on lipid profile and IR pattern in South Indian patients with T2DM and Heart Failure (HF).",
      "This randomized trial was conducted over 180 days in 58 patients with T2DM and HF, assigned in a 1:1 ratio to standard therapy or standard therapy plus dapagliflozin 10 mg daily.",
      "Lipid, glycemic, and IR parameters were assessed at baseline, 12 weeks, and 24 weeks.",
      "Dapagliflozin group showed marked improvements in BMI (p = 0.01), TC (p = 0.02), TG (p = 0.01), HDL (p = 0.001), LDL (p = 0.002), and VLDL (p = 0.01), FPG (p = 0.0001), PPG (p = 0.002) and HbA1c (p = 0.01), HOMA-IR (p = 0.002), HOMA2%B (p = 0.003), and decreased insulin levels (p = 0.001) by 24 weeks.",
      "In contrast, significant changes were noted only in LDL (p = 0.01), HDL (p = 0.03), and TG (p = 0.01) in the standard group.",
      "A positive correlation was observed between the mean change in TG and HOMA-IR after 24 weeks of dapagliflozin treatment.",
      "Dapagliflozin improved lipid profile and reduced IR, demonstrating benefits in T2DM and HF patients, which aligned with the findings from the larger SGLT2i trials.",
      "Study limitations included the small sample size, single-center setting, and an open-label design.",
      "Dapagliflozin improved lipid and IR, highlighting its potential as an adjunctive therapy in patients with co-morbid T2DM and HF.",
      "CTRI/2024/01/06208."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41580006",
    "source": "pubmed",
    "sentences": [
      "Semaglutide has demonstrated significant weight loss benefits, but comprehensive evidence on its long-term efficacy and safety in non-diabetic adults with overweight or obesity remains limited.",
      "This meta-analysis provides updated evidence by incorporating oral semaglutide data, extended follow-up duration, and comprehensive subgroup analyses.",
      "We systematically searched PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov databases from inception to April 30, 2024.",
      "Randomized controlled trials comparing semaglutide with placebo in non-diabetic adults with BMI ≥27 kg/m Seven RCTs involving 5411 participants were included in this review.",
      "Semaglutide significantly reduced absolute weight (WMD -12.24 kg, 95 % CI -13.25 to -11.22), percentage weight change (WMD -12.15 %, 95 % CI -13.63 to -10.67), BMI (WMD -4.32 kg/m Both oral and subcutaneous semaglutide significantly improve weight management in non-diabetic adults.",
      "While the safety profile is generally acceptable, elevated serious adverse events warrant careful patient selection and monitoring.",
      "Optimal outcomes occur with lifestyle interventions at doses ≥2.4 mg weekly."
    ],
    "summary_sentences": [
      "Semaglutide has demonstrated significant weight loss benefits, but comprehensive evidence on its long-term efficacy and safety in non-diabetic adults with overweight or obesity remains limited.",
      "This meta-analysis provides updated evidence by incorporating oral semaglutide data, extended follow-up duration, and comprehensive subgroup analyses.",
      "We systematically searched PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov databases from inception to April 30, 2024.",
      "Randomized controlled trials comparing semaglutide with placebo in non-diabetic adults with BMI ≥27 kg/m Seven RCTs involving 5411 participants were included in this review.",
      "Semaglutide significantly reduced absolute weight (WMD -12.24 kg, 95 % CI -13.25 to -11.22), percentage weight change (WMD -12.15 %, 95 % CI -13.63 to -10.67), BMI (WMD -4.32 kg/m Both oral and subcutaneous semaglutide significantly improve weight management in non-diabetic adults.",
      "While the safety profile is generally acceptable, elevated serious adverse events warrant careful patient selection and monitoring.",
      "Optimal outcomes occur with lifestyle interventions at doses ≥2.4 mg weekly."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41579235",
    "source": "pubmed",
    "sentences": [
      "Obesity is associated with impaired physical fitness, including physical functional performance and cardiorespiratory fitness, which affect health-related quality of life and mortality.",
      "We aimed to investigate the efficacy of a moderate-to-vigorous intensity exercise program and glucagon-like peptide-1 receptor agonist treatment alone or in combination during weight maintenance for physical fitness.",
      "This is secondary analysis of a randomized controlled trial involving 193 adults with obesity (age 18-65 years, body mass index 32-43 kg/m Participants randomized to exercise performed a median 2.65 session/week (116 min",
      "/week at 79% of maximum heart rate) with no significant difference between those who received placebo or liraglutide.",
      "Compared with liraglutide alone, the combined treatment decreased time to complete a stair climb test by 1.2 s [95% confidence interval 0.6-1.9] (corresponding to 8.6%) and improved peak oxygen consumption by 3.0 mL/min/kg fat-free mass [95% confidence interval 0.5-5.5].",
      "Exercise alone led to similar benefits, whereas liraglutide alone did not improve physical fitness.",
      "Compared with placebo (- 7.8%), relative muscle strength (strength normalized to body weight) was higher with exercise (- 0.4%), liraglutide (+ 1.0%), and the combined treatment (+ 3.3%) because of lower weight and preserved absolute strength.",
      "Structured exercise combined with glucagon-like peptide-1-based obesity pharmacotherapy led to clinically meaningful improvements in physical functional performance and cardiorespiratory fitness, in contrast to pharmacotherapy alone.",
      "EudraCT number, 2015-005585-32; ClinicalTrials.gov number, NCT04122716."
    ],
    "summary_sentences": [
      "Obesity is associated with impaired physical fitness, including physical functional performance and cardiorespiratory fitness, which affect health-related quality of life and mortality.",
      "We aimed to investigate the efficacy of a moderate-to-vigorous intensity exercise program and glucagon-like peptide-1 receptor agonist treatment alone or in combination during weight maintenance for physical fitness.",
      "This is secondary analysis of a randomized controlled trial involving 193 adults with obesity (age 18-65 years, body mass index 32-43 kg/m Participants randomized to exercise performed a median 2.65 session/week (116 min",
      "/week at 79% of maximum heart rate) with no significant difference between those who received placebo or liraglutide.",
      "Compared with liraglutide alone, the combined treatment decreased time to complete a stair climb test by 1.2 s [95% confidence interval 0.6-1.9] (corresponding to 8.6%) and improved peak oxygen consumption by 3.0 mL/min/kg fat-free mass [95% confidence interval 0.5-5.5].",
      "Exercise alone led to similar benefits, whereas liraglutide alone did not improve physical fitness.",
      "Compared with placebo (- 7.8%), relative muscle strength (strength normalized to body weight) was higher with exercise (- 0.4%), liraglutide (+ 1.0%), and the combined treatment (+ 3.3%) because of lower weight and preserved absolute strength.",
      "Structured exercise combined with glucagon-like peptide-1-based obesity pharmacotherapy led to clinically meaningful improvements in physical functional performance and cardiorespiratory fitness, in contrast to pharmacotherapy alone.",
      "EudraCT number, 2015-005585-32; ClinicalTrials.gov number, NCT04122716."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41578591",
    "source": "pubmed",
    "sentences": [
      "This study is aimed to systematically evaluate the efficacy and safety of Finerenone (BAY 94-8862) in the treatment of diabetic kidney disease.",
      "Databases including PubMed, Embase, and Web of science were searched for randomized controlled trials that assessed Finerenone in patients with diabetic kidney disease and were published up to January 7, 2025.",
      "The quality evaluation of literatures and meta-analysis were performed using RevMan 5.4 software and independently operated by 2 experimenters.",
      "Seven randomized controlled trials involving 33,455 patients were included.",
      "The efficacy outcomes were the ratio of urine albumin creatine ratio at posttreatment versus at baseline (mean difference: -0.30; 95% confidence interval",
      "[CI; -0.32, -0.27]; P < .00001; I2 = 0%), the primary composite outcome (hazard ratio [HR]: 0.81; 95% CI",
      "[0.76, 0.87]; P < .00001; I2 = 13%), the secondary composite outcome (HR: 0.82; 95% CI",
      "[0.74, 0.91];",
      "P = .0001; I2 = 0%), kidney failure (HR: 0.76; 95% CI",
      "[0.70, 0.83]; P < .00001; I2 = 0%), and the risk of end stage kidney disease (HR: 0.87; 95% CI",
      "[0.77, 0.99]; P = .03; I2 = 46%).",
      "The safety outcome was the incidence of adverse events (risk ratio: 1.00; 95% CI",
      "[0.99, 1.00]; P = .38; I2 = 0%) and the number of patients suffering from hyperkalemia (risk ratio: 2.19; 95% CI",
      "[2.04, 2.34]; P < .00001; I2 = 0%).",
      "Results of meta-analysis showed that Finerenone could significantly reduce urine albumin creatine ratio levels.",
      "It has a protective effect on kidney, delaying the progression of chronic kidney disease and reducing the risk of end stage kidney disease.",
      "Furthermore, there was no difference in the risk of overall adverse events."
    ],
    "summary_sentences": [
      "This study is aimed to systematically evaluate the efficacy and safety of Finerenone (BAY 94-8862) in the treatment of diabetic kidney disease.",
      "Databases including PubMed, Embase, and Web of science were searched for randomized controlled trials that assessed Finerenone in patients with diabetic kidney disease and were published up to January 7, 2025.",
      "The quality evaluation of literatures and meta-analysis were performed using RevMan 5.4 software and independently operated by 2 experimenters.",
      "Seven randomized controlled trials involving 33,455 patients were included.",
      "The efficacy outcomes were the ratio of urine albumin creatine ratio at posttreatment versus at baseline (mean difference: -0.30; 95% confidence interval",
      "[CI; -0.32, -0.27]; P < .00001; I2 = 0%), the primary composite outcome (hazard ratio [HR]: 0.81; 95% CI",
      "[0.76, 0.87]; P < .00001; I2 = 13%), the secondary composite outcome (HR: 0.82; 95% CI",
      "[0.74, 0.91];",
      "P = .0001; I2 = 0%), kidney failure (HR: 0.76; 95% CI",
      "[0.70, 0.83]; P < .00001; I2 = 0%), and the risk of end stage kidney disease (HR: 0.87; 95% CI",
      "[0.77, 0.99]; P = .03; I2 = 46%).",
      "The safety outcome was the incidence of adverse events (risk ratio: 1.00; 95% CI",
      "[0.99, 1.00]; P = .38; I2 = 0%) and the number of patients suffering from hyperkalemia (risk ratio: 2.19; 95% CI",
      "[2.04, 2.34]; P < .00001; I2 = 0%).",
      "Results of meta-analysis showed that Finerenone could significantly reduce urine albumin creatine ratio levels.",
      "It has a protective effect on kidney, delaying the progression of chronic kidney disease and reducing the risk of end stage kidney disease.",
      "Furthermore, there was no difference in the risk of overall adverse events."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41578078",
    "source": "pubmed",
    "sentences": [
      "This study aims to evaluate the efficacy, safety, and immunogenicity of ZRC-3285 (aflibercept biosimilar) with Eylea This phase III, multicenter, double-blind study was conducted across 27 sites in India and randomized (2:1) patients with nAMD into either the test aflibercept (ZRC-3285, Zydus Lifesciences Ltd.) or Eylea Over 12 weeks, all patients in the ZRC-3285 (122, 100%) and Eylea Efficacy, immunogenicity, and safety profiles of ZRC-3285 were found to be similar to those of Eylea Clinical trial Registry of India (CTRI):",
      "CTRI/2023/09/057655",
      "[Registered on 14/09/2023]."
    ],
    "summary_sentences": [
      "This study aims to evaluate the efficacy, safety, and immunogenicity of ZRC-3285 (aflibercept biosimilar) with Eylea This phase III, multicenter, double-blind study was conducted across 27 sites in India and randomized (2:1) patients with nAMD into either the test aflibercept (ZRC-3285, Zydus Lifesciences Ltd.) or Eylea Over 12 weeks, all patients in the ZRC-3285 (122, 100%) and Eylea Efficacy, immunogenicity, and safety profiles of ZRC-3285 were found to be similar to those of Eylea Clinical trial Registry of India (CTRI):",
      "CTRI/2023/09/057655",
      "[Registered on 14/09/2023]."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41576380",
    "source": "pubmed",
    "sentences": [
      "The global burden of type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS) continues to rise, with these conditions significantly increasing risks of cardiovascular disease, disability, and mortality.",
      "Traditional Chinese Medicine (TCM) syndrome differentiation, a cornerstone of TCM practice, guides diagnosis and treatment by identifying patterns of disharmony.",
      "However, large-scale studies investigating TCM syndrome patterns in T2DM comorbid with MetS remain scarce.",
      "This cross-sectional study aims to characterize TCM syndrome profiles in a population diagnosed with T2DM and MetS and evaluate their diagnostic relevance.",
      "This cross-sectional study will enroll a cohort of 470 participants diagnosed with T2DM and MetS. All participants will undergo comprehensive assessments, including the Syndrome Differentiation Questionnaire for T2DM and MetS, demographic and anthropometric measurements, biochemical profiling (eg, fasting glucose, glycosylated hemoglobin, and lipid panel), dietary measurement (Food Frequency Questionnaire), physical activity measurement (International Physical Activity Questionnaire Short Form), sleep quality evaluation (Pittsburgh Sleep Quality Index), quality-of-life assessment (Audit of Diabetes-Dependent Quality of Life), stroke risk estimation (Framingham Stroke Risk Score), and retinal imaging.",
      "Latent class analysis will be used to identify the TCM syndrome patterns.",
      "Factor analysis will be employed to identify core TCM syndrome factors.",
      "Hierarchical cluster analysis will be performed to classify TCM syndrome elements, and logistic regression will examine associations between syndrome differentiation, metabolic parameters, lifestyle factors, and disease progression.",
      "This trial was registered on November 17, 2024.",
      "Participant recruitment for this study was initiated in November 2024.",
      "As of October 2025, more than 450 eligible participants have been enrolled and have completed data collection.",
      "Recruitment is scheduled to conclude on December 31, 2025.",
      "As the first large-scale clinical study to systematically characterize TCM syndrome differentiation in T2DM-MetS comorbidity, this research will establish syndrome profiles associated with metabolic parameters, lifestyle factors, and disease progression.",
      "The findings are expected to provide a framework for integrating TCM syndrome differentiation into chronic disease management, ultimately contributing to personalized treatment strategies and improved patient outcomes in integrative medicine.",
      "ClinicalTrials.gov",
      "NCT06703684; https://clinicaltrials.gov/study/NCT06703684.",
      "DERR1-10.2196/86217."
    ],
    "summary_sentences": [
      "The global burden of type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS) continues to rise, with these conditions significantly increasing risks of cardiovascular disease, disability, and mortality.",
      "Traditional Chinese Medicine (TCM) syndrome differentiation, a cornerstone of TCM practice, guides diagnosis and treatment by identifying patterns of disharmony.",
      "However, large-scale studies investigating TCM syndrome patterns in T2DM comorbid with MetS remain scarce.",
      "This cross-sectional study aims to characterize TCM syndrome profiles in a population diagnosed with T2DM and MetS and evaluate their diagnostic relevance.",
      "This cross-sectional study will enroll a cohort of 470 participants diagnosed with T2DM and MetS. All participants will undergo comprehensive assessments, including the Syndrome Differentiation Questionnaire for T2DM and MetS, demographic and anthropometric measurements, biochemical profiling (eg, fasting glucose, glycosylated hemoglobin, and lipid panel), dietary measurement (Food Frequency Questionnaire), physical activity measurement (International Physical Activity Questionnaire Short Form), sleep quality evaluation (Pittsburgh Sleep Quality Index), quality-of-life assessment (Audit of Diabetes-Dependent Quality of Life), stroke risk estimation (Framingham Stroke Risk Score), and retinal imaging.",
      "Latent class analysis will be used to identify the TCM syndrome patterns.",
      "Factor analysis will be employed to identify core TCM syndrome factors.",
      "Hierarchical cluster analysis will be performed to classify TCM syndrome elements, and logistic regression will examine associations between syndrome differentiation, metabolic parameters, lifestyle factors, and disease progression.",
      "This trial was registered on November 17, 2024.",
      "Participant recruitment for this study was initiated in November 2024.",
      "As of October 2025, more than 450 eligible participants have been enrolled and have completed data collection.",
      "Recruitment is scheduled to conclude on December 31, 2025.",
      "As the first large-scale clinical study to systematically characterize TCM syndrome differentiation in T2DM-MetS comorbidity, this research will establish syndrome profiles associated with metabolic parameters, lifestyle factors, and disease progression.",
      "The findings are expected to provide a framework for integrating TCM syndrome differentiation into chronic disease management, ultimately contributing to personalized treatment strategies and improved patient outcomes in integrative medicine.",
      "ClinicalTrials.gov",
      "NCT06703684; https://clinicaltrials.gov/study/NCT06703684.",
      "DERR1-10.2196/86217."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41575748",
    "source": "pubmed",
    "sentences": [
      "Older patients with diabetes often experience high levels of mental distress, which may complicate diabetes management and negatively impact health outcomes.",
      "To evaluate whether an interactive virtual assistant device built with a behavioral intervention model can improve mental health and diabetes-related outcomes in older adults with diabetes.",
      "This open randomized clinical trial was conducted at an academic medical center in Brazil between June 22, 2023, and February 8, 2024.",
      "Participants aged 65 years or older with type 2 diabetes were included.",
      "Participants were randomized 1:1 to receive the interactive virtual assistant device (Smart Speaker Echo Dot, 3rd generation",
      "[Amazon]) for home use over a 12-week period or to continue with usual care.",
      "The device was programmed with a behavioral intervention model aimed at enhancing mental health and diabetes management.",
      "The primary outcome was the between-group mean difference (MD) in mental distress, assessed using the Self-Reporting Questionnaire, in which scores range from 0 to 20, with higher scores indicating greater mental distress.",
      "Secondary outcomes included quality of life (assessed using the 36-Item Short Form Health Survey), perceived stress (assessed using the Perceived Stress Scale), adherence to diabetes self-care behaviors (assessed using the Self-Care Inventory Revised questionnaire), and glycemic control (hemoglobin A1c).",
      "All outcomes were assessed at the 12-week follow-up.",
      "Among 112 participants (mean [SD] age, 72.5",
      "[5.7] years; 71 females [63.4%]), the mean (SD) hemoglobin A1c level was 7.9% (1.5%), and outcome measures were available for 103 participants (52 in the intervention group and 51 in the usual care group).",
      "At 12 weeks, the fully adjusted mean (SE) Self-Reporting Questionnaire score was 6.29 (0.44) for participants in the intervention group and 7.75 (0.42) for those in the usual care group, resulting in a fully adjusted MD of -1.46 (95% CI, -2.73 to -0.19; P = .02), suggesting a reduction in mental distress among the intervention group.",
      "Subgroup analyses showed consistent improvement favoring the intervention across all subgroups.",
      "The intervention was also associated with improvements in quality of life (MD, 9.46",
      "[95% CI, 3.65 to 15.26]; P = .001), adherence to diabetes self-care behaviors (MD, 3.40",
      "[95% CI, 1.61 to 5.19]; P < .001), and glycemic control (MD, -0.48% [95% CI, -0.85 to -0.11]; P = .01).",
      "No difference was observed regarding perceived stress (MD, -3.00",
      "[95% CI, -6.20 to 0.20]; P = .07),",
      "and no participants withdrew due to adverse events.",
      "In this randomized clinical trial of older adults with diabetes, participants in the smart speaker group showed significant improvements in mental distress, quality of life, diabetes self-care, and glycemic control.",
      "These findings suggest that this easily implemented self-management intervention could enhance health outcomes in this population. ClinicalTrials.gov",
      "Identifier: NCT05329376."
    ],
    "summary_sentences": [
      "Older patients with diabetes often experience high levels of mental distress, which may complicate diabetes management and negatively impact health outcomes.",
      "To evaluate whether an interactive virtual assistant device built with a behavioral intervention model can improve mental health and diabetes-related outcomes in older adults with diabetes.",
      "This open randomized clinical trial was conducted at an academic medical center in Brazil between June 22, 2023, and February 8, 2024.",
      "Participants aged 65 years or older with type 2 diabetes were included.",
      "Participants were randomized 1:1 to receive the interactive virtual assistant device (Smart Speaker Echo Dot, 3rd generation",
      "[Amazon]) for home use over a 12-week period or to continue with usual care.",
      "The device was programmed with a behavioral intervention model aimed at enhancing mental health and diabetes management.",
      "The primary outcome was the between-group mean difference (MD) in mental distress, assessed using the Self-Reporting Questionnaire, in which scores range from 0 to 20, with higher scores indicating greater mental distress.",
      "Secondary outcomes included quality of life (assessed using the 36-Item Short Form Health Survey), perceived stress (assessed using the Perceived Stress Scale), adherence to diabetes self-care behaviors (assessed using the Self-Care Inventory Revised questionnaire), and glycemic control (hemoglobin A1c).",
      "All outcomes were assessed at the 12-week follow-up.",
      "Among 112 participants (mean [SD] age, 72.5",
      "[5.7] years; 71 females [63.4%]), the mean (SD) hemoglobin A1c level was 7.9% (1.5%), and outcome measures were available for 103 participants (52 in the intervention group and 51 in the usual care group).",
      "At 12 weeks, the fully adjusted mean (SE) Self-Reporting Questionnaire score was 6.29 (0.44) for participants in the intervention group and 7.75 (0.42) for those in the usual care group, resulting in a fully adjusted MD of -1.46 (95% CI, -2.73 to -0.19; P = .02), suggesting a reduction in mental distress among the intervention group.",
      "Subgroup analyses showed consistent improvement favoring the intervention across all subgroups.",
      "The intervention was also associated with improvements in quality of life (MD, 9.46",
      "[95% CI, 3.65 to 15.26]; P = .001), adherence to diabetes self-care behaviors (MD, 3.40",
      "[95% CI, 1.61 to 5.19]; P < .001), and glycemic control (MD, -0.48% [95% CI, -0.85 to -0.11]; P = .01).",
      "No difference was observed regarding perceived stress (MD, -3.00",
      "[95% CI, -6.20 to 0.20]; P = .07),",
      "and no participants withdrew due to adverse events.",
      "In this randomized clinical trial of older adults with diabetes, participants in the smart speaker group showed significant improvements in mental distress, quality of life, diabetes self-care, and glycemic control.",
      "These findings suggest that this easily implemented self-management intervention could enhance health outcomes in this population. ClinicalTrials.gov",
      "Identifier: NCT05329376."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41575476",
    "source": "pubmed",
    "sentences": [
      "Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by hepatic steatosis alongside metabolic comorbidities like type 2 diabetes mellitus (T2DM), dyslipidaemia, overweight, or obesity.",
      "Liver damage could be prevented promoting consumption of fruits and vegetables, the main source of phenolic compounds.",
      "These molecules have been previously related with antioxidant and anti-obesity properties.",
      "Therefore, the objective of this study is to determine the antioxidant capacity and potential preventive activity of an autochthonous apple pulp extract, Amarilla de Octubre, and its main phenolic compound, procyanidin B2 (PB2), in an in vitro model of liver steatosis.",
      "Antioxidant activity was assessed by xanthine/xanthine oxidase (X/XO) system and nitric oxide scavenging production.",
      "Monoamine oxidase A (MAO-A) inhibition was also determined due to its implication in detoxification processes in liver.",
      "Human hepatocytes (HepG2 cell line) were selected to test their potential cytotoxicity, oxidative stress situations (ROS production) and the potential effect in lipid metabolism by overloading cells with oleic acid.",
      "Fat accumulation and gene expression related to lipid metabolism (PPARγ, CD36 and FAS) were also analysed by Oil Red O and qPCR respectively.",
      "PB2 showed promising results as an antioxidant compound in scavenging and enzymatic inhibition-related experiments.",
      "However, Amarilla de Octubre not only reduce fat accumulation, but also modulates the expression of PPARγ, CD36, and FAS and demonstrates slightly lower efficacy than PB2 in scavenging and enzymatic inhibition-related experiments.",
      "These results highlight the potential of apples to mitigate pathogenic conditions associated with metabolic disorders such as obesity, emphasizing the role of dietary polyphenols in this protective effect."
    ],
    "summary_sentences": [
      "Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by hepatic steatosis alongside metabolic comorbidities like type 2 diabetes mellitus (T2DM), dyslipidaemia, overweight, or obesity.",
      "Liver damage could be prevented promoting consumption of fruits and vegetables, the main source of phenolic compounds.",
      "These molecules have been previously related with antioxidant and anti-obesity properties.",
      "Therefore, the objective of this study is to determine the antioxidant capacity and potential preventive activity of an autochthonous apple pulp extract, Amarilla de Octubre, and its main phenolic compound, procyanidin B2 (PB2), in an in vitro model of liver steatosis.",
      "Antioxidant activity was assessed by xanthine/xanthine oxidase (X/XO) system and nitric oxide scavenging production.",
      "Monoamine oxidase A (MAO-A) inhibition was also determined due to its implication in detoxification processes in liver.",
      "Human hepatocytes (HepG2 cell line) were selected to test their potential cytotoxicity, oxidative stress situations (ROS production) and the potential effect in lipid metabolism by overloading cells with oleic acid.",
      "Fat accumulation and gene expression related to lipid metabolism (PPARγ, CD36 and FAS) were also analysed by Oil Red O and qPCR respectively.",
      "PB2 showed promising results as an antioxidant compound in scavenging and enzymatic inhibition-related experiments.",
      "However, Amarilla de Octubre not only reduce fat accumulation, but also modulates the expression of PPARγ, CD36, and FAS and demonstrates slightly lower efficacy than PB2 in scavenging and enzymatic inhibition-related experiments.",
      "These results highlight the potential of apples to mitigate pathogenic conditions associated with metabolic disorders such as obesity, emphasizing the role of dietary polyphenols in this protective effect."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41575388",
    "source": "pubmed",
    "sentences": [
      "The 10-year Action for Health in Diabetes (Look AHEAD) clinical trial compared a multidomain intensive lifestyle intervention to a diabetes support and education program with respect to major cardiovascular disease events (primary outcome) and other diabetes- and obesity-related outcomes.",
      "Follow-up of the cohort continues to add other aging-related outcomes and conditions to identify the long-term consequences of factors related to lifestyle and medical care.",
      "In this transition to a study of aging among individuals at risk for accelerated aging due to type 2 diabetes and overweight or obesity, the investigators have retrospectively reframed the study using the perspective of geroscience.",
      "This perspective strengthens the importance of lifestyle changes as a core component for medical care for these individuals to slow biological aging."
    ],
    "summary_sentences": [
      "The 10-year Action for Health in Diabetes (Look AHEAD) clinical trial compared a multidomain intensive lifestyle intervention to a diabetes support and education program with respect to major cardiovascular disease events (primary outcome) and other diabetes- and obesity-related outcomes.",
      "Follow-up of the cohort continues to add other aging-related outcomes and conditions to identify the long-term consequences of factors related to lifestyle and medical care.",
      "In this transition to a study of aging among individuals at risk for accelerated aging due to type 2 diabetes and overweight or obesity, the investigators have retrospectively reframed the study using the perspective of geroscience.",
      "This perspective strengthens the importance of lifestyle changes as a core component for medical care for these individuals to slow biological aging."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41574965",
    "source": "pubmed",
    "sentences": [
      "Effective anti-obesity interventions that preserve lean mass are of increasing clinical significance for optimizing metabolic health.",
      "This study investigated whether lorcaserin, a centrally acting weight loss agent, modifies body composition, circulating lipidomic profiles, and muscle-regulating hormones within the myostatin-activin-follistatin-IGF-1 (MAFI) axes.",
      "Forty-eight adults with obesity were randomized to lorcaserin (10 mg twice daily) or placebo for 6 months in a double-blind trial.",
      "Regional body composition, hormones and lipidomics were assessed.",
      "Changes were analysed using linear mixed models with fixed effects for time, treatment and interaction.",
      "Adjusted deltas and endpoints were compared by analysis of covariance controlling for baseline body mass index.",
      "Lipidomic profiles were analysed using principal component and partial least-squares discriminant analyses.",
      "Lorcaserin reduced total body weight (time*treatment, p = 0.004).",
      "Adjusted delta and endpoint comparisons showed reductions in total body (p = 0.031) and abdominal fat mass (p = 0.002).",
      "Lipidomic assessments revealed primarily lower levels of triglyceride-rich lipoproteins with treatment.",
      "No significant changes in MAFI axes components were detected in linear mixed models.",
      "Lorcaserin treatment was associated with greater abdominal fat mass loss, favourable lipid profile changes, while MAFI components remained largely unaffected.",
      "Lorcaserin may improve cardiometabolic health primarily through reductions in central adiposity."
    ],
    "summary_sentences": [
      "Effective anti-obesity interventions that preserve lean mass are of increasing clinical significance for optimizing metabolic health.",
      "This study investigated whether lorcaserin, a centrally acting weight loss agent, modifies body composition, circulating lipidomic profiles, and muscle-regulating hormones within the myostatin-activin-follistatin-IGF-1 (MAFI) axes.",
      "Forty-eight adults with obesity were randomized to lorcaserin (10 mg twice daily) or placebo for 6 months in a double-blind trial.",
      "Regional body composition, hormones and lipidomics were assessed.",
      "Changes were analysed using linear mixed models with fixed effects for time, treatment and interaction.",
      "Adjusted deltas and endpoints were compared by analysis of covariance controlling for baseline body mass index.",
      "Lipidomic profiles were analysed using principal component and partial least-squares discriminant analyses.",
      "Lorcaserin reduced total body weight (time*treatment, p = 0.004).",
      "Adjusted delta and endpoint comparisons showed reductions in total body (p = 0.031) and abdominal fat mass (p = 0.002).",
      "Lipidomic assessments revealed primarily lower levels of triglyceride-rich lipoproteins with treatment.",
      "No significant changes in MAFI axes components were detected in linear mixed models.",
      "Lorcaserin treatment was associated with greater abdominal fat mass loss, favourable lipid profile changes, while MAFI components remained largely unaffected.",
      "Lorcaserin may improve cardiometabolic health primarily through reductions in central adiposity."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41574641",
    "source": "pubmed",
    "sentences": [
      "The aim in this human trial is to compare the efficacy and safety of polygalacturonic-caprylic acid (PG-CAP) ointment to MediHoney in chronic wounds at three international medical centres.",
      "In this prospective open-label study, patients with chronic full-thickness wounds were randomised to daily treatment with PG-CAP ointment or MediHoney.",
      "Assessments were obtained weekly for 6 weeks.",
      "The validated Pressure Ulcer Scale for Healing (PUSH) score was used to track healing.",
      "Efficacies were compared using the Wilcoxon rank-sum test for continuous variables and chi-square or Fisher's exact test for categorical variables.",
      "Twenty-six patients with chronic wounds were included.",
      "Baseline characteristics were comparable between the groups; however, the history of diabetes mellitus was higher in the PG-CAP group (p = 0.011).",
      "All 13 PG-CAP patients showed improvement (100%), compared to only 69% of the 13 MediHoney patients (p = 0.023).",
      "Half of the failures in the MediHoney arm were associated with death (15%).",
      "No failures, adverse events or deaths occurred in the PG-CAP arm.",
      "PG-CAP wound ointment is a novel combination of two plant-based compounds that pose minimal risk of promoting antimicrobial resistance, was highly effective for eradicating wound-pathogen biofilms in vitro and promoted chronic wound healing in vivo with minimal inflammatory reactions.",
      "Our findings support PG-CAP as safe, noninferior and possibly more effective than MediHoney in healing chronic contaminated wounds."
    ],
    "summary_sentences": [
      "The aim in this human trial is to compare the efficacy and safety of polygalacturonic-caprylic acid (PG-CAP) ointment to MediHoney in chronic wounds at three international medical centres.",
      "In this prospective open-label study, patients with chronic full-thickness wounds were randomised to daily treatment with PG-CAP ointment or MediHoney.",
      "Assessments were obtained weekly for 6 weeks.",
      "The validated Pressure Ulcer Scale for Healing (PUSH) score was used to track healing.",
      "Efficacies were compared using the Wilcoxon rank-sum test for continuous variables and chi-square or Fisher's exact test for categorical variables.",
      "Twenty-six patients with chronic wounds were included.",
      "Baseline characteristics were comparable between the groups; however, the history of diabetes mellitus was higher in the PG-CAP group (p = 0.011).",
      "All 13 PG-CAP patients showed improvement (100%), compared to only 69% of the 13 MediHoney patients (p = 0.023).",
      "Half of the failures in the MediHoney arm were associated with death (15%).",
      "No failures, adverse events or deaths occurred in the PG-CAP arm.",
      "PG-CAP wound ointment is a novel combination of two plant-based compounds that pose minimal risk of promoting antimicrobial resistance, was highly effective for eradicating wound-pathogen biofilms in vitro and promoted chronic wound healing in vivo with minimal inflammatory reactions.",
      "Our findings support PG-CAP as safe, noninferior and possibly more effective than MediHoney in healing chronic contaminated wounds."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41573507",
    "source": "pubmed",
    "sentences": [
      "Severe aortic stenosis (AS) is associated with an increased risk of adverse outcomes in patients undergoing percutaneous coronary intervention (PCI).",
      "While Impella-supported high-risk PCI (HRPCI) has demonstrated improved outcomes, its safety in patients with AS remains inadequately established.",
      "We evaluated the effectiveness and safety of Impella support in patients with AS undergoing HRPCI.",
      "Patients from the PROTECT III study (NCT04136392), a single-arm, FDA-audited, multicenter investigation of Impella-supported HRPCI, were assessed.",
      "AS severity was classified as none/trivial, mild, moderate, or severe.",
      "The primary outcome was 90-day major adverse cardiac and cerebrovascular events [MACCE, defined as the composite of all-cause mortality, MI, stroke/transient ischemic attack (TIA), and revascularization].",
      "Secondary outcomes included in-hospital complications, stroke/TIA, and vascular complications requiring surgery.",
      "Of the 594 patients with available echocardiographic data, 490 had none/trivial AS, while 34, 24, and 46 had mild, moderate, or severe AS, respectively.",
      "Patients with AS were older, had fewer incidences of diabetes, were more likely to have left main disease, and had higher left ventricular ejection fraction.",
      "Severely calcified lesions and atherectomy were more frequent among patients with moderate or severe AS.",
      "No significant differences were observed in PCI-related complications, stroke/TIA, and 30-day or 90-day MACCE across AS severity groups.",
      "However, transfusion rates were higher in patients with AS.",
      "In patients undergoing Impella-supported HRPCI, 90-day MACCE and PCI-related complications were similar across all levels of AS severity.",
      "These findings suggest that the procedure is safe in this complex, high-risk population."
    ],
    "summary_sentences": [
      "Severe aortic stenosis (AS) is associated with an increased risk of adverse outcomes in patients undergoing percutaneous coronary intervention (PCI).",
      "While Impella-supported high-risk PCI (HRPCI) has demonstrated improved outcomes, its safety in patients with AS remains inadequately established.",
      "We evaluated the effectiveness and safety of Impella support in patients with AS undergoing HRPCI.",
      "Patients from the PROTECT III study (NCT04136392), a single-arm, FDA-audited, multicenter investigation of Impella-supported HRPCI, were assessed.",
      "AS severity was classified as none/trivial, mild, moderate, or severe.",
      "The primary outcome was 90-day major adverse cardiac and cerebrovascular events [MACCE, defined as the composite of all-cause mortality, MI, stroke/transient ischemic attack (TIA), and revascularization].",
      "Secondary outcomes included in-hospital complications, stroke/TIA, and vascular complications requiring surgery.",
      "Of the 594 patients with available echocardiographic data, 490 had none/trivial AS, while 34, 24, and 46 had mild, moderate, or severe AS, respectively.",
      "Patients with AS were older, had fewer incidences of diabetes, were more likely to have left main disease, and had higher left ventricular ejection fraction.",
      "Severely calcified lesions and atherectomy were more frequent among patients with moderate or severe AS.",
      "No significant differences were observed in PCI-related complications, stroke/TIA, and 30-day or 90-day MACCE across AS severity groups.",
      "However, transfusion rates were higher in patients with AS.",
      "In patients undergoing Impella-supported HRPCI, 90-day MACCE and PCI-related complications were similar across all levels of AS severity.",
      "These findings suggest that the procedure is safe in this complex, high-risk population."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41573193",
    "source": "pubmed",
    "sentences": [
      "To evaluate and compare the efficacy of different antidiabetic agents in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM).",
      "We systematically searched PubMed, Embase, the Cochrane Library, and Web of Science for relevant randomized controlled trials up to April 20, 2025.",
      "Primary outcomes were alanine aminotransferase (ALT), aspartate aminotransferase (AST), and triglycerides.",
      "Secondary outcomes included HDL, LDL, fasting plasma glucose (FPG), body mass index (BMI), and glycated hemoglobin (HbA1c).",
      "All statistical analyses were performed using R version 4.5.0.",
      "A total of 21 randomized controlled trials were included, covering 15 antidiabetic agents and involving 1,717 participants.",
      "Ertugliflozin was the most effective in reducing ALT and AST levels, followed by pioglitazone and metformin for ALT, and pioglitazone and ipragliflozin for AST.",
      "Ertugliflozin also showed favorable effects on triglycerides, BMI, HDL, LDL, and liver stiffness.",
      "However, most comparisons did not reach statistical significance.",
      "Ertugliflozin appears to be among the most effective treatment options for improving liver function and metabolic parameters in patients with MASLD and T2DM.",
      "However, these findings should be interpreted with caution, and further high-quality studies are needed to confirm these results.",
      "Ertugliflozin may be the most effective option for improving liver function and metabolic parameters in patients with MASLD and T2DM.",
      "Further studies are needed to confirm these findings."
    ],
    "summary_sentences": [
      "To evaluate and compare the efficacy of different antidiabetic agents in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM).",
      "We systematically searched PubMed, Embase, the Cochrane Library, and Web of Science for relevant randomized controlled trials up to April 20, 2025.",
      "Primary outcomes were alanine aminotransferase (ALT), aspartate aminotransferase (AST), and triglycerides.",
      "Secondary outcomes included HDL, LDL, fasting plasma glucose (FPG), body mass index (BMI), and glycated hemoglobin (HbA1c).",
      "All statistical analyses were performed using R version 4.5.0.",
      "A total of 21 randomized controlled trials were included, covering 15 antidiabetic agents and involving 1,717 participants.",
      "Ertugliflozin was the most effective in reducing ALT and AST levels, followed by pioglitazone and metformin for ALT, and pioglitazone and ipragliflozin for AST.",
      "Ertugliflozin also showed favorable effects on triglycerides, BMI, HDL, LDL, and liver stiffness.",
      "However, most comparisons did not reach statistical significance.",
      "Ertugliflozin appears to be among the most effective treatment options for improving liver function and metabolic parameters in patients with MASLD and T2DM.",
      "However, these findings should be interpreted with caution, and further high-quality studies are needed to confirm these results.",
      "Ertugliflozin may be the most effective option for improving liver function and metabolic parameters in patients with MASLD and T2DM.",
      "Further studies are needed to confirm these findings."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41573113",
    "source": "pubmed",
    "sentences": [
      "The prevalence of cardiovascular diseases (CVD) and CVD risk factors such as Type 2 Diabetes Mellitus (T2DM), hypertension and hypercholesterolemia has increased steadily worldwide.",
      "Population health screening is a common effort that promotes early detection, better prognosis and reduces disease burden.",
      "However, despite nationwide efforts, screening uptake for CVD risk factors in Singapore has remained moderately low (60.2%).",
      "Profiles of individuals who do not screen remain largely unknown, making them harder to reach via mainstream screening efforts.",
      "Existing literature has yet to organise factors systematically influencing CVD screening uptake, making it difficult to select a set of robust strategies to promote CVD screening uptake.",
      "This study aims to identify determinants of screening uptake for T2DM, hypertension and hypercholesterolemia in eligible adults residing in Western Singapore, and develop an implementation strategy toolkit to enhance screening uptake in this population.",
      "Prospective, theory-informed, two-phased, multi-method study design.",
      "identifier",
      "[CRD42024566701]."
    ],
    "summary_sentences": [
      "The prevalence of cardiovascular diseases (CVD) and CVD risk factors such as Type 2 Diabetes Mellitus (T2DM), hypertension and hypercholesterolemia has increased steadily worldwide.",
      "Population health screening is a common effort that promotes early detection, better prognosis and reduces disease burden.",
      "However, despite nationwide efforts, screening uptake for CVD risk factors in Singapore has remained moderately low (60.2%).",
      "Profiles of individuals who do not screen remain largely unknown, making them harder to reach via mainstream screening efforts.",
      "Existing literature has yet to organise factors systematically influencing CVD screening uptake, making it difficult to select a set of robust strategies to promote CVD screening uptake.",
      "This study aims to identify determinants of screening uptake for T2DM, hypertension and hypercholesterolemia in eligible adults residing in Western Singapore, and develop an implementation strategy toolkit to enhance screening uptake in this population.",
      "Prospective, theory-informed, two-phased, multi-method study design.",
      "identifier",
      "[CRD42024566701]."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41572974",
    "source": "pubmed",
    "sentences": [
      "Preoperative oral carbohydrate alleviates postoperative insulin resistance and enhances recovery.",
      "Its utility in type 2 diabetes mellitus (T2DM) is debated due to hyperglycemia risks.",
      "Isomaltulose, a low-glycemic-index carbohydrate, has been shown to effectively attenuate postprandial glucose fluctuations and reduce metabolic stress on pancreatic β-cells in T2DM patients.",
      "This study investigated the effects of preoperative oral isomaltulose in patients with T2DM undergoing elective laparoscopic non-gastrointestinal surgery.",
      "60 T2DM patients were randomized to receive either 300 mL of a solution containing 50 g isomaltulose (isomaltulose group) or plain water (Control group) 2-3 h preoperatively.",
      "The primary outcome was insulin resistance, assessed by the homeostasis model assessment (HOMA-IR) at 24 h post surgery.",
      "Secondary outcomes included perioperative glycemic variability, serum insulin levels, Perlas grade (assessed by pre-anesthesia gastric ultrasound), incidence of regurgitation and aspiration, perioperative subjective comfort scores, postoperative nausea and vomiting incidence (PONV), time of first flatus after surgery, surgical wound complications, length of postoperative hospital stay.",
      "Baseline characteristics were comparable.",
      "At 24 h postoperatively, the Isomaltulose group exhibited significantly lower HOMA-IR",
      "[6.89 ± 3.38 vs. 11.60 ± 4.34; mean difference = 4.71, 95% CI (2.70, 6.72), In well-controlled T2DM patients, preoperative oral isomaltulose was associated with lower postoperative insulin resistance and reduced glycemic variability, without delaying gastric emptying.",
      "These metabolic benefits were accompanied by a transient elevation in pre-induction blood glucose, which should be weighed in clinical decision making.",
      "https://www.chictr.org.cn/index.html, identifier ChiCTR2500098088."
    ],
    "summary_sentences": [
      "Preoperative oral carbohydrate alleviates postoperative insulin resistance and enhances recovery.",
      "Its utility in type 2 diabetes mellitus (T2DM) is debated due to hyperglycemia risks.",
      "Isomaltulose, a low-glycemic-index carbohydrate, has been shown to effectively attenuate postprandial glucose fluctuations and reduce metabolic stress on pancreatic β-cells in T2DM patients.",
      "This study investigated the effects of preoperative oral isomaltulose in patients with T2DM undergoing elective laparoscopic non-gastrointestinal surgery.",
      "60 T2DM patients were randomized to receive either 300 mL of a solution containing 50 g isomaltulose (isomaltulose group) or plain water (Control group) 2-3 h preoperatively.",
      "The primary outcome was insulin resistance, assessed by the homeostasis model assessment (HOMA-IR) at 24 h post surgery.",
      "Secondary outcomes included perioperative glycemic variability, serum insulin levels, Perlas grade (assessed by pre-anesthesia gastric ultrasound), incidence of regurgitation and aspiration, perioperative subjective comfort scores, postoperative nausea and vomiting incidence (PONV), time of first flatus after surgery, surgical wound complications, length of postoperative hospital stay.",
      "Baseline characteristics were comparable.",
      "At 24 h postoperatively, the Isomaltulose group exhibited significantly lower HOMA-IR",
      "[6.89 ± 3.38 vs. 11.60 ± 4.34; mean difference = 4.71, 95% CI (2.70, 6.72), In well-controlled T2DM patients, preoperative oral isomaltulose was associated with lower postoperative insulin resistance and reduced glycemic variability, without delaying gastric emptying.",
      "These metabolic benefits were accompanied by a transient elevation in pre-induction blood glucose, which should be weighed in clinical decision making.",
      "https://www.chictr.org.cn/index.html, identifier ChiCTR2500098088."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41572243",
    "source": "pubmed",
    "sentences": [
      "The common recommendation for hypoglycemia treatment, oral ingestion of 15 g of simple carbohydrates and glucose recheck in 15 min, was predominantly based on expert opinion, and two small-sized studies of intravenous insulin-induced hypoglycemia in people living with type 1 diabetes mellitus (T1D).",
      "The evidence for \"15 grams/15 minutes\" treatment for people living with type 2 diabetes mellitus (T2D) needs to be explored.",
      "The objective of this systematic review is to determine which oral carbohydrate treatments were studied in adults living with T2D for timely resolution of hypoglycemia events.",
      "Medline, Embase, Scopus, and Cochrane Central Register of Controlled Trials were searched from January 1990 to 24 March 2025, for full-text studies of oral treatment for hypoglycemia in T2D. Two authors screened the results and extracted data.",
      "Inclusion criteria included age >",
      "= 18 years with T2D, treated with a defined quantity of simple carbohydrates, and reported hypoglycemia event resolution as a defined time of first glucose recheck after treatment completion.",
      "Exclusion criteria included non-oral route of hypoglycemia treatment.",
      "The Newcastle-Ottawa scale was used for risk of bias assessment.",
      "Three studies were included, which reported on 152 insulin-treated adults who experienced 366 hypoglycemia events.",
      "None of these three studies presented if the participants were or were not on sulfonylurea concurrently, nor did they present a breakdown of the types of insulin(s) (long-acting versus rapid-acting) for the participants.",
      "All studies had different oral hypoglycemia treatments and various glucose recheck times.",
      "Hence, data synthesis was not possible.",
      "There was near 100% hypoglycemia resolution with 15 g carbohydrates at 30-minute recheck in a study of mild hypoglycemia in hospitalized people living with type 2 diabetes.",
      "An at-home study showed 95% hypoglycemia resolution with 30 g carbohydrates at 10-minute recheck, although rebound hyperglycemia became a concern.",
      "The studies had low risk of bias.",
      "Three studies provided a very limited evidence base for hypoglycemia treatment in T2D. Future studies are encouraged to identify and analyze people living with T2D who are treated with sulfonylurea, with or without insulin therapy, to reflect hypoglycemia treatment over the breadth of T2D pharmacotherapy.",
      "Not applicable.",
      "Prospero registration number CRD420251032322.",
      "No amendments.",
      "Study protocol can be obtained by sending a written request to the corresponding author."
    ],
    "summary_sentences": [
      "The common recommendation for hypoglycemia treatment, oral ingestion of 15 g of simple carbohydrates and glucose recheck in 15 min, was predominantly based on expert opinion, and two small-sized studies of intravenous insulin-induced hypoglycemia in people living with type 1 diabetes mellitus (T1D).",
      "The evidence for \"15 grams/15 minutes\" treatment for people living with type 2 diabetes mellitus (T2D) needs to be explored.",
      "The objective of this systematic review is to determine which oral carbohydrate treatments were studied in adults living with T2D for timely resolution of hypoglycemia events.",
      "Medline, Embase, Scopus, and Cochrane Central Register of Controlled Trials were searched from January 1990 to 24 March 2025, for full-text studies of oral treatment for hypoglycemia in T2D. Two authors screened the results and extracted data.",
      "Inclusion criteria included age >",
      "= 18 years with T2D, treated with a defined quantity of simple carbohydrates, and reported hypoglycemia event resolution as a defined time of first glucose recheck after treatment completion.",
      "Exclusion criteria included non-oral route of hypoglycemia treatment.",
      "The Newcastle-Ottawa scale was used for risk of bias assessment.",
      "Three studies were included, which reported on 152 insulin-treated adults who experienced 366 hypoglycemia events.",
      "None of these three studies presented if the participants were or were not on sulfonylurea concurrently, nor did they present a breakdown of the types of insulin(s) (long-acting versus rapid-acting) for the participants.",
      "All studies had different oral hypoglycemia treatments and various glucose recheck times.",
      "Hence, data synthesis was not possible.",
      "There was near 100% hypoglycemia resolution with 15 g carbohydrates at 30-minute recheck in a study of mild hypoglycemia in hospitalized people living with type 2 diabetes.",
      "An at-home study showed 95% hypoglycemia resolution with 30 g carbohydrates at 10-minute recheck, although rebound hyperglycemia became a concern.",
      "The studies had low risk of bias.",
      "Three studies provided a very limited evidence base for hypoglycemia treatment in T2D. Future studies are encouraged to identify and analyze people living with T2D who are treated with sulfonylurea, with or without insulin therapy, to reflect hypoglycemia treatment over the breadth of T2D pharmacotherapy.",
      "Not applicable.",
      "Prospero registration number CRD420251032322.",
      "No amendments.",
      "Study protocol can be obtained by sending a written request to the corresponding author."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41572076",
    "source": "pubmed",
    "sentences": [
      "Type 2 diabetes mellitus (T2DM) is a systemic metabolic disorder increasingly implicated in central nervous system (CNS) dysfunction, yet the molecular substrates underlying diabetes-induced dopaminergic (DAergic) dysregulation remain poorly defined.",
      "This study evaluated region-specific alterations in DAergic neurotransmission within the hippocampus, striatum, and prefrontal cortex, and their association with social behavioral deficits in diabetic mice.",
      "According to the weight and age of the animal, two groups were designated as the control group and the diabetes group.",
      "The control group was designated as group 1, and the diabetic group was designated as group 2.",
      "In group 2, diabetes was caused by injecting 50 mg/kg of streptozotocin for five consecutive days in them.",
      "The behavioural tests were performed after eight weeks of inducing diabetes.",
      "On the 60th day, from the striatum, hippocampus, and cortex, total RNA was taken out after the dissection.",
      "Real-time polymerase chain reaction was used to carry out expression analysis.",
      "STZ-induced diabetic mice showed normal sociability and social novelty preference but exhibited a marked decline in social recognition memory, indicating selective impairment of long-term social cognition.",
      "Region-specific dysregulation of dopaminergic signaling was evident, particularly in the striatum and cortex.",
      "These transcriptional alterations likely represent compensatory neuroadaptive mechanisms responding to oxidative and neuronal stress induced by diabetes, suggesting that T2DM-driven dopaminergic imbalance contributes to cognitive and neurobehavioral dysfunction.",
      "T2DM induces differential dysregulation of dopaminergic signaling across cortical and subcortical regions, contributing to selective deficits in social cognition.",
      "These findings highlight potential therapeutic targets for mitigating diabetes-associated neurobehavioral dysfunction."
    ],
    "summary_sentences": [
      "Type 2 diabetes mellitus (T2DM) is a systemic metabolic disorder increasingly implicated in central nervous system (CNS) dysfunction, yet the molecular substrates underlying diabetes-induced dopaminergic (DAergic) dysregulation remain poorly defined.",
      "This study evaluated region-specific alterations in DAergic neurotransmission within the hippocampus, striatum, and prefrontal cortex, and their association with social behavioral deficits in diabetic mice.",
      "According to the weight and age of the animal, two groups were designated as the control group and the diabetes group.",
      "The control group was designated as group 1, and the diabetic group was designated as group 2.",
      "In group 2, diabetes was caused by injecting 50 mg/kg of streptozotocin for five consecutive days in them.",
      "The behavioural tests were performed after eight weeks of inducing diabetes.",
      "On the 60th day, from the striatum, hippocampus, and cortex, total RNA was taken out after the dissection.",
      "Real-time polymerase chain reaction was used to carry out expression analysis.",
      "STZ-induced diabetic mice showed normal sociability and social novelty preference but exhibited a marked decline in social recognition memory, indicating selective impairment of long-term social cognition.",
      "Region-specific dysregulation of dopaminergic signaling was evident, particularly in the striatum and cortex.",
      "These transcriptional alterations likely represent compensatory neuroadaptive mechanisms responding to oxidative and neuronal stress induced by diabetes, suggesting that T2DM-driven dopaminergic imbalance contributes to cognitive and neurobehavioral dysfunction.",
      "T2DM induces differential dysregulation of dopaminergic signaling across cortical and subcortical regions, contributing to selective deficits in social cognition.",
      "These findings highlight potential therapeutic targets for mitigating diabetes-associated neurobehavioral dysfunction."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41571659",
    "source": "pubmed",
    "sentences": [
      "An inverse relationship between physical activity and mortality has been observed in epidemiological surveys, but not in randomized clinical trials.",
      "This post hoc, not pre-specified analysis of the Italian Diabetes and Exercise Study_2 randomized clinical trial assesses the effect of a physical activity-based counseling intervention on long-term mortality in people with type 2 diabetes.",
      "Three hundred physically inactive and sedentary individuals are recruited in three outpatient diabetes clinics in Rome from October 2012 to February 2014.",
      "Participants are randomized 1:1 to a Control group receiving standard care and an Intervention group receiving a one-month theoretical and practical counseling targeting both PA and sedentary behavior, each year for 3 years.",
      "For this analysis, all-cause and cause-specific mortality are the primary and secondary endpoint, respectively.",
      "The vital status is verified on 30 June 2024 and all participants are analyzed.",
      "After a 10.3-year follow-up, the number of deaths is significantly lower among Intervention than Control participants (18 vs 35, p = 0.010), mainly due to fewer cancer deaths.",
      "Age-and sex-adjusted hazard ratios for mortality are significantly lower in Intervention versus Control participants (0.498 [0.282-0.879], p = 0.016) and between-group differences remain after further adjustment for treatments and baseline cardiometabolic risk profile, major complications, and physical activity and fitness level (0.414 [0.229-0.750], p = 0.004).",
      "Limitations include the post hoc type of analysis, a post-trial observational follow-up with no assessment of physical activity and fitness parameters, possible unmeasured confounders, and the non-generalizability to different populations.",
      "A behavioral counselling targeting all domains of physical activity and sedentary behavior is associated with reduced long-term mortality risk in people with type 2 diabetes.",
      "ClinicalTrials.gov",
      "Identifier: NCT01600937."
    ],
    "summary_sentences": [
      "An inverse relationship between physical activity and mortality has been observed in epidemiological surveys, but not in randomized clinical trials.",
      "This post hoc, not pre-specified analysis of the Italian Diabetes and Exercise Study_2 randomized clinical trial assesses the effect of a physical activity-based counseling intervention on long-term mortality in people with type 2 diabetes.",
      "Three hundred physically inactive and sedentary individuals are recruited in three outpatient diabetes clinics in Rome from October 2012 to February 2014.",
      "Participants are randomized 1:1 to a Control group receiving standard care and an Intervention group receiving a one-month theoretical and practical counseling targeting both PA and sedentary behavior, each year for 3 years.",
      "For this analysis, all-cause and cause-specific mortality are the primary and secondary endpoint, respectively.",
      "The vital status is verified on 30 June 2024 and all participants are analyzed.",
      "After a 10.3-year follow-up, the number of deaths is significantly lower among Intervention than Control participants (18 vs 35, p = 0.010), mainly due to fewer cancer deaths.",
      "Age-and sex-adjusted hazard ratios for mortality are significantly lower in Intervention versus Control participants (0.498 [0.282-0.879], p = 0.016) and between-group differences remain after further adjustment for treatments and baseline cardiometabolic risk profile, major complications, and physical activity and fitness level (0.414 [0.229-0.750], p = 0.004).",
      "Limitations include the post hoc type of analysis, a post-trial observational follow-up with no assessment of physical activity and fitness parameters, possible unmeasured confounders, and the non-generalizability to different populations.",
      "A behavioral counselling targeting all domains of physical activity and sedentary behavior is associated with reduced long-term mortality risk in people with type 2 diabetes.",
      "ClinicalTrials.gov",
      "Identifier: NCT01600937."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41571410",
    "source": "pubmed",
    "sentences": [
      "Night shift work is well known to cause health disruption in the short and long term.",
      "Among healthcare workers, sleep deprivation is a common concern with many nurses reporting sleep of <6 hour per 24-hour period.",
      "Consequences of this chronic sleep restriction have been associated with long-term health issues such as endothelial dysfunction, which plays a key role in the development of cardiovascular diseases, arterial hypertension and type 2 diabetes.",
      "While countermeasures such as nap at work have been suggested to mitigate these deleterious effects, the impact of such intervention on endothelial function remains unclear.",
      "Therefore, the aim of the present study will be to investigate the effect of a 30 min nap opportunity during night shift work on endothelial function in healthcare workers working in 12-hour shifts.",
      "A 12-week randomised controlled trial will be performed with two conditions: (1) a 30 min nap opportunity during night shift work in a dedicated quiet room with a bed and (2) a control condition including a 30 min rest period in a break room.",
      "A total of 80 nurses and assistant nurses from interventional care units working a 2×12 hour shift schedule will be recruited.",
      "The main outcome will be endothelial dysfunction assessed through the reactive hyperaemia index using the EndoPAT device.",
      "Secondary outcomes will include other cardiovascular risk biomarkers, including arterial stiffness (pulse wave velocity), blood pressure, heart rate variability, proinflammatory blood parameters, self-reported fatigue, recovery needs, sleep quality and sleepiness, which will be assessed using validated questionnaires.",
      "Our study will address whether napping on the night shift can decrease cardiovascular risk through early cardiovascular biomarkers, including endothelial function, arterial stiffness and heart rate variability.",
      "If effective, such interventions could contribute to the development of more sustainable and health-conscious shift work practices, benefiting both workers and the organisations that employ them.",
      "The study protocol is in accordance with ethical principles established by the 18th World Medical Assembly (Helsinki 1964) and received approval from an institutional review board 'comité de protection des personnes EST III' (23CH138).",
      "Written informed consent will be obtained from all participants.",
      "NCT05955729; ClinicalTrials.gov 2023-A01109-36 Registered on 21 July 2023."
    ],
    "summary_sentences": [
      "Night shift work is well known to cause health disruption in the short and long term.",
      "Among healthcare workers, sleep deprivation is a common concern with many nurses reporting sleep of <6 hour per 24-hour period.",
      "Consequences of this chronic sleep restriction have been associated with long-term health issues such as endothelial dysfunction, which plays a key role in the development of cardiovascular diseases, arterial hypertension and type 2 diabetes.",
      "While countermeasures such as nap at work have been suggested to mitigate these deleterious effects, the impact of such intervention on endothelial function remains unclear.",
      "Therefore, the aim of the present study will be to investigate the effect of a 30 min nap opportunity during night shift work on endothelial function in healthcare workers working in 12-hour shifts.",
      "A 12-week randomised controlled trial will be performed with two conditions: (1) a 30 min nap opportunity during night shift work in a dedicated quiet room with a bed and (2) a control condition including a 30 min rest period in a break room.",
      "A total of 80 nurses and assistant nurses from interventional care units working a 2×12 hour shift schedule will be recruited.",
      "The main outcome will be endothelial dysfunction assessed through the reactive hyperaemia index using the EndoPAT device.",
      "Secondary outcomes will include other cardiovascular risk biomarkers, including arterial stiffness (pulse wave velocity), blood pressure, heart rate variability, proinflammatory blood parameters, self-reported fatigue, recovery needs, sleep quality and sleepiness, which will be assessed using validated questionnaires.",
      "Our study will address whether napping on the night shift can decrease cardiovascular risk through early cardiovascular biomarkers, including endothelial function, arterial stiffness and heart rate variability.",
      "If effective, such interventions could contribute to the development of more sustainable and health-conscious shift work practices, benefiting both workers and the organisations that employ them.",
      "The study protocol is in accordance with ethical principles established by the 18th World Medical Assembly (Helsinki 1964) and received approval from an institutional review board 'comité de protection des personnes EST III' (23CH138).",
      "Written informed consent will be obtained from all participants.",
      "NCT05955729; ClinicalTrials.gov 2023-A01109-36 Registered on 21 July 2023."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41571333",
    "source": "pubmed",
    "sentences": [
      "Shunting of glycolytic intermediates into the pentose phosphate pathway via transketolase activation by benfotiamine has been suggested to protect from hyperglycemia-induced microvascular damage, but the long-term effects of benfotiamine on diabetic sensorimotor polyneuropathy (DSPN) remain unclear.",
      "This 1:1 randomized double-blind, placebo-controlled parallel group monocentric phase II trial compared the efficacy and safety of 1-year treatment with benfotiamine 300 mg two times per day versus placebo over 12 months in participants with type 2 diabetes and mild-to-moderate symptomatic DSPN.",
      "The primary endpoint was the change in corneal nerve fiber length (CNFL) assessed by corneal confocal microscopy (CCM) from baseline to 12 months.",
      "Secondary endpoints included three other CCM parameters, skin biopsy (four parameters), nerve conduction studies (13 measures), quantitative sensory testing (six parameters), cardiovascular autonomic function tests (17 indices), sudomotor function tests (five parameters), 15 clinical scores and scales for neuropathic symptoms and signs and 13 health-related quality of life and depression instruments.",
      "Pharmacokinetics included measurement of six thiamine analytes in blood.",
      "A total of 57 participants underwent randomization.",
      "The changes from baseline to 12 months in CNFL did not differ between the two groups.",
      "The corresponding changes in the secondary morphometric, functional and clinical neuropathic outcomes as well as quality of life were also similar in the two groups.",
      "Only the Neuropathy Symptom Score tended to improve after benfotiamine treatment (p=0.098 vs placebo).",
      "Benfotiamine treatment increased the concentrations of all six thiamine analytes studied (p≤0.003 vs placebo).",
      "Safety analysis showed no relevant differences between the groups in the rates of adverse events.",
      "In type 2 diabetes individuals with mild-to-moderate symptomatic DSPN, treatment with benfotiamine for 12 months was well tolerated, but had no significant effects on multiple morphometric, neurophysiological and clinical measures of neuropathy.",
      "European Clinical Trials Database (EudraCT) 2017-003054-16 registered on April 10 (https://eudract.ema.europa.eu/), 2018 and German Register for Clinical Trials DRKS00014832 registered on August 3, 2018 (https://drks.de/search/de)."
    ],
    "summary_sentences": [
      "Shunting of glycolytic intermediates into the pentose phosphate pathway via transketolase activation by benfotiamine has been suggested to protect from hyperglycemia-induced microvascular damage, but the long-term effects of benfotiamine on diabetic sensorimotor polyneuropathy (DSPN) remain unclear.",
      "This 1:1 randomized double-blind, placebo-controlled parallel group monocentric phase II trial compared the efficacy and safety of 1-year treatment with benfotiamine 300 mg two times per day versus placebo over 12 months in participants with type 2 diabetes and mild-to-moderate symptomatic DSPN.",
      "The primary endpoint was the change in corneal nerve fiber length (CNFL) assessed by corneal confocal microscopy (CCM) from baseline to 12 months.",
      "Secondary endpoints included three other CCM parameters, skin biopsy (four parameters), nerve conduction studies (13 measures), quantitative sensory testing (six parameters), cardiovascular autonomic function tests (17 indices), sudomotor function tests (five parameters), 15 clinical scores and scales for neuropathic symptoms and signs and 13 health-related quality of life and depression instruments.",
      "Pharmacokinetics included measurement of six thiamine analytes in blood.",
      "A total of 57 participants underwent randomization.",
      "The changes from baseline to 12 months in CNFL did not differ between the two groups.",
      "The corresponding changes in the secondary morphometric, functional and clinical neuropathic outcomes as well as quality of life were also similar in the two groups.",
      "Only the Neuropathy Symptom Score tended to improve after benfotiamine treatment (p=0.098 vs placebo).",
      "Benfotiamine treatment increased the concentrations of all six thiamine analytes studied (p≤0.003 vs placebo).",
      "Safety analysis showed no relevant differences between the groups in the rates of adverse events.",
      "In type 2 diabetes individuals with mild-to-moderate symptomatic DSPN, treatment with benfotiamine for 12 months was well tolerated, but had no significant effects on multiple morphometric, neurophysiological and clinical measures of neuropathy.",
      "European Clinical Trials Database (EudraCT) 2017-003054-16 registered on April 10 (https://eudract.ema.europa.eu/), 2018 and German Register for Clinical Trials DRKS00014832 registered on August 3, 2018 (https://drks.de/search/de)."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41571285",
    "source": "pubmed",
    "sentences": [
      "Glycemic control (GC) is hard to implement safely in intensive care due to patient variability.",
      "GC has been wrongly blamed for increased hypoglycemic risk instead of protocol design, limiting its adoption.",
      "Stochastic TARgeted (STAR) is a model-based, patient-specific, risk-based GC framework modulating intravenous (IV) insulin and nutrition, accounting for both inter- and intra-patient variability.",
      "This study assesses STAR GC's ability to provide safe and effective control across a large cohort.",
      "This study was performed in Christchurch Hospital Intensive Care Unit, New Zealand.",
      "Patients were treated with STAR GC between April 2019 and December 2024.",
      "The STAR GC episodes not complying with filtering criteria were excluded.",
      "Results are analyzed in terms of performance, safety, and workload.",
      "Of 1340 adult ICU patients totaling 1958 STAR GC episodes, 1085 patients and 1430 episodes (86 010 h of control) remained after filtering.",
      "In total, 71% of blood glucose (BG) measurements were in the target band for a median [interquartile range, IQR] BG of 124 [110-148] mg/dL. Only three (0.21%) severe hypoglycemia events (BG < 40 mg/dL) occurred, two unrelated to the control design.",
      "High median [IQR] nutrition delivery (89.0 [17.2-100.0])",
      "%goal feed was achieved with median [IQR] insulin rate of 4.5 [2.0-6.0] U/h. Results were consistent per-patient and improved once in the target band.",
      "STAR provides safe, effective control for all patients in this large cohort, with minimal hypoglycemia and high nutrition rates.",
      "The protocol adapts to patients' specific needs and tolerances, encouraging STAR's adoption in other ICUs.",
      "The quality of control also enables prospective assessment of the future of GC's impact on patient outcomes."
    ],
    "summary_sentences": [
      "Glycemic control (GC) is hard to implement safely in intensive care due to patient variability.",
      "GC has been wrongly blamed for increased hypoglycemic risk instead of protocol design, limiting its adoption.",
      "Stochastic TARgeted (STAR) is a model-based, patient-specific, risk-based GC framework modulating intravenous (IV) insulin and nutrition, accounting for both inter- and intra-patient variability.",
      "This study assesses STAR GC's ability to provide safe and effective control across a large cohort.",
      "This study was performed in Christchurch Hospital Intensive Care Unit, New Zealand.",
      "Patients were treated with STAR GC between April 2019 and December 2024.",
      "The STAR GC episodes not complying with filtering criteria were excluded.",
      "Results are analyzed in terms of performance, safety, and workload.",
      "Of 1340 adult ICU patients totaling 1958 STAR GC episodes, 1085 patients and 1430 episodes (86 010 h of control) remained after filtering.",
      "In total, 71% of blood glucose (BG) measurements were in the target band for a median [interquartile range, IQR] BG of 124 [110-148] mg/dL. Only three (0.21%) severe hypoglycemia events (BG < 40 mg/dL) occurred, two unrelated to the control design.",
      "High median [IQR] nutrition delivery (89.0 [17.2-100.0])",
      "%goal feed was achieved with median [IQR] insulin rate of 4.5 [2.0-6.0] U/h. Results were consistent per-patient and improved once in the target band.",
      "STAR provides safe, effective control for all patients in this large cohort, with minimal hypoglycemia and high nutrition rates.",
      "The protocol adapts to patients' specific needs and tolerances, encouraging STAR's adoption in other ICUs.",
      "The quality of control also enables prospective assessment of the future of GC's impact on patient outcomes."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41570241",
    "source": "pubmed",
    "sentences": [
      "Substantial observational evidence exists in support of bariatric surgery being associated with reduction in risk for a wide range of outcomes, including cardiovascular disease (CVD) in patients with diabetes.",
      "Two recent studies, however, argued that much of that prior work suffers from various sources of underappreciated bias as well as design decisions that compromise whether one can conceive of a corresponding target trial.",
      "Furthermore, results based on analyses of claims data from Optum and electronic health record data from the Veterans Administration (VA) are presented as providing evidence of no CVD benefit for bariatric surgery in patients with diabetes.",
      "In this paper, we use data from a prior Kaiser Permanente study to emulate a trial that mimics the methods employed in the VA study.",
      "This new analysis finds a reduction in risk of CVD in patients with diabetes, consistent with pre-existing evidence.",
      "We discuss possible mechanisms by which the discrepant results can be reconciled, including issues of statistical validity that arise from small samples, whether recent work on transportability indicates that we should not always expect results to always be concordant and the role of conservatism associated with \"clinical trial thinking\".",
      "We conclude with a discussion of what standards should be used when considering the work of others in the literature and the role that evidence triangulation may be play in the future."
    ],
    "summary_sentences": [
      "Substantial observational evidence exists in support of bariatric surgery being associated with reduction in risk for a wide range of outcomes, including cardiovascular disease (CVD) in patients with diabetes.",
      "Two recent studies, however, argued that much of that prior work suffers from various sources of underappreciated bias as well as design decisions that compromise whether one can conceive of a corresponding target trial.",
      "Furthermore, results based on analyses of claims data from Optum and electronic health record data from the Veterans Administration (VA) are presented as providing evidence of no CVD benefit for bariatric surgery in patients with diabetes.",
      "In this paper, we use data from a prior Kaiser Permanente study to emulate a trial that mimics the methods employed in the VA study.",
      "This new analysis finds a reduction in risk of CVD in patients with diabetes, consistent with pre-existing evidence.",
      "We discuss possible mechanisms by which the discrepant results can be reconciled, including issues of statistical validity that arise from small samples, whether recent work on transportability indicates that we should not always expect results to always be concordant and the role of conservatism associated with \"clinical trial thinking\".",
      "We conclude with a discussion of what standards should be used when considering the work of others in the literature and the role that evidence triangulation may be play in the future."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41569702",
    "source": "pubmed",
    "sentences": [
      "Statistical inference in multicenter clinical trials is often compromised when relying on asymptotic normal approximations, particularly in designs characterized by a small number of centers or severe imbalance in patient enrollment.",
      "Such deviations from asymptotic assumptions frequently result in unreliable p-values and a breakdown of error control.",
      "To resolve this, we introduce a high-precision saddlepoint approximation framework for aggregate permutation tests within hierarchically structured data.",
      "The theoretical core of our approach is the derivation of a multilevel nested cumulant generating function that explicitly models the trial hierarchy, analytically integrating patient-level linear rank statistics with the stochastic aggregation process across centers.",
      "A significant innovation of this work is the extension to the bivariate setting to address co-primary endpoints, providing a robust inferential solution for mixed continuous (efficacy) and discrete (safety) outcomes where standard multivariate normality is unattainable.",
      "The resulting framework yields simulation-free, highly accurate tail probabilities even in finite-sample regimes.",
      "Extensive simulation studies confirm that our method maintains strict Type I error control in scenarios where asymptotic methods exhibit substantial inflation.",
      "Furthermore, an application to the multicenter diabetes prevention program trial demonstrates the method's practical utility: it correctly identifies a significant cardiovascular risk factor that standard approximations failed to detect, thereby preventing a critical Type II error and ensuring valid clinical conclusions."
    ],
    "summary_sentences": [
      "Statistical inference in multicenter clinical trials is often compromised when relying on asymptotic normal approximations, particularly in designs characterized by a small number of centers or severe imbalance in patient enrollment.",
      "Such deviations from asymptotic assumptions frequently result in unreliable p-values and a breakdown of error control.",
      "To resolve this, we introduce a high-precision saddlepoint approximation framework for aggregate permutation tests within hierarchically structured data.",
      "The theoretical core of our approach is the derivation of a multilevel nested cumulant generating function that explicitly models the trial hierarchy, analytically integrating patient-level linear rank statistics with the stochastic aggregation process across centers.",
      "A significant innovation of this work is the extension to the bivariate setting to address co-primary endpoints, providing a robust inferential solution for mixed continuous (efficacy) and discrete (safety) outcomes where standard multivariate normality is unattainable.",
      "The resulting framework yields simulation-free, highly accurate tail probabilities even in finite-sample regimes.",
      "Extensive simulation studies confirm that our method maintains strict Type I error control in scenarios where asymptotic methods exhibit substantial inflation.",
      "Furthermore, an application to the multicenter diabetes prevention program trial demonstrates the method's practical utility: it correctly identifies a significant cardiovascular risk factor that standard approximations failed to detect, thereby preventing a critical Type II error and ensuring valid clinical conclusions."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41569475",
    "source": "pubmed",
    "sentences": [
      "This review summarizes the pharmacologic profiles, clinical trial evidence, and practical considerations for the use of first-generation obesity medications phentermine, orlistat, phentermine/topiramate extended-release, bupropion/naltrexone sustained-release, and liraglutide 3.0 mg.",
      "Understanding the mechanisms, benefits, and limitations of these agents is essential for delivering comprehensive cardiometabolic care.",
      "First-generation obesity medications continue to play an important role in clinical practice.",
      "These agents can be highly effective in appropriately selected patients.",
      "While mean weight loss is less than newer incretin-based therapies, trial data demonstrate that a substantial proportion of individuals on first-generation agents achieve ≥ 10% total body weight loss.",
      "First-generation obesity medications represent a cost-effective, evidence-based component of comprehensive obesity care-and remain critical tools to address atherosclerosis and other cardiometabolic complications of obesity."
    ],
    "summary_sentences": [
      "This review summarizes the pharmacologic profiles, clinical trial evidence, and practical considerations for the use of first-generation obesity medications phentermine, orlistat, phentermine/topiramate extended-release, bupropion/naltrexone sustained-release, and liraglutide 3.0 mg.",
      "Understanding the mechanisms, benefits, and limitations of these agents is essential for delivering comprehensive cardiometabolic care.",
      "First-generation obesity medications continue to play an important role in clinical practice.",
      "These agents can be highly effective in appropriately selected patients.",
      "While mean weight loss is less than newer incretin-based therapies, trial data demonstrate that a substantial proportion of individuals on first-generation agents achieve ≥ 10% total body weight loss.",
      "First-generation obesity medications represent a cost-effective, evidence-based component of comprehensive obesity care-and remain critical tools to address atherosclerosis and other cardiometabolic complications of obesity."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41567808",
    "source": "pubmed",
    "sentences": [
      "Advanced liver fibrosis, a key complication of metabolic dysfunction-associated steatotic liver disease, has been increasingly linked to extrahepatic conditions, including type 2 diabetes, obesity, and cardiovascular disease.",
      "However, the specific association of liver fibrosis in the development and progression of subclinical atheromatous disease across vascular territories remains poorly understood.",
      "This study evaluates the utility of two non-invasive indices to predict liver fibrosis and their associations with subclinical atheromatous plaque burden and distribution.",
      "Atheromatous plaque burden (plaque presence, number, and total area) was assessed in the carotid and femoral territories via ultrasonography in 3,981 middle-aged participants without known cardiovascular disease, diabetes, or liver disease from the ILERVAS cohort (ClinicalTrials.gov Identifier: NCT03228459).",
      "The fibrosis-4 (FIB-4) and the NAFLD Fibrosis Score (NFS) were evaluated.",
      "FIB-4 risk categories were defined as low (<1.30), intermediate (1.30-2.67), and high (>2.67).",
      "Participants in the intermediate and high-risk FIB-4 categories exhibited a higher prevalence of carotid atheromatous disease (56.8% vs. 49.5%, p<0.001), a greater number of plaques (p<0.001), and a larger total plaque area (p=0.007).",
      "Multivariable analyses confirmed FIB-4 as an independent predictor of carotid plaque burden (OR: 1.14, 95% CI 1.05-1.24, p=0.003), even adjusting for traditional cardiovascular risk factors.",
      "Moving from low to high FIB-4 cut-offs was associated with 12.6% higher odds of carotid atherosclerosis.",
      "NFS was also independently associated with carotid atheromatosis (OR 1.10, 95% CI 1.05-1.15, p<0.001).",
      "No significant associations were found in the femoral territory for either index.",
      "Estimated liver fibrosis, particularly FIB-4, is a valuable marker for identifying carotid subclinical atherosclerosis in populations without known liver disease.",
      "These findings highlight the importance of vascular territory-specific evaluations and support their utility in integrated liver and cardiovascular risk assessment strategies."
    ],
    "summary_sentences": [
      "Advanced liver fibrosis, a key complication of metabolic dysfunction-associated steatotic liver disease, has been increasingly linked to extrahepatic conditions, including type 2 diabetes, obesity, and cardiovascular disease.",
      "However, the specific association of liver fibrosis in the development and progression of subclinical atheromatous disease across vascular territories remains poorly understood.",
      "This study evaluates the utility of two non-invasive indices to predict liver fibrosis and their associations with subclinical atheromatous plaque burden and distribution.",
      "Atheromatous plaque burden (plaque presence, number, and total area) was assessed in the carotid and femoral territories via ultrasonography in 3,981 middle-aged participants without known cardiovascular disease, diabetes, or liver disease from the ILERVAS cohort (ClinicalTrials.gov Identifier: NCT03228459).",
      "The fibrosis-4 (FIB-4) and the NAFLD Fibrosis Score (NFS) were evaluated.",
      "FIB-4 risk categories were defined as low (<1.30), intermediate (1.30-2.67), and high (>2.67).",
      "Participants in the intermediate and high-risk FIB-4 categories exhibited a higher prevalence of carotid atheromatous disease (56.8% vs. 49.5%, p<0.001), a greater number of plaques (p<0.001), and a larger total plaque area (p=0.007).",
      "Multivariable analyses confirmed FIB-4 as an independent predictor of carotid plaque burden (OR: 1.14, 95% CI 1.05-1.24, p=0.003), even adjusting for traditional cardiovascular risk factors.",
      "Moving from low to high FIB-4 cut-offs was associated with 12.6% higher odds of carotid atherosclerosis.",
      "NFS was also independently associated with carotid atheromatosis (OR 1.10, 95% CI 1.05-1.15, p<0.001).",
      "No significant associations were found in the femoral territory for either index.",
      "Estimated liver fibrosis, particularly FIB-4, is a valuable marker for identifying carotid subclinical atherosclerosis in populations without known liver disease.",
      "These findings highlight the importance of vascular territory-specific evaluations and support their utility in integrated liver and cardiovascular risk assessment strategies."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41567689",
    "source": "pubmed",
    "sentences": [
      "The intersection of obesity and asthma represents a complex clinical challenge characterized by increased symptom burden, reduced treatment efficacy, and multifactorial pathophysiology.",
      "Obesity-associated asthma is a heterogeneous condition shaped by underlying metabolic dysfunctions such as insulin resistance and altered inflammatory processes.",
      "Current research often oversimplifies the relationship between obesity and asthma by relying primarily on body mass index as a measure, thereby overlooking key metabolic factors that may influence disease severity and treatment response.",
      "There is a critical need for clinical trials that account for this metabolic complexity, so we designed a proof-of-concept study with this in mind.",
      "Using the GLP-1R Agonists in the Treatment of Adult, Symptomatic, Obese Asthma (GATA-3) trial (ClinicalTrials.gov NCT05254314) as a conceptual framework, we propose an evolved model for future asthma research.",
      "While not a direct report of GATA-3 findings, it emphasizes the integration of comprehensive metabolic profiling-including insulin sensitivity and body composition-alongside traditional inflammatory and respiratory metrics in randomized controlled asthma trials.",
      "The GATA-3 study design serves as an example of the first placebo-controlled trial to evaluate the glucagon-like peptide 1 receptor pathway's role in asthma management independent of weight loss.",
      "The trial underscores essential design elements such as accurate asthma diagnosis, recognition of endotype heterogeneity, and implementation of outcome measures tailored to this phenotype.",
      "Advancing our understanding of obesity-associated asthma requires moving beyond body mass index-focused models to fully consider the metabolic complexity of the disease.",
      "Integrating detailed metabolic assessments into research and clinical practice will be vital for identifying responsive subpopulations, optimizing treatment strategies, and ultimately improving patient outcomes."
    ],
    "summary_sentences": [
      "The intersection of obesity and asthma represents a complex clinical challenge characterized by increased symptom burden, reduced treatment efficacy, and multifactorial pathophysiology.",
      "Obesity-associated asthma is a heterogeneous condition shaped by underlying metabolic dysfunctions such as insulin resistance and altered inflammatory processes.",
      "Current research often oversimplifies the relationship between obesity and asthma by relying primarily on body mass index as a measure, thereby overlooking key metabolic factors that may influence disease severity and treatment response.",
      "There is a critical need for clinical trials that account for this metabolic complexity, so we designed a proof-of-concept study with this in mind.",
      "Using the GLP-1R Agonists in the Treatment of Adult, Symptomatic, Obese Asthma (GATA-3) trial (ClinicalTrials.gov NCT05254314) as a conceptual framework, we propose an evolved model for future asthma research.",
      "While not a direct report of GATA-3 findings, it emphasizes the integration of comprehensive metabolic profiling-including insulin sensitivity and body composition-alongside traditional inflammatory and respiratory metrics in randomized controlled asthma trials.",
      "The GATA-3 study design serves as an example of the first placebo-controlled trial to evaluate the glucagon-like peptide 1 receptor pathway's role in asthma management independent of weight loss.",
      "The trial underscores essential design elements such as accurate asthma diagnosis, recognition of endotype heterogeneity, and implementation of outcome measures tailored to this phenotype.",
      "Advancing our understanding of obesity-associated asthma requires moving beyond body mass index-focused models to fully consider the metabolic complexity of the disease.",
      "Integrating detailed metabolic assessments into research and clinical practice will be vital for identifying responsive subpopulations, optimizing treatment strategies, and ultimately improving patient outcomes."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41567495",
    "source": "pubmed",
    "sentences": [
      "A pilot study of a multilevel, 6-month intervention (MAP) designed to increase patient portal use among patients with type 2 diabetes at community health centers (CHCs) showed promising results.",
      "The aim of this implementation analysis is to (1) describe the nurse-patient interactions and documentation of care during MAP, (2) report MAP implementation successes and challenges, and (3) describe participants' use of other online health resources.",
      "Data were collected from MAP nurses ( The content of portal messages between nurses and participants was educational and supportive.",
      "Numerous health-related social needs that influence participant diabetes self-management were identified, many of which were handled with relevant referrals.",
      "Participant-reported challenges changed over time, with technical barriers decreasing and competing demands increasing.",
      "Participants increased their use of online resources for health improvement.",
      "Addressing implementation challenges may allow the expansion of programs like MAP in CHCs and ultimately improve diabetes outcomes.",
      "clinicaltrials.gov, identifier NCT05180721."
    ],
    "summary_sentences": [
      "A pilot study of a multilevel, 6-month intervention (MAP) designed to increase patient portal use among patients with type 2 diabetes at community health centers (CHCs) showed promising results.",
      "The aim of this implementation analysis is to (1) describe the nurse-patient interactions and documentation of care during MAP, (2) report MAP implementation successes and challenges, and (3) describe participants' use of other online health resources.",
      "Data were collected from MAP nurses ( The content of portal messages between nurses and participants was educational and supportive.",
      "Numerous health-related social needs that influence participant diabetes self-management were identified, many of which were handled with relevant referrals.",
      "Participant-reported challenges changed over time, with technical barriers decreasing and competing demands increasing.",
      "Participants increased their use of online resources for health improvement.",
      "Addressing implementation challenges may allow the expansion of programs like MAP in CHCs and ultimately improve diabetes outcomes.",
      "clinicaltrials.gov, identifier NCT05180721."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41566786",
    "source": "pubmed",
    "sentences": [
      "A reduced compliance, due to urogenital minor infections, frequently compromises the clinical efficacy of SGLT2 inhibitors in subjects with type 2 diabetes (T2D).",
      "The combined use of SGLT2 inhibitors and dipeptidyl-peptidase four inhibitors seems to reduce the incidence of such side effects.",
      "We evaluated how these drugs, alone or in combination, might influence resident urinary microbiota.",
      "An open label, randomised clinical study was conducted on 30 T2D individuals for 12 weeks to compare the impact of Empagliflozin and Empagliflozin/Linagliptin on clinical parameters and urinary microbiota.",
      "Fifteen healthy individuals served as baseline controls.",
      "The composition of urinary bacterial populations was evaluated by Real-Time quantitative PCR and 16S rRNA gene sequencing.",
      "BMI was reduced by both treatments, while fasting glucose and HbA1c significantly improved only with the combination.",
      "At baseline, T2D showed a higher total bacterial load and abundance of Bacillota than controls.",
      "The prevalence and proportion of bacterial species profoundly differed between the groups, revealing a urinary dysbiosis in T2D. A different effect of Empagliflozin alone or combined with Linagliptin on microbial populations was observed: Empagliflozin increased the total bacterial load of Bacillota and Aerococcus, while the combination therapy restored a microbial community similar to that of controls, further reducing the prevalence of potential urinary pathogens.",
      "In T2D subjects, the combination of Empagliflozin and Ligandliptin might help in restoring a normal composition of the urinary microbiota, likely improving compliance and persistence in therapy with SGLT2 inhibitors."
    ],
    "summary_sentences": [
      "A reduced compliance, due to urogenital minor infections, frequently compromises the clinical efficacy of SGLT2 inhibitors in subjects with type 2 diabetes (T2D).",
      "The combined use of SGLT2 inhibitors and dipeptidyl-peptidase four inhibitors seems to reduce the incidence of such side effects.",
      "We evaluated how these drugs, alone or in combination, might influence resident urinary microbiota.",
      "An open label, randomised clinical study was conducted on 30 T2D individuals for 12 weeks to compare the impact of Empagliflozin and Empagliflozin/Linagliptin on clinical parameters and urinary microbiota.",
      "Fifteen healthy individuals served as baseline controls.",
      "The composition of urinary bacterial populations was evaluated by Real-Time quantitative PCR and 16S rRNA gene sequencing.",
      "BMI was reduced by both treatments, while fasting glucose and HbA1c significantly improved only with the combination.",
      "At baseline, T2D showed a higher total bacterial load and abundance of Bacillota than controls.",
      "The prevalence and proportion of bacterial species profoundly differed between the groups, revealing a urinary dysbiosis in T2D. A different effect of Empagliflozin alone or combined with Linagliptin on microbial populations was observed: Empagliflozin increased the total bacterial load of Bacillota and Aerococcus, while the combination therapy restored a microbial community similar to that of controls, further reducing the prevalence of potential urinary pathogens.",
      "In T2D subjects, the combination of Empagliflozin and Ligandliptin might help in restoring a normal composition of the urinary microbiota, likely improving compliance and persistence in therapy with SGLT2 inhibitors."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41564845",
    "source": "pubmed",
    "sentences": [
      "Maladaptive inflammation and cellular senescence contribute to diabetic kidney disease (DKD) pathogenesis and represent important therapeutic targets.",
      "Senolytic agents selectively remove senescent cells and reduce inflammation-associated tissue damage.",
      "In our pilot clinical trial in patients with DKD, the senolytic combination dasatinib plus quercetin (D + Q) reduced systemic inflammation, senescent cell abundance, and macrophage infiltration in fat.",
      "However, D + Q senotherapeutic effects on diabetic kidney injury, senescence, inflammation, and geroprotective factors have not been established.",
      "Diabetes mellitus was induced with intraperitoneal streptozotocin in male C57BL/6J mice, followed by a 5-day oral gavage regimen of either D + Q (5 and 50 mg/kg, respectively) or vehicle.",
      "Kidney function and markers of injury, fibrosis, inflammation, cellular senescence, and geroprotective factors were measured.",
      "In vitro studies examined reparative effects of D + Q in high glucose-treated human renal tubular epithelial cells (HK2), endothelial cells (HUVECs), and U937-derived macrophages.",
      "D + Q improved kidney function and reduced markers of kidney injury (glomerular and tubular), fibrosis, senescence (p16 A \"hit-and-run\" senolytic treatment with D + Q improved kidney function and mitigated murine DKD by modulating the inflammatory landscape, reducing senescent cell abundance, and restoring geroprotective factors.",
      "Taken together, the beneficial effects in kidneys of mice and prior systemic effects in humans, support the rationale for further clinical investigations applying D + Q to enhance healthspan in individuals with DKD.",
      "This research was supported by National Institutes of Health (NIH):",
      "[DK123492, DK109134, and AG076537 (LJH); DK120292 and HL158691 (LOL); AG087387 (YZ); R37AG013925 (TT and JLK)]; NIDDK Diabetes Complications Consortium",
      "[DK115255, DK076169 (LJH)]; Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery (LJH); TT and JLK are supported by a grant from the Hevolution Foundation (HF-GRO-23-1199148-3), Cedars-Sinai Medical Center, the Connor Fund, and Robert J. and Theresa W. Ryan."
    ],
    "summary_sentences": [
      "Maladaptive inflammation and cellular senescence contribute to diabetic kidney disease (DKD) pathogenesis and represent important therapeutic targets.",
      "Senolytic agents selectively remove senescent cells and reduce inflammation-associated tissue damage.",
      "In our pilot clinical trial in patients with DKD, the senolytic combination dasatinib plus quercetin (D + Q) reduced systemic inflammation, senescent cell abundance, and macrophage infiltration in fat.",
      "However, D + Q senotherapeutic effects on diabetic kidney injury, senescence, inflammation, and geroprotective factors have not been established.",
      "Diabetes mellitus was induced with intraperitoneal streptozotocin in male C57BL/6J mice, followed by a 5-day oral gavage regimen of either D + Q (5 and 50 mg/kg, respectively) or vehicle.",
      "Kidney function and markers of injury, fibrosis, inflammation, cellular senescence, and geroprotective factors were measured.",
      "In vitro studies examined reparative effects of D + Q in high glucose-treated human renal tubular epithelial cells (HK2), endothelial cells (HUVECs), and U937-derived macrophages.",
      "D + Q improved kidney function and reduced markers of kidney injury (glomerular and tubular), fibrosis, senescence (p16 A \"hit-and-run\" senolytic treatment with D + Q improved kidney function and mitigated murine DKD by modulating the inflammatory landscape, reducing senescent cell abundance, and restoring geroprotective factors.",
      "Taken together, the beneficial effects in kidneys of mice and prior systemic effects in humans, support the rationale for further clinical investigations applying D + Q to enhance healthspan in individuals with DKD.",
      "This research was supported by National Institutes of Health (NIH):",
      "[DK123492, DK109134, and AG076537 (LJH); DK120292 and HL158691 (LOL); AG087387 (YZ); R37AG013925 (TT and JLK)]; NIDDK Diabetes Complications Consortium",
      "[DK115255, DK076169 (LJH)]; Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery (LJH); TT and JLK are supported by a grant from the Hevolution Foundation (HF-GRO-23-1199148-3), Cedars-Sinai Medical Center, the Connor Fund, and Robert J. and Theresa W. Ryan."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41564354",
    "source": "pubmed",
    "sentences": [
      "Antigen-specific therapy is needed to induce tolerance in type 1 diabetes at early disease stages or in combination with immunotherapy.",
      "We conducted a phase I trial in type 1 diabetes of a novel plasmid construct expressing the islet antigen preproinsulin (PPI) and immunomodulatory cytokines transforming growth factor-β1 (TGF-β1), interleukin-10 (IL-10), and IL-2.",
      "The therapy was safe and well tolerated.",
      "Dose-dependent changes in DNA plasmid levels and type 1 interferon signatures were detected; however, global and antigen-specific immune changes to PPI, IL-2, IL-10, or TGF-β1 were not observed.",
      "Further trials are needed to assess efficacy."
    ],
    "summary_sentences": [
      "Antigen-specific therapy is needed to induce tolerance in type 1 diabetes at early disease stages or in combination with immunotherapy.",
      "We conducted a phase I trial in type 1 diabetes of a novel plasmid construct expressing the islet antigen preproinsulin (PPI) and immunomodulatory cytokines transforming growth factor-β1 (TGF-β1), interleukin-10 (IL-10), and IL-2.",
      "The therapy was safe and well tolerated.",
      "Dose-dependent changes in DNA plasmid levels and type 1 interferon signatures were detected; however, global and antigen-specific immune changes to PPI, IL-2, IL-10, or TGF-β1 were not observed.",
      "Further trials are needed to assess efficacy."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41563732",
    "source": "pubmed",
    "sentences": [
      "To evaluate treatment group differences in Rasch-calibrated and non-Rasch-calibrated health-related quality-of-life domain scores and visual acuity (VA) across randomized clinical trials of laser versus anti-vascular endothelial growth factor (VEGF) in proliferative diabetic retinopathy.",
      "We simulated 10,000 randomized controlled trials (RCTs), using random sample-and-replace bootstrapping methods from open-source data obtained from individual patient VA and National Eye Institute Visual Function Questionnaire-25 (VFQ-25) responses in the Diabetic Retinopathy Clinical Research (DRCR) Retina Network Protocol S, comparing ranibizumab with panretinal photocoagulation for proliferative diabetic retinopathy.",
      "We calculated Pearson correlation coefficients between treatment group differences in mean VA and mean domain scores and ranked them.",
      "We also calculated mean effect sizes for each domain and composite across RCTs.",
      "Correlations between treatment group differences (mean VA vs. mean domain score) in rank order were as follows:",
      "Rasch combined, 0.408; Rasch socioemotional, 0.394; original composite, 0.388; near activities, 0.385; Rasch visual function, 0.383; and mental health, 0.380.",
      "Correlations were weaker for the remaining 10 domains.",
      "The largest effect sizes were found with the original composite, mental health, dependency, and peripheral vision, slightly larger than Rasch combined and Rasch socioemotional scales.",
      "Treatment group differences in Rasch calibrated VFQ-25 domains (visual function, socioemotional, combined) had the highest correlation with differences in VA, although the original multidimensional non-Rasch composite and near activities were similar.",
      "Use of Rasch calibrated scores is recommended for desirable psychometrics, but it may be acceptable to use the raw scored original composite instrument."
    ],
    "summary_sentences": [
      "To evaluate treatment group differences in Rasch-calibrated and non-Rasch-calibrated health-related quality-of-life domain scores and visual acuity (VA) across randomized clinical trials of laser versus anti-vascular endothelial growth factor (VEGF) in proliferative diabetic retinopathy.",
      "We simulated 10,000 randomized controlled trials (RCTs), using random sample-and-replace bootstrapping methods from open-source data obtained from individual patient VA and National Eye Institute Visual Function Questionnaire-25 (VFQ-25) responses in the Diabetic Retinopathy Clinical Research (DRCR) Retina Network Protocol S, comparing ranibizumab with panretinal photocoagulation for proliferative diabetic retinopathy.",
      "We calculated Pearson correlation coefficients between treatment group differences in mean VA and mean domain scores and ranked them.",
      "We also calculated mean effect sizes for each domain and composite across RCTs.",
      "Correlations between treatment group differences (mean VA vs. mean domain score) in rank order were as follows:",
      "Rasch combined, 0.408; Rasch socioemotional, 0.394; original composite, 0.388; near activities, 0.385; Rasch visual function, 0.383; and mental health, 0.380.",
      "Correlations were weaker for the remaining 10 domains.",
      "The largest effect sizes were found with the original composite, mental health, dependency, and peripheral vision, slightly larger than Rasch combined and Rasch socioemotional scales.",
      "Treatment group differences in Rasch calibrated VFQ-25 domains (visual function, socioemotional, combined) had the highest correlation with differences in VA, although the original multidimensional non-Rasch composite and near activities were similar.",
      "Use of Rasch calibrated scores is recommended for desirable psychometrics, but it may be acceptable to use the raw scored original composite instrument."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41563617",
    "source": "pubmed",
    "sentences": [
      "To compare the functional and anatomical outcomes of pars plana vitrectomy (PPV) with or without internal limiting membrane (ILM) peeling in patients suffering with non-resolving vitreous hemorrhage and tractional retinal detachment.",
      "Fifty-seven patients (57 eyes) suffering from PDR were randomly assigned to undergo PPV with ILM peeling (n = 26) or without ILM peeling (n = 31).",
      "Outcomes assessed over a 6-month follow-up included best-corrected visual acuity (BCVA), need for additional anti-VEGF injections, frequency of reoperations, central macular thickness (CMT), development of epiretinal membrane (ERM), macular traction, and vascular parameters derived from OCT imaging.",
      "Both groups showed statistically significant improvements in BCVA postoperatively (p < 0.001), with no significant difference between them (p = 0.846).",
      "The ILM peeling group required fewer repeat anti-VEGF injections (7.7% vs. 35.5%, p = 0.030) and exhibited a significantly lower incidence of secondary ERM (11.5% vs. 51.6%, p = 0.004).",
      "ERM formation correlated with iatrogenic retinal tears (p = 0.007) and tractional retinal detachment (TRD) (p < 0.001).",
      "Reoperations for ERM removal occurred exclusively in the non-ILM peeling group.",
      "No significant intergroup differences were found in CMT, foveal avascular zone (FAZ) area, or vessel density.",
      "ILM peeling during diabetic vitrectomy effectively minimizes the risk of postoperative ERM formation and reduces the need for further Anti-VEGF injections for DME.",
      "However, it does not confer a significant advantage in terms of visual acuity improvements."
    ],
    "summary_sentences": [
      "To compare the functional and anatomical outcomes of pars plana vitrectomy (PPV) with or without internal limiting membrane (ILM) peeling in patients suffering with non-resolving vitreous hemorrhage and tractional retinal detachment.",
      "Fifty-seven patients (57 eyes) suffering from PDR were randomly assigned to undergo PPV with ILM peeling (n = 26) or without ILM peeling (n = 31).",
      "Outcomes assessed over a 6-month follow-up included best-corrected visual acuity (BCVA), need for additional anti-VEGF injections, frequency of reoperations, central macular thickness (CMT), development of epiretinal membrane (ERM), macular traction, and vascular parameters derived from OCT imaging.",
      "Both groups showed statistically significant improvements in BCVA postoperatively (p < 0.001), with no significant difference between them (p = 0.846).",
      "The ILM peeling group required fewer repeat anti-VEGF injections (7.7% vs. 35.5%, p = 0.030) and exhibited a significantly lower incidence of secondary ERM (11.5% vs. 51.6%, p = 0.004).",
      "ERM formation correlated with iatrogenic retinal tears (p = 0.007) and tractional retinal detachment (TRD) (p < 0.001).",
      "Reoperations for ERM removal occurred exclusively in the non-ILM peeling group.",
      "No significant intergroup differences were found in CMT, foveal avascular zone (FAZ) area, or vessel density.",
      "ILM peeling during diabetic vitrectomy effectively minimizes the risk of postoperative ERM formation and reduces the need for further Anti-VEGF injections for DME.",
      "However, it does not confer a significant advantage in terms of visual acuity improvements."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41562938",
    "source": "pubmed",
    "sentences": [
      "The rising prevalence of Type 2 Diabetes Mellitus (T2DM), coupled with sedentary behavior and an increase in obesity rates in South Asian countries, calls for effective management strategies.",
      "We aimed to assess the efficacy of lifestyle interventions on glycemic control among adults with T2DM in South Asian countries.",
      "A systematic review and meta-analysis of randomized controlled trials (RCTs) were conducted to assess the effectiveness of lifestyle interventions on glycemic control in adults diagnosed with T2DM in South Asia.",
      "We conducted a comprehensive search in CINAHL, Embase, PubMed, Cochrane Library, Web of Science (WoS), and Scopus to identify related studies published from 2000 to 13 June 2024.",
      "We assessed the risk of bias using the ROB 2.0 tool and calculated the pooled mean differences in HbA1c and FBG levels under a random-effects model.",
      "We conducted subgroup and leave-one-out sensitivity analyses to assess and explore sources of heterogeneity.",
      "PROSPERO Registration: CRD42024552286.",
      "We included 16 RCTs with a total of 1499 participants.",
      "Lifestyle interventions reduced HbA1c levels by 0.86% (95% CI: -1.30 to -0.42, Lifestyle modifications yielded a clinically significant reduction in HbA1c and FBG in adults with T2DM in South Asia.",
      "Although heterogeneity of the included studies was substantial, the direction of the effects was uniformly consistent across subgroups.",
      "To further validate these findings and assess their long-term effects, large-scale and standardized RCTs conducted for longer durations are necessary."
    ],
    "summary_sentences": [
      "The rising prevalence of Type 2 Diabetes Mellitus (T2DM), coupled with sedentary behavior and an increase in obesity rates in South Asian countries, calls for effective management strategies.",
      "We aimed to assess the efficacy of lifestyle interventions on glycemic control among adults with T2DM in South Asian countries.",
      "A systematic review and meta-analysis of randomized controlled trials (RCTs) were conducted to assess the effectiveness of lifestyle interventions on glycemic control in adults diagnosed with T2DM in South Asia.",
      "We conducted a comprehensive search in CINAHL, Embase, PubMed, Cochrane Library, Web of Science (WoS), and Scopus to identify related studies published from 2000 to 13 June 2024.",
      "We assessed the risk of bias using the ROB 2.0 tool and calculated the pooled mean differences in HbA1c and FBG levels under a random-effects model.",
      "We conducted subgroup and leave-one-out sensitivity analyses to assess and explore sources of heterogeneity.",
      "PROSPERO Registration: CRD42024552286.",
      "We included 16 RCTs with a total of 1499 participants.",
      "Lifestyle interventions reduced HbA1c levels by 0.86% (95% CI: -1.30 to -0.42, Lifestyle modifications yielded a clinically significant reduction in HbA1c and FBG in adults with T2DM in South Asia.",
      "Although heterogeneity of the included studies was substantial, the direction of the effects was uniformly consistent across subgroups.",
      "To further validate these findings and assess their long-term effects, large-scale and standardized RCTs conducted for longer durations are necessary."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41562647",
    "source": "pubmed",
    "sentences": [
      "Number needed to treat (NNT) and cost per event avoided (CPEA) are measures used to represent the clinical and economic value of chronic treatments and are commonly calculated based on primary endpoints from trials.",
      "This approach, although widely used, does not reflect the complete value of a treatment, as it does not consider outcomes beyond the primary endpoints.",
      "This research aims to overcome this limitation by developing multiple composite NNTs to derive the CPEA to estimate a total value of semaglutide and dulaglutide in people with established cardiovascular disease.",
      "Two cardiovascular outcomes trials were selected, SELECT (NCT03574597, semaglutide 2.4 mg) and REWIND (NCT01394952, dulaglutide 1.5 mg).",
      "NNT was calculated as NNT = 1/ARR where ARR = control event rate - experimental event rate.",
      "NNT was estimated for 3-point major adverse cardiovascular events (MACE-3; primary endpoint of the trials), 5-point MACE (MACE-5), and cardiovascular-kidney-metabolic events (CKM).",
      "CPEA of MACE-3, MACE-5, and CKM was calculated as NNT*duration of mean follow-up (semaglutide) or duration of median follow-up (dulaglutide)*estimated net price.",
      "The NNT decreased as the number of outcomes in the composite endpoint increased, where NNT This research illustrates the limitations of using a NNT focused only on the primary endpoint, as it does not capture the total benefit of the treatment.",
      "When considering the value of treatments through NNT or CPEA analyses, a composite endpoint capturing broader benefit should be utilized.",
      "This study demonstrates how to assess the clinical and economic value of different drugs and how to assist decision-makers and payers for informed decision-making.",
      "This is substantial in diabetes and obesity, due to the surging costs of treating these diseases, both preventive and curative as well.",
      "We use data (from clinical trials) for semaglutide and dulaglutide in people with cardiovascular disease as an example.",
      "We calculated the number of people that need to be treated to avoid one major adverse cardiovascular event (MACE) and how much it would cost.",
      "We show that it is important to include several types of outcomes (here we look at different types of cardiovascular, kidney and metabolic outcomes), beyond the primary endpoint of a trial, to capture the full value of treatment."
    ],
    "summary_sentences": [
      "Number needed to treat (NNT) and cost per event avoided (CPEA) are measures used to represent the clinical and economic value of chronic treatments and are commonly calculated based on primary endpoints from trials.",
      "This approach, although widely used, does not reflect the complete value of a treatment, as it does not consider outcomes beyond the primary endpoints.",
      "This research aims to overcome this limitation by developing multiple composite NNTs to derive the CPEA to estimate a total value of semaglutide and dulaglutide in people with established cardiovascular disease.",
      "Two cardiovascular outcomes trials were selected, SELECT (NCT03574597, semaglutide 2.4 mg) and REWIND (NCT01394952, dulaglutide 1.5 mg).",
      "NNT was calculated as NNT = 1/ARR where ARR = control event rate - experimental event rate.",
      "NNT was estimated for 3-point major adverse cardiovascular events (MACE-3; primary endpoint of the trials), 5-point MACE (MACE-5), and cardiovascular-kidney-metabolic events (CKM).",
      "CPEA of MACE-3, MACE-5, and CKM was calculated as NNT*duration of mean follow-up (semaglutide) or duration of median follow-up (dulaglutide)*estimated net price.",
      "The NNT decreased as the number of outcomes in the composite endpoint increased, where NNT This research illustrates the limitations of using a NNT focused only on the primary endpoint, as it does not capture the total benefit of the treatment.",
      "When considering the value of treatments through NNT or CPEA analyses, a composite endpoint capturing broader benefit should be utilized.",
      "This study demonstrates how to assess the clinical and economic value of different drugs and how to assist decision-makers and payers for informed decision-making.",
      "This is substantial in diabetes and obesity, due to the surging costs of treating these diseases, both preventive and curative as well.",
      "We use data (from clinical trials) for semaglutide and dulaglutide in people with cardiovascular disease as an example.",
      "We calculated the number of people that need to be treated to avoid one major adverse cardiovascular event (MACE) and how much it would cost.",
      "We show that it is important to include several types of outcomes (here we look at different types of cardiovascular, kidney and metabolic outcomes), beyond the primary endpoint of a trial, to capture the full value of treatment."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41562388",
    "source": "pubmed",
    "sentences": [
      "This study compared the effects of phentermine-topiramate-ER (mid-dose 7.5/46 mg) versus placebo on weight loss and cardiovascular disease (CVD) risk outcomes when used as an adjunct to a digitally enhanced lifestyle intervention (DELI).",
      "We conducted a 12-month, randomized, double-blind, placebo-controlled trial at a single tertiary academic center in the United States (June 2020-June 2022).",
      "Eighty participants with obesity (BMI ≥ 30 kg/m At 3 months, the phentermine-topiramate group lost a mean of 10.82 kg versus 4.04 kg in the placebo group (mean difference -6.78 kg; p = 0.002).",
      "At 12 months, weight loss was 15.32 kg versus 5.85 kg, respectively (mean difference -9.48 kg; p < 0.001).",
      "Participants receiving phentermine-topiramate-ER experienced a 3.35% reduction in the estimated atherosclerotic CVD risk compared to baseline (p = 0.004).",
      "Phentermine-topiramate-ER, when combined with a DELI, produced significant and sustained weight loss and reduced CVD risk in adults with obesity.",
      "ClinicalTrials.gov: NCT04408586."
    ],
    "summary_sentences": [
      "This study compared the effects of phentermine-topiramate-ER (mid-dose 7.5/46 mg) versus placebo on weight loss and cardiovascular disease (CVD) risk outcomes when used as an adjunct to a digitally enhanced lifestyle intervention (DELI).",
      "We conducted a 12-month, randomized, double-blind, placebo-controlled trial at a single tertiary academic center in the United States (June 2020-June 2022).",
      "Eighty participants with obesity (BMI ≥ 30 kg/m At 3 months, the phentermine-topiramate group lost a mean of 10.82 kg versus 4.04 kg in the placebo group (mean difference -6.78 kg; p = 0.002).",
      "At 12 months, weight loss was 15.32 kg versus 5.85 kg, respectively (mean difference -9.48 kg; p < 0.001).",
      "Participants receiving phentermine-topiramate-ER experienced a 3.35% reduction in the estimated atherosclerotic CVD risk compared to baseline (p = 0.004).",
      "Phentermine-topiramate-ER, when combined with a DELI, produced significant and sustained weight loss and reduced CVD risk in adults with obesity.",
      "ClinicalTrials.gov: NCT04408586."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41561835",
    "source": "pubmed",
    "sentences": [
      "Aerobic and resistance training can effectively improve clinical management in people with type 2 diabetes (T2D).",
      "Low vitamin D (VitD) levels are associated with T2D risk and metabolic disturbances, and may help reduce this risk, particularly in individuals with low VitD levels.",
      "In this line, many individuals with T2D, who may also be older adults or have osteoporosis, regularly include VitD treatment in their healthcare routines.",
      "Although the impact of exercise has been extensively studied, its effect on diabetic patients taking VitD remains limited.",
      "The aim of this study is to investigate the effect of aerobic and resistance training on clinical parameters in patients with T2D already taking VitD.",
      "The DIAVITEX study is a randomized controlled superiority trial, with four parallel arms, including 80 individuals with T2D. Patients will be selected at the Primary Care Centers and stratified according to their pre-existing VitD treatment.",
      "Participants will subsequently be randomized to the exercise intervention or control as follows:",
      "Group 1, Exercise + VitD users ( Expected improvements in insulin resistance, glycated hemoglobin, lipid profile, and inflammatory markers are anticipated following a 16-week regimen of exercise in patients with T2D on VitD.",
      "The study was registered on September 21, 2024, with the identifier number NCT06081387, https://clinicaltrials.gov/study/NCT06081387."
    ],
    "summary_sentences": [
      "Aerobic and resistance training can effectively improve clinical management in people with type 2 diabetes (T2D).",
      "Low vitamin D (VitD) levels are associated with T2D risk and metabolic disturbances, and may help reduce this risk, particularly in individuals with low VitD levels.",
      "In this line, many individuals with T2D, who may also be older adults or have osteoporosis, regularly include VitD treatment in their healthcare routines.",
      "Although the impact of exercise has been extensively studied, its effect on diabetic patients taking VitD remains limited.",
      "The aim of this study is to investigate the effect of aerobic and resistance training on clinical parameters in patients with T2D already taking VitD.",
      "The DIAVITEX study is a randomized controlled superiority trial, with four parallel arms, including 80 individuals with T2D. Patients will be selected at the Primary Care Centers and stratified according to their pre-existing VitD treatment.",
      "Participants will subsequently be randomized to the exercise intervention or control as follows:",
      "Group 1, Exercise + VitD users ( Expected improvements in insulin resistance, glycated hemoglobin, lipid profile, and inflammatory markers are anticipated following a 16-week regimen of exercise in patients with T2D on VitD.",
      "The study was registered on September 21, 2024, with the identifier number NCT06081387, https://clinicaltrials.gov/study/NCT06081387."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41561058",
    "source": "pubmed",
    "sentences": [
      "Diabetes Mellitus (DM) represents a global health crisis, currently affecting approximately 9% of the world's population.",
      "Its prevalence continues to rise steadily, with a noticeable trend toward onset at younger ages.",
      "Projections indicate that the prevalence will reach 12% by 2045 equivalent to 820 million cases-positioning DM as one of the most serious public health threats worldwide.",
      "Pathogenetically, DM is classified into Type 1 Diabetes Mellitus (T1DM) and Type 2 Diabetes Mellitus (T2DM), with T2DM accounting for over 90% of all cases.",
      "T2DM is characterized by pancreatic β-cell dysfunction and insulin resistance, and is recognized as a multisystem metabolic disorder involving pathways such as the gut-brain axis, insulin/peripheral resistance, etc strongly correlated with obesity and cardiovascular diseases.",
      "Recent advances in basic medical research and clinical therapeutics have optimized the application of glucagon-like peptide-1 (GLP-1), establishing it as a cornerstone incretin based therapy for T2DM management.",
      "In parallel, metabolic surgery has demonstrated significant potential in ameliorating symptoms of T2DM.",
      "This article comprehensively reviews current trends in T2DM treatment, the molecular profile of GLP-1, biological characteristics of GLP-1-secreting L-cells, the development of GLP-1-related pharmaceuticals, and advances in metabolic surgery (MS).",
      "We searched the primary literature in PubMed, Embase and SciELO from inception to June 2025, using the terms \"diabetes\", \"type 2 diabetes mellitus\", \"glucagon-like peptide-1\", \"L-cell\", \"metabolic surgery\", \"jejunostomy\", \"GLP-1 receptor agonists\" as well as their combinations.",
      "We included basic/mechanistic studies, human observational studies, randomized clinical trials and observational"
    ],
    "summary_sentences": [
      "Diabetes Mellitus (DM) represents a global health crisis, currently affecting approximately 9% of the world's population.",
      "Its prevalence continues to rise steadily, with a noticeable trend toward onset at younger ages.",
      "Projections indicate that the prevalence will reach 12% by 2045 equivalent to 820 million cases-positioning DM as one of the most serious public health threats worldwide.",
      "Pathogenetically, DM is classified into Type 1 Diabetes Mellitus (T1DM) and Type 2 Diabetes Mellitus (T2DM), with T2DM accounting for over 90% of all cases.",
      "T2DM is characterized by pancreatic β-cell dysfunction and insulin resistance, and is recognized as a multisystem metabolic disorder involving pathways such as the gut-brain axis, insulin/peripheral resistance, etc strongly correlated with obesity and cardiovascular diseases.",
      "Recent advances in basic medical research and clinical therapeutics have optimized the application of glucagon-like peptide-1 (GLP-1), establishing it as a cornerstone incretin based therapy for T2DM management.",
      "In parallel, metabolic surgery has demonstrated significant potential in ameliorating symptoms of T2DM.",
      "This article comprehensively reviews current trends in T2DM treatment, the molecular profile of GLP-1, biological characteristics of GLP-1-secreting L-cells, the development of GLP-1-related pharmaceuticals, and advances in metabolic surgery (MS).",
      "We searched the primary literature in PubMed, Embase and SciELO from inception to June 2025, using the terms \"diabetes\", \"type 2 diabetes mellitus\", \"glucagon-like peptide-1\", \"L-cell\", \"metabolic surgery\", \"jejunostomy\", \"GLP-1 receptor agonists\" as well as their combinations.",
      "We included basic/mechanistic studies, human observational studies, randomized clinical trials and observational"
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41561051",
    "source": "pubmed",
    "sentences": [
      "The role of worsening insulin resistance (IR) in type 2 diabetes (T2D) progression among lean individuals is not well understood.",
      "We examined whether declining insulin sensitivity (IS), independent of beta-cell function (BCF), is associated with diabetes progression.",
      "In a 10-year longitudinal Korean cohort with normal glucose tolerance (N = 2,810; age 50 ± 8y; BMI 24.1 ± 2.8 kg/m²), participants underwent biannual oral glucose tolerance tests.",
      "Longitudinal changes in IS, BCF, BMI, and fat mass were evaluated.",
      "Participants were stratified by baseline BCF (low/high), diabetes progression status (non-progressors [Non-p], progressors to prediabetes [PreDM-p], or",
      "T2D [T2D-p] over time), and degree of IS decline (large/small).",
      "Both T2D-p and PreDM-p showed greater IS decline than Non-p.",
      "At baseline, PreDM-p had IS comparable to T2D-p, but T2D-p declined more steeply.",
      "T2D-p and PreDM-p also had lower BCF at baseline, which remained low.",
      "Across baseline BCF groups (high/low), greater IS decline was consistently associated with higher risk of progression (all P<0.001).",
      "The effect size of IS decline exceeded that of BCF deterioration.",
      "Declining IS, independent of BCF, is associated with progression to T2D in lean Koreans.",
      "Preserving IS through lifestyle interventions is crucial for diabetes prevention, particularly in those with low BCF.",
      "Insulin resistance, β-cell function, disposition index, oral glucose tolerance test, body mass index."
    ],
    "summary_sentences": [
      "The role of worsening insulin resistance (IR) in type 2 diabetes (T2D) progression among lean individuals is not well understood.",
      "We examined whether declining insulin sensitivity (IS), independent of beta-cell function (BCF), is associated with diabetes progression.",
      "In a 10-year longitudinal Korean cohort with normal glucose tolerance (N = 2,810; age 50 ± 8y; BMI 24.1 ± 2.8 kg/m²), participants underwent biannual oral glucose tolerance tests.",
      "Longitudinal changes in IS, BCF, BMI, and fat mass were evaluated.",
      "Participants were stratified by baseline BCF (low/high), diabetes progression status (non-progressors [Non-p], progressors to prediabetes [PreDM-p], or",
      "T2D [T2D-p] over time), and degree of IS decline (large/small).",
      "Both T2D-p and PreDM-p showed greater IS decline than Non-p.",
      "At baseline, PreDM-p had IS comparable to T2D-p, but T2D-p declined more steeply.",
      "T2D-p and PreDM-p also had lower BCF at baseline, which remained low.",
      "Across baseline BCF groups (high/low), greater IS decline was consistently associated with higher risk of progression (all P<0.001).",
      "The effect size of IS decline exceeded that of BCF deterioration.",
      "Declining IS, independent of BCF, is associated with progression to T2D in lean Koreans.",
      "Preserving IS through lifestyle interventions is crucial for diabetes prevention, particularly in those with low BCF.",
      "Insulin resistance, β-cell function, disposition index, oral glucose tolerance test, body mass index."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41561040",
    "source": "pubmed",
    "sentences": [
      "Lenvatinib, a multi-kinase inhibitor widely used in the treatment of radioiodine-refractory differentiated thyroid carcinoma (RR-DTC), has shown remarkable efficacy and improvement in progression-free survival (PFS), although its use is associated with a variety of side effects.",
      "Among them, adrenal insufficiency (AI) remains under-recognized and potentially underestimated, and it may be involved in fatigue, one of the most frequent adverse events (AEs) Lenvatinib-related.",
      "In this prospective study, we report the incidence, development, and time course of primary AI (PAI) during Lenvatinib treatment in patients with RR-DTC followed at a single tertiary care center.",
      "The study was conducted on 39 consecutive patients with RR-DTC.",
      "Eight patients were excluded because they had a follow-up of less than 6 months or were receiving glucocorticoids for RR-DTC-related indications.",
      "We studied 31 patients selected for Lenvatinib therapy from June 2017 to December 2024.",
      "The median follow-up duration was 42.58 ± 29.53 months (range, 6-97 months).",
      "Performance status was evaluated for each patient using the Eastern Cooperative Oncology Group (ECOG) scale.",
      "Adrenal function was assessed by measuring serum cortisol and adrenocorticotropic hormone (ACTH) levels, and through the 250 μg ACTH stimulation test.",
      "Additionally, fatigue intensity was evaluated using the Common Terminology Criteria for Adverse Events (CTCAE) grading scale.",
      "Peak cortisol levels below 500 nmol/L (18.1 µg/dL) at 30 or 60 minutes after ACTH injection were indicative of adrenal insufficiency (AI) (PAI-18.1).",
      "A cutoff of 386.2 nmol/L (14 µg/dL) has also been used (PAI-14).",
      "In patients with primary adrenal insufficiency (PAI), steroid replacement therapy with cortisone acetate (CA) was initiated at doses ranging from 25 to 37.5 mg/day.",
      "Throughout follow-up, the ACTH stimulation test was repeated every 3 to 9 months, with a 72-hour discontinuation of CA prior to testing.",
      "During Lenvatinib treatment, 24 of 31 patients (77.4%) developed primary AI (PAI)-18.1, and 14 of 31 patients (45.2%) developed PAI-14.",
      "Patients with a cortisol peak below 646.6 nmol/L at the initial ACTH stimulation test, prior to starting Lenvatinib, demonstrated a higher risk of developing both PAI-18.1 and PAI-14 during treatment.",
      "Patients who developed PAI during Lenvatinib treatment had significantly lower cortisol peak levels on the initial ACTH stimulation test performed before treatment initiation compared to those who did not develop PAI.",
      "Fatigue was observed in 28 of 31 patients (90%) during Lenvatinib treatment.",
      "Among patients who developed PAI, a significant improvement in fatigue was observed following initiation of CA therapy.",
      "Our findings suggest a higher occurrence of PAI, which may contribute to fatigue associated with Lenvatinib treatment.",
      "Routine adrenal function testing and early recognition of PAI are essential for timely diagnosis and effective glucocorticoid replacement therapy, enabling patients to continue Lenvatinib treatment with improved tolerability and adherence."
    ],
    "summary_sentences": [
      "Lenvatinib, a multi-kinase inhibitor widely used in the treatment of radioiodine-refractory differentiated thyroid carcinoma (RR-DTC), has shown remarkable efficacy and improvement in progression-free survival (PFS), although its use is associated with a variety of side effects.",
      "Among them, adrenal insufficiency (AI) remains under-recognized and potentially underestimated, and it may be involved in fatigue, one of the most frequent adverse events (AEs) Lenvatinib-related.",
      "In this prospective study, we report the incidence, development, and time course of primary AI (PAI) during Lenvatinib treatment in patients with RR-DTC followed at a single tertiary care center.",
      "The study was conducted on 39 consecutive patients with RR-DTC.",
      "Eight patients were excluded because they had a follow-up of less than 6 months or were receiving glucocorticoids for RR-DTC-related indications.",
      "We studied 31 patients selected for Lenvatinib therapy from June 2017 to December 2024.",
      "The median follow-up duration was 42.58 ± 29.53 months (range, 6-97 months).",
      "Performance status was evaluated for each patient using the Eastern Cooperative Oncology Group (ECOG) scale.",
      "Adrenal function was assessed by measuring serum cortisol and adrenocorticotropic hormone (ACTH) levels, and through the 250 μg ACTH stimulation test.",
      "Additionally, fatigue intensity was evaluated using the Common Terminology Criteria for Adverse Events (CTCAE) grading scale.",
      "Peak cortisol levels below 500 nmol/L (18.1 µg/dL) at 30 or 60 minutes after ACTH injection were indicative of adrenal insufficiency (AI) (PAI-18.1).",
      "A cutoff of 386.2 nmol/L (14 µg/dL) has also been used (PAI-14).",
      "In patients with primary adrenal insufficiency (PAI), steroid replacement therapy with cortisone acetate (CA) was initiated at doses ranging from 25 to 37.5 mg/day.",
      "Throughout follow-up, the ACTH stimulation test was repeated every 3 to 9 months, with a 72-hour discontinuation of CA prior to testing.",
      "During Lenvatinib treatment, 24 of 31 patients (77.4%) developed primary AI (PAI)-18.1, and 14 of 31 patients (45.2%) developed PAI-14.",
      "Patients with a cortisol peak below 646.6 nmol/L at the initial ACTH stimulation test, prior to starting Lenvatinib, demonstrated a higher risk of developing both PAI-18.1 and PAI-14 during treatment.",
      "Patients who developed PAI during Lenvatinib treatment had significantly lower cortisol peak levels on the initial ACTH stimulation test performed before treatment initiation compared to those who did not develop PAI.",
      "Fatigue was observed in 28 of 31 patients (90%) during Lenvatinib treatment.",
      "Among patients who developed PAI, a significant improvement in fatigue was observed following initiation of CA therapy.",
      "Our findings suggest a higher occurrence of PAI, which may contribute to fatigue associated with Lenvatinib treatment.",
      "Routine adrenal function testing and early recognition of PAI are essential for timely diagnosis and effective glucocorticoid replacement therapy, enabling patients to continue Lenvatinib treatment with improved tolerability and adherence."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41559929",
    "source": "pubmed",
    "sentences": [
      "Eloralintide (LY3841136) is a potent, long-acting selective amylin receptor agonist currently under development for the treatment of obesity with once-weekly subcutaneous dosing.",
      "This 12-week Phase 1, randomised, placebo-controlled, participant- and investigator-blinded, multiple ascending dose study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamic profiles of eloralintide upon once-weekly subcutaneous dosing without dose escalation in participants with obesity or overweight.",
      "From 30 March 2022 to 25 January 2024, at three centres in the United States, 100 participants with a mean age of 44 years, 29% female participants, and mean body mass index of 32.6 kg/m",
      "Eloralintide once weekly was well tolerated with minimal gastrointestinal adverse events and resulted in clinically meaningful weight loss."
    ],
    "summary_sentences": [
      "Eloralintide (LY3841136) is a potent, long-acting selective amylin receptor agonist currently under development for the treatment of obesity with once-weekly subcutaneous dosing.",
      "This 12-week Phase 1, randomised, placebo-controlled, participant- and investigator-blinded, multiple ascending dose study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamic profiles of eloralintide upon once-weekly subcutaneous dosing without dose escalation in participants with obesity or overweight.",
      "From 30 March 2022 to 25 January 2024, at three centres in the United States, 100 participants with a mean age of 44 years, 29% female participants, and mean body mass index of 32.6 kg/m",
      "Eloralintide once weekly was well tolerated with minimal gastrointestinal adverse events and resulted in clinically meaningful weight loss."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41559825",
    "source": "pubmed",
    "sentences": [
      "Cardiometabolic diseases (CMDs) are the leading global cause of mortality, driven by interrelated metabolic and cardiovascular factors.",
      "Sex differences significantly shape risk.",
      "We investigated sex-specific differences in cardiometabolic risk factors through univariate analyses and multivariate principal component analysis (PCA), with the goal of identifying meaningful patterns and potential biomarkers to support tailored prevention strategies.",
      "A cross-sectional study was conducted on 1715 individuals (929F/786 M; 58.1 ± 13.5 years).",
      "Clinical and biochemical variables were compared by sex, including markers of metabolic, atherogenic cardiovascular, and renal risk.",
      "All parameters were measured using certified and standardized methods to ensure reproducibility.",
      "PCA was applied to explore underlying patterns of association.",
      "Correlation analyses revealed significant associations only between insulin resistance markers and atherogenic cardiovascular risk indices, suggesting largely independent effects of other parameters.",
      "In contrast, PCA identified coherent clusters: lipid/atherogenic markers, glycemic and insulin-resistance indices, and adiposity measures, while renal function emerged as a distinct domain.",
      "Sex differences were evident, with men displaying a less favorable cardiometabolic profile.",
      "PCA showed that in females, variance was mainly explained by triglyceride-related indices (TG, TG/HDL, AIP), adiposity measures, and blood pressure, whereas in males, lipid and atherogenic markers (TC, LDL, CRI indices, non-HDL, LCI) predominated, with adiposity and blood pressure forming separate clusters in both sexes.",
      "Lifestyle variables (smoking, alcohol consumption, fatigue) also modulated risk, whereas family history of diabetes and hypertension showed weak associations.",
      "Overall, cardiometabolic risk emerges as a multidimensional construct shaped by distinct yet overlapping biological and behavioral domains, with sex and lifestyle exerting specific influences, underscoring the need for individualized, sex-specific prevention strategies.",
      "The study protocol was registered in ClinicalTrials.gov (ID: NCT0642756)."
    ],
    "summary_sentences": [
      "Cardiometabolic diseases (CMDs) are the leading global cause of mortality, driven by interrelated metabolic and cardiovascular factors.",
      "Sex differences significantly shape risk.",
      "We investigated sex-specific differences in cardiometabolic risk factors through univariate analyses and multivariate principal component analysis (PCA), with the goal of identifying meaningful patterns and potential biomarkers to support tailored prevention strategies.",
      "A cross-sectional study was conducted on 1715 individuals (929F/786 M; 58.1 ± 13.5 years).",
      "Clinical and biochemical variables were compared by sex, including markers of metabolic, atherogenic cardiovascular, and renal risk.",
      "All parameters were measured using certified and standardized methods to ensure reproducibility.",
      "PCA was applied to explore underlying patterns of association.",
      "Correlation analyses revealed significant associations only between insulin resistance markers and atherogenic cardiovascular risk indices, suggesting largely independent effects of other parameters.",
      "In contrast, PCA identified coherent clusters: lipid/atherogenic markers, glycemic and insulin-resistance indices, and adiposity measures, while renal function emerged as a distinct domain.",
      "Sex differences were evident, with men displaying a less favorable cardiometabolic profile.",
      "PCA showed that in females, variance was mainly explained by triglyceride-related indices (TG, TG/HDL, AIP), adiposity measures, and blood pressure, whereas in males, lipid and atherogenic markers (TC, LDL, CRI indices, non-HDL, LCI) predominated, with adiposity and blood pressure forming separate clusters in both sexes.",
      "Lifestyle variables (smoking, alcohol consumption, fatigue) also modulated risk, whereas family history of diabetes and hypertension showed weak associations.",
      "Overall, cardiometabolic risk emerges as a multidimensional construct shaped by distinct yet overlapping biological and behavioral domains, with sex and lifestyle exerting specific influences, underscoring the need for individualized, sex-specific prevention strategies.",
      "The study protocol was registered in ClinicalTrials.gov (ID: NCT0642756)."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41559729",
    "source": "pubmed",
    "sentences": [
      "Women with a history of gestational diabetes mellitus (GDM) have a substantial 20-50% risk of developing diabetes postpartum.",
      "Understanding the precise mechanisms by which lifestyle interventions prevent diabetes is crucial for optimizing clinical care.",
      "This study aimed to quantify the extent to which weight change mediates the observed 46% reduction in postpartum diabetes risk achieved by an intensive lifestyle intervention in women with prior GDM.",
      "This secondary mediation analysis utilized data from the Tianjin GDM Prevention Program (NCT01554358), a large-scale, 4.5-year randomized controlled trial conducted in China.",
      "A total of 1180 women with a recent history of GDM diagnosed according to the 1999 WHO criteria (mean age 32.4 ± 3.50 years; mean BMI 23.9 ± 3.83 kg/m Weight reduction demonstrated a continuous, dose-dependent association with a lower incidence of postpartum diabetes, without evidence of a threshold effect.",
      "Overall, changes in weight indices mediated 13.0-18.8% of the intervention's protective effect.",
      "This mediation proportion was significantly higher among women who were overweight at baseline, accounting for 24.3-34.7% of the intervention's benefit.",
      "Within this overweight subgroup, changes in waist circumference and body fat individually accounted for over 30% of the total mediated effect.",
      "Weight loss is a quantifiable and clinically relevant, though partial, mechanism by which lifestyle intervention reduces postpartum diabetes risk, particularly in overweight women with a history of GDM.",
      "These findings underscore the importance of continuous monitoring and management of even modest weight changes as a key component of diabetes prevention strategies for this high-risk population.",
      "NCT01554358.",
      "Retrospectively registered clinical trial."
    ],
    "summary_sentences": [
      "Women with a history of gestational diabetes mellitus (GDM) have a substantial 20-50% risk of developing diabetes postpartum.",
      "Understanding the precise mechanisms by which lifestyle interventions prevent diabetes is crucial for optimizing clinical care.",
      "This study aimed to quantify the extent to which weight change mediates the observed 46% reduction in postpartum diabetes risk achieved by an intensive lifestyle intervention in women with prior GDM.",
      "This secondary mediation analysis utilized data from the Tianjin GDM Prevention Program (NCT01554358), a large-scale, 4.5-year randomized controlled trial conducted in China.",
      "A total of 1180 women with a recent history of GDM diagnosed according to the 1999 WHO criteria (mean age 32.4 ± 3.50 years; mean BMI 23.9 ± 3.83 kg/m Weight reduction demonstrated a continuous, dose-dependent association with a lower incidence of postpartum diabetes, without evidence of a threshold effect.",
      "Overall, changes in weight indices mediated 13.0-18.8% of the intervention's protective effect.",
      "This mediation proportion was significantly higher among women who were overweight at baseline, accounting for 24.3-34.7% of the intervention's benefit.",
      "Within this overweight subgroup, changes in waist circumference and body fat individually accounted for over 30% of the total mediated effect.",
      "Weight loss is a quantifiable and clinically relevant, though partial, mechanism by which lifestyle intervention reduces postpartum diabetes risk, particularly in overweight women with a history of GDM.",
      "These findings underscore the importance of continuous monitoring and management of even modest weight changes as a key component of diabetes prevention strategies for this high-risk population.",
      "NCT01554358.",
      "Retrospectively registered clinical trial."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41559701",
    "source": "pubmed",
    "sentences": [
      "This investigation employed a prospective observational design to examine pruritus, a common dermatological manifestation in type 2 diabetes mellitus (T2DM) patients that significantly impacts both physical health and psychological status.",
      "The primary aim was to elucidate potential risk factors contributing to pruritic symptoms in this patient population.",
      "We consecutively enrolled T2DM patients presenting to our endocrinology department from April to December 2023.",
      "Comprehensive data collection included demographic characteristics, pruritus symptom profiles, and standard biochemical parameters through structured questionnaires.",
      "Non-invasive cutaneous assessments measured transepidermal water loss (TEWL) and stratum corneum hydration (SCH).",
      "Flow cytometric analysis quantified Th1/Th2 cell populations, while serum concentrations of IL-4 and IFN-γ were determined via ELISA.",
      "Among 110 participants (26 non-pruritic, 84 pruritic), multivariate analysis identified several significant associations (P < 0.05).",
      "Key correlates included fasting plasma glucose (FPG), diabetes duration, presence of diabetic peripheral neuropathy (DPN) or nephropathy, hyperuricemia, IL-4 and IFN-γ levels, and SCH in both upper and lower limbs.",
      "Logistic regression showed that FPG, diabetes duration, presence of hyperuricemia, IL-4, and SCH measurements inl ower limbs were the risk factor of pruritus combined T2DM.",
      "In chronic pruritus cases, severe symptoms correlated with elevated FPG, increased DPN prevalence, and reduced lower limb SCH compared to milder cases (P < 0.05).",
      "Acute pruritus severity showed similar FPG associations, with additional significant SCH reductions in both extremities compared to moderate cases (P < 0.05).",
      "Our findings suggest that FPG, diabetes duration, presence of hyperuricemia, IL-4, and SCH measurements in lower limbs were the risk factor of pruritus combined T2DM.",
      "Chronic pruritus severity appears related to metabolic control, neurological involvement, immune inflammation and skin hydration, while acute cases primarily associate with metabolic, immune inflammation and skin hydration.",
      "The observed Th1/Th2 imbalance, with progressive ratio decline accompanying symptom worsening, potentially indicates type 2 inflammatory pathway activation in diabetic patients experiencing pruritus."
    ],
    "summary_sentences": [
      "This investigation employed a prospective observational design to examine pruritus, a common dermatological manifestation in type 2 diabetes mellitus (T2DM) patients that significantly impacts both physical health and psychological status.",
      "The primary aim was to elucidate potential risk factors contributing to pruritic symptoms in this patient population.",
      "We consecutively enrolled T2DM patients presenting to our endocrinology department from April to December 2023.",
      "Comprehensive data collection included demographic characteristics, pruritus symptom profiles, and standard biochemical parameters through structured questionnaires.",
      "Non-invasive cutaneous assessments measured transepidermal water loss (TEWL) and stratum corneum hydration (SCH).",
      "Flow cytometric analysis quantified Th1/Th2 cell populations, while serum concentrations of IL-4 and IFN-γ were determined via ELISA.",
      "Among 110 participants (26 non-pruritic, 84 pruritic), multivariate analysis identified several significant associations (P < 0.05).",
      "Key correlates included fasting plasma glucose (FPG), diabetes duration, presence of diabetic peripheral neuropathy (DPN) or nephropathy, hyperuricemia, IL-4 and IFN-γ levels, and SCH in both upper and lower limbs.",
      "Logistic regression showed that FPG, diabetes duration, presence of hyperuricemia, IL-4, and SCH measurements inl ower limbs were the risk factor of pruritus combined T2DM.",
      "In chronic pruritus cases, severe symptoms correlated with elevated FPG, increased DPN prevalence, and reduced lower limb SCH compared to milder cases (P < 0.05).",
      "Acute pruritus severity showed similar FPG associations, with additional significant SCH reductions in both extremities compared to moderate cases (P < 0.05).",
      "Our findings suggest that FPG, diabetes duration, presence of hyperuricemia, IL-4, and SCH measurements in lower limbs were the risk factor of pruritus combined T2DM.",
      "Chronic pruritus severity appears related to metabolic control, neurological involvement, immune inflammation and skin hydration, while acute cases primarily associate with metabolic, immune inflammation and skin hydration.",
      "The observed Th1/Th2 imbalance, with progressive ratio decline accompanying symptom worsening, potentially indicates type 2 inflammatory pathway activation in diabetic patients experiencing pruritus."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41558753",
    "source": "pubmed",
    "sentences": [
      "The increasing incidence of type 2 diabetes mellitus (T2DM) among women of reproductive age poses significant health risks for both mothers and their fetuses.",
      "Optimising blood glucose levels during pregnancy is particularly challenging, even with a combination of oral antidiabetic agents and insulin therapy.",
      "Hydroxychloroquine (HCQ) has been shown to lower glucose levels in non-pregnant populations and has demonstrated safety in pregnant women with systemic lupus erythematosus and rheumatoid diseases.",
      "In addition to its glucose-lowering effects, HCQ also exhibits immunomodulatory, antioxidant and anti-inflammatory properties.",
      "Given that both T2DM and pregnancy are pro-inflammatory states, inadequate glycaemic control may exacerbate adverse pregnancy outcomes.",
      "We hypothesise that adjunctive treatment with HCQ in this cohort could improve glycaemic control, reduce systemic inflammation and subsequently lower the risk of adverse pregnancy outcomes.",
      "This is a prospective, open-label, randomised controlled trial involving 56 pregnant women diagnosed with T2DM.",
      "Participants will be randomly allocated, using computerised randomisation software, into either a control group receiving standard care or an intervention group receiving standard care with HCQ 200 mg daily.",
      "The primary outcomes will be the difference in glycaemic parameters and inflammatory markers.",
      "Secondary outcomes include the assessment of pregnancy outcomes between the groups, such as gestational age at delivery, postpartum haemorrhage, fetal macrosomia and shoulder dystocia.",
      "This protocol has been approved by the National University of Malaysia Ethics Committee (JEP-2023-866).",
      "Study findings will be disseminated via presentations at academic conferences, publications in peer-reviewed journals and professional training and meetings to healthcare professionals.",
      "This study was registered in ClinicalTrials.gov (NCT06319560) on 23 January 2024."
    ],
    "summary_sentences": [
      "The increasing incidence of type 2 diabetes mellitus (T2DM) among women of reproductive age poses significant health risks for both mothers and their fetuses.",
      "Optimising blood glucose levels during pregnancy is particularly challenging, even with a combination of oral antidiabetic agents and insulin therapy.",
      "Hydroxychloroquine (HCQ) has been shown to lower glucose levels in non-pregnant populations and has demonstrated safety in pregnant women with systemic lupus erythematosus and rheumatoid diseases.",
      "In addition to its glucose-lowering effects, HCQ also exhibits immunomodulatory, antioxidant and anti-inflammatory properties.",
      "Given that both T2DM and pregnancy are pro-inflammatory states, inadequate glycaemic control may exacerbate adverse pregnancy outcomes.",
      "We hypothesise that adjunctive treatment with HCQ in this cohort could improve glycaemic control, reduce systemic inflammation and subsequently lower the risk of adverse pregnancy outcomes.",
      "This is a prospective, open-label, randomised controlled trial involving 56 pregnant women diagnosed with T2DM.",
      "Participants will be randomly allocated, using computerised randomisation software, into either a control group receiving standard care or an intervention group receiving standard care with HCQ 200 mg daily.",
      "The primary outcomes will be the difference in glycaemic parameters and inflammatory markers.",
      "Secondary outcomes include the assessment of pregnancy outcomes between the groups, such as gestational age at delivery, postpartum haemorrhage, fetal macrosomia and shoulder dystocia.",
      "This protocol has been approved by the National University of Malaysia Ethics Committee (JEP-2023-866).",
      "Study findings will be disseminated via presentations at academic conferences, publications in peer-reviewed journals and professional training and meetings to healthcare professionals.",
      "This study was registered in ClinicalTrials.gov (NCT06319560) on 23 January 2024."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41558509",
    "source": "pubmed",
    "sentences": [
      "Previous studies suggest that children from lower socioeconomic status may be at higher risk of unhealthy eating.",
      "This study aims to examine the cumulative socioeconomic vulnerabilities and their association with dietary patterns and obesity levels in European children.",
      "A total of 9664 parent-child dyads (79% mothers; 50.8% girls) from six European countries participated in the study.",
      "Families provided baseline information on energy balance-related behaviours and socioeconomic factors through questionnaires.",
      "Children's dietary habits were evaluated using semi-quantitative food frequency questionnaires, and anthropometric data were collected.",
      "Vulnerabilities were quantified through a composition of variables based on household income, parental education and employment.",
      "Multivariable and logistic regression analyses were performed.",
      "The study found significant associations between socioeconomic vulnerability and children's dietary habits and body mass index.",
      "Higher vulnerability was linked to a lower probability of fruit and vegetable intake, and a higher probability of consuming red meat, and energy-dense snacks.",
      "Children with the highest vulnerability had nearly four times higher odds of overweight/obesity (OR = 3.82, 95% CI: 3.05-4.76).",
      "The findings of this study indicate that European children from families with a high socioeconomic vulnerability tend to have an unhealthy dietary profile and a higher degree of obesity.",
      "Therefore, public health programs should prioritise families facing high socioeconomic vulnerabilities promoting healthy eating to prevent childhood obesity at early stages.",
      "Clinical trials registry http://clinicaltrials.gov: NCT02393872."
    ],
    "summary_sentences": [
      "Previous studies suggest that children from lower socioeconomic status may be at higher risk of unhealthy eating.",
      "This study aims to examine the cumulative socioeconomic vulnerabilities and their association with dietary patterns and obesity levels in European children.",
      "A total of 9664 parent-child dyads (79% mothers; 50.8% girls) from six European countries participated in the study.",
      "Families provided baseline information on energy balance-related behaviours and socioeconomic factors through questionnaires.",
      "Children's dietary habits were evaluated using semi-quantitative food frequency questionnaires, and anthropometric data were collected.",
      "Vulnerabilities were quantified through a composition of variables based on household income, parental education and employment.",
      "Multivariable and logistic regression analyses were performed.",
      "The study found significant associations between socioeconomic vulnerability and children's dietary habits and body mass index.",
      "Higher vulnerability was linked to a lower probability of fruit and vegetable intake, and a higher probability of consuming red meat, and energy-dense snacks.",
      "Children with the highest vulnerability had nearly four times higher odds of overweight/obesity (OR = 3.82, 95% CI: 3.05-4.76).",
      "The findings of this study indicate that European children from families with a high socioeconomic vulnerability tend to have an unhealthy dietary profile and a higher degree of obesity.",
      "Therefore, public health programs should prioritise families facing high socioeconomic vulnerabilities promoting healthy eating to prevent childhood obesity at early stages.",
      "Clinical trials registry http://clinicaltrials.gov: NCT02393872."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41557987",
    "source": "pubmed",
    "sentences": [
      "To address previous inconsistencies in reports of differential adherence to diabetes medications, we examined medication adherence and evaluated treatment group differences in a substudy of participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).",
      "GRADE participants (type 2 diabetes duration <10 years, HbA1c 6.8%-8.5%, on metformin alone) were randomly assigned to add insulin glargine, glimepiride, liraglutide, or sitagliptin.",
      "Adherence was measured semiannually for 3 years using a validated three-item scale (0-100, lowest to highest adherence) in a substudy (N = 1,739).",
      "Analyses included evaluation of adherence over time and testing treatment group differences in adherence and in the association between adherence and primary (HbA1c ≥7.0%) and secondary (HbA1c >7.5%) glycemic outcomes.",
      "Overall mean ± SD adherence (average of participant-level mean ± SD) was high over 3 years of follow-up at 88.7 ± 10.01, on a scale of 0-100, and decreased slightly by 3 years relative to baseline (-2.0 ± 14.7; P < 0.0001).",
      "No intergroup differences were observed until 3 years, when adherence was 5% and 3% higher for the glimepiride and sitagliptin groups, respectively, than for liraglutide (both P < 0.05).",
      "Over follow-up and across groups, a 10-point decrease in adherence was associated with 15% and 19% increased risk of reaching primary (HbA1c ≥7.0%) and secondary (HbA1c >7.5%) glycemic outcomes (both P < 0.0001).",
      "Lower adherence was somewhat more predictive of the secondary outcome for those assigned to glargine or liraglutide, compared with glimepiride or sitagliptin (each P < 0.05).",
      "No other comparisons were significant.",
      "Medication adherence was consistently high in GRADE.",
      "Observed treatment group differences were small and of unclear clinical significance.",
      "Overall, lower adherence robustly predicted worsening glycemic control, highlighting the importance of ongoing assessment."
    ],
    "summary_sentences": [
      "To address previous inconsistencies in reports of differential adherence to diabetes medications, we examined medication adherence and evaluated treatment group differences in a substudy of participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).",
      "GRADE participants (type 2 diabetes duration <10 years, HbA1c 6.8%-8.5%, on metformin alone) were randomly assigned to add insulin glargine, glimepiride, liraglutide, or sitagliptin.",
      "Adherence was measured semiannually for 3 years using a validated three-item scale (0-100, lowest to highest adherence) in a substudy (N = 1,739).",
      "Analyses included evaluation of adherence over time and testing treatment group differences in adherence and in the association between adherence and primary (HbA1c ≥7.0%) and secondary (HbA1c >7.5%) glycemic outcomes.",
      "Overall mean ± SD adherence (average of participant-level mean ± SD) was high over 3 years of follow-up at 88.7 ± 10.01, on a scale of 0-100, and decreased slightly by 3 years relative to baseline (-2.0 ± 14.7; P < 0.0001).",
      "No intergroup differences were observed until 3 years, when adherence was 5% and 3% higher for the glimepiride and sitagliptin groups, respectively, than for liraglutide (both P < 0.05).",
      "Over follow-up and across groups, a 10-point decrease in adherence was associated with 15% and 19% increased risk of reaching primary (HbA1c ≥7.0%) and secondary (HbA1c >7.5%) glycemic outcomes (both P < 0.0001).",
      "Lower adherence was somewhat more predictive of the secondary outcome for those assigned to glargine or liraglutide, compared with glimepiride or sitagliptin (each P < 0.05).",
      "No other comparisons were significant.",
      "Medication adherence was consistently high in GRADE.",
      "Observed treatment group differences were small and of unclear clinical significance.",
      "Overall, lower adherence robustly predicted worsening glycemic control, highlighting the importance of ongoing assessment."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41557360",
    "source": "pubmed",
    "sentences": [
      "No randomized clinical trial has directly compared the effectiveness of sodium-glucose cotransporter-2 inhibitor (SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment in reducing acute and chronic kidney outcomes.",
      "To examine the comparative effectiveness of SGLT2i and GLP-1RA treatment for acute and chronic kidney outcomes in individuals with type 2 diabetes.",
      "This comparative effectiveness study with a target trial emulation design used nationwide, population-based data from Denmark.",
      "Participants were individuals with metformin-treated type 2 diabetes who initiated SGLT2i or GLP-1RA treatment from January 2014 to November 2020, with follow-up through October 2024.",
      "Initiation of an SGLT2i or a GLP-1RA.",
      "The 2 coprimary outcomes were chronic kidney disease (CKD; 40% reduction in estimated glomerular filtration rate [eGFR], severe albuminuria, or kidney failure) and acute kidney injury (AKI).",
      "Secondary outcomes included the individual components of CKD, albuminuria, and death.",
      "Intention-to-treat effects were estimated using inverse probability of treatment weights, comparing risks for CKD assessed by the Aalen-Johansen estimator, and AKI burden by mean cumulative counts (MCCs; mean number of events per individual as multiple AKI events were possible).",
      "Subgroup analyses included stratification by preexisting cardiovascular or kidney disease.",
      "The study included 36 279 individuals who initiated an SGLT2i and 18 782 who initiated a GLP-1RA (median [IQR] age, 63",
      "[55-71] years vs 61",
      "[52-70] years), with comparable diabetes duration, eGFR, and urine albumin-creatinine ratios.",
      "The weighted 5-year risk of CKD was 6.7% (95% CI, 6.4%-7.0%) for SGLT2i initiators and 8.2% (95% CI, 7.8%-8.6%) for GLP-1RA initiators (risk ratio: 0.81",
      "[95% CI, 0.76-0.87]; risk difference: -1.5%",
      "[95% CI, -2.0% to -1.0%]).",
      "The 5-year MCC of AKI per 100 individuals was 25.2 (95% CI, 24.4-26.1) for SGLT2i initiators and 28.7 (95% CI, 27.4-30.0) for GLP-1RA initiators (MCC ratio: 0.88",
      "[95% CI, 0.83-0.93]; MCC difference: -3.5",
      "[95% CI, -5.0 to -2.0]).",
      "In contrast, the secondary outcomes of albuminuria and mortality were slightly reduced in GLP-1RA initiators.",
      "Results were consistent across subgroups, with the most pronounced CKD and AKI reductions with SGLT2i observed among individuals without preexisting kidney disease.",
      "This comparative effectiveness study found that initiation of SGLT2i vs GLP-1RA treatment in individuals with type 2 diabetes was associated with a lower 5-year risk of CKD and a lower 5-year count of AKI.",
      "These findings underscore the potential of SGLT2i treatment for primary prevention of kidney disease in individuals with type 2 diabetes."
    ],
    "summary_sentences": [
      "No randomized clinical trial has directly compared the effectiveness of sodium-glucose cotransporter-2 inhibitor (SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment in reducing acute and chronic kidney outcomes.",
      "To examine the comparative effectiveness of SGLT2i and GLP-1RA treatment for acute and chronic kidney outcomes in individuals with type 2 diabetes.",
      "This comparative effectiveness study with a target trial emulation design used nationwide, population-based data from Denmark.",
      "Participants were individuals with metformin-treated type 2 diabetes who initiated SGLT2i or GLP-1RA treatment from January 2014 to November 2020, with follow-up through October 2024.",
      "Initiation of an SGLT2i or a GLP-1RA.",
      "The 2 coprimary outcomes were chronic kidney disease (CKD; 40% reduction in estimated glomerular filtration rate [eGFR], severe albuminuria, or kidney failure) and acute kidney injury (AKI).",
      "Secondary outcomes included the individual components of CKD, albuminuria, and death.",
      "Intention-to-treat effects were estimated using inverse probability of treatment weights, comparing risks for CKD assessed by the Aalen-Johansen estimator, and AKI burden by mean cumulative counts (MCCs; mean number of events per individual as multiple AKI events were possible).",
      "Subgroup analyses included stratification by preexisting cardiovascular or kidney disease.",
      "The study included 36 279 individuals who initiated an SGLT2i and 18 782 who initiated a GLP-1RA (median [IQR] age, 63",
      "[55-71] years vs 61",
      "[52-70] years), with comparable diabetes duration, eGFR, and urine albumin-creatinine ratios.",
      "The weighted 5-year risk of CKD was 6.7% (95% CI, 6.4%-7.0%) for SGLT2i initiators and 8.2% (95% CI, 7.8%-8.6%) for GLP-1RA initiators (risk ratio: 0.81",
      "[95% CI, 0.76-0.87]; risk difference: -1.5%",
      "[95% CI, -2.0% to -1.0%]).",
      "The 5-year MCC of AKI per 100 individuals was 25.2 (95% CI, 24.4-26.1) for SGLT2i initiators and 28.7 (95% CI, 27.4-30.0) for GLP-1RA initiators (MCC ratio: 0.88",
      "[95% CI, 0.83-0.93]; MCC difference: -3.5",
      "[95% CI, -5.0 to -2.0]).",
      "In contrast, the secondary outcomes of albuminuria and mortality were slightly reduced in GLP-1RA initiators.",
      "Results were consistent across subgroups, with the most pronounced CKD and AKI reductions with SGLT2i observed among individuals without preexisting kidney disease.",
      "This comparative effectiveness study found that initiation of SGLT2i vs GLP-1RA treatment in individuals with type 2 diabetes was associated with a lower 5-year risk of CKD and a lower 5-year count of AKI.",
      "These findings underscore the potential of SGLT2i treatment for primary prevention of kidney disease in individuals with type 2 diabetes."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41555833",
    "source": "pubmed",
    "sentences": [
      "The effective target for systolic blood pressure (SBP) control in patients with diabetes was inconsistent.",
      "We evaluated the emulated effect of maintaining SBP below clinical thresholds on the risk of cardiovascular disease (CVD) and all-cause mortality.",
      "This study included 4264 patients with type 2 diabetes from the Kailaun study.",
      "We implemented the parametric g-formula to simulate the hypothetical interventions on reducing SBP below 140, 130 and 120 mmHg over time, accounting for time-varying confounding, reporting risk ratio (RR) and number needed to treat (NNT) for 10-year risk of CVD and all-cause mortality.",
      "Maintaining SBP below 140, 130 and 120 mmHg was associated with an 18%, 24%, and 31% relative risk reduction in the risk of CVD, with the RR (95% confidence interval",
      "[CI]) of 0.82 (0.75-0.88), 0.76 (0.69-0.86), and 0.69 (0.58-0.84), and the NNT of 32, 24, and 19, respectively, compared to no intervention.",
      "However, the benefits in reducing the risk of all-cause mortality did not reach a significant level with maintaining SBP below 140 and 130 mmHg, with the RR (95% CI) of 0.98 (0.93-1.06) and 1.04 (0.95-1.12), respectively.",
      "The risk of all-cause mortality significantly increased 15% with maintaining SBP ≤120 mmHg (RR, 1.15; 95% CI, 1.02-1.32).",
      "Subgroup analyses showed that maintaining SBP ≤120 mmHg tended to bring more harms than benefits in patients aged ≥60 years or without antihypertensive agents.",
      "Among Chinese patients with type 2 diabetes, maintaining SBP ≤120 mmHg may not be an optimal target, in terms of the risk-benefit association of CVD and all-cause mortality."
    ],
    "summary_sentences": [
      "The effective target for systolic blood pressure (SBP) control in patients with diabetes was inconsistent.",
      "We evaluated the emulated effect of maintaining SBP below clinical thresholds on the risk of cardiovascular disease (CVD) and all-cause mortality.",
      "This study included 4264 patients with type 2 diabetes from the Kailaun study.",
      "We implemented the parametric g-formula to simulate the hypothetical interventions on reducing SBP below 140, 130 and 120 mmHg over time, accounting for time-varying confounding, reporting risk ratio (RR) and number needed to treat (NNT) for 10-year risk of CVD and all-cause mortality.",
      "Maintaining SBP below 140, 130 and 120 mmHg was associated with an 18%, 24%, and 31% relative risk reduction in the risk of CVD, with the RR (95% confidence interval",
      "[CI]) of 0.82 (0.75-0.88), 0.76 (0.69-0.86), and 0.69 (0.58-0.84), and the NNT of 32, 24, and 19, respectively, compared to no intervention.",
      "However, the benefits in reducing the risk of all-cause mortality did not reach a significant level with maintaining SBP below 140 and 130 mmHg, with the RR (95% CI) of 0.98 (0.93-1.06) and 1.04 (0.95-1.12), respectively.",
      "The risk of all-cause mortality significantly increased 15% with maintaining SBP ≤120 mmHg (RR, 1.15; 95% CI, 1.02-1.32).",
      "Subgroup analyses showed that maintaining SBP ≤120 mmHg tended to bring more harms than benefits in patients aged ≥60 years or without antihypertensive agents.",
      "Among Chinese patients with type 2 diabetes, maintaining SBP ≤120 mmHg may not be an optimal target, in terms of the risk-benefit association of CVD and all-cause mortality."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41554550",
    "source": "pubmed",
    "sentences": [
      "Insulin resistance is associated with increased platelet reactivity.",
      "We sought to investigate the effects of insulin resistance on dual antiplatelet therapy in We conducted a post hoc analysis of the Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events II (CHANCE-2) trial, in which we randomized patients with minor stroke or TIA who carried Among 4954 patients included, 3122 (63.0%) had high insulin resistance and 1832 (37.0%) had low insulin resistance.",
      "Compared with clopidogrel-ASA, ticagrelor-ASA reduced the risk of recurrent stroke in the low-insulin resistance group (71 [7.8%] v. 36",
      "[3.9%]; hazard ratio [HR] 0.52, 95% confidence interval",
      "[CI] 0.34 to 0.79), but not in the high-insulin resistance group (120 [7.7%] v. 120",
      "[7.7%]; HR 0.96, 95% CI 0.74 to 1.24) ( In ClinicalTrials.gov, NCT04078737."
    ],
    "summary_sentences": [
      "Insulin resistance is associated with increased platelet reactivity.",
      "We sought to investigate the effects of insulin resistance on dual antiplatelet therapy in We conducted a post hoc analysis of the Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events II (CHANCE-2) trial, in which we randomized patients with minor stroke or TIA who carried Among 4954 patients included, 3122 (63.0%) had high insulin resistance and 1832 (37.0%) had low insulin resistance.",
      "Compared with clopidogrel-ASA, ticagrelor-ASA reduced the risk of recurrent stroke in the low-insulin resistance group (71 [7.8%] v. 36",
      "[3.9%]; hazard ratio [HR] 0.52, 95% confidence interval",
      "[CI] 0.34 to 0.79), but not in the high-insulin resistance group (120 [7.7%] v. 120",
      "[7.7%]; HR 0.96, 95% CI 0.74 to 1.24) ( In ClinicalTrials.gov, NCT04078737."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41553852",
    "source": "pubmed",
    "sentences": [
      "Chronic obstructive pulmonary disease (COPD) is a leading global health burden, with high prevalence of comorbidities (e.g., hypertension and diabetes) that further increase healthcare utilization and mortality.",
      "Integrated care is proposed as a potential management strategy for COPD patients with comorbidities, but its overall effects remain unclear due to inconsistent evidence from prior studies.",
      "To systematically evaluate the effects of integrated care on key health outcomes in patients with COPD and at least one comorbidity.",
      "Systematic review and meta-analysis.",
      "Databases including MEDLINE, EMBASE, CENTRAL, CINAHL, and ClinicalTrial.gov were searched.",
      "Eligible studies were randomized controlled trials (RCTs) evaluating integrated care in patients with COPD and comorbidities.",
      "Two independent reviewers conducted study screening, data extraction, and quality assessment.",
      "Effects of integrated care were assessed using a random-effects model.",
      "Seven RCTs from high-income countries were included.",
      "Common integrated care components were health education, self-management support, and (in two studies) telemonitoring.",
      "Meta-analysis showed that integrated care significantly reduced the number of COPD exacerbations and all-cause hospitalizations.",
      "No significant effects were observed for all-cause emergency visits or CAT scores.",
      "Integrated care effectively reduces COPD exacerbations and all-cause hospitalizations in patients with COPD and comorbidities, supporting its clinical value.",
      "However, high heterogeneity across studies, limited generalizability to non-high-income countries (e.g., China), and lack of impact on patient-reported outcomes (CAT scores) highlight the need for further localized research.",
      "Registered with PROSPERO, Registration ID: CRD420251170533."
    ],
    "summary_sentences": [
      "Chronic obstructive pulmonary disease (COPD) is a leading global health burden, with high prevalence of comorbidities (e.g., hypertension and diabetes) that further increase healthcare utilization and mortality.",
      "Integrated care is proposed as a potential management strategy for COPD patients with comorbidities, but its overall effects remain unclear due to inconsistent evidence from prior studies.",
      "To systematically evaluate the effects of integrated care on key health outcomes in patients with COPD and at least one comorbidity.",
      "Systematic review and meta-analysis.",
      "Databases including MEDLINE, EMBASE, CENTRAL, CINAHL, and ClinicalTrial.gov were searched.",
      "Eligible studies were randomized controlled trials (RCTs) evaluating integrated care in patients with COPD and comorbidities.",
      "Two independent reviewers conducted study screening, data extraction, and quality assessment.",
      "Effects of integrated care were assessed using a random-effects model.",
      "Seven RCTs from high-income countries were included.",
      "Common integrated care components were health education, self-management support, and (in two studies) telemonitoring.",
      "Meta-analysis showed that integrated care significantly reduced the number of COPD exacerbations and all-cause hospitalizations.",
      "No significant effects were observed for all-cause emergency visits or CAT scores.",
      "Integrated care effectively reduces COPD exacerbations and all-cause hospitalizations in patients with COPD and comorbidities, supporting its clinical value.",
      "However, high heterogeneity across studies, limited generalizability to non-high-income countries (e.g., China), and lack of impact on patient-reported outcomes (CAT scores) highlight the need for further localized research.",
      "Registered with PROSPERO, Registration ID: CRD420251170533."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41553774",
    "source": "pubmed",
    "sentences": [
      "No medications are currently approved for the prevention of recurrent acute pancreatitis.",
      "This trial evaluated whether naldemedine, a peripherally acting μ-opioid receptor antagonist, reduces the risk of acute pancreatitis in patients with recurrent acute pancreatitis.",
      "This was a multicentre, double-blinded, placebo-controlled randomised trial conducted at four Danish pancreatitis referral centres.",
      "Participants aged 18-75 years with recurrent acute pancreatitis, both with and without a diagnosis of chronic pancreatitis, were randomised to receive naldemedine 0.2 mg or a matching placebo daily for up to 12 months.",
      "The primary outcome was acute pancreatitis recurrence, defined by the revised Atlanta Criteria.",
      "Secondary outcomes included pain flares, gastrointestinal symptoms, and quality of life.",
      "At the end of follow-up, the participant's global impression of change, safety and tolerability outcomes, new-onset diabetes and pancreatic exocrine insufficiency were assessed.",
      "74 participants (mean age: 46 years; 41% female) were randomised to naldemedine (n = 36) or placebo (n = 38).",
      "During a median follow-up time of 365 days (IQR, 352-370), participants in the naldemedine group had a numerically lower risk of acute pancreatitis compared to placebo (HR 0.54; 95% CI, 0.29-1.01; p = 0.05).",
      "No differences were observed between the groups for secondary efficacy, safety, and tolerability outcomes.",
      "Participants treated with naldemedine for at least 1 year had a lower risk of acute pancreatitis (HR 0.49; 95% CI, 0.24-0.97; p = 0.04).",
      "Treatment with naldemedine was safe and well-tolerated and may reduce the risk of recurrent acute pancreatitis.",
      "A larger confirmatory trial is needed to verify these findings.",
      "ClinicalTrials.gov",
      "Identifier: PAMORA-RAP: NCT04966559."
    ],
    "summary_sentences": [
      "No medications are currently approved for the prevention of recurrent acute pancreatitis.",
      "This trial evaluated whether naldemedine, a peripherally acting μ-opioid receptor antagonist, reduces the risk of acute pancreatitis in patients with recurrent acute pancreatitis.",
      "This was a multicentre, double-blinded, placebo-controlled randomised trial conducted at four Danish pancreatitis referral centres.",
      "Participants aged 18-75 years with recurrent acute pancreatitis, both with and without a diagnosis of chronic pancreatitis, were randomised to receive naldemedine 0.2 mg or a matching placebo daily for up to 12 months.",
      "The primary outcome was acute pancreatitis recurrence, defined by the revised Atlanta Criteria.",
      "Secondary outcomes included pain flares, gastrointestinal symptoms, and quality of life.",
      "At the end of follow-up, the participant's global impression of change, safety and tolerability outcomes, new-onset diabetes and pancreatic exocrine insufficiency were assessed.",
      "74 participants (mean age: 46 years; 41% female) were randomised to naldemedine (n = 36) or placebo (n = 38).",
      "During a median follow-up time of 365 days (IQR, 352-370), participants in the naldemedine group had a numerically lower risk of acute pancreatitis compared to placebo (HR 0.54; 95% CI, 0.29-1.01; p = 0.05).",
      "No differences were observed between the groups for secondary efficacy, safety, and tolerability outcomes.",
      "Participants treated with naldemedine for at least 1 year had a lower risk of acute pancreatitis (HR 0.49; 95% CI, 0.24-0.97; p = 0.04).",
      "Treatment with naldemedine was safe and well-tolerated and may reduce the risk of recurrent acute pancreatitis.",
      "A larger confirmatory trial is needed to verify these findings.",
      "ClinicalTrials.gov",
      "Identifier: PAMORA-RAP: NCT04966559."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41553750",
    "source": "pubmed",
    "sentences": [
      "It is estimated that type 2 diabetes (T2D) impacts an estimated 5.3 million Canadians, despite the condition being largely preventable.",
      "Laboratory-based diabetes prevention programs (DPPs) have limited effectiveness when translated into community settings due to their low-quality delivery and inability to reach people in the community most in need.",
      "To date, no community-based DPPs have been implemented nationwide across Canada.",
      "Small Steps for Big Changes (SSBC) is a diet and physical activity counseling intervention that significantly reduces the risk of developing T2D and has been designed for feasible delivery by community-dwelling peers.",
      "To ensure maximum public health impact, SSBC must be optimally implemented, demonstrate effectiveness for diverse groups, and be sustainable over time.",
      "This project aims to adapt SSBC and evaluate the implementation, effectiveness, and sustainability of SSBC in diverse urban communities across Canada.",
      "A hybrid type 2 implementation-effectiveness study design using multiple and mixed methods will be used to evaluate the implementation and effectiveness of SSBC over 6 years in partnership with 11 regional Young Men's Christian Associations across 8 provinces in Canada.",
      "Beginning in 2024, we will (1) adapt and implement SSBC in diverse urban cities across Canada; (2) examine the implementation (including implementation strategies), effectiveness, and cost-effectiveness of SSBC (2024-2028); and (3) determine the sustainability of SSBC at each delivery location (2028-2029).",
      "Data will be collected from SSBC clients, coaches, site leads, and senior leadership municipality partners.",
      "The project will be overseen by an advisory group and 3 committees focused on sex, gender, and inclusivity; program evaluation; and diabetes prevention engagement.",
      "This study has received ethical approval from the University of British Columbia Clinical Research Ethics Board (H23-01930).",
      "Funding for this project began in October 2022, and Institutional Review Board approval was obtained in October 2023.",
      "Program implementation within each region is occurring in a phased approach, with partners beginning program delivery in one site (2024-2025) before expanding to any additional locations (2025-2027).",
      "Program enrollment occurs continuously during the implementation phase across all sites.",
      "From 2024-2025, a total of 13 delivery sites began program delivery, 722 participants have enrolled in the program, and 406 have begun the program (153/342, 44.7% non-Western or Eastern European; 80/345, 23.2% men or 82/347, 23.6% male).",
      "An additional 13 sites have confirmed they will launch the program in 2026.",
      "This study will demonstrate that SSBC can be scaled up nationwide to effectively and equitably reduce the Canadian population-level risk of T2D.",
      "This work will determine best practice implementation determinants, outcomes, and strategies critical for sustaining DPP implementation across Canada and beyond.",
      "Project findings will be shared with municipality partners and will be copresented with partners and SSBC clients to community organizations, local interested parties, and academics.",
      "ClinicalTrials.gov",
      "NCT06440395; https://clinicaltrials.gov/study/NCT06440395.",
      "DERR1-10.2196/80276."
    ],
    "summary_sentences": [
      "It is estimated that type 2 diabetes (T2D) impacts an estimated 5.3 million Canadians, despite the condition being largely preventable.",
      "Laboratory-based diabetes prevention programs (DPPs) have limited effectiveness when translated into community settings due to their low-quality delivery and inability to reach people in the community most in need.",
      "To date, no community-based DPPs have been implemented nationwide across Canada.",
      "Small Steps for Big Changes (SSBC) is a diet and physical activity counseling intervention that significantly reduces the risk of developing T2D and has been designed for feasible delivery by community-dwelling peers.",
      "To ensure maximum public health impact, SSBC must be optimally implemented, demonstrate effectiveness for diverse groups, and be sustainable over time.",
      "This project aims to adapt SSBC and evaluate the implementation, effectiveness, and sustainability of SSBC in diverse urban communities across Canada.",
      "A hybrid type 2 implementation-effectiveness study design using multiple and mixed methods will be used to evaluate the implementation and effectiveness of SSBC over 6 years in partnership with 11 regional Young Men's Christian Associations across 8 provinces in Canada.",
      "Beginning in 2024, we will (1) adapt and implement SSBC in diverse urban cities across Canada; (2) examine the implementation (including implementation strategies), effectiveness, and cost-effectiveness of SSBC (2024-2028); and (3) determine the sustainability of SSBC at each delivery location (2028-2029).",
      "Data will be collected from SSBC clients, coaches, site leads, and senior leadership municipality partners.",
      "The project will be overseen by an advisory group and 3 committees focused on sex, gender, and inclusivity; program evaluation; and diabetes prevention engagement.",
      "This study has received ethical approval from the University of British Columbia Clinical Research Ethics Board (H23-01930).",
      "Funding for this project began in October 2022, and Institutional Review Board approval was obtained in October 2023.",
      "Program implementation within each region is occurring in a phased approach, with partners beginning program delivery in one site (2024-2025) before expanding to any additional locations (2025-2027).",
      "Program enrollment occurs continuously during the implementation phase across all sites.",
      "From 2024-2025, a total of 13 delivery sites began program delivery, 722 participants have enrolled in the program, and 406 have begun the program (153/342, 44.7% non-Western or Eastern European; 80/345, 23.2% men or 82/347, 23.6% male).",
      "An additional 13 sites have confirmed they will launch the program in 2026.",
      "This study will demonstrate that SSBC can be scaled up nationwide to effectively and equitably reduce the Canadian population-level risk of T2D.",
      "This work will determine best practice implementation determinants, outcomes, and strategies critical for sustaining DPP implementation across Canada and beyond.",
      "Project findings will be shared with municipality partners and will be copresented with partners and SSBC clients to community organizations, local interested parties, and academics.",
      "ClinicalTrials.gov",
      "NCT06440395; https://clinicaltrials.gov/study/NCT06440395.",
      "DERR1-10.2196/80276."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41553512",
    "source": "pubmed",
    "sentences": [
      "Heart failure (HF) patients with concomitant coronary artery disease (CAD) and type 2 diabetes mellitus (DM) represent a particularly high-risk population with increased morbidity and mortality.",
      "Acute coronary syndrome (ACS) often serves as a critical event that can trigger optimization of guideline-directed medical therapy (GDMT).",
      "However, the impact of ACS on long-term adherence patterns and outcomes in this population remains unclear.",
      "We retrospectively studied 431 patients with HF (LVEF ≤ 40%), CAD, and DM presenting with ACS between 2019 and 2022.",
      "Adherence to nine evidence-based therapies was scored (0-9) and classified as poor (0-3), intermediate (4-6), or good (7-9).",
      "Adherence was assessed before ACS and over 36 months of follow-up.",
      "Primary outcomes were rehospitalization and all-cause mortality, analyzed using Cox regression and Kaplan-Meier methods.",
      "Mean age was 62.1 ± 10.2 years, and 64.7% were male.",
      "Before ACS, 45.9% had poor adherence and only 16.0% had good adherence.",
      "After ACS, poor adherence dropped to 7.9%, while good adherence rose to 62.2% (p < 0.001).",
      "Statin use increased from 22.3% to 82.4%, ACEi/ARB/ARNI from 58.2% to 89.3%, beta-blockers from 44.8% to 86.8%, and MRAs from 23.4% to 67.3%.",
      "Gender-specific analyses showed parallel gains: poor adherence declined from 44.8% to 6.5% in men and from 40.1% to 5.3% in women, with good adherence exceeding 67% in both groups.",
      "Patients with good adherence had significantly lower risks of rehospitalization (HR 0.52) and mortality (HR 0.46).",
      "Independent adverse outcome predictors were low hemoglobin, high HbA1c, impaired renal function, and reduced LVEF.",
      "ACS serves as a catalyst for improved GDMT adherence in HF patients with CAD and DM.",
      "Higher adherence is strongly associated with reduced rehospitalization and mortality, underscoring the need for sustained adherence strategies and multidisciplinary care models to optimize long-term outcomes."
    ],
    "summary_sentences": [
      "Heart failure (HF) patients with concomitant coronary artery disease (CAD) and type 2 diabetes mellitus (DM) represent a particularly high-risk population with increased morbidity and mortality.",
      "Acute coronary syndrome (ACS) often serves as a critical event that can trigger optimization of guideline-directed medical therapy (GDMT).",
      "However, the impact of ACS on long-term adherence patterns and outcomes in this population remains unclear.",
      "We retrospectively studied 431 patients with HF (LVEF ≤ 40%), CAD, and DM presenting with ACS between 2019 and 2022.",
      "Adherence to nine evidence-based therapies was scored (0-9) and classified as poor (0-3), intermediate (4-6), or good (7-9).",
      "Adherence was assessed before ACS and over 36 months of follow-up.",
      "Primary outcomes were rehospitalization and all-cause mortality, analyzed using Cox regression and Kaplan-Meier methods.",
      "Mean age was 62.1 ± 10.2 years, and 64.7% were male.",
      "Before ACS, 45.9% had poor adherence and only 16.0% had good adherence.",
      "After ACS, poor adherence dropped to 7.9%, while good adherence rose to 62.2% (p < 0.001).",
      "Statin use increased from 22.3% to 82.4%, ACEi/ARB/ARNI from 58.2% to 89.3%, beta-blockers from 44.8% to 86.8%, and MRAs from 23.4% to 67.3%.",
      "Gender-specific analyses showed parallel gains: poor adherence declined from 44.8% to 6.5% in men and from 40.1% to 5.3% in women, with good adherence exceeding 67% in both groups.",
      "Patients with good adherence had significantly lower risks of rehospitalization (HR 0.52) and mortality (HR 0.46).",
      "Independent adverse outcome predictors were low hemoglobin, high HbA1c, impaired renal function, and reduced LVEF.",
      "ACS serves as a catalyst for improved GDMT adherence in HF patients with CAD and DM.",
      "Higher adherence is strongly associated with reduced rehospitalization and mortality, underscoring the need for sustained adherence strategies and multidisciplinary care models to optimize long-term outcomes."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41553109",
    "source": "pubmed",
    "sentences": [
      "Identifying the optimal metabolic bariatric surgery approach for patients with severe obesity with a BMI ≥50 kg/m2 remains challenging.",
      "The aim of this long-term follow-up of a randomized clinical trial (RCT) was to compare distal long alimentary limb Roux-en-Y gastric bypass (RYGB) with standard RYGB for 10-year weight loss and nutritional outcomes.",
      "Secondary analysis of a 10-year follow-up of an RCT with initially 113 patients (BMI 50-60 kg/m2) randomized to either standard (n = 57, 50 cm biliopancreatic/150 cm alimentary limb) or distal long alimentary limb RYGB (n = 56, 50 cm biliopancreatic/150 cm common limb) from March 2011 to April 2013 at two Norwegian hospitals.",
      "The final data collection date was 15 August 2023.",
      "The primary focus was weight loss (BMI reduction, %total weight loss) and other secondary outcomes included cardiometabolic risk factors, nutritional status, and health-related quality of life (HRQOL).",
      "Of 113 patients, 79 (69.9%, mean age 50 (s.d. 8.7) years, 50 (63%) females) patients were available for 10-year follow-up (41 standard RYGB, 38 distal RYGB).",
      "The 10-year mortality rate was 3.5% (4/113) and all deaths occurred after distal RYGB.",
      "One death may have been associated with the surgery in a patient with previously undiagnosed liver cirrhosis at the time of operation.",
      "Mean BMI reduction from baseline was 12.0 kg/m2 (95% c.i., 10.8 to 13.2) after standard RYGB and 14.7 kg/m2 (95% c.i., 13.5 to 15.9) after distal RYGB with a between-group difference of 2.7 kg/m2 (95% c.i., 1.0 to 4.5, P = 0.002).",
      "The mean percentage total weight loss from baseline was 23.0% (95% c.i., 20.8 to 25.2) after standard RYGB and 28.2% (95% c.i., 26.0 to 30.5) after distal RYGB, with a between-group difference of 5.3% (95% c.i., 2.1 to 8.4, P = 0.001).",
      "The distal RYGB group had higher rates of malnutrition (1/57 standard versus 5/56 distal; P = 0.12), diarrhoea (7/57 standard versus 15/56 distal; P = 0.05), and vitamin D deficiency (24/41 standard versus 32/38 distal; P = 0.01).",
      "There were no differences between the groups in the prevalence of type 2 diabetes, hypertension, dyslipidaemia, or metabolic syndrome at 10-year follow-up.",
      "Four patients underwent revisional surgery due to malnutrition after distal RYGB.",
      "There were no statistically significant differences in HRQOL scores between the groups at 10 years (SF-36 physical 44.2 versus 44.1, mental 50.3 versus 47.3; OWLQOL 63 versus 61; all P > 0.2).",
      "Distal long alimentary limb RYGB resulted in greater weight loss after 10 years with a higher risk of malnutrition, diarrhoea, and vitamin D deficiency.",
      "Clinicaltrials.gov NCT00821197."
    ],
    "summary_sentences": [
      "Identifying the optimal metabolic bariatric surgery approach for patients with severe obesity with a BMI ≥50 kg/m2 remains challenging.",
      "The aim of this long-term follow-up of a randomized clinical trial (RCT) was to compare distal long alimentary limb Roux-en-Y gastric bypass (RYGB) with standard RYGB for 10-year weight loss and nutritional outcomes.",
      "Secondary analysis of a 10-year follow-up of an RCT with initially 113 patients (BMI 50-60 kg/m2) randomized to either standard (n = 57, 50 cm biliopancreatic/150 cm alimentary limb) or distal long alimentary limb RYGB (n = 56, 50 cm biliopancreatic/150 cm common limb) from March 2011 to April 2013 at two Norwegian hospitals.",
      "The final data collection date was 15 August 2023.",
      "The primary focus was weight loss (BMI reduction, %total weight loss) and other secondary outcomes included cardiometabolic risk factors, nutritional status, and health-related quality of life (HRQOL).",
      "Of 113 patients, 79 (69.9%, mean age 50 (s.d. 8.7) years, 50 (63%) females) patients were available for 10-year follow-up (41 standard RYGB, 38 distal RYGB).",
      "The 10-year mortality rate was 3.5% (4/113) and all deaths occurred after distal RYGB.",
      "One death may have been associated with the surgery in a patient with previously undiagnosed liver cirrhosis at the time of operation.",
      "Mean BMI reduction from baseline was 12.0 kg/m2 (95% c.i., 10.8 to 13.2) after standard RYGB and 14.7 kg/m2 (95% c.i., 13.5 to 15.9) after distal RYGB with a between-group difference of 2.7 kg/m2 (95% c.i., 1.0 to 4.5, P = 0.002).",
      "The mean percentage total weight loss from baseline was 23.0% (95% c.i., 20.8 to 25.2) after standard RYGB and 28.2% (95% c.i., 26.0 to 30.5) after distal RYGB, with a between-group difference of 5.3% (95% c.i., 2.1 to 8.4, P = 0.001).",
      "The distal RYGB group had higher rates of malnutrition (1/57 standard versus 5/56 distal; P = 0.12), diarrhoea (7/57 standard versus 15/56 distal; P = 0.05), and vitamin D deficiency (24/41 standard versus 32/38 distal; P = 0.01).",
      "There were no differences between the groups in the prevalence of type 2 diabetes, hypertension, dyslipidaemia, or metabolic syndrome at 10-year follow-up.",
      "Four patients underwent revisional surgery due to malnutrition after distal RYGB.",
      "There were no statistically significant differences in HRQOL scores between the groups at 10 years (SF-36 physical 44.2 versus 44.1, mental 50.3 versus 47.3; OWLQOL 63 versus 61; all P > 0.2).",
      "Distal long alimentary limb RYGB resulted in greater weight loss after 10 years with a higher risk of malnutrition, diarrhoea, and vitamin D deficiency.",
      "Clinicaltrials.gov NCT00821197."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41551204",
    "source": "pubmed",
    "sentences": [
      "We aim to evaluate the effectiveness of the novel real-time continuous glucose monitoring (rtCGM) system \" This prospective, open-label, randomized controlled trial included 172 patients with T2D from the Fatebenefratelli-Sacco Hospital in Milan.",
      "Participants were randomized into 2 groups: 86 patients received the After 6 months, the The use of the NCT07089979."
    ],
    "summary_sentences": [
      "We aim to evaluate the effectiveness of the novel real-time continuous glucose monitoring (rtCGM) system \" This prospective, open-label, randomized controlled trial included 172 patients with T2D from the Fatebenefratelli-Sacco Hospital in Milan.",
      "Participants were randomized into 2 groups: 86 patients received the After 6 months, the The use of the NCT07089979."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41550964",
    "source": "pubmed",
    "sentences": [
      "Research shows that the microbiome of the skin is present as an active contributor to wound healing processes by moving past its historical infection-related function.",
      "The review investigates how commensal and probiotic bacteria affect immunomodulation while accelerating epithelial growth, together with tissue repair processes.",
      "Researchers use modern methods to link immunological concepts with material science along with synthetic biological techniques to study engineered probiotics which transform current wound treatments.",
      "The research study represents an extensive integration of recent findings concerning probiotic-mediated immunomodulatory operations and engineered approaches that improve probiotic delivery systems and their performance during skin wound healing procedures.",
      "Recent genetically engineered"
    ],
    "summary_sentences": [
      "Research shows that the microbiome of the skin is present as an active contributor to wound healing processes by moving past its historical infection-related function.",
      "The review investigates how commensal and probiotic bacteria affect immunomodulation while accelerating epithelial growth, together with tissue repair processes.",
      "Researchers use modern methods to link immunological concepts with material science along with synthetic biological techniques to study engineered probiotics which transform current wound treatments.",
      "The research study represents an extensive integration of recent findings concerning probiotic-mediated immunomodulatory operations and engineered approaches that improve probiotic delivery systems and their performance during skin wound healing procedures.",
      "Recent genetically engineered"
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41550872",
    "source": "pubmed",
    "sentences": [
      "The optimal combination therapy for heart failure with reduced ejection fraction (HFrEF) involving sodium-glucose transporter 2 inhibitors (SGLT2i), angiotensin receptor-neprilysin inhibitors (ARNI), and conventional triple therapy remains uncertain due to the lack of direct comparative evidence.",
      "We conducted a Bayesian network meta-analysis of randomized controlled trials (RCTs) comparing six treatment regimens.",
      "Primary outcome was the composite of cardiovascular death and hospitalization.",
      "Secondary outcomes included all-cause mortality, Kansas City Cardiomyopathy Questionnaire (KCCQ) scores, 6-minute walk distance (6MWD), N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, and adverse events (hypotension, hyperkalemia, renal events).",
      "All analyses were performed under a Bayesian statistical framework, and the relative efficacy and safety of the six regimens were ranked using surface under the cumulative ranking curve (SUCRA) probabilities.",
      "A total of 22 studies (21 RCTs) involving 24,499 patients were included.",
      "For the primary composite outcome, Sotagliflozin-based quadruple therapy ranked first (SUCRA: 90.8%; OR: 0.49, 95%CI: 0.16 to 1.47).",
      "Dapagliflozin+triple therapy (SUCRA: 76.8%; OR: 0.83, 95%CI: 0.69 to 0.98) and ARNI+BB+MRA (SUCRA: 76.6%; OR: 0.83, 95%CI: 0.75 to 0.92) demonstrated significant reductions in all-cause mortality.",
      "ARNI-based triple therapy was associated with a significantly increased risk of hypotension (OR: 1.67, 95%CI: 1.48 to 1.90), whereas Dapagliflozin and Empagliflozin showed protective effects against renal adverse events.",
      "No regimen significantly increased hyperkalemia risk.",
      "Additionally, a statistically significant interaction was observed between treatment effects and baseline diabetes burden for the primary outcome ( This network meta-analysis demonstrates that while all quadruple therapy regimens improve outcomes in HFrEF, important distinctions exist.",
      "Sotagliflozin-based therapy may offer advantages in preventing hospitalizations, whereas Dapagliflozin and ARNI are comparable for mortality reduction.",
      "The safety profiles differ significantly, particularly regarding hypotension risk with ARNI and renal protection with SGLT2i.",
      "The choice of regimen should be individualized based on patient priorities, comorbidities, and safety tolerability profiles.",
      "https://www.crd.york.ac.uk/PROSPERO/view/CRD420251112344 , identifier CRD420251112344."
    ],
    "summary_sentences": [
      "The optimal combination therapy for heart failure with reduced ejection fraction (HFrEF) involving sodium-glucose transporter 2 inhibitors (SGLT2i), angiotensin receptor-neprilysin inhibitors (ARNI), and conventional triple therapy remains uncertain due to the lack of direct comparative evidence.",
      "We conducted a Bayesian network meta-analysis of randomized controlled trials (RCTs) comparing six treatment regimens.",
      "Primary outcome was the composite of cardiovascular death and hospitalization.",
      "Secondary outcomes included all-cause mortality, Kansas City Cardiomyopathy Questionnaire (KCCQ) scores, 6-minute walk distance (6MWD), N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, and adverse events (hypotension, hyperkalemia, renal events).",
      "All analyses were performed under a Bayesian statistical framework, and the relative efficacy and safety of the six regimens were ranked using surface under the cumulative ranking curve (SUCRA) probabilities.",
      "A total of 22 studies (21 RCTs) involving 24,499 patients were included.",
      "For the primary composite outcome, Sotagliflozin-based quadruple therapy ranked first (SUCRA: 90.8%; OR: 0.49, 95%CI: 0.16 to 1.47).",
      "Dapagliflozin+triple therapy (SUCRA: 76.8%; OR: 0.83, 95%CI: 0.69 to 0.98) and ARNI+BB+MRA (SUCRA: 76.6%; OR: 0.83, 95%CI: 0.75 to 0.92) demonstrated significant reductions in all-cause mortality.",
      "ARNI-based triple therapy was associated with a significantly increased risk of hypotension (OR: 1.67, 95%CI: 1.48 to 1.90), whereas Dapagliflozin and Empagliflozin showed protective effects against renal adverse events.",
      "No regimen significantly increased hyperkalemia risk.",
      "Additionally, a statistically significant interaction was observed between treatment effects and baseline diabetes burden for the primary outcome ( This network meta-analysis demonstrates that while all quadruple therapy regimens improve outcomes in HFrEF, important distinctions exist.",
      "Sotagliflozin-based therapy may offer advantages in preventing hospitalizations, whereas Dapagliflozin and ARNI are comparable for mortality reduction.",
      "The safety profiles differ significantly, particularly regarding hypotension risk with ARNI and renal protection with SGLT2i.",
      "The choice of regimen should be individualized based on patient priorities, comorbidities, and safety tolerability profiles.",
      "https://www.crd.york.ac.uk/PROSPERO/view/CRD420251112344 , identifier CRD420251112344."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41550704",
    "source": "pubmed",
    "sentences": [
      "All patients who qualified for primary open shoulder surgery via a deltopectoral approach were prospectively included in our single-blinded, two-arm randomized clinical trial.",
      "For every patient, a skin swab from the surgical area was taken before the standard preparation of the skin.",
      "In the disinfection group, the subcutaneous layer was treated with povidone iodine solution after exposure of the deltoid fascia.",
      "The cautery group underwent subcutaneous tissue dissection using an electrocautery.",
      "After fully exposing the proximal humerus, 5 swabs were collected from various locations for microbiological analysis, following a rigorous protocol.",
      "All cultures were incubated for 14 days under both aerobic and anaerobic conditions.",
      "Between February 2020 and July 2021, 210 shoulders were enrolled in 2 groups (140 disinfection vs. 70 cautery).",
      "The 2 groups showed no significant differences in terms of sex, age, body mass index, or diabetes prevalence.",
      "The subcutaneous disinfection protocol led to a significant decrease in the overall positive culture rate of the operating field for all bacteria ( Disinfection of the subcutaneous tissue reduces the contamination rate of"
    ],
    "summary_sentences": [
      "All patients who qualified for primary open shoulder surgery via a deltopectoral approach were prospectively included in our single-blinded, two-arm randomized clinical trial.",
      "For every patient, a skin swab from the surgical area was taken before the standard preparation of the skin.",
      "In the disinfection group, the subcutaneous layer was treated with povidone iodine solution after exposure of the deltoid fascia.",
      "The cautery group underwent subcutaneous tissue dissection using an electrocautery.",
      "After fully exposing the proximal humerus, 5 swabs were collected from various locations for microbiological analysis, following a rigorous protocol.",
      "All cultures were incubated for 14 days under both aerobic and anaerobic conditions.",
      "Between February 2020 and July 2021, 210 shoulders were enrolled in 2 groups (140 disinfection vs. 70 cautery).",
      "The 2 groups showed no significant differences in terms of sex, age, body mass index, or diabetes prevalence.",
      "The subcutaneous disinfection protocol led to a significant decrease in the overall positive culture rate of the operating field for all bacteria ( Disinfection of the subcutaneous tissue reduces the contamination rate of"
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41548600",
    "source": "pubmed",
    "sentences": [
      "Diabetic peripheral neuropathy (DPN) is the most common complication of type 2 diabetes mellitus (T2DM) and is associated with substantial morbidity, mortality, and healthcare costs.",
      "Vitamin B-12 plays a critical role in nerve protection and regeneration.",
      "However, clinical evidence regarding the effectiveness and optimal dose of vitamin B-12 supplementation for managing DPN in individuals with low serum vitamin B-12 levels remains inconclusive.",
      "The aim of this study is to compare the effects of 2 different daily doses of oral vitamin B-12 supplementation on neuropathic parameters in patients with DPN and low serum vitamin B-12.",
      "This 16 wk, randomized controlled trial enrolled adults with T2DM, DPN, and low serum vitamin B12 levels (<200 pg/mL).",
      "Patients were randomly assigned (1:1) to receive either 1000 μg or 2000 μg of oral vitamin B12 (methylcobalamin) daily.",
      "The primary outcomes were changes in neuropathic parameters, assessed by the numerical rating scale (NRS), Michigan neuropathy screening instrument examination (MNSIE), and neuropathy disability score (NDS).",
      "Secondary outcomes included serum B-12 levels and metabolic parameters.",
      "Of the 35 participants randomly assigned, 32 completed the 16-wk trial.",
      "Serum vitamin B-12 levels increased significantly in both groups, with a greater rise noted in the 2000 μg group (P = 0.049).",
      "Both the 1000 μg and 2000 μg groups experienced significant improvements in neuropathy symptoms.",
      "Mean ± SD NRS scores decreased from 7.00 ± 2.03 to 5.60 ± 2.19 (P = 0.016) in the 1000 μg group, and from 6.18 ± 2.40 to 4.42 ± 2.50 (P = 0.007) in the 2000 μg group.",
      "Similarly, MNSIE scores improved from 5.70 ± 1.66 to 5.22 ± 1.99 (P = 0.033) and from 5.40 ± 1.68 to 4.47 ± 2.25 (P = 0.022), respectively.",
      "No significant difference in these neuropathic outcomes was observed between groups.",
      "The NDS remained unchanged in both groups (P > 0.05).",
      "In addition, the 1000 μg dose was associated with significant improvements in hemoglobin A1c levels, whereas the 2000 μg dose was linked to a significant decline in estimated glomerular filtration rate.",
      "In patients with DPN and low serum vitamin B-12 levels, 16 wk of daily supplementation with either 1000 μg or 2000 μg of vitamin B-12 similarly improves neuropathic symptoms.",
      "Apart from higher serum B-12 levels, the 2000 μg dose did not offer additional neuropathic or metabolic benefits."
    ],
    "summary_sentences": [
      "Diabetic peripheral neuropathy (DPN) is the most common complication of type 2 diabetes mellitus (T2DM) and is associated with substantial morbidity, mortality, and healthcare costs.",
      "Vitamin B-12 plays a critical role in nerve protection and regeneration.",
      "However, clinical evidence regarding the effectiveness and optimal dose of vitamin B-12 supplementation for managing DPN in individuals with low serum vitamin B-12 levels remains inconclusive.",
      "The aim of this study is to compare the effects of 2 different daily doses of oral vitamin B-12 supplementation on neuropathic parameters in patients with DPN and low serum vitamin B-12.",
      "This 16 wk, randomized controlled trial enrolled adults with T2DM, DPN, and low serum vitamin B12 levels (<200 pg/mL).",
      "Patients were randomly assigned (1:1) to receive either 1000 μg or 2000 μg of oral vitamin B12 (methylcobalamin) daily.",
      "The primary outcomes were changes in neuropathic parameters, assessed by the numerical rating scale (NRS), Michigan neuropathy screening instrument examination (MNSIE), and neuropathy disability score (NDS).",
      "Secondary outcomes included serum B-12 levels and metabolic parameters.",
      "Of the 35 participants randomly assigned, 32 completed the 16-wk trial.",
      "Serum vitamin B-12 levels increased significantly in both groups, with a greater rise noted in the 2000 μg group (P = 0.049).",
      "Both the 1000 μg and 2000 μg groups experienced significant improvements in neuropathy symptoms.",
      "Mean ± SD NRS scores decreased from 7.00 ± 2.03 to 5.60 ± 2.19 (P = 0.016) in the 1000 μg group, and from 6.18 ± 2.40 to 4.42 ± 2.50 (P = 0.007) in the 2000 μg group.",
      "Similarly, MNSIE scores improved from 5.70 ± 1.66 to 5.22 ± 1.99 (P = 0.033) and from 5.40 ± 1.68 to 4.47 ± 2.25 (P = 0.022), respectively.",
      "No significant difference in these neuropathic outcomes was observed between groups.",
      "The NDS remained unchanged in both groups (P > 0.05).",
      "In addition, the 1000 μg dose was associated with significant improvements in hemoglobin A1c levels, whereas the 2000 μg dose was linked to a significant decline in estimated glomerular filtration rate.",
      "In patients with DPN and low serum vitamin B-12 levels, 16 wk of daily supplementation with either 1000 μg or 2000 μg of vitamin B-12 similarly improves neuropathic symptoms.",
      "Apart from higher serum B-12 levels, the 2000 μg dose did not offer additional neuropathic or metabolic benefits."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41547366",
    "source": "pubmed",
    "sentences": [
      "GLP-1 receptor agonists were initially developed to treat type 2 diabetes and have had a transformative effect on its therapy, and are highly effective for glycaemic control, with the added benefit of bodyweight reduction and a low risk of causing hypoglycaemia.",
      "GLP-1 receptor agonists reduce risks for major adverse cardiovascular events (eg, non-fatal myocardial infarction, stroke, and cardiovascular death), and the risk of admission to or treatment within hospital for heart failure.",
      "These drugs reduce albuminuria and slow the decline in estimated glomerular filtration rate over time, therefore delaying or preventing kidney failure.",
      "Furthermore, GLP-1 receptor agonists (eg, liraglutide and semaglutide) and the dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor co-agonist tirzepatide have been approved for treatment of obesity, with clinical trials establishing benefits for various obesity-related conditions: prevention of type 2 diabetes; risk for major adverse cardiovascular events; heart failure, especially with preserved ejection fraction; regression of steatosis and prevention of fibrosis in steatotic liver disease; and symptomatic improvements in obstructive sleep apnoea and knee osteoarthritis.",
      "Current developments include the exploration of novel indications (eg, neurodegenerative diseases and substance use disorders) with suggestive evidence of efficacy, and the development of small-molecule GLP-1 receptor agonists for oral treatment to improve convenience.",
      "Dual (ie, GLP-1-glucagon and GLP-1-amylin) and triple (ie, GIP-GLP-1-glucagon) receptor agonists activating multiple receptors promise greater efficacy than mono-agonists, especially for weight loss.",
      "However, some clinical development programmes have a high burden of adverse gastrointestinal events, and dose-escalation regimens should be optimised to reach acceptable tolerability."
    ],
    "summary_sentences": [
      "GLP-1 receptor agonists were initially developed to treat type 2 diabetes and have had a transformative effect on its therapy, and are highly effective for glycaemic control, with the added benefit of bodyweight reduction and a low risk of causing hypoglycaemia.",
      "GLP-1 receptor agonists reduce risks for major adverse cardiovascular events (eg, non-fatal myocardial infarction, stroke, and cardiovascular death), and the risk of admission to or treatment within hospital for heart failure.",
      "These drugs reduce albuminuria and slow the decline in estimated glomerular filtration rate over time, therefore delaying or preventing kidney failure.",
      "Furthermore, GLP-1 receptor agonists (eg, liraglutide and semaglutide) and the dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor co-agonist tirzepatide have been approved for treatment of obesity, with clinical trials establishing benefits for various obesity-related conditions: prevention of type 2 diabetes; risk for major adverse cardiovascular events; heart failure, especially with preserved ejection fraction; regression of steatosis and prevention of fibrosis in steatotic liver disease; and symptomatic improvements in obstructive sleep apnoea and knee osteoarthritis.",
      "Current developments include the exploration of novel indications (eg, neurodegenerative diseases and substance use disorders) with suggestive evidence of efficacy, and the development of small-molecule GLP-1 receptor agonists for oral treatment to improve convenience.",
      "Dual (ie, GLP-1-glucagon and GLP-1-amylin) and triple (ie, GIP-GLP-1-glucagon) receptor agonists activating multiple receptors promise greater efficacy than mono-agonists, especially for weight loss.",
      "However, some clinical development programmes have a high burden of adverse gastrointestinal events, and dose-escalation regimens should be optimised to reach acceptable tolerability."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41546594",
    "source": "pubmed",
    "sentences": [
      "Exercise training is recommended in coronary heart disease (CHD) and type 2 diabetes (T2DM) patients alike; however, uncertainty remains on the influence of exercise intensity and duration in older patients with both entities.",
      "To address this, we performed a secondary analysis including 201 patients (67.9 ± 8.2 years; 84.1% men) from the LeIKD trial (NCT038359), which introduced 6 months of home-based telemedicine-supported exercise intervention in patients with CHD and T2DM.",
      "We assessed the relationships between exercise duration and intensity with change in peak oxygen uptake (V̇O"
    ],
    "summary_sentences": [
      "Exercise training is recommended in coronary heart disease (CHD) and type 2 diabetes (T2DM) patients alike; however, uncertainty remains on the influence of exercise intensity and duration in older patients with both entities.",
      "To address this, we performed a secondary analysis including 201 patients (67.9 ± 8.2 years; 84.1% men) from the LeIKD trial (NCT038359), which introduced 6 months of home-based telemedicine-supported exercise intervention in patients with CHD and T2DM.",
      "We assessed the relationships between exercise duration and intensity with change in peak oxygen uptake (V̇O"
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41546589",
    "source": "pubmed",
    "sentences": [
      "Metabolic syndrome (MetS) significantly increases risks for diabetes and cardiovascular diseases.",
      "Dendrobium officinale, a Traditional Chinese Medicine (TCM), shows potential in treating MetS, yet its active components and mechanisms remain unclear.",
      "To identify the key active constituents of D. officinale and elucidate their mechanisms against MetS using integrated clinical and experimental approaches.",
      "A clinical trial (n=37) evaluated D. officinale powder efficacy in MetS patients.",
      "Network pharmacology predicted active compounds and targets.",
      "Molecular docking assessed compound-target interactions.",
      "Enzyme kinetic assay measured inhibition of protein tyrosine phosphatase 1B (PTP1B).",
      "Clinical results showed significant improvements in triglycerides (TG), fasting blood glucose (FBG), body mass index (BMI), and waist circumference.",
      "Network pharmacology and molecular docking identified Vicenin II and Schaftoside as key compounds targeting PTP1B. Enzyme assays confirmed both potently inhibited PTP1B activity (IC50 values: Vicenin II",
      "6.94±0.22 μM; Schaftoside 6.33±0.21 μM), stronger than positive control NaVO4 (IC50 12.65±1.60 μM).",
      "Kinetic analysis indicated Vicenin II as a competitive inhibitor and Schaftoside as mixed-type.",
      "Dendrobium officinale effectively improves MetS parameters.",
      "Vicenin II and Schaftoside are identified as key active constituents, likely exerting therapeutic effects through potent PTP1B inhibition."
    ],
    "summary_sentences": [
      "Metabolic syndrome (MetS) significantly increases risks for diabetes and cardiovascular diseases.",
      "Dendrobium officinale, a Traditional Chinese Medicine (TCM), shows potential in treating MetS, yet its active components and mechanisms remain unclear.",
      "To identify the key active constituents of D. officinale and elucidate their mechanisms against MetS using integrated clinical and experimental approaches.",
      "A clinical trial (n=37) evaluated D. officinale powder efficacy in MetS patients.",
      "Network pharmacology predicted active compounds and targets.",
      "Molecular docking assessed compound-target interactions.",
      "Enzyme kinetic assay measured inhibition of protein tyrosine phosphatase 1B (PTP1B).",
      "Clinical results showed significant improvements in triglycerides (TG), fasting blood glucose (FBG), body mass index (BMI), and waist circumference.",
      "Network pharmacology and molecular docking identified Vicenin II and Schaftoside as key compounds targeting PTP1B. Enzyme assays confirmed both potently inhibited PTP1B activity (IC50 values: Vicenin II",
      "6.94±0.22 μM; Schaftoside 6.33±0.21 μM), stronger than positive control NaVO4 (IC50 12.65±1.60 μM).",
      "Kinetic analysis indicated Vicenin II as a competitive inhibitor and Schaftoside as mixed-type.",
      "Dendrobium officinale effectively improves MetS parameters.",
      "Vicenin II and Schaftoside are identified as key active constituents, likely exerting therapeutic effects through potent PTP1B inhibition."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41546109",
    "source": "pubmed",
    "sentences": [
      "Governments worldwide consider randomised controlled trials (RCTs) as the accepted gold standard design to evaluate healthcare interventions.",
      "However, enrolling participants into RCTs can be challenging, with recruitment processes serving as a crucial determinant of any clinical trial or program's success.",
      "This study aimed to characterise the relative effectiveness and cost of different strategies used to recruit individuals into a randomised controlled trial of an Australian Lifestyle Change Program (AUS2PREVENT) to prevent or delay type 2 diabetes in South Australia.",
      "Targeted recruitment over a 12-month period through General Practitioner (GP) clinics was the primary strategy used to recruit individuals at risk of, or with prediabetes.",
      "After protocol amendments, around 25,000 individuals were identified as having prediabetes and being potentially eligible for the trial from 279 GP clinics across metropolitan Adelaide.",
      "Additional channels that were used to recruit high-risk individuals included radio, online media (e.g. Facebook, Instagram, webpages), email distribution lists, and member-oriented magazines/ newsletters associated with the supporting health and community organisations.",
      "Of the 1393 expressions of interest, 587 individuals completed the pre-screening survey and reported the referral channel.",
      "Radio, email, and online media generated the greatest number of individuals expressing interest in the trial (284 vs 151 vs 91, respectively) and accounted for the final 67 individuals who were enrolled and randomised.",
      "Only 4 individuals reported being referred by their GP.",
      "Promotion through radio, GP clinics, and online media was the costliest strategy.",
      "Although feasibility precision targets were achieved, continuing to recruit for a fully powered main trial to demonstrate the effectiveness of the AUS2PREVENT Program under current timelines and resources was not viable, and underscores the need for major design or strategy changes.",
      "Effective, timely, and cost-efficient recruitment for preventive health trials requires an adaptive, multi-channel strategy tailored to high-risk populations, supported by strong coordination among health organisations, trust-building efforts, and substantial marketing resources.",
      "The trial is registered on the Australian New Zealand Clinical Trials Registry (ANZCTR), Universal Trial Number U1111-1220-5636."
    ],
    "summary_sentences": [
      "Governments worldwide consider randomised controlled trials (RCTs) as the accepted gold standard design to evaluate healthcare interventions.",
      "However, enrolling participants into RCTs can be challenging, with recruitment processes serving as a crucial determinant of any clinical trial or program's success.",
      "This study aimed to characterise the relative effectiveness and cost of different strategies used to recruit individuals into a randomised controlled trial of an Australian Lifestyle Change Program (AUS2PREVENT) to prevent or delay type 2 diabetes in South Australia.",
      "Targeted recruitment over a 12-month period through General Practitioner (GP) clinics was the primary strategy used to recruit individuals at risk of, or with prediabetes.",
      "After protocol amendments, around 25,000 individuals were identified as having prediabetes and being potentially eligible for the trial from 279 GP clinics across metropolitan Adelaide.",
      "Additional channels that were used to recruit high-risk individuals included radio, online media (e.g. Facebook, Instagram, webpages), email distribution lists, and member-oriented magazines/ newsletters associated with the supporting health and community organisations.",
      "Of the 1393 expressions of interest, 587 individuals completed the pre-screening survey and reported the referral channel.",
      "Radio, email, and online media generated the greatest number of individuals expressing interest in the trial (284 vs 151 vs 91, respectively) and accounted for the final 67 individuals who were enrolled and randomised.",
      "Only 4 individuals reported being referred by their GP.",
      "Promotion through radio, GP clinics, and online media was the costliest strategy.",
      "Although feasibility precision targets were achieved, continuing to recruit for a fully powered main trial to demonstrate the effectiveness of the AUS2PREVENT Program under current timelines and resources was not viable, and underscores the need for major design or strategy changes.",
      "Effective, timely, and cost-efficient recruitment for preventive health trials requires an adaptive, multi-channel strategy tailored to high-risk populations, supported by strong coordination among health organisations, trust-building efforts, and substantial marketing resources.",
      "The trial is registered on the Australian New Zealand Clinical Trials Registry (ANZCTR), Universal Trial Number U1111-1220-5636."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41545950",
    "source": "pubmed",
    "sentences": [
      "Evidence on psychophysiological responses such as heart rate (HR) and electrodermal response (EDR) during long-term supportive periodontal therapy (SPT) is limited.",
      "This observational cross-sectional pilot study aimed to explore associations between patient-related factors and physiological stress markers during routine SPT visits, focusing on adherence-related variables.",
      "A sample of n = 75 patients was examined in a questionnaire-based, cross-sectional survey, indicating sufficient adherence to SPT of ≥ 2 years (a maximum deviation ± 6 months between SPT intervals) at a specialized department for periodontology.",
      "At the preliminary last SPT visit, in addition to dental parameters, we assessed socio-demographic, treatment-related (critical attitudes/complaints), psychological variables-such as dental fear, oral health-related quality of life, dental anticipatory trauma symptoms, childhood traumata, depression, and personality functioning-and vital parameters such as HR and EDR.",
      "The primary endpoint was the difference in HR and EDR across predefined procedural clusters reflecting varying invasiveness (three clusters: non-invasive (n-iC), minimally invasive (m-iC), and invasive (iC).",
      "Analyses were performed using non-parametric tests and exploratory correlation analyses.",
      "The mean (standard deviation) of HR differed significantly across intervention clusters (n-iC/m-iC/iC: 73.06[11.96]/67.66[9.60]/69.46[10.00] bpm; p ≤ 0.001), while EDR revealed no significant differences (n-iC/m-iC/iC: 69.64[156.65]/61.72[172.20]/75.10[154.07] µS; p ≥ 0.075).",
      "EDR negatively correlated with the number of teeth m-iC-interventions (r = -0.423; p = 0.003).",
      "Moreover, EDR and HR were significantly related to certain variables such as long-term medication and number of general diseases (p < 0.001).",
      "Significant correlations included a positive association between Oral Health Impact Profile scores and dental anxiety (r = 0.233; p = 0.040) and a negative correlation with the total number of teeth (r = -0.378; p < 0.001).",
      "Socio-demographic and treatment-related factors were intertwined with patient and dental parameters in SPT and appeared to influence adherence.",
      "HR varied across clusters, but no clear link between vital signs and psychological stress could be established.",
      "The clinical trial was prospectively registered in the DRKS-German Clinical Trials Register ( https://www.drks.de ) with the registration-ID DRKS00031969 (06/05/2023)."
    ],
    "summary_sentences": [
      "Evidence on psychophysiological responses such as heart rate (HR) and electrodermal response (EDR) during long-term supportive periodontal therapy (SPT) is limited.",
      "This observational cross-sectional pilot study aimed to explore associations between patient-related factors and physiological stress markers during routine SPT visits, focusing on adherence-related variables.",
      "A sample of n = 75 patients was examined in a questionnaire-based, cross-sectional survey, indicating sufficient adherence to SPT of ≥ 2 years (a maximum deviation ± 6 months between SPT intervals) at a specialized department for periodontology.",
      "At the preliminary last SPT visit, in addition to dental parameters, we assessed socio-demographic, treatment-related (critical attitudes/complaints), psychological variables-such as dental fear, oral health-related quality of life, dental anticipatory trauma symptoms, childhood traumata, depression, and personality functioning-and vital parameters such as HR and EDR.",
      "The primary endpoint was the difference in HR and EDR across predefined procedural clusters reflecting varying invasiveness (three clusters: non-invasive (n-iC), minimally invasive (m-iC), and invasive (iC).",
      "Analyses were performed using non-parametric tests and exploratory correlation analyses.",
      "The mean (standard deviation) of HR differed significantly across intervention clusters (n-iC/m-iC/iC: 73.06[11.96]/67.66[9.60]/69.46[10.00] bpm; p ≤ 0.001), while EDR revealed no significant differences (n-iC/m-iC/iC: 69.64[156.65]/61.72[172.20]/75.10[154.07] µS; p ≥ 0.075).",
      "EDR negatively correlated with the number of teeth m-iC-interventions (r = -0.423; p = 0.003).",
      "Moreover, EDR and HR were significantly related to certain variables such as long-term medication and number of general diseases (p < 0.001).",
      "Significant correlations included a positive association between Oral Health Impact Profile scores and dental anxiety (r = 0.233; p = 0.040) and a negative correlation with the total number of teeth (r = -0.378; p < 0.001).",
      "Socio-demographic and treatment-related factors were intertwined with patient and dental parameters in SPT and appeared to influence adherence.",
      "HR varied across clusters, but no clear link between vital signs and psychological stress could be established.",
      "The clinical trial was prospectively registered in the DRKS-German Clinical Trials Register ( https://www.drks.de ) with the registration-ID DRKS00031969 (06/05/2023)."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41544737",
    "source": "pubmed",
    "sentences": [
      "To report the true frequency and risk factors for acute NAION progression and identify modifiable features to reduce vision worsening.",
      "Secondary case-control analysis of the QRK207 multicenter, double-masked, sham-controlled, randomized clinical trial.",
      "We analyzed 599 study eyes with acute NAION (of 729 individuals prospectively enrolled in the QRK207 trial) with separate screening and Day 1 (mean 2.5-day interval) evaluations for progression.",
      "No participants included in this analysis received treatment.",
      "The Month 2 analysis included only the 167 sham-injected study eyes.",
      "Visual outcomes were assessed using best-corrected visual acuity (BCVA) using Early Treatment Diabetic Retinopathy Study (ETDRS) charts and standardized automated perimetry.",
      "We defined progression as ≥10 ETDRS letter loss (also analyzed ≥15 ETDRS letter loss) or worsening of censored corrected average total deviation (avgTD) using quantile regression to define progression and recovery thresholds.",
      "We evaluated systemic and ophthalmic features associated with progression.",
      "From screening to Day 1, 7.3% (43/583) eyes had ≥10 ETDRS letter loss and 4.1% eyes had ≥15 ETDRS letter loss.",
      "Diabetes mellitus, hypertension, hyperlipidemia (HLD), and cardiovascular risk factors did not increase risk of progression.",
      "Previous fellow-eye (FE) NAION and obstructive sleep apnea (OSA) were significantly associated with ≥10 ETDRS letter loss.",
      "Only FE NAION remained a risk factor ≥ 15 ETDRS letter loss.",
      "Of the 167 sham-injected eyes with screening to Month 2 evaluation, 21.6% (36/167) had ≥10 ETDRS letter loss and 14.4% (24/167) had ≥15 ETDRS letter loss.",
      "91.6% of eyes (33/36) progressed within 22 days of symptom onset (by Day 8).",
      "Of the 139 sham-injected eyes with Day 1 to Month 2 evaluation, 18.7% had ≥10 ETDRS letter loss and 13.7% had ≥15 ETDRS letter loss.",
      "TD progression from screening to Day 1 occurred in 32.1% (192/599) eyes, 66.1% remained stable, and 1.8% improved.",
      "FE NAION and HLD were associated with TD progression.",
      "Worsening of vision in NAION occurs acutely.",
      "The results do not support cardiovascular risk factors as important hazard features for NAION progression.",
      "The only consistent factor associated with progression for both BCVA and VF loss was previous FE NAION."
    ],
    "summary_sentences": [
      "To report the true frequency and risk factors for acute NAION progression and identify modifiable features to reduce vision worsening.",
      "Secondary case-control analysis of the QRK207 multicenter, double-masked, sham-controlled, randomized clinical trial.",
      "We analyzed 599 study eyes with acute NAION (of 729 individuals prospectively enrolled in the QRK207 trial) with separate screening and Day 1 (mean 2.5-day interval) evaluations for progression.",
      "No participants included in this analysis received treatment.",
      "The Month 2 analysis included only the 167 sham-injected study eyes.",
      "Visual outcomes were assessed using best-corrected visual acuity (BCVA) using Early Treatment Diabetic Retinopathy Study (ETDRS) charts and standardized automated perimetry.",
      "We defined progression as ≥10 ETDRS letter loss (also analyzed ≥15 ETDRS letter loss) or worsening of censored corrected average total deviation (avgTD) using quantile regression to define progression and recovery thresholds.",
      "We evaluated systemic and ophthalmic features associated with progression.",
      "From screening to Day 1, 7.3% (43/583) eyes had ≥10 ETDRS letter loss and 4.1% eyes had ≥15 ETDRS letter loss.",
      "Diabetes mellitus, hypertension, hyperlipidemia (HLD), and cardiovascular risk factors did not increase risk of progression.",
      "Previous fellow-eye (FE) NAION and obstructive sleep apnea (OSA) were significantly associated with ≥10 ETDRS letter loss.",
      "Only FE NAION remained a risk factor ≥ 15 ETDRS letter loss.",
      "Of the 167 sham-injected eyes with screening to Month 2 evaluation, 21.6% (36/167) had ≥10 ETDRS letter loss and 14.4% (24/167) had ≥15 ETDRS letter loss.",
      "91.6% of eyes (33/36) progressed within 22 days of symptom onset (by Day 8).",
      "Of the 139 sham-injected eyes with Day 1 to Month 2 evaluation, 18.7% had ≥10 ETDRS letter loss and 13.7% had ≥15 ETDRS letter loss.",
      "TD progression from screening to Day 1 occurred in 32.1% (192/599) eyes, 66.1% remained stable, and 1.8% improved.",
      "FE NAION and HLD were associated with TD progression.",
      "Worsening of vision in NAION occurs acutely.",
      "The results do not support cardiovascular risk factors as important hazard features for NAION progression.",
      "The only consistent factor associated with progression for both BCVA and VF loss was previous FE NAION."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41543854",
    "source": "pubmed",
    "sentences": [
      "Berberine is a potential therapy for metabolic disorders, yet its effects on visceral adipose tissue (VAT) and liver fat remain uncertain.",
      "To evaluate the efficacy and safety of berberine in reducing VAT area and liver fat content in diabetes-free individuals with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD).",
      "In this multicenter, double-blind randomized clinical trial, diabetes-free individuals with obesity and MASLD were enrolled at 11 hospitals in China between July 6 and December 29, 2023, with a follow-up duration of 6 months.",
      "Participants were randomly assigned to receive either oral berberine, 1 g/d, or a matching placebo.",
      "The primary outcomes were relative percentage change in VAT area and absolute change in liver fat content assessed by computed tomography.",
      "Other outcomes included changes in parameters of glucose, lipids, and inflammation.",
      "Analyses were conducted according to the intention-to-treat principle.",
      "Among 337 randomized participants (mean [SD] age, 41.8",
      "[10.6] years; 221 [65.6%] male), 169 received berberine and 168 placebo.",
      "The mean (SD) medication adherence rates were 90.3% (14.7%) for berberine and 90.7% (17.4%) for placebo.",
      "No significant differences were observed between study arms for VAT area (1.4% [97.5% CI, -2.4% to 5.2%]) or liver fat content (0.9% [97.5% CI, -0.4% to 2.1%).",
      "Berberine was associated with larger reductions in low-density lipoprotein cholesterol (-7.72 [95% CI, -13.13 to -1.93] mg/dL), apolipoprotein B (-3.42",
      "[95% CI, -6.33 to -0.51] mg/dL) and high-sensitivity C-reactive protein (hs-CRP) (-0.072",
      "[95% CI, -0.140 to -0.004] mg/dL) vs placebo, but not other secondary outcomes.",
      "The incidence of adverse events was similar between study arms.",
      "Post hoc analyses suggested consistent patterns of larger reductions in low-density lipoprotein cholesterol, apolipoprotein B, and hs-CRP levels in participants with higher baseline hs-CRP levels.",
      "In this randomized clinical trial of diabetes-free individuals with obesity and MASLD, a 6-month berberine treatment at a daily dose of 1 g had an excellent safety profile but did not reduce VAT area or liver fat content.",
      "ClinicalTrials.gov",
      "Identifier: NCT05647915."
    ],
    "summary_sentences": [
      "Berberine is a potential therapy for metabolic disorders, yet its effects on visceral adipose tissue (VAT) and liver fat remain uncertain.",
      "To evaluate the efficacy and safety of berberine in reducing VAT area and liver fat content in diabetes-free individuals with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD).",
      "In this multicenter, double-blind randomized clinical trial, diabetes-free individuals with obesity and MASLD were enrolled at 11 hospitals in China between July 6 and December 29, 2023, with a follow-up duration of 6 months.",
      "Participants were randomly assigned to receive either oral berberine, 1 g/d, or a matching placebo.",
      "The primary outcomes were relative percentage change in VAT area and absolute change in liver fat content assessed by computed tomography.",
      "Other outcomes included changes in parameters of glucose, lipids, and inflammation.",
      "Analyses were conducted according to the intention-to-treat principle.",
      "Among 337 randomized participants (mean [SD] age, 41.8",
      "[10.6] years; 221 [65.6%] male), 169 received berberine and 168 placebo.",
      "The mean (SD) medication adherence rates were 90.3% (14.7%) for berberine and 90.7% (17.4%) for placebo.",
      "No significant differences were observed between study arms for VAT area (1.4% [97.5% CI, -2.4% to 5.2%]) or liver fat content (0.9% [97.5% CI, -0.4% to 2.1%).",
      "Berberine was associated with larger reductions in low-density lipoprotein cholesterol (-7.72 [95% CI, -13.13 to -1.93] mg/dL), apolipoprotein B (-3.42",
      "[95% CI, -6.33 to -0.51] mg/dL) and high-sensitivity C-reactive protein (hs-CRP) (-0.072",
      "[95% CI, -0.140 to -0.004] mg/dL) vs placebo, but not other secondary outcomes.",
      "The incidence of adverse events was similar between study arms.",
      "Post hoc analyses suggested consistent patterns of larger reductions in low-density lipoprotein cholesterol, apolipoprotein B, and hs-CRP levels in participants with higher baseline hs-CRP levels.",
      "In this randomized clinical trial of diabetes-free individuals with obesity and MASLD, a 6-month berberine treatment at a daily dose of 1 g had an excellent safety profile but did not reduce VAT area or liver fat content.",
      "ClinicalTrials.gov",
      "Identifier: NCT05647915."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41543478",
    "source": "pubmed",
    "sentences": [
      "Metabolic dysfunction-associated steatohepatitis (MASH) is the most common chronic liver disease worldwide, with a particularly high incidence among individuals with type 2 diabetes and obesity.",
      "Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as effective weight loss agents, with growing evidence suggesting potential benefits in MASH.",
      "This study aimed to evaluate the efficacy and safety of GLP-1RAs in improving the histologic features of MASH.",
      "This study is a meta-analysis of randomized controlled trials evaluating the effect of FDA-approved GLP-1RAs in patients with biopsy-confirmed MASH, up to May 2025.",
      "The primary outcomes were resolution of MASH without worsening of fibrosis and a ≥1 improvement in fibrosis stage without worsening of MASH at 12-18 months.",
      "Secondary outcomes included ≥1-point improvements in the nonalcoholic fatty liver disease activity score, changes in liver histologic features, and the incidence of serious adverse events.",
      "A total of 6 randomized controlled trials with 1555 patients (1082 GLP-1RA and 473 placebo) with MASH were included.",
      "At 18 months, a significantly greater proportion of patients in the GLP-1RA group achieved MASH resolution without worsening fibrosis compared with the placebo group (OR: 4.16, 95% CI: 2.33-7.42, p<0.001).",
      "A subgroup analysis excluding studies with patients with cirrhosis showed a significant benefit on fibrosis regression (OR: 2.02, 95% CI: 1.56-2.62, p=0.01).",
      "GLP-1RAs significantly improved nonalcoholic fatty liver disease activity scores and liver histologic features, including balloon degeneration, lobular inflammation, and steatosis, compared with placebo.",
      "The pooled serious adverse event rate for GLP-1RAs was comparable to placebo.",
      "In patients with noncirrhotic MASH, GLP-1RAs appear to be associated with both MASH resolution without fibrosis worsening and ≥1-stage fibrosis regression without MASH worsening."
    ],
    "summary_sentences": [
      "Metabolic dysfunction-associated steatohepatitis (MASH) is the most common chronic liver disease worldwide, with a particularly high incidence among individuals with type 2 diabetes and obesity.",
      "Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as effective weight loss agents, with growing evidence suggesting potential benefits in MASH.",
      "This study aimed to evaluate the efficacy and safety of GLP-1RAs in improving the histologic features of MASH.",
      "This study is a meta-analysis of randomized controlled trials evaluating the effect of FDA-approved GLP-1RAs in patients with biopsy-confirmed MASH, up to May 2025.",
      "The primary outcomes were resolution of MASH without worsening of fibrosis and a ≥1 improvement in fibrosis stage without worsening of MASH at 12-18 months.",
      "Secondary outcomes included ≥1-point improvements in the nonalcoholic fatty liver disease activity score, changes in liver histologic features, and the incidence of serious adverse events.",
      "A total of 6 randomized controlled trials with 1555 patients (1082 GLP-1RA and 473 placebo) with MASH were included.",
      "At 18 months, a significantly greater proportion of patients in the GLP-1RA group achieved MASH resolution without worsening fibrosis compared with the placebo group (OR: 4.16, 95% CI: 2.33-7.42, p<0.001).",
      "A subgroup analysis excluding studies with patients with cirrhosis showed a significant benefit on fibrosis regression (OR: 2.02, 95% CI: 1.56-2.62, p=0.01).",
      "GLP-1RAs significantly improved nonalcoholic fatty liver disease activity scores and liver histologic features, including balloon degeneration, lobular inflammation, and steatosis, compared with placebo.",
      "The pooled serious adverse event rate for GLP-1RAs was comparable to placebo.",
      "In patients with noncirrhotic MASH, GLP-1RAs appear to be associated with both MASH resolution without fibrosis worsening and ≥1-stage fibrosis regression without MASH worsening."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41541001",
    "source": "pubmed",
    "sentences": [
      "The objective of this study is to explore the effect of bedside normobaric saturated oxygen inhalation combined with upper and lower limb rehabilitation training on diabetic lower extremity arterial disease (LEAD).",
      "From January 2022 to December 2023, 60 DM-LEAD patients from the Second Hospital of Hebei Medical University were randomly divided into control (30 cases) and study (30 cases) groups.",
      "Both received standard treatment; the control group added MOTOmed-based limb rehabilitation training, and the study group further received atmospheric saturated oxygen therapy.",
      "Pre- and posttreatment indices (VAS, Barthel index, blood glucose, blood lipid, inflammatory factors, ABI, TcPO Both groups improved posttreatment (all The combined therapy improves pain and daily living abilities, delays DM-LEAD progression, may reduce amputation risk, and improves outcomes.",
      "Long-term effects need further study."
    ],
    "summary_sentences": [
      "The objective of this study is to explore the effect of bedside normobaric saturated oxygen inhalation combined with upper and lower limb rehabilitation training on diabetic lower extremity arterial disease (LEAD).",
      "From January 2022 to December 2023, 60 DM-LEAD patients from the Second Hospital of Hebei Medical University were randomly divided into control (30 cases) and study (30 cases) groups.",
      "Both received standard treatment; the control group added MOTOmed-based limb rehabilitation training, and the study group further received atmospheric saturated oxygen therapy.",
      "Pre- and posttreatment indices (VAS, Barthel index, blood glucose, blood lipid, inflammatory factors, ABI, TcPO Both groups improved posttreatment (all The combined therapy improves pain and daily living abilities, delays DM-LEAD progression, may reduce amputation risk, and improves outcomes.",
      "Long-term effects need further study."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41540820",
    "source": "pubmed",
    "sentences": [
      "IntroductionIn the health technology assessment (HTA) of biologic treatments for rheumatoid arthritis (RA), there is limited randomized evidence on treatment effectiveness after first-line treatment failure.",
      "We demonstrate how real-world data (RWD) could fill this evidence gap.",
      "MethodsTarget trial emulation (TTE) minimizes biases in the causal analysis of RWD by prespecifying a protocol for a hypothetical randomized clinical trial (RCT) that would estimate the effect of interest.",
      "The application of TTE for HTA was illustrated using RWD from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis to estimate the effectiveness of rituximab versus nonbiologic therapy (NBT) after first-line biologic failure, in terms of European Alliance of Associations for Rheumatology response achievement.",
      "The effectiveness estimates from RWD were combined with RCT estimates in a meta-analysis.",
      "The pooled estimates were entered into an economic model to estimate the incremental cost-effectiveness ratio (ICER) comparing biologic versus NBT strategies.",
      "ResultsBased on RWD, rituximab was associated with higher probabilities of achieving a moderate or good response (0.215 v. 0.174) and a good response (0.090 v. 0.066) as compared with NBT.",
      "These probabilities were lower than those estimated from RCT data (moderate or good 0.650; good 0.150).",
      "The economic model estimated less time on treatment and lower costs associated with biologics when based on RWD compared with RCT data (mean £63,500 v. £70,000).",
      "This resulted in a higher ICER based on RWD compared with RCT data (mean £46,800 v. £34,700 per quality-adjusted life-year gained).ConclusionsRWD can provide supplemental evidence on treatment effectiveness where randomized evidence is limited.",
      "This can make a meaningful difference to cost-effectiveness estimates.",
      "Our results are not intended to inform current RA management.",
      "HighlightsIn health technology assessment, real-world data (RWD) can provide supplemental evidence on treatment effectiveness where there is limited randomized evidence.",
      "Target trial emulation was applied using RWD to estimate the clinical effectiveness of biologic treatment; these estimates were combined with estimates from an RCT in a meta-analysis, and the pooled estimates were entered into an economic model for rheumatoid arthritis.",
      "Treatment effect estimates based on combining RWD and RCT data were more modest compared with the effectiveness estimates from the RCT data alone, leading to a difference in the estimate of cost-effectiveness comparing biologics with nonbiologic therapy."
    ],
    "summary_sentences": [
      "IntroductionIn the health technology assessment (HTA) of biologic treatments for rheumatoid arthritis (RA), there is limited randomized evidence on treatment effectiveness after first-line treatment failure.",
      "We demonstrate how real-world data (RWD) could fill this evidence gap.",
      "MethodsTarget trial emulation (TTE) minimizes biases in the causal analysis of RWD by prespecifying a protocol for a hypothetical randomized clinical trial (RCT) that would estimate the effect of interest.",
      "The application of TTE for HTA was illustrated using RWD from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis to estimate the effectiveness of rituximab versus nonbiologic therapy (NBT) after first-line biologic failure, in terms of European Alliance of Associations for Rheumatology response achievement.",
      "The effectiveness estimates from RWD were combined with RCT estimates in a meta-analysis.",
      "The pooled estimates were entered into an economic model to estimate the incremental cost-effectiveness ratio (ICER) comparing biologic versus NBT strategies.",
      "ResultsBased on RWD, rituximab was associated with higher probabilities of achieving a moderate or good response (0.215 v. 0.174) and a good response (0.090 v. 0.066) as compared with NBT.",
      "These probabilities were lower than those estimated from RCT data (moderate or good 0.650; good 0.150).",
      "The economic model estimated less time on treatment and lower costs associated with biologics when based on RWD compared with RCT data (mean £63,500 v. £70,000).",
      "This resulted in a higher ICER based on RWD compared with RCT data (mean £46,800 v. £34,700 per quality-adjusted life-year gained).ConclusionsRWD can provide supplemental evidence on treatment effectiveness where randomized evidence is limited.",
      "This can make a meaningful difference to cost-effectiveness estimates.",
      "Our results are not intended to inform current RA management.",
      "HighlightsIn health technology assessment, real-world data (RWD) can provide supplemental evidence on treatment effectiveness where there is limited randomized evidence.",
      "Target trial emulation was applied using RWD to estimate the clinical effectiveness of biologic treatment; these estimates were combined with estimates from an RCT in a meta-analysis, and the pooled estimates were entered into an economic model for rheumatoid arthritis.",
      "Treatment effect estimates based on combining RWD and RCT data were more modest compared with the effectiveness estimates from the RCT data alone, leading to a difference in the estimate of cost-effectiveness comparing biologics with nonbiologic therapy."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41540694",
    "source": "pubmed",
    "sentences": [
      "To explore the therapeutic mechanism of The active components and disease targets of JZQBR were screened using TCMSP and GeneCards databases, followed by protein-protein interaction analysis and GO and KEGG enrichment analyses.",
      "In the animal experiments, Network pharmacology identified 65 potential targets, with quercetin, kaempferol, and luteolin as the core components and IL-6, IL-1β, and TNF‑α as the key targets.",
      "The targets were enriched mainly in the pathways involving inflammatory responses and diabetic complications.",
      "In the JZQBR improves T2DM complicated with hyperlipidemia possibly by multi-target regulation of the inflammation-metabolism network."
    ],
    "summary_sentences": [
      "To explore the therapeutic mechanism of The active components and disease targets of JZQBR were screened using TCMSP and GeneCards databases, followed by protein-protein interaction analysis and GO and KEGG enrichment analyses.",
      "In the animal experiments, Network pharmacology identified 65 potential targets, with quercetin, kaempferol, and luteolin as the core components and IL-6, IL-1β, and TNF‑α as the key targets.",
      "The targets were enriched mainly in the pathways involving inflammatory responses and diabetic complications.",
      "In the JZQBR improves T2DM complicated with hyperlipidemia possibly by multi-target regulation of the inflammation-metabolism network."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41540107",
    "source": "pubmed",
    "sentences": [
      "In patients with stable coronary artery disease (CAD), the long-term benefits of revascularization over medical therapy remain unclear.",
      "In the Fractional Flow Reserve versus Angiography for Multivessel Evaluation 2 trial, patients with hemodynamically significant stenoses (fractional flow reserve (FFR) ≤ 0.80) were randomized to receive FFR-guided percutaneous coronary intervention (PCI) plus medical therapy (n = 447) or medical therapy alone (n = 441).",
      "At 5 years, FFR-guided PCI reduced the risk of the primary composite outcome of time to death, myocardial infarction or urgent revascularization, largely because of fewer urgent revascularizations.",
      "We now report the long-term clinical outcomes from this trial.",
      "Sixteen hospitals, contributing 748 randomized patients (161 women, 21.5%), participated in the long-term follow-up.",
      "The primary composite outcome was analyzed hierarchically using the unstratified win ratio, which addressed differential missingness of data on nonfatal outcomes in deceased patients by prioritizing comparisons on time to death.",
      "At a median follow-up of 11.2 years, the primary endpoint occurred in 150 of 447 patients (33.6%) in the PCI group versus 182 of 441 (41.3%) in the medical therapy group.",
      "PCI was superior in 29.2% of comparisons, medical therapy in 23.3%, and the two groups were tied in 47.5%, resulting in a win ratio of 1.25 in favor of PCI (95% confidence interval (CI) 1.01-1.56, P = 0.043).",
      "The corresponding win difference was 5.9% (95% CI 0.2-11.6), and the number needed to treat was 17 (95% CI 9-500).",
      "Win ratios were 0.88 for all-cause death (95% CI 0.66-1.17), 1.50 for myocardial infarction (95% CI 0.98-2.31) and 4.57 for urgent revascularization (95% CI 2.53-8.24).",
      "During long-term follow-up, FFR-guided PCI in patients with stable CAD and hemodynamically significant stenoses reduced the composite of death, myocardial infarction or urgent revascularization, primarily because of fewer urgent revascularizations.",
      "These long-term findings reaffirm the efficacy of FFR-guided PCI over medical therapy in patients with stable CAD.",
      "ClinicalTrials.gov",
      "registration: NCT06159231 ."
    ],
    "summary_sentences": [
      "In patients with stable coronary artery disease (CAD), the long-term benefits of revascularization over medical therapy remain unclear.",
      "In the Fractional Flow Reserve versus Angiography for Multivessel Evaluation 2 trial, patients with hemodynamically significant stenoses (fractional flow reserve (FFR) ≤ 0.80) were randomized to receive FFR-guided percutaneous coronary intervention (PCI) plus medical therapy (n = 447) or medical therapy alone (n = 441).",
      "At 5 years, FFR-guided PCI reduced the risk of the primary composite outcome of time to death, myocardial infarction or urgent revascularization, largely because of fewer urgent revascularizations.",
      "We now report the long-term clinical outcomes from this trial.",
      "Sixteen hospitals, contributing 748 randomized patients (161 women, 21.5%), participated in the long-term follow-up.",
      "The primary composite outcome was analyzed hierarchically using the unstratified win ratio, which addressed differential missingness of data on nonfatal outcomes in deceased patients by prioritizing comparisons on time to death.",
      "At a median follow-up of 11.2 years, the primary endpoint occurred in 150 of 447 patients (33.6%) in the PCI group versus 182 of 441 (41.3%) in the medical therapy group.",
      "PCI was superior in 29.2% of comparisons, medical therapy in 23.3%, and the two groups were tied in 47.5%, resulting in a win ratio of 1.25 in favor of PCI (95% confidence interval (CI) 1.01-1.56, P = 0.043).",
      "The corresponding win difference was 5.9% (95% CI 0.2-11.6), and the number needed to treat was 17 (95% CI 9-500).",
      "Win ratios were 0.88 for all-cause death (95% CI 0.66-1.17), 1.50 for myocardial infarction (95% CI 0.98-2.31) and 4.57 for urgent revascularization (95% CI 2.53-8.24).",
      "During long-term follow-up, FFR-guided PCI in patients with stable CAD and hemodynamically significant stenoses reduced the composite of death, myocardial infarction or urgent revascularization, primarily because of fewer urgent revascularizations.",
      "These long-term findings reaffirm the efficacy of FFR-guided PCI over medical therapy in patients with stable CAD.",
      "ClinicalTrials.gov",
      "registration: NCT06159231 ."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41539943",
    "source": "pubmed",
    "sentences": [
      "This review compared antiobesity strategies-obesity management medications (OMM), endoscopic bariatric procedures (EBP), and metabolic bariatric surgery (MBS)-with lifestyle intervention, placebo, or no therapy (LSI/Pbo/NT).",
      "This network meta-analysis included randomized clinical trials comparing OMM, EBP, and MBS versus LSI/Pbo/NT or active comparators in adults with obesity.",
      "MEDLINE and Embase were searched up to December 1, 2024.",
      "The primary endpoint was total body weight loss percentage (TBWL%), analyzed at 26-52, 53-104, 105-156, and ≥ 156 weeks.",
      "This study was registered with PROSPERO (CRD42024623707).",
      "Of 139 RCTs, 54 evaluated MBS (n = 61,961), 21 EBP (n = 2934), and 64 OMM (n = 5991).",
      "At 26-52 weeks, most treatments showed significant effects versus the reference.",
      "TBWL% exceeded 10% with most surgeries and tirzepatide.",
      "Long-term data were lacking for most OMM and all EBP.",
      "Most treatments maintained their efficacy over time, except greater curvature plication.",
      "EBP and MBS were generally associated with a higher SAE risk than OMM; BPD showed the highest long-term SAE incidence.",
      "MBS appears superior in the long term (particularly for higher-efficacy procedures, such as RYGB, SG, SADI, and BPD).",
      "EBP, except ESG, was less effective than newer OMM.",
      "Semaglutide and tirzepatide showed no inferior short-term results in comparison with MBS."
    ],
    "summary_sentences": [
      "This review compared antiobesity strategies-obesity management medications (OMM), endoscopic bariatric procedures (EBP), and metabolic bariatric surgery (MBS)-with lifestyle intervention, placebo, or no therapy (LSI/Pbo/NT).",
      "This network meta-analysis included randomized clinical trials comparing OMM, EBP, and MBS versus LSI/Pbo/NT or active comparators in adults with obesity.",
      "MEDLINE and Embase were searched up to December 1, 2024.",
      "The primary endpoint was total body weight loss percentage (TBWL%), analyzed at 26-52, 53-104, 105-156, and ≥ 156 weeks.",
      "This study was registered with PROSPERO (CRD42024623707).",
      "Of 139 RCTs, 54 evaluated MBS (n = 61,961), 21 EBP (n = 2934), and 64 OMM (n = 5991).",
      "At 26-52 weeks, most treatments showed significant effects versus the reference.",
      "TBWL% exceeded 10% with most surgeries and tirzepatide.",
      "Long-term data were lacking for most OMM and all EBP.",
      "Most treatments maintained their efficacy over time, except greater curvature plication.",
      "EBP and MBS were generally associated with a higher SAE risk than OMM; BPD showed the highest long-term SAE incidence.",
      "MBS appears superior in the long term (particularly for higher-efficacy procedures, such as RYGB, SG, SADI, and BPD).",
      "EBP, except ESG, was less effective than newer OMM.",
      "Semaglutide and tirzepatide showed no inferior short-term results in comparison with MBS."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41539443",
    "source": "pubmed",
    "sentences": [
      "We evaluated the effectiveness of a lifestyle modification (LSM) intervention in prediabetes remission among women with isolated impaired fasting glucose (i-IFG).",
      "We conducted a community-based, parallel-group, open-label, randomised controlled trial in Kerala, India.",
      "Women aged 30-60 years with i-IFG were randomly assigned (1:1) to receive either a 12-month LSM program or standard care (diabetes information booklet).",
      "Randomization was computer-generated with allocation concealed until assignment.",
      "The primary outcome was prediabetes remission based on oral glucose tolerance testing at 12 months.",
      "Secondary outcomes included progression to type 2 diabetes and changes in glycaemic markers, anthropometric measures, body composition, and blood pressure.",
      "Analyses followed the intention-to-treat approach.",
      "Of 1092 participants randomised, 1080 (98.9 %) completed the 12-month follow-up.",
      "Prediabetes remission was significantly higher in the LSM group than in controls (45.9 % vs 6.3 %; RR 7.04, 95 % CI 5.12-10.06).",
      "LSM also produced greater improvements in fasting plasma glucose (-5.2 mg/dL), HbA1c (-0.09 %), HOMA2-IR (log) (-0.38), weight (-3.7 kg), waist circumference (-1.4 cm), fat mass (-2.9 kg), and fat-free mass (+0.86 kg).",
      "The number needed to treat for prediabetes remission was 2.8 (1.8-4.0).",
      "A structured LSM intervention effectively promotes prediabetes remission in women with i-IFG and improves cardio metabolic health."
    ],
    "summary_sentences": [
      "We evaluated the effectiveness of a lifestyle modification (LSM) intervention in prediabetes remission among women with isolated impaired fasting glucose (i-IFG).",
      "We conducted a community-based, parallel-group, open-label, randomised controlled trial in Kerala, India.",
      "Women aged 30-60 years with i-IFG were randomly assigned (1:1) to receive either a 12-month LSM program or standard care (diabetes information booklet).",
      "Randomization was computer-generated with allocation concealed until assignment.",
      "The primary outcome was prediabetes remission based on oral glucose tolerance testing at 12 months.",
      "Secondary outcomes included progression to type 2 diabetes and changes in glycaemic markers, anthropometric measures, body composition, and blood pressure.",
      "Analyses followed the intention-to-treat approach.",
      "Of 1092 participants randomised, 1080 (98.9 %) completed the 12-month follow-up.",
      "Prediabetes remission was significantly higher in the LSM group than in controls (45.9 % vs 6.3 %; RR 7.04, 95 % CI 5.12-10.06).",
      "LSM also produced greater improvements in fasting plasma glucose (-5.2 mg/dL), HbA1c (-0.09 %), HOMA2-IR (log) (-0.38), weight (-3.7 kg), waist circumference (-1.4 cm), fat mass (-2.9 kg), and fat-free mass (+0.86 kg).",
      "The number needed to treat for prediabetes remission was 2.8 (1.8-4.0).",
      "A structured LSM intervention effectively promotes prediabetes remission in women with i-IFG and improves cardio metabolic health."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41539381",
    "source": "pubmed",
    "sentences": [
      "Influenza infection is a well-established trigger of severe respiratory and cardiovascular complications, particularly in older adults, frail individuals, and patients with underlying cardiovascular disease.",
      "Seasonal peaks are consistently associated with excess hospitalizations and mortality.",
      "Epidemiological studies have shown sharp increases in acute cardiac events during and immediately after influenza infection, including a high-rate of acute coronary syndromes and heart failure.",
      "The cardiovascular impact of influenza is mediated by multiple mechanisms.",
      "Systemic inflammation, plaque destabilization, metabolic imbalance, endothelial dysfunction, and pro-thrombotic activation collectively contribute to acute coronary syndromes, myocarditis, arrhythmias, and acute or worsening heart failure.",
      "These complications generate a substantial clinical and socioeconomic burden, particularly in elderly and high-risk individuals.",
      "Despite the availability of effective and inexpensive vaccines, influenza vaccination remains underused in high-risk cardiovascular populations.",
      "Randomized trials and meta-analyses consistently support vaccination as a powerful preventive tool, associated with a 25-37% reduction in major adverse cardiovascular events and mortality, with benefits comparable to established cardioprotective therapies.",
      "Evidence is strongest in patients with coronary artery disease, ACS, diabetes, and in older adults, although results in heart failure populations remain more heterogeneous.",
      "Enhanced vaccines including adjuvanted, high-dose, and cell-based formulations offer superior protection in elderly and immunocompromised individuals and are increasingly recommended by national and international health authorities.",
      "Given the robust evidence linking influenza to cardiovascular events and the proven protective role of vaccination, systematic implementation of tailored influenza immunization strategies in patients with CVD is essential to optimize preventive care."
    ],
    "summary_sentences": [
      "Influenza infection is a well-established trigger of severe respiratory and cardiovascular complications, particularly in older adults, frail individuals, and patients with underlying cardiovascular disease.",
      "Seasonal peaks are consistently associated with excess hospitalizations and mortality.",
      "Epidemiological studies have shown sharp increases in acute cardiac events during and immediately after influenza infection, including a high-rate of acute coronary syndromes and heart failure.",
      "The cardiovascular impact of influenza is mediated by multiple mechanisms.",
      "Systemic inflammation, plaque destabilization, metabolic imbalance, endothelial dysfunction, and pro-thrombotic activation collectively contribute to acute coronary syndromes, myocarditis, arrhythmias, and acute or worsening heart failure.",
      "These complications generate a substantial clinical and socioeconomic burden, particularly in elderly and high-risk individuals.",
      "Despite the availability of effective and inexpensive vaccines, influenza vaccination remains underused in high-risk cardiovascular populations.",
      "Randomized trials and meta-analyses consistently support vaccination as a powerful preventive tool, associated with a 25-37% reduction in major adverse cardiovascular events and mortality, with benefits comparable to established cardioprotective therapies.",
      "Evidence is strongest in patients with coronary artery disease, ACS, diabetes, and in older adults, although results in heart failure populations remain more heterogeneous.",
      "Enhanced vaccines including adjuvanted, high-dose, and cell-based formulations offer superior protection in elderly and immunocompromised individuals and are increasingly recommended by national and international health authorities.",
      "Given the robust evidence linking influenza to cardiovascular events and the proven protective role of vaccination, systematic implementation of tailored influenza immunization strategies in patients with CVD is essential to optimize preventive care."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41536962",
    "source": "pubmed",
    "sentences": [
      "Little is known regarding strategies to improve influenza vaccination uptake among individuals with atrial fibrillation (AF).",
      "We assessed the effect of electronically delivered behavioural nudges on influenza vaccination uptake and clinical outcomes according to AF status.",
      "This is a prespecified analysis of the nationwide randomized NUDGE-FLU-CHRONIC trial in which citizens aged 18-64 years with a chronic disease were randomized to usual care or six different electronic nudge letters aiming to increase influenza vaccination uptake during the 2023-2024 influenza season.",
      "The primary endpoint was receipt of an influenza vaccine on or before 1 January 2024.",
      "We reported absolute differences and relative risks (RRs) of each intervention letter vs. usual care on influenza vaccination uptake and assessed effect modification by AF status using binomial regression.",
      "Among 299 881 randomized participants, 19 481 (6.5%) had a history of AF (median age 58.5 years, 27.8% female).",
      "During follow-up, 41.5% of participants with a history of AF received influenza vaccination compared with 35.8% of those without ( In this prespecified, secondary analysis, electronic nudge letters highlighting the importance of influenza vaccination were especially effective in increasing influenza vaccination uptake among young and middle-aged adults with AF, supporting simple electronic letters as an efficient public health strategy to improve vaccination coverage in high-risk groups."
    ],
    "summary_sentences": [
      "Little is known regarding strategies to improve influenza vaccination uptake among individuals with atrial fibrillation (AF).",
      "We assessed the effect of electronically delivered behavioural nudges on influenza vaccination uptake and clinical outcomes according to AF status.",
      "This is a prespecified analysis of the nationwide randomized NUDGE-FLU-CHRONIC trial in which citizens aged 18-64 years with a chronic disease were randomized to usual care or six different electronic nudge letters aiming to increase influenza vaccination uptake during the 2023-2024 influenza season.",
      "The primary endpoint was receipt of an influenza vaccine on or before 1 January 2024.",
      "We reported absolute differences and relative risks (RRs) of each intervention letter vs. usual care on influenza vaccination uptake and assessed effect modification by AF status using binomial regression.",
      "Among 299 881 randomized participants, 19 481 (6.5%) had a history of AF (median age 58.5 years, 27.8% female).",
      "During follow-up, 41.5% of participants with a history of AF received influenza vaccination compared with 35.8% of those without ( In this prespecified, secondary analysis, electronic nudge letters highlighting the importance of influenza vaccination were especially effective in increasing influenza vaccination uptake among young and middle-aged adults with AF, supporting simple electronic letters as an efficient public health strategy to improve vaccination coverage in high-risk groups."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41536501",
    "source": "pubmed",
    "sentences": [
      "Metabolic and bariatric surgery (MBS) is an effective treatment for adolescent severe obesity.",
      "Little is known about subsequent healthcare utilisation for individuals who have undergone MBS as adolescents, both related and unrelated to the surgical intervention.",
      "This study aimed to document healthcare utilisation events across 5 years after MBS, comparing procedure types and evaluating factors associated with these events.",
      "The Teen-Longitudinal Assessment of Bariatric Surgery (Teen-LABS) study prospectively enrolled 228 adolescents prior to MBS (Roux-en-Y gastric bypass or vertical sleeve gastrectomy) across 5 US children's hospitals.",
      "Healthcare utilisation event data collection was standardised, and rigorously collected; events were categorised by system and classified as related or unrelated to the MBS intervention.",
      "Factors influencing/predicting the likelihood of healthcare utilisation events were evaluated using negative binomial regression modelling.",
      "Mean baseline age and body mass index (BMI) of participants at surgery were 17 ± 1·6 years and 53 kg/m Healthcare utilisation events were common after bariatric surgery and early post-operative surgical complications predicted later healthcare utilisation events.",
      "Healthcare utilisation events were more common after sleeve gastrectomy than RYGB in patients without type 2 diabetes at baseline.",
      "Findings will better inform surgical candidates of real-world expectations after surgery, and allow providers to consider closer monitoring of those with a 30-day healthcare utilisation event.",
      "National Institutes for Health (NIH) research support was provided through the following grants: NIH UM1DK072493 and NIH UM1DK095710.",
      "The contents of this manuscript are the authors' sole responsibility and do not necessarily represent official NIH views."
    ],
    "summary_sentences": [
      "Metabolic and bariatric surgery (MBS) is an effective treatment for adolescent severe obesity.",
      "Little is known about subsequent healthcare utilisation for individuals who have undergone MBS as adolescents, both related and unrelated to the surgical intervention.",
      "This study aimed to document healthcare utilisation events across 5 years after MBS, comparing procedure types and evaluating factors associated with these events.",
      "The Teen-Longitudinal Assessment of Bariatric Surgery (Teen-LABS) study prospectively enrolled 228 adolescents prior to MBS (Roux-en-Y gastric bypass or vertical sleeve gastrectomy) across 5 US children's hospitals.",
      "Healthcare utilisation event data collection was standardised, and rigorously collected; events were categorised by system and classified as related or unrelated to the MBS intervention.",
      "Factors influencing/predicting the likelihood of healthcare utilisation events were evaluated using negative binomial regression modelling.",
      "Mean baseline age and body mass index (BMI) of participants at surgery were 17 ± 1·6 years and 53 kg/m Healthcare utilisation events were common after bariatric surgery and early post-operative surgical complications predicted later healthcare utilisation events.",
      "Healthcare utilisation events were more common after sleeve gastrectomy than RYGB in patients without type 2 diabetes at baseline.",
      "Findings will better inform surgical candidates of real-world expectations after surgery, and allow providers to consider closer monitoring of those with a 30-day healthcare utilisation event.",
      "National Institutes for Health (NIH) research support was provided through the following grants: NIH UM1DK072493 and NIH UM1DK095710.",
      "The contents of this manuscript are the authors' sole responsibility and do not necessarily represent official NIH views."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41536268",
    "source": "pubmed",
    "sentences": [
      "A systematic review and meta-analysis of real-world studies on tirzepatide is essential to strengthen evidence of its effectiveness in improving glycated hemoglobin (HbA1c) and body weight in patients with type 2 diabetes.",
      "13 real-world studies (N = 89 296; duration 3-18 months) with moderate to serious bias revealed a mean HbA1c reduction of 0.91% (95% confidence interval [CI]: -1.04 to -0.79), weight loss of 9.7 kg (95% CI:",
      "-14.05 to -5.35), and body mass index decrease of 2.09 kg/m2 (95% CI: -3.27 to -0.92).",
      "Overall, 64% of tirzepatide users reached HbA1c <7%.",
      "Furthermore, tirzepatide lowered HbA1c (mean difference [MD] -0.38%; 95% CI: -0.44 to -0.33) and body weight (MD -6.27 kg; 95% CI: -9.22 to -0.33) more than the control.",
      "47%, 23%, 9%, and 4% of tirzepatide users lost ≥5%, ≥10%, ≥15%, and ≥ 20% of their baseline weight, respectively.",
      "Tirzepatide's effects on HbA1c and weight in observational studies support clinical trial findings."
    ],
    "summary_sentences": [
      "A systematic review and meta-analysis of real-world studies on tirzepatide is essential to strengthen evidence of its effectiveness in improving glycated hemoglobin (HbA1c) and body weight in patients with type 2 diabetes.",
      "13 real-world studies (N = 89 296; duration 3-18 months) with moderate to serious bias revealed a mean HbA1c reduction of 0.91% (95% confidence interval [CI]: -1.04 to -0.79), weight loss of 9.7 kg (95% CI:",
      "-14.05 to -5.35), and body mass index decrease of 2.09 kg/m2 (95% CI: -3.27 to -0.92).",
      "Overall, 64% of tirzepatide users reached HbA1c <7%.",
      "Furthermore, tirzepatide lowered HbA1c (mean difference [MD] -0.38%; 95% CI: -0.44 to -0.33) and body weight (MD -6.27 kg; 95% CI: -9.22 to -0.33) more than the control.",
      "47%, 23%, 9%, and 4% of tirzepatide users lost ≥5%, ≥10%, ≥15%, and ≥ 20% of their baseline weight, respectively.",
      "Tirzepatide's effects on HbA1c and weight in observational studies support clinical trial findings."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41535531",
    "source": "pubmed",
    "sentences": [
      "Chronic spontaneous urticaria (CSU) is a mast cell-driven disease that affects approximately 1% of the population.",
      "Second-generation non-sedating H"
    ],
    "summary_sentences": [
      "Chronic spontaneous urticaria (CSU) is a mast cell-driven disease that affects approximately 1% of the population.",
      "Second-generation non-sedating H"
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41534390",
    "source": "pubmed",
    "sentences": [
      "The optimal intensity of blood pressure (BP) control in patients with and without type 2 diabetes mellitus (T2D) remains unclear.",
      "We performed a systematic review and meta-analysis of randomized controlled trials comparing intensive versus standard BP control, stratified by T2D status.",
      "Primary outcomes were all-cause mortality and serious adverse events (SAEs); secondary outcomes included death from cardiovascular causes and occurrence of myocardial infarction (MI) and stroke.",
      "Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using DerSimonian-Laird random-effects models.",
      "Heterogeneity was assessed with the I Six trials comprising 41,210 participants were included.",
      "Intensive BP control significantly reduced death from cardiovascular causes (OR 0.72; 95% CI 0.56-0.93), incidence of MI (OR 0.85; 95% CI 0.74-0.97), and stroke (OR 0.78; 95% CI 0.68-0.89).",
      "The reduction in all-cause mortality was significant in patients without T2D (OR 0.73; 95% CI 0.59-0.90), but not in those with T2D (OR 0.99; 95% CI 0.85-1.14).",
      "Intensive control was associated with a non-significant increase in SAEs overall (OR 1.15; 95% CI 0.90-1.46), with higher estimates in patients with T2D. Intensive BP control reduces cardiovascular events and mortality in non-diabetic patients.",
      "In those with T2D, benefits are attenuated and may be counterbalanced by safety concerns.",
      "BP targets should be individualized based on diabetes status and clinical context."
    ],
    "summary_sentences": [
      "The optimal intensity of blood pressure (BP) control in patients with and without type 2 diabetes mellitus (T2D) remains unclear.",
      "We performed a systematic review and meta-analysis of randomized controlled trials comparing intensive versus standard BP control, stratified by T2D status.",
      "Primary outcomes were all-cause mortality and serious adverse events (SAEs); secondary outcomes included death from cardiovascular causes and occurrence of myocardial infarction (MI) and stroke.",
      "Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using DerSimonian-Laird random-effects models.",
      "Heterogeneity was assessed with the I Six trials comprising 41,210 participants were included.",
      "Intensive BP control significantly reduced death from cardiovascular causes (OR 0.72; 95% CI 0.56-0.93), incidence of MI (OR 0.85; 95% CI 0.74-0.97), and stroke (OR 0.78; 95% CI 0.68-0.89).",
      "The reduction in all-cause mortality was significant in patients without T2D (OR 0.73; 95% CI 0.59-0.90), but not in those with T2D (OR 0.99; 95% CI 0.85-1.14).",
      "Intensive control was associated with a non-significant increase in SAEs overall (OR 1.15; 95% CI 0.90-1.46), with higher estimates in patients with T2D. Intensive BP control reduces cardiovascular events and mortality in non-diabetic patients.",
      "In those with T2D, benefits are attenuated and may be counterbalanced by safety concerns.",
      "BP targets should be individualized based on diabetes status and clinical context."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41533371",
    "source": "pubmed",
    "sentences": [
      "Pancreas divisum is implicated as an obstructive cause for acute pancreatitis.",
      "Observational data suggest endoscopic retrograde cholangiopancreatography (ERCP) with minor papillotomy reduces the risk of pancreatitis episodes.",
      "Even though this endoscopic procedure is widely used in practice, clinical trials are lacking.",
      "To determine whether ERCP with minor papillotomy reduces the risk of acute pancreatitis among adults with unexplained acute recurrent pancreatitis and pancreas divisum.",
      "This multicenter, sham-controlled, double-blind randomized clinical trial enrolled adults with 2 or more episodes of acute pancreatitis and pancreas divisum.",
      "Adults with other etiologies for acute pancreatitis or concomitant chronic calcific pancreatitis were excluded.",
      "The trial was conducted between September 1, 2018, and August 30, 2024, at 21 referral centers in the US and Canada.",
      "Last follow-up occurred on February 15, 2025.",
      "Participants were randomized in a 1:1 ratio to ERCP with minor papillotomy or sham ERCP.",
      "The primary outcome was development of acute pancreatitis more than 30 days after randomization as a time-to-event outcome.",
      "The secondary outcomes included acute pancreatitis episode frequency and development of chronic calcific pancreatitis, diabetes, and exocrine pancreatic dysfunction.",
      "A total of 148 participants were randomized (mean age, 54",
      "[SD, 19.5] years; 68.2% female; 95.3% non-Hispanic or Latino and 87.2% White; mean lifetime acute pancreatitis episodes, 3",
      "[SD, 2]; mean duct diameter, 2.2 [SD, 1.3] mm) and followed up for a median of 34 months (IQR, 21.7-45.7 months).",
      "Of the 75 participants in the ERCP with minor papillotomy group, 26 (34.7%) developed acute pancreatitis compared with 32 of 73 participants (43.8%) in the sham ERCP group (adjusted hazard ratio, 0.83",
      "[95% CI, 0.49 to 1.41]).",
      "The incidence rate ratio for acute recurrent pancreatitis episode frequency was 0.25 (95% CI, 0.18 to 0.34) in the ERCP with minor papillotomy group vs 0.30 (95% CI, 0.23 to 0.41) in the sham ERCP group.",
      "There were no between-group differences in frequency and incidence of chronic calcific pancreatitis (4.0% in the ERCP with minor papillotomy group vs 2.7% in the sham ERCP group; risk difference",
      "[RD], 0.01 [95% CI, -0.05 to 0.07]), diabetes (15.8% vs 12.8%, respectively; RD, 0.03",
      "[95% CI, -0.13 to 0.19]), and exocrine pancreatic dysfunction (7.7% vs 17.2%; RD, -0.10",
      "[95% CI, -0.27 to 0.08]).",
      "The adverse event of acute pancreatitis within 30 days of randomization occurred more frequently in the ERCP with minor papillotomy group (14.7%) vs the sham ERCP group (8.2%) (RD, 0.06",
      "[95% CI, -0.04 to 0.17]).",
      "Among patients with unexplained acute recurrent pancreatitis and pancreas divisum, ERCP with minor papillotomy does not reduce the risk of another episode of acute pancreatitis or related sequelae.",
      "ClinicalTrials.gov",
      "Identifier: NCT03609944."
    ],
    "summary_sentences": [
      "Pancreas divisum is implicated as an obstructive cause for acute pancreatitis.",
      "Observational data suggest endoscopic retrograde cholangiopancreatography (ERCP) with minor papillotomy reduces the risk of pancreatitis episodes.",
      "Even though this endoscopic procedure is widely used in practice, clinical trials are lacking.",
      "To determine whether ERCP with minor papillotomy reduces the risk of acute pancreatitis among adults with unexplained acute recurrent pancreatitis and pancreas divisum.",
      "This multicenter, sham-controlled, double-blind randomized clinical trial enrolled adults with 2 or more episodes of acute pancreatitis and pancreas divisum.",
      "Adults with other etiologies for acute pancreatitis or concomitant chronic calcific pancreatitis were excluded.",
      "The trial was conducted between September 1, 2018, and August 30, 2024, at 21 referral centers in the US and Canada.",
      "Last follow-up occurred on February 15, 2025.",
      "Participants were randomized in a 1:1 ratio to ERCP with minor papillotomy or sham ERCP.",
      "The primary outcome was development of acute pancreatitis more than 30 days after randomization as a time-to-event outcome.",
      "The secondary outcomes included acute pancreatitis episode frequency and development of chronic calcific pancreatitis, diabetes, and exocrine pancreatic dysfunction.",
      "A total of 148 participants were randomized (mean age, 54",
      "[SD, 19.5] years; 68.2% female; 95.3% non-Hispanic or Latino and 87.2% White; mean lifetime acute pancreatitis episodes, 3",
      "[SD, 2]; mean duct diameter, 2.2 [SD, 1.3] mm) and followed up for a median of 34 months (IQR, 21.7-45.7 months).",
      "Of the 75 participants in the ERCP with minor papillotomy group, 26 (34.7%) developed acute pancreatitis compared with 32 of 73 participants (43.8%) in the sham ERCP group (adjusted hazard ratio, 0.83",
      "[95% CI, 0.49 to 1.41]).",
      "The incidence rate ratio for acute recurrent pancreatitis episode frequency was 0.25 (95% CI, 0.18 to 0.34) in the ERCP with minor papillotomy group vs 0.30 (95% CI, 0.23 to 0.41) in the sham ERCP group.",
      "There were no between-group differences in frequency and incidence of chronic calcific pancreatitis (4.0% in the ERCP with minor papillotomy group vs 2.7% in the sham ERCP group; risk difference",
      "[RD], 0.01 [95% CI, -0.05 to 0.07]), diabetes (15.8% vs 12.8%, respectively; RD, 0.03",
      "[95% CI, -0.13 to 0.19]), and exocrine pancreatic dysfunction (7.7% vs 17.2%; RD, -0.10",
      "[95% CI, -0.27 to 0.08]).",
      "The adverse event of acute pancreatitis within 30 days of randomization occurred more frequently in the ERCP with minor papillotomy group (14.7%) vs the sham ERCP group (8.2%) (RD, 0.06",
      "[95% CI, -0.04 to 0.17]).",
      "Among patients with unexplained acute recurrent pancreatitis and pancreas divisum, ERCP with minor papillotomy does not reduce the risk of another episode of acute pancreatitis or related sequelae.",
      "ClinicalTrials.gov",
      "Identifier: NCT03609944."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41532138",
    "source": "pubmed",
    "sentences": [
      "We analyzed the cross-sectional associations of 24 inflammatory cytokines with diabetic retinopathy (DR) severity.",
      "Prospective, clinical trial at a tertiary academic medical center.",
      "Three hundred twenty-eight eyes of 164 patients with diabetes with varying severity of DR, including none.",
      "All diabetic eyes had aqueous sampling of both eyes, ETDRS visual acuity, and color fundus photographs.",
      "Three groups were enrolled according to grading of baseline color fundus photographs: 23 (46 eyes) patients with diabetes with no DR, 118 (236 eyes) patients with diabetes with moderate nonproliferative DR (NPDR), and 23 (46 eyes) patients with diabetes with proliferative DR.",
      "The moderate NPDR group was further subdivided into mild-moderate and moderate-severe groups based on the ETDRS severity scale.",
      "Blood was drawn to measure hemoglobin A1c.",
      "A microparticle bead-based multiplex assay was used to measure: fibroblast growth factor-2, eotaxin, granulocyte colony-stimulating factor, FMS-like tyrosine kinase 3, GRO, interleukin (IL)-10, monocyte chemotactic protein (MCP)-3, macrophage-derived chemokine, soluble CD40L, IL-17A, IL-1 receptor antagonist, IL-1β, IL-2, IL-4, IL-6, IL-8, induced protein 10, MCP-1, macrophage inflammatory protein-1β, tumor necrosis factor-α, VEGF-A, regulated on activation normal T expressed and secreted, and platelet-derived growth factor-AA and -AB/BB.",
      "Triplicate testing of all cytokines was performed.",
      "Aqueous cytokines, DR severity, hemoglobin A1c.",
      "Median and interquartile ranges of VEGF-A by grade of eye were 100.57 (80.93-145.67), 153.40 (112.86-206.24), 223.45 (135.27-319.21), and 295.60 (177.46-388.89) pg/mL among no DR, mild-moderate NPDR, moderate-severe NPDR, and proliferative DR groups, respectively.",
      "Median and interquartile ranges of IL-6 were 5.45 (3.16-7.86), 8.28 (4.78-20.68), 12.80 (8.24-27.49), and 17.14 (10.31-52.61) pg/mL and of IL-8 were 7.06 (4.10-13.08), 10.53 (6.45-15.85), 16.25 (11.61-24.10), and 20.61 (14.00-27.65) pg/mL among no DR, mild-moderate NPDR, moderate-severe NPDR, and proliferative DR groups, respectively.",
      "Similar positive linear relationships were seen with IL-4 and MCP-1.",
      "Compared with the no DR group, significant progressive odds ratios were observed among all DR severity groups for VEGF-A, IL-6, IL-8, and IL-4.",
      "Significant progressive odds ratios from mild-moderate NPDR to moderate-severe NPDR were observed for FMS-like tyrosine kinase 3, IL-10, induced protein 10, MCP-1, macrophage-derived chemokine, and platelet-derived growth factor-AA.",
      "The majority of cytokines demonstrated no relationship with hemoglobin A1c.",
      "We report that several key inflammatory cytokines demonstrate cross-sectional associations with DR severity.",
      "Our results lend support to the presumption that inflammatory cytokines are important biomarkers that associate with DR severity and may represent novel targets for inhibition.",
      "The authors have no proprietary or commercial interest in any materials discussed in this article."
    ],
    "summary_sentences": [
      "We analyzed the cross-sectional associations of 24 inflammatory cytokines with diabetic retinopathy (DR) severity.",
      "Prospective, clinical trial at a tertiary academic medical center.",
      "Three hundred twenty-eight eyes of 164 patients with diabetes with varying severity of DR, including none.",
      "All diabetic eyes had aqueous sampling of both eyes, ETDRS visual acuity, and color fundus photographs.",
      "Three groups were enrolled according to grading of baseline color fundus photographs: 23 (46 eyes) patients with diabetes with no DR, 118 (236 eyes) patients with diabetes with moderate nonproliferative DR (NPDR), and 23 (46 eyes) patients with diabetes with proliferative DR.",
      "The moderate NPDR group was further subdivided into mild-moderate and moderate-severe groups based on the ETDRS severity scale.",
      "Blood was drawn to measure hemoglobin A1c.",
      "A microparticle bead-based multiplex assay was used to measure: fibroblast growth factor-2, eotaxin, granulocyte colony-stimulating factor, FMS-like tyrosine kinase 3, GRO, interleukin (IL)-10, monocyte chemotactic protein (MCP)-3, macrophage-derived chemokine, soluble CD40L, IL-17A, IL-1 receptor antagonist, IL-1β, IL-2, IL-4, IL-6, IL-8, induced protein 10, MCP-1, macrophage inflammatory protein-1β, tumor necrosis factor-α, VEGF-A, regulated on activation normal T expressed and secreted, and platelet-derived growth factor-AA and -AB/BB.",
      "Triplicate testing of all cytokines was performed.",
      "Aqueous cytokines, DR severity, hemoglobin A1c.",
      "Median and interquartile ranges of VEGF-A by grade of eye were 100.57 (80.93-145.67), 153.40 (112.86-206.24), 223.45 (135.27-319.21), and 295.60 (177.46-388.89) pg/mL among no DR, mild-moderate NPDR, moderate-severe NPDR, and proliferative DR groups, respectively.",
      "Median and interquartile ranges of IL-6 were 5.45 (3.16-7.86), 8.28 (4.78-20.68), 12.80 (8.24-27.49), and 17.14 (10.31-52.61) pg/mL and of IL-8 were 7.06 (4.10-13.08), 10.53 (6.45-15.85), 16.25 (11.61-24.10), and 20.61 (14.00-27.65) pg/mL among no DR, mild-moderate NPDR, moderate-severe NPDR, and proliferative DR groups, respectively.",
      "Similar positive linear relationships were seen with IL-4 and MCP-1.",
      "Compared with the no DR group, significant progressive odds ratios were observed among all DR severity groups for VEGF-A, IL-6, IL-8, and IL-4.",
      "Significant progressive odds ratios from mild-moderate NPDR to moderate-severe NPDR were observed for FMS-like tyrosine kinase 3, IL-10, induced protein 10, MCP-1, macrophage-derived chemokine, and platelet-derived growth factor-AA.",
      "The majority of cytokines demonstrated no relationship with hemoglobin A1c.",
      "We report that several key inflammatory cytokines demonstrate cross-sectional associations with DR severity.",
      "Our results lend support to the presumption that inflammatory cytokines are important biomarkers that associate with DR severity and may represent novel targets for inhibition.",
      "The authors have no proprietary or commercial interest in any materials discussed in this article."
    ],
    "meta": {
      "abstract_only": true
    }
  },
  {
    "doc_id": "PMID_41531815",
    "source": "pubmed",
    "sentences": [
      "The aim of this study was to evaluate the effectiveness of WeChat-based remote care guidance as a supplement to standard care for patients with diabetic foot ulcers.",
      "Our specific objectives were to compare healing rates, self-management behaviors, and patient satisfaction between the two groups, with a focus on identifying patient subgroups that might benefit most from this approach.",
      "A retrospective cohort study was conducted at Fujian Maternity and Child Health Hospital between June 2021 and December 2022, with follow-up until December 2024.",
      "Among 131 eligible patients with diabetic foot ulcers (Wagner grades 1-4), 59 received WeChat -based guidance (intervention) while 72 received standard care (control).",
      "Primary outcomes included wound healing rate and time-to-healing.",
      "Quality of life (WHOQOL-BREF) and treatment satisfaction (DTSQs) were assessed at baseline, 3, 6, 12, and 24 months.",
      "Analyses were adjusted for demographic characteristics, clinical parameters, and disease severity indicators.",
      "The intervention group showed significantly higher healing rates (88.1% WeChat-based remote care guidance was associated with better diabetic foot ulcer healing outcomes, particularly for moderate-severity ulcers and patients undergoing interventional procedures.",
      "Our findings also suggest associations between this approach and improvements in quality of life and treatment satisfaction."
    ],
    "summary_sentences": [
      "The aim of this study was to evaluate the effectiveness of WeChat-based remote care guidance as a supplement to standard care for patients with diabetic foot ulcers.",
      "Our specific objectives were to compare healing rates, self-management behaviors, and patient satisfaction between the two groups, with a focus on identifying patient subgroups that might benefit most from this approach.",
      "A retrospective cohort study was conducted at Fujian Maternity and Child Health Hospital between June 2021 and December 2022, with follow-up until December 2024.",
      "Among 131 eligible patients with diabetic foot ulcers (Wagner grades 1-4), 59 received WeChat -based guidance (intervention) while 72 received standard care (control).",
      "Primary outcomes included wound healing rate and time-to-healing.",
      "Quality of life (WHOQOL-BREF) and treatment satisfaction (DTSQs) were assessed at baseline, 3, 6, 12, and 24 months.",
      "Analyses were adjusted for demographic characteristics, clinical parameters, and disease severity indicators.",
      "The intervention group showed significantly higher healing rates (88.1% WeChat-based remote care guidance was associated with better diabetic foot ulcer healing outcomes, particularly for moderate-severity ulcers and patients undergoing interventional procedures.",
      "Our findings also suggest associations between this approach and improvements in quality of life and treatment satisfaction."
    ],
    "meta": {
      "abstract_only": true
    }
  }
]